,source,target,value,type,source layer,target layer,normalized value
0,IGLC7,Initial triggering of complement,0.007152421740923776,0,0,1,0.007834582777450206
1,IGLC7,Initial triggering of complement,0.007572073269597619,1,0,1,0.008294258501026051
2,IGLC7,Regulation of Complement cascade,0.007152421740923776,0,0,1,0.007834582777450206
3,IGLC7,Regulation of Complement cascade,0.007572073269597619,1,0,1,0.008294258501026051
4,IGLC7,FCGR activation,0.007152421740923776,0,0,1,0.007834582777450206
5,IGLC7,FCGR activation,0.007572073269597619,1,0,1,0.008294258501026051
6,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.007152421740923776,0,0,1,0.007834582777450206
7,IGLC7,Regulation of actin dynamics for phagocytic cup formation,0.007572073269597619,1,0,1,0.008294258501026051
8,IGLC7,Role of phospholipids in phagocytosis,0.007152421740923776,0,0,1,0.007834582777450206
9,IGLC7,Role of phospholipids in phagocytosis,0.007572073269597619,1,0,1,0.008294258501026051
10,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.007152421740923776,0,0,1,0.007834582777450206
11,IGLC7,Role of LAT2/NTAL/LAB on calcium mobilization,0.007572073269597619,1,0,1,0.008294258501026051
12,IGLC7,FCERI mediated MAPK activation,0.007152421740923776,0,0,1,0.007834582777450206
13,IGLC7,FCERI mediated MAPK activation,0.007572073269597619,1,0,1,0.008294258501026051
14,IGLC7,FCERI mediated Ca+2 mobilization,0.007152421740923776,0,0,1,0.007834582777450206
15,IGLC7,FCERI mediated Ca+2 mobilization,0.007572073269597619,1,0,1,0.008294258501026051
16,IGLC7,FCERI mediated NF-kB activation,0.007152421740923776,0,0,1,0.007834582777450206
17,IGLC7,FCERI mediated NF-kB activation,0.007572073269597619,1,0,1,0.008294258501026051
18,IGLC7,Parasite infection,0.007152421740923776,0,0,1,0.007834582777450206
19,IGLC7,Parasite infection,0.007572073269597619,1,0,1,0.008294258501026051
20,IGLC7,Leishmania parasite growth and survival,0.007152421740923776,0,0,1,0.007834582777450206
21,IGLC7,Leishmania parasite growth and survival,0.007572073269597619,1,0,1,0.008294258501026051
22,IGLC7,Potential therapeutics for SARS,0.007152421740923776,0,0,1,0.007834582777450206
23,IGLC7,Potential therapeutics for SARS,0.007572073269597619,1,0,1,0.008294258501026051
24,IGLC7,CD22 mediated BCR regulation,0.007152421740923776,0,0,1,0.007834582777450206
25,IGLC7,CD22 mediated BCR regulation,0.007572073269597619,1,0,1,0.008294258501026051
26,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007152421740923776,0,0,1,0.007834582777450206
27,IGLC7,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007572073269597619,1,0,1,0.008294258501026051
28,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007152421740923776,0,0,1,0.007834582777450206
29,IGLC7,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007572073269597619,1,0,1,0.008294258501026051
30,IGLC7,Scavenging of heme from plasma,0.007152421740923776,0,0,1,0.007834582777450206
31,IGLC7,Scavenging of heme from plasma,0.007572073269597619,1,0,1,0.008294258501026051
32,RB27B,Platelet degranulation ,3.990567627245116e-05,0,0,1,4.371167352419985e-05
33,RB27B,Platelet degranulation ,2.009147094030466e-05,1,0,1,2.2007691646860584e-05
34,RB27B,RAB GEFs exchange GTP for GDP on RABs,3.990567627245116e-05,0,0,1,4.371167352419985e-05
35,RB27B,RAB GEFs exchange GTP for GDP on RABs,2.009147094030466e-05,1,0,1,2.2007691646860584e-05
36,RB27B,RAB geranylgeranylation,3.990567627245116e-05,0,0,1,4.371167352419985e-05
37,RB27B,RAB geranylgeranylation,2.009147094030466e-05,1,0,1,2.2007691646860584e-05
38,QSOX1,Platelet degranulation ,0.003961318839501842,0,0,1,0.004339128966399818
39,QSOX1,Platelet degranulation ,0.0034754165697237567,1,0,1,0.00380688384828187
40,QSOX1,Neutrophil degranulation,0.003961318839501842,0,0,1,0.004339128966399818
41,QSOX1,Neutrophil degranulation,0.0034754165697237567,1,0,1,0.00380688384828187
42,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003961318839501842,0,0,1,0.004339128966399818
43,QSOX1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0034754165697237567,1,0,1,0.00380688384828187
44,QSOX1,Post-translational protein phosphorylation,0.003961318839501842,0,0,1,0.004339128966399818
45,QSOX1,Post-translational protein phosphorylation,0.0034754165697237567,1,0,1,0.00380688384828187
46,NRP1,Neurophilin interactions with VEGF and VEGFR,0.0004683404194605052,0,0,1,0.0005130083092408887
47,NRP1,Neurophilin interactions with VEGF and VEGFR,0.0005623958433282353,1,0,1,0.0006160342535505883
48,NRP1,Semaphorin interactions,0.0004683404194605052,0,0,1,0.0005130083092408887
49,NRP1,Semaphorin interactions,0.0005623958433282353,1,0,1,0.0006160342535505883
50,NRP1,L1CAM interactions,0.0004683404194605052,0,0,1,0.0005130083092408887
51,NRP1,L1CAM interactions,0.0005623958433282353,1,0,1,0.0006160342535505883
52,NRP1,Signaling by ROBO receptors,0.0004683404194605052,0,0,1,0.0005130083092408887
53,NRP1,Signaling by ROBO receptors,0.0005623958433282353,1,0,1,0.0006160342535505883
54,NRP1,SARS-CoV-2 Infection,0.0004683404194605052,0,0,1,0.0005130083092408887
55,NRP1,SARS-CoV-2 Infection,0.0005623958433282353,1,0,1,0.0006160342535505883
56,APOL1,Scavenging of heme from plasma,0.0030840168324891056,0,0,1,0.00337815442606507
57,APOL1,Scavenging of heme from plasma,0.003328553159135112,1,0,1,0.0036460133642817498
58,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0030840168324891056,0,0,1,0.00337815442606507
59,APOL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003328553159135112,1,0,1,0.0036460133642817498
60,APOL1,Post-translational protein phosphorylation,0.0030840168324891056,0,0,1,0.00337815442606507
61,APOL1,Post-translational protein phosphorylation,0.003328553159135112,1,0,1,0.0036460133642817498
62,ARPC3,RHO GTPase Effectors,0.0003116580457091987,0,0,1,0.00034138238009601997
63,ARPC3,RHO GTPase Effectors,0.0002941117750797183,1,0,1,0.0003221626368172277
64,ARPC3,Regulation of actin dynamics for phagocytic cup formation,0.0003116580457091987,0,0,1,0.00034138238009601997
65,ARPC3,Regulation of actin dynamics for phagocytic cup formation,0.0002941117750797183,1,0,1,0.0003221626368172277
66,ARPC3,EPH-Ephrin signaling,0.0003116580457091987,0,0,1,0.00034138238009601997
67,ARPC3,EPH-Ephrin signaling,0.0002941117750797183,1,0,1,0.0003221626368172277
68,ARPC3,Parasite infection,0.0003116580457091987,0,0,1,0.00034138238009601997
69,ARPC3,Parasite infection,0.0002941117750797183,1,0,1,0.0003221626368172277
70,ACTN4,Platelet degranulation ,0.0008886404916689008,0,0,1,0.000973394431083262
71,ACTN4,Platelet degranulation ,0.0006475086324064647,1,0,1,0.000709264660761856
72,ACTN4,Nephrin family interactions,0.0008886404916689008,0,0,1,0.000973394431083262
73,ACTN4,Nephrin family interactions,0.0006475086324064647,1,0,1,0.000709264660761856
74,FLNB,Antiviral mechanism by IFN-stimulated genes,5.445945069294596e-05,0,0,1,5.965351176470847e-05
75,FLNB,Antiviral mechanism by IFN-stimulated genes,0.00014721835046878964,1,0,1,0.00016125927621242877
76,PGRP1,Neutrophil degranulation,0.00011512782633512016,0,0,1,0.00012610812366524617
77,PGRP1,Neutrophil degranulation,0.00012144329726827794,1,0,1,0.00013302593159053984
78,FCN3,Initial triggering of complement,0.0014514194604297178,0,0,1,0.001589848350590981
79,FCN3,Initial triggering of complement,0.0015471019037792254,1,0,1,0.001694656491095513
80,IDHC,NADPH regeneration,0.0034641453672465184,0,0,1,0.003794537656738931
81,IDHC,NADPH regeneration,0.00436247818450902,1,0,1,0.004778548817360748
82,IDHC,KEAP1-NFE2L2 pathway,0.0034641453672465184,0,0,1,0.003794537656738931
83,IDHC,KEAP1-NFE2L2 pathway,0.00436247818450902,1,0,1,0.004778548817360748
84,IDHC,Neutrophil degranulation,0.0034641453672465184,0,0,1,0.003794537656738931
85,IDHC,Neutrophil degranulation,0.00436247818450902,1,0,1,0.004778548817360748
86,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0034641453672465184,0,0,1,0.003794537656738931
87,IDHC,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.00436247818450902,1,0,1,0.004778548817360748
88,UTS2,Class A/1 (Rhodopsin-like receptors),0.001329020823888022,0,0,1,0.001455775964402369
89,UTS2,Class A/1 (Rhodopsin-like receptors),0.001033617734544447,1,0,1,0.0011321988544376756
90,UTS2,G alpha (q) signalling events,0.001329020823888022,0,0,1,0.001455775964402369
91,UTS2,G alpha (q) signalling events,0.001033617734544447,1,0,1,0.0011321988544376756
92,APOM,Retinoid metabolism and transport,0.004613991568937867,0,0,1,0.005054050249088397
93,APOM,Retinoid metabolism and transport,0.0045153556912751105,1,0,1,0.00494600699096314
94,VNN1,Vitamin B5 (pantothenate) metabolism,0.0004009301520468606,0,0,1,0.00043916879876005927
95,VNN1,Vitamin B5 (pantothenate) metabolism,0.0006783006256735803,1,0,1,0.000742993435276591
96,VNN1,Neutrophil degranulation,0.0004009301520468606,0,0,1,0.00043916879876005927
97,VNN1,Neutrophil degranulation,0.0006783006256735803,1,0,1,0.000742993435276591
98,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.0004009301520468606,0,0,1,0.00043916879876005927
99,VNN1,Post-translational modification: synthesis of GPI-anchored proteins,0.0006783006256735803,1,0,1,0.000742993435276591
100,FSTL3,Antagonism of Activin by Follistatin,0.00013836487657504292,0,0,1,0.00015156140371538632
101,FSTL3,Antagonism of Activin by Follistatin,0.0001651749895974745,1,0,1,0.00018092852681793247
102,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00013836487657504292,0,0,1,0.00015156140371538632
103,FSTL3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0001651749895974745,1,0,1,0.00018092852681793247
104,FSTL3,Post-translational protein phosphorylation,0.00013836487657504292,0,0,1,0.00015156140371538632
105,FSTL3,Post-translational protein phosphorylation,0.0001651749895974745,1,0,1,0.00018092852681793247
106,K2C75,Formation of the cornified envelope,0.00022967250143540645,0,0,1,0.0002515774781434158
107,K2C75,Formation of the cornified envelope,0.00022560436685074966,1,0,1,0.000247121345897894
108,PAK4,RHO GTPase cycle,0.0006700265226904175,0,0,1,0.0007339301910945772
109,PAK4,RHO GTPase cycle,0.00047509454088636805,1,0,1,0.0005204066038768308
110,PAK4,Signaling by ROBO receptors,0.0006700265226904175,0,0,1,0.0007339301910945772
111,PAK4,Signaling by ROBO receptors,0.00047509454088636805,1,0,1,0.0005204066038768308
112,ADH1B,Ethanol oxidation,0.000116893606886853,0,0,1,0.000128042315244052
113,ADH1B,Ethanol oxidation,8.469248511347604e-05,1,0,1,9.277001682562956e-05
114,LDHA,Pyruvate metabolism,0.0005272034595414362,0,0,1,0.0005774854020006426
115,LDHA,Pyruvate metabolism,0.0008463761204148071,1,0,1,0.000927099102434994
116,AL1A1,Ethanol oxidation,0.0017062598998365253,0,0,1,0.0018689941546129554
117,AL1A1,Ethanol oxidation,0.0017981607297631594,1,0,1,0.0019696600109420028
118,AL1A1,RA biosynthesis pathway,0.0017062598998365253,0,0,1,0.0018689941546129554
119,AL1A1,RA biosynthesis pathway,0.0017981607297631594,1,0,1,0.0019696600109420028
120,AL1A1,Fructose catabolism,0.0017062598998365253,0,0,1,0.0018689941546129554
121,AL1A1,Fructose catabolism,0.0017981607297631594,1,0,1,0.0019696600109420028
122,DHE3,Transcriptional activation of mitochondrial biogenesis,6.609893753747326e-05,0,0,1,7.240311273534617e-05
123,DHE3,Transcriptional activation of mitochondrial biogenesis,0.0003361005424244121,1,0,1,0.000368156075878976
124,DHE3,Glutamate and glutamine metabolism,6.609893753747326e-05,0,0,1,7.240311273534617e-05
125,DHE3,Glutamate and glutamine metabolism,0.0003361005424244121,1,0,1,0.000368156075878976
126,CERU,Metal ion SLC transporters,0.0024200055954240966,0,0,1,0.0026508132274641293
127,CERU,Metal ion SLC transporters,0.0025176187697872,1,0,1,0.0027577362421322546
128,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0024200055954240966,0,0,1,0.0026508132274641293
129,CERU,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),0.0025176187697872,1,0,1,0.0027577362421322546
130,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.0024200055954240966,0,0,1,0.0026508132274641293
131,CERU,Defective CP causes aceruloplasminemia (ACERULOP),0.0025176187697872,1,0,1,0.0027577362421322546
132,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0024200055954240966,0,0,1,0.0026508132274641293
133,CERU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0025176187697872,1,0,1,0.0027577362421322546
134,CERU,Post-translational protein phosphorylation,0.0024200055954240966,0,0,1,0.0026508132274641293
135,CERU,Post-translational protein phosphorylation,0.0025176187697872,1,0,1,0.0027577362421322546
136,OTC,Urea cycle,0.0003686064254754899,0,0,1,0.00040376220213138195
137,OTC,Urea cycle,0.0001258775196935678,1,0,1,0.00013788306724373922
138,OTC,Mitochondrial protein import,0.0003686064254754899,0,0,1,0.00040376220213138195
139,OTC,Mitochondrial protein import,0.0001258775196935678,1,0,1,0.00013788306724373922
140,F13A,Interleukin-4 and Interleukin-13 signaling,0.004505407996112995,0,0,1,0.004935110536025855
141,F13A,Interleukin-4 and Interleukin-13 signaling,0.0037779443358664454,1,0,1,0.004138265149912983
142,F13A,Platelet degranulation ,0.004505407996112995,0,0,1,0.004935110536025855
143,F13A,Platelet degranulation ,0.0037779443358664454,1,0,1,0.004138265149912983
144,F13A,Common Pathway of Fibrin Clot Formation,0.004505407996112995,0,0,1,0.004935110536025855
145,F13A,Common Pathway of Fibrin Clot Formation,0.0037779443358664454,1,0,1,0.004138265149912983
146,PGK1,Glycolysis,9.270497292744912e-05,0,0,1,0.00010154669433510979
147,PGK1,Glycolysis,6.647376939910371e-05,1,0,1,7.281369412357261e-05
148,PGK1,Gluconeogenesis,9.270497292744912e-05,0,0,1,0.00010154669433510979
149,PGK1,Gluconeogenesis,6.647376939910371e-05,1,0,1,7.281369412357261e-05
150,PGK1,Response of Mtb to phagocytosis,9.270497292744912e-05,0,0,1,0.00010154669433510979
151,PGK1,Response of Mtb to phagocytosis,6.647376939910371e-05,1,0,1,7.281369412357261e-05
152,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.021614739202142595,0,0,1,0.023676241366370077
153,THRB,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.018587098582198626,1,0,1,0.020359840024765454
154,THRB,Regulation of Complement cascade,0.021614739202142595,0,0,1,0.023676241366370077
155,THRB,Regulation of Complement cascade,0.018587098582198626,1,0,1,0.020359840024765454
156,THRB,Class A/1 (Rhodopsin-like receptors),0.021614739202142595,0,0,1,0.023676241366370077
157,THRB,Class A/1 (Rhodopsin-like receptors),0.018587098582198626,1,0,1,0.020359840024765454
158,THRB,G alpha (q) signalling events,0.021614739202142595,0,0,1,0.023676241366370077
159,THRB,G alpha (q) signalling events,0.018587098582198626,1,0,1,0.020359840024765454
160,THRB,Defective factor XII causes hereditary angioedema,0.021614739202142595,0,0,1,0.023676241366370077
161,THRB,Defective factor XII causes hereditary angioedema,0.018587098582198626,1,0,1,0.020359840024765454
162,THRB,Defective factor VIII causes hemophilia A,0.021614739202142595,0,0,1,0.023676241366370077
163,THRB,Defective factor VIII causes hemophilia A,0.018587098582198626,1,0,1,0.020359840024765454
164,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.021614739202142595,0,0,1,0.023676241366370077
165,THRB,Intrinsic Pathway of Fibrin Clot Formation,0.018587098582198626,1,0,1,0.020359840024765454
166,THRB,Common Pathway of Fibrin Clot Formation,0.021614739202142595,0,0,1,0.023676241366370077
167,THRB,Common Pathway of Fibrin Clot Formation,0.018587098582198626,1,0,1,0.020359840024765454
168,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.021614739202142595,0,0,1,0.023676241366370077
169,THRB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.018587098582198626,1,0,1,0.020359840024765454
170,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.021614739202142595,0,0,1,0.023676241366370077
171,THRB,Thrombin signalling through proteinase activated receptors (PARs),0.018587098582198626,1,0,1,0.020359840024765454
172,C1R,Initial triggering of complement,0.0005371042677421973,0,0,1,0.0005883304981404156
173,C1R,Initial triggering of complement,0.0005727669911854908,1,0,1,0.0006273945479135362
174,C1R,Regulation of Complement cascade,0.0005371042677421973,0,0,1,0.0005883304981404156
175,C1R,Regulation of Complement cascade,0.0005727669911854908,1,0,1,0.0006273945479135362
176,HPT,Neutrophil degranulation,0.0015153354640280695,0,0,1,0.001659860332425041
177,HPT,Neutrophil degranulation,0.0016535639107377424,1,0,1,0.0018112722942992896
178,HPT,Scavenging of heme from plasma,0.0015153354640280695,0,0,1,0.001659860332425041
179,HPT,Scavenging of heme from plasma,0.0016535639107377424,1,0,1,0.0018112722942992896
180,HPTR,Scavenging of heme from plasma,0.0007558001930307822,0,0,1,0.0008278845110086766
181,HPTR,Scavenging of heme from plasma,0.0008510170776061927,1,0,1,0.0009321826901482959
182,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.010758524351585209,0,0,1,0.01178461682613556
183,FA9,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.00934188252631891,1,0,1,0.010232863021890021
184,FA9,Defective factor VIII causes hemophilia A,0.010758524351585209,0,0,1,0.01178461682613556
185,FA9,Defective factor VIII causes hemophilia A,0.00934188252631891,1,0,1,0.010232863021890021
186,FA9,Defective factor IX causes hemophilia B,0.010758524351585209,0,0,1,0.01178461682613556
187,FA9,Defective factor IX causes hemophilia B,0.00934188252631891,1,0,1,0.010232863021890021
188,FA9,Defective factor IX causes thrombophilia,0.010758524351585209,0,0,1,0.01178461682613556
189,FA9,Defective factor IX causes thrombophilia,0.00934188252631891,1,0,1,0.010232863021890021
190,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.010758524351585209,0,0,1,0.01178461682613556
191,FA9,Extrinsic Pathway of Fibrin Clot Formation,0.00934188252631891,1,0,1,0.010232863021890021
192,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.010758524351585209,0,0,1,0.01178461682613556
193,FA9,Intrinsic Pathway of Fibrin Clot Formation,0.00934188252631891,1,0,1,0.010232863021890021
194,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.02565290917510044,0,0,1,0.028099551130325067
195,FA10,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.021995238171474356,1,0,1,0.02409303036175434
196,FA10,Defective factor VIII causes hemophilia A,0.02565290917510044,0,0,1,0.028099551130325067
197,FA10,Defective factor VIII causes hemophilia A,0.021995238171474356,1,0,1,0.02409303036175434
198,FA10,Defective factor IX causes hemophilia B,0.02565290917510044,0,0,1,0.028099551130325067
199,FA10,Defective factor IX causes hemophilia B,0.021995238171474356,1,0,1,0.02409303036175434
200,FA10,Defective factor IX causes thrombophilia,0.02565290917510044,0,0,1,0.028099551130325067
201,FA10,Defective factor IX causes thrombophilia,0.021995238171474356,1,0,1,0.02409303036175434
202,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.02565290917510044,0,0,1,0.028099551130325067
203,FA10,Extrinsic Pathway of Fibrin Clot Formation,0.021995238171474356,1,0,1,0.02409303036175434
204,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.02565290917510044,0,0,1,0.028099551130325067
205,FA10,Intrinsic Pathway of Fibrin Clot Formation,0.021995238171474356,1,0,1,0.02409303036175434
206,FA10,Common Pathway of Fibrin Clot Formation,0.02565290917510044,0,0,1,0.028099551130325067
207,FA10,Common Pathway of Fibrin Clot Formation,0.021995238171474356,1,0,1,0.02409303036175434
208,CFAD,Initial triggering of complement,0.0003182339393885376,0,0,1,0.0003485854485436921
209,CFAD,Initial triggering of complement,0.00017512750423174375,1,0,1,0.00019183026088372826
210,CFAD,Platelet degranulation ,0.0003182339393885376,0,0,1,0.0003485854485436921
211,CFAD,Platelet degranulation ,0.00017512750423174375,1,0,1,0.00019183026088372826
212,CFAD,Neutrophil degranulation,0.0003182339393885376,0,0,1,0.0003485854485436921
213,CFAD,Neutrophil degranulation,0.00017512750423174375,1,0,1,0.00019183026088372826
214,PLMN,Platelet degranulation ,0.005676057963909198,0,0,1,0.006217411050219837
215,PLMN,Platelet degranulation ,0.005332341338373392,1,0,1,0.005840912508566681
216,PLMN,Dissolution of Fibrin Clot,0.005676057963909198,0,0,1,0.006217411050219837
217,PLMN,Dissolution of Fibrin Clot,0.005332341338373392,1,0,1,0.005840912508566681
218,PLMN,Activation of Matrix Metalloproteinases,0.005676057963909198,0,0,1,0.006217411050219837
219,PLMN,Activation of Matrix Metalloproteinases,0.005332341338373392,1,0,1,0.005840912508566681
220,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005676057963909198,0,0,1,0.006217411050219837
221,PLMN,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005332341338373392,1,0,1,0.005840912508566681
222,PLMN,Signaling by PDGF,0.005676057963909198,0,0,1,0.006217411050219837
223,PLMN,Signaling by PDGF,0.005332341338373392,1,0,1,0.005840912508566681
224,FA12,Defective factor XII causes hereditary angioedema,0.0005890543305647998,0,0,1,0.000645235289583104
225,FA12,Defective factor XII causes hereditary angioedema,0.0004369121043728234,1,0,1,0.00047858252381755473
226,FA12,Defective SERPING1 causes hereditary angioedema,0.0005890543305647998,0,0,1,0.000645235289583104
227,FA12,Defective SERPING1 causes hereditary angioedema,0.0004369121043728234,1,0,1,0.00047858252381755473
228,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.0005890543305647998,0,0,1,0.000645235289583104
229,FA12,Intrinsic Pathway of Fibrin Clot Formation,0.0004369121043728234,1,0,1,0.00047858252381755473
230,CFAB,Initial triggering of complement,0.0034797715471462385,0,0,1,0.00381165418095327
231,CFAB,Initial triggering of complement,0.0034069680837669255,1,0,1,0.0037319070993366
232,CFAB,Activation of C3 and C5,0.0034797715471462385,0,0,1,0.00381165418095327
233,CFAB,Activation of C3 and C5,0.0034069680837669255,1,0,1,0.0037319070993366
234,CFAB,Regulation of Complement cascade,0.0034797715471462385,0,0,1,0.00381165418095327
235,CFAB,Regulation of Complement cascade,0.0034069680837669255,1,0,1,0.0037319070993366
236,CAH1,Interleukin-12 family signaling,0.003594170094471467,0,0,1,0.003936963470744088
237,CAH1,Interleukin-12 family signaling,0.003864417315475441,1,0,1,0.004232985475601152
238,CAH1,Reversible hydration of carbon dioxide,0.003594170094471467,0,0,1,0.003936963470744088
239,CAH1,Reversible hydration of carbon dioxide,0.003864417315475441,1,0,1,0.004232985475601152
240,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.003594170094471467,0,0,1,0.003936963470744088
241,CAH1,Erythrocytes take up carbon dioxide and release oxygen,0.003864417315475441,1,0,1,0.004232985475601152
242,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.003594170094471467,0,0,1,0.003936963470744088
243,CAH1,Erythrocytes take up oxygen and release carbon dioxide,0.003864417315475441,1,0,1,0.004232985475601152
244,CAH2,Reversible hydration of carbon dioxide,0.00676275620374091,0,0,1,0.007407752954327323
245,CAH2,Reversible hydration of carbon dioxide,0.006730471823960165,1,0,1,0.0073723894571828975
246,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.00676275620374091,0,0,1,0.007407752954327323
247,CAH2,Erythrocytes take up carbon dioxide and release oxygen,0.006730471823960165,1,0,1,0.0073723894571828975
248,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.00676275620374091,0,0,1,0.007407752954327323
249,CAH2,Erythrocytes take up oxygen and release carbon dioxide,0.006730471823960165,1,0,1,0.0073723894571828975
250,ASSY,Urea cycle,9.995338334959015e-05,0,0,1,0.00010948642069831809
251,ASSY,Urea cycle,5.751445003043415e-05,1,0,1,6.299988115700265e-05
252,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.015973975975746006,0,0,1,0.01749749128339561
253,ANT3,Intrinsic Pathway of Fibrin Clot Formation,0.014438380851134951,1,0,1,0.01581543902862177
254,ANT3,Common Pathway of Fibrin Clot Formation,0.015973975975746006,0,0,1,0.01749749128339561
255,ANT3,Common Pathway of Fibrin Clot Formation,0.014438380851134951,1,0,1,0.01581543902862177
256,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.015973975975746006,0,0,1,0.01749749128339561
257,ANT3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.014438380851134951,1,0,1,0.01581543902862177
258,ANT3,Post-translational protein phosphorylation,0.015973975975746006,0,0,1,0.01749749128339561
259,ANT3,Post-translational protein phosphorylation,0.014438380851134951,1,0,1,0.01581543902862177
260,A1AT,COPII-mediated vesicle transport,0.0023930057243652407,0,0,1,0.0026212382481839267
261,A1AT,COPII-mediated vesicle transport,0.00272344368854162,1,0,1,0.002983191678354224
262,A1AT,Cargo concentration in the ER,0.0023930057243652407,0,0,1,0.0026212382481839267
263,A1AT,Cargo concentration in the ER,0.00272344368854162,1,0,1,0.002983191678354224
264,A1AT,Platelet degranulation ,0.0023930057243652407,0,0,1,0.0026212382481839267
265,A1AT,Platelet degranulation ,0.00272344368854162,1,0,1,0.002983191678354224
266,A1AT,Neutrophil degranulation,0.0023930057243652407,0,0,1,0.0026212382481839267
267,A1AT,Neutrophil degranulation,0.00272344368854162,1,0,1,0.002983191678354224
268,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0023930057243652407,0,0,1,0.0026212382481839267
269,A1AT,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00272344368854162,1,0,1,0.002983191678354224
270,A1AT,Post-translational protein phosphorylation,0.0023930057243652407,0,0,1,0.0026212382481839267
271,A1AT,Post-translational protein phosphorylation,0.00272344368854162,1,0,1,0.002983191678354224
272,AACT,Platelet degranulation ,0.001987645703436475,0,0,1,0.0021772170825325307
273,AACT,Platelet degranulation ,0.001738854612334864,1,0,1,0.0019046975824064127
274,AACT,Neutrophil degranulation,0.001987645703436475,0,0,1,0.0021772170825325307
275,AACT,Neutrophil degranulation,0.001738854612334864,1,0,1,0.0019046975824064127
276,ANGT,Class A/1 (Rhodopsin-like receptors),0.00580465749325999,0,0,1,0.006358275738340114
277,ANGT,Class A/1 (Rhodopsin-like receptors),0.005321147277798649,1,0,1,0.005828650816322386
278,ANGT,G alpha (q) signalling events,0.00580465749325999,0,0,1,0.006358275738340114
279,ANGT,G alpha (q) signalling events,0.005321147277798649,1,0,1,0.005828650816322386
280,ANGT,G alpha (i) signalling events,0.00580465749325999,0,0,1,0.006358275738340114
281,ANGT,G alpha (i) signalling events,0.005321147277798649,1,0,1,0.005828650816322386
282,ANGT,PPARA activates gene expression,0.00580465749325999,0,0,1,0.006358275738340114
283,ANGT,PPARA activates gene expression,0.005321147277798649,1,0,1,0.005828650816322386
284,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.00580465749325999,0,0,1,0.006358275738340114
285,ANGT,Metabolism of Angiotensinogen to Angiotensins,0.005321147277798649,1,0,1,0.005828650816322386
286,A2MG,Platelet degranulation ,0.005796184096398803,0,0,1,0.006348994192659534
287,A2MG,Platelet degranulation ,0.005177023513677682,1,0,1,0.005670781272117127
288,A2MG,HDL assembly,0.005796184096398803,0,0,1,0.006348994192659534
289,A2MG,HDL assembly,0.005177023513677682,1,0,1,0.005670781272117127
290,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.005796184096398803,0,0,1,0.006348994192659534
291,A2MG,Intrinsic Pathway of Fibrin Clot Formation,0.005177023513677682,1,0,1,0.005670781272117127
292,CO3,Initial triggering of complement,0.001953989802387202,0,0,1,0.002140351255506208
293,CO3,Initial triggering of complement,0.002368612380377073,1,0,1,0.002594518393061201
294,CO3,Activation of C3 and C5,0.001953989802387202,0,0,1,0.002140351255506208
295,CO3,Activation of C3 and C5,0.002368612380377073,1,0,1,0.002594518393061201
296,CO3,Regulation of Complement cascade,0.001953989802387202,0,0,1,0.002140351255506208
297,CO3,Regulation of Complement cascade,0.002368612380377073,1,0,1,0.002594518393061201
298,CO3,Class A/1 (Rhodopsin-like receptors),0.001953989802387202,0,0,1,0.002140351255506208
299,CO3,Class A/1 (Rhodopsin-like receptors),0.002368612380377073,1,0,1,0.002594518393061201
300,CO3,G alpha (i) signalling events,0.001953989802387202,0,0,1,0.002140351255506208
301,CO3,G alpha (i) signalling events,0.002368612380377073,1,0,1,0.002594518393061201
302,CO3,Cell recruitment (pro-inflammatory response),0.001953989802387202,0,0,1,0.002140351255506208
303,CO3,Cell recruitment (pro-inflammatory response),0.002368612380377073,1,0,1,0.002594518393061201
304,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001953989802387202,0,0,1,0.002140351255506208
305,CO3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002368612380377073,1,0,1,0.002594518393061201
306,CO3,Neutrophil degranulation,0.001953989802387202,0,0,1,0.002140351255506208
307,CO3,Neutrophil degranulation,0.002368612380377073,1,0,1,0.002594518393061201
308,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001953989802387202,0,0,1,0.002140351255506208
309,CO3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002368612380377073,1,0,1,0.002594518393061201
310,CO3,Post-translational protein phosphorylation,0.001953989802387202,0,0,1,0.002140351255506208
311,CO3,Post-translational protein phosphorylation,0.002368612380377073,1,0,1,0.002594518393061201
312,CO5,Terminal pathway of complement,0.001979822361791605,0,0,1,0.002168647590976641
313,CO5,Terminal pathway of complement,0.0016849618970744755,1,0,1,0.0018456648583720864
314,CO5,Activation of C3 and C5,0.001979822361791605,0,0,1,0.002168647590976641
315,CO5,Activation of C3 and C5,0.0016849618970744755,1,0,1,0.0018456648583720864
316,CO5,Regulation of Complement cascade,0.001979822361791605,0,0,1,0.002168647590976641
317,CO5,Regulation of Complement cascade,0.0016849618970744755,1,0,1,0.0018456648583720864
318,CO5,Class A/1 (Rhodopsin-like receptors),0.001979822361791605,0,0,1,0.002168647590976641
319,CO5,Class A/1 (Rhodopsin-like receptors),0.0016849618970744755,1,0,1,0.0018456648583720864
320,CO5,G alpha (i) signalling events,0.001979822361791605,0,0,1,0.002168647590976641
321,CO5,G alpha (i) signalling events,0.0016849618970744755,1,0,1,0.0018456648583720864
322,TIMP1,Interleukin-10 signaling,0.0028090028127564603,0,0,1,0.003076910989841683
323,TIMP1,Interleukin-10 signaling,0.002698430134500418,1,0,1,0.002955792460747586
324,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.0028090028127564603,0,0,1,0.003076910989841683
325,TIMP1,Interleukin-4 and Interleukin-13 signaling,0.002698430134500418,1,0,1,0.002955792460747586
326,TIMP1,Platelet degranulation ,0.0028090028127564603,0,0,1,0.003076910989841683
327,TIMP1,Platelet degranulation ,0.002698430134500418,1,0,1,0.002955792460747586
328,TIMP1,Activation of Matrix Metalloproteinases,0.0028090028127564603,0,0,1,0.003076910989841683
329,TIMP1,Activation of Matrix Metalloproteinases,0.002698430134500418,1,0,1,0.002955792460747586
330,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0028090028127564603,0,0,1,0.003076910989841683
331,TIMP1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002698430134500418,1,0,1,0.002955792460747586
332,TIMP1,Post-translational protein phosphorylation,0.0028090028127564603,0,0,1,0.003076910989841683
333,TIMP1,Post-translational protein phosphorylation,0.002698430134500418,1,0,1,0.002955792460747586
334,CYTC,Neutrophil degranulation,0.0048232074047298385,0,0,1,0.0052832200104976175
335,CYTC,Neutrophil degranulation,0.005171767236102999,1,0,1,0.005665023677941089
336,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0048232074047298385,0,0,1,0.0052832200104976175
337,CYTC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005171767236102999,1,0,1,0.005665023677941089
338,CYTC,Amyloid fiber formation,0.0048232074047298385,0,0,1,0.0052832200104976175
339,CYTC,Amyloid fiber formation,0.005171767236102999,1,0,1,0.005665023677941089
340,CYTC,Post-translational protein phosphorylation,0.0048232074047298385,0,0,1,0.0052832200104976175
341,CYTC,Post-translational protein phosphorylation,0.005171767236102999,1,0,1,0.005665023677941089
342,KNG1,Class A/1 (Rhodopsin-like receptors),0.023239989389076256,0,0,1,0.02545649952015641
343,KNG1,Class A/1 (Rhodopsin-like receptors),0.021432757302464238,1,0,1,0.023476902973211568
344,KNG1,G alpha (q) signalling events,0.023239989389076256,0,0,1,0.02545649952015641
345,KNG1,G alpha (q) signalling events,0.021432757302464238,1,0,1,0.023476902973211568
346,KNG1,G alpha (i) signalling events,0.023239989389076256,0,0,1,0.02545649952015641
347,KNG1,G alpha (i) signalling events,0.021432757302464238,1,0,1,0.023476902973211568
348,KNG1,Platelet degranulation ,0.023239989389076256,0,0,1,0.02545649952015641
349,KNG1,Platelet degranulation ,0.021432757302464238,1,0,1,0.023476902973211568
350,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.023239989389076256,0,0,1,0.02545649952015641
351,KNG1,Intrinsic Pathway of Fibrin Clot Formation,0.021432757302464238,1,0,1,0.023476902973211568
352,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.023239989389076256,0,0,1,0.02545649952015641
353,KNG1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.021432757302464238,1,0,1,0.023476902973211568
354,KNG1,Post-translational protein phosphorylation,0.023239989389076256,0,0,1,0.02545649952015641
355,KNG1,Post-translational protein phosphorylation,0.021432757302464238,1,0,1,0.023476902973211568
356,IGF2,IGF1R signaling cascade,0.004605272622338908,0,0,1,0.005044499734404555
357,IGF2,IGF1R signaling cascade,0.004788974910708727,1,0,1,0.00524572259804046
358,IGF2,Platelet degranulation ,0.004605272622338908,0,0,1,0.005044499734404555
359,IGF2,Platelet degranulation ,0.004788974910708727,1,0,1,0.00524572259804046
360,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004605272622338908,0,0,1,0.005044499734404555
361,IGF2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004788974910708727,1,0,1,0.00524572259804046
362,IGJ,Scavenging of heme from plasma,0.0011397888253373027,0,0,1,0.0012484959953947715
363,IGJ,Scavenging of heme from plasma,0.0012900251679091959,1,0,1,0.001413061104206272
364,KVD33,Initial triggering of complement,0.0006209377987098438,0,0,1,0.000680159638211109
365,KVD33,Initial triggering of complement,0.0007894945412338386,1,0,1,0.0008647924520796936
366,KVD33,Regulation of Complement cascade,0.0006209377987098438,0,0,1,0.000680159638211109
367,KVD33,Regulation of Complement cascade,0.0007894945412338386,1,0,1,0.0008647924520796936
368,KVD33,FCGR activation,0.0006209377987098438,0,0,1,0.000680159638211109
369,KVD33,FCGR activation,0.0007894945412338386,1,0,1,0.0008647924520796936
370,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.0006209377987098438,0,0,1,0.000680159638211109
371,KVD33,Regulation of actin dynamics for phagocytic cup formation,0.0007894945412338386,1,0,1,0.0008647924520796936
372,KVD33,Role of phospholipids in phagocytosis,0.0006209377987098438,0,0,1,0.000680159638211109
373,KVD33,Role of phospholipids in phagocytosis,0.0007894945412338386,1,0,1,0.0008647924520796936
374,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.0006209377987098438,0,0,1,0.000680159638211109
375,KVD33,Role of LAT2/NTAL/LAB on calcium mobilization,0.0007894945412338386,1,0,1,0.0008647924520796936
376,KVD33,FCERI mediated MAPK activation,0.0006209377987098438,0,0,1,0.000680159638211109
377,KVD33,FCERI mediated MAPK activation,0.0007894945412338386,1,0,1,0.0008647924520796936
378,KVD33,FCERI mediated Ca+2 mobilization,0.0006209377987098438,0,0,1,0.000680159638211109
379,KVD33,FCERI mediated Ca+2 mobilization,0.0007894945412338386,1,0,1,0.0008647924520796936
380,KVD33,FCERI mediated NF-kB activation,0.0006209377987098438,0,0,1,0.000680159638211109
381,KVD33,FCERI mediated NF-kB activation,0.0007894945412338386,1,0,1,0.0008647924520796936
382,KVD33,Parasite infection,0.0006209377987098438,0,0,1,0.000680159638211109
383,KVD33,Parasite infection,0.0007894945412338386,1,0,1,0.0008647924520796936
384,KVD33,Leishmania parasite growth and survival,0.0006209377987098438,0,0,1,0.000680159638211109
385,KVD33,Leishmania parasite growth and survival,0.0007894945412338386,1,0,1,0.0008647924520796936
386,KVD33,Potential therapeutics for SARS,0.0006209377987098438,0,0,1,0.000680159638211109
387,KVD33,Potential therapeutics for SARS,0.0007894945412338386,1,0,1,0.0008647924520796936
388,KVD33,CD22 mediated BCR regulation,0.0006209377987098438,0,0,1,0.000680159638211109
389,KVD33,CD22 mediated BCR regulation,0.0007894945412338386,1,0,1,0.0008647924520796936
390,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0006209377987098438,0,0,1,0.000680159638211109
391,KVD33,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0007894945412338386,1,0,1,0.0008647924520796936
392,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0006209377987098438,0,0,1,0.000680159638211109
393,KVD33,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007894945412338386,1,0,1,0.0008647924520796936
394,KVD33,Scavenging of heme from plasma,0.0006209377987098438,0,0,1,0.000680159638211109
395,KVD33,Scavenging of heme from plasma,0.0007894945412338386,1,0,1,0.0008647924520796936
396,KVD16,Initial triggering of complement,0.0033824427944470934,0,0,1,0.0037050427146181003
397,KVD16,Initial triggering of complement,0.0037146478000234075,1,0,1,0.004068931717468594
398,KVD16,Regulation of Complement cascade,0.0033824427944470934,0,0,1,0.0037050427146181003
399,KVD16,Regulation of Complement cascade,0.0037146478000234075,1,0,1,0.004068931717468594
400,KVD16,FCGR activation,0.0033824427944470934,0,0,1,0.0037050427146181003
401,KVD16,FCGR activation,0.0037146478000234075,1,0,1,0.004068931717468594
402,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.0033824427944470934,0,0,1,0.0037050427146181003
403,KVD16,Regulation of actin dynamics for phagocytic cup formation,0.0037146478000234075,1,0,1,0.004068931717468594
404,KVD16,Role of phospholipids in phagocytosis,0.0033824427944470934,0,0,1,0.0037050427146181003
405,KVD16,Role of phospholipids in phagocytosis,0.0037146478000234075,1,0,1,0.004068931717468594
406,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.0033824427944470934,0,0,1,0.0037050427146181003
407,KVD16,Role of LAT2/NTAL/LAB on calcium mobilization,0.0037146478000234075,1,0,1,0.004068931717468594
408,KVD16,FCERI mediated MAPK activation,0.0033824427944470934,0,0,1,0.0037050427146181003
409,KVD16,FCERI mediated MAPK activation,0.0037146478000234075,1,0,1,0.004068931717468594
410,KVD16,FCERI mediated Ca+2 mobilization,0.0033824427944470934,0,0,1,0.0037050427146181003
411,KVD16,FCERI mediated Ca+2 mobilization,0.0037146478000234075,1,0,1,0.004068931717468594
412,KVD16,FCERI mediated NF-kB activation,0.0033824427944470934,0,0,1,0.0037050427146181003
413,KVD16,FCERI mediated NF-kB activation,0.0037146478000234075,1,0,1,0.004068931717468594
414,KVD16,Parasite infection,0.0033824427944470934,0,0,1,0.0037050427146181003
415,KVD16,Parasite infection,0.0037146478000234075,1,0,1,0.004068931717468594
416,KVD16,Leishmania parasite growth and survival,0.0033824427944470934,0,0,1,0.0037050427146181003
417,KVD16,Leishmania parasite growth and survival,0.0037146478000234075,1,0,1,0.004068931717468594
418,KVD16,Potential therapeutics for SARS,0.0033824427944470934,0,0,1,0.0037050427146181003
419,KVD16,Potential therapeutics for SARS,0.0037146478000234075,1,0,1,0.004068931717468594
420,KVD16,CD22 mediated BCR regulation,0.0033824427944470934,0,0,1,0.0037050427146181003
421,KVD16,CD22 mediated BCR regulation,0.0037146478000234075,1,0,1,0.004068931717468594
422,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0033824427944470934,0,0,1,0.0037050427146181003
423,KVD16,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0037146478000234075,1,0,1,0.004068931717468594
424,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0033824427944470934,0,0,1,0.0037050427146181003
425,KVD16,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0037146478000234075,1,0,1,0.004068931717468594
426,KVD16,Scavenging of heme from plasma,0.0033824427944470934,0,0,1,0.0037050427146181003
427,KVD16,Scavenging of heme from plasma,0.0037146478000234075,1,0,1,0.004068931717468594
428,KV105,Initial triggering of complement,0.005193968057436977,0,0,1,0.005689341898925352
429,KV105,Initial triggering of complement,0.00561135140332443,1,0,1,0.006146533112157982
430,KV105,Regulation of Complement cascade,0.005193968057436977,0,0,1,0.005689341898925352
431,KV105,Regulation of Complement cascade,0.00561135140332443,1,0,1,0.006146533112157982
432,KV105,FCGR activation,0.005193968057436977,0,0,1,0.005689341898925352
433,KV105,FCGR activation,0.00561135140332443,1,0,1,0.006146533112157982
434,KV105,Regulation of actin dynamics for phagocytic cup formation,0.005193968057436977,0,0,1,0.005689341898925352
435,KV105,Regulation of actin dynamics for phagocytic cup formation,0.00561135140332443,1,0,1,0.006146533112157982
436,KV105,Role of phospholipids in phagocytosis,0.005193968057436977,0,0,1,0.005689341898925352
437,KV105,Role of phospholipids in phagocytosis,0.00561135140332443,1,0,1,0.006146533112157982
438,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.005193968057436977,0,0,1,0.005689341898925352
439,KV105,Role of LAT2/NTAL/LAB on calcium mobilization,0.00561135140332443,1,0,1,0.006146533112157982
440,KV105,FCERI mediated MAPK activation,0.005193968057436977,0,0,1,0.005689341898925352
441,KV105,FCERI mediated MAPK activation,0.00561135140332443,1,0,1,0.006146533112157982
442,KV105,FCERI mediated Ca+2 mobilization,0.005193968057436977,0,0,1,0.005689341898925352
443,KV105,FCERI mediated Ca+2 mobilization,0.00561135140332443,1,0,1,0.006146533112157982
444,KV105,FCERI mediated NF-kB activation,0.005193968057436977,0,0,1,0.005689341898925352
445,KV105,FCERI mediated NF-kB activation,0.00561135140332443,1,0,1,0.006146533112157982
446,KV105,Parasite infection,0.005193968057436977,0,0,1,0.005689341898925352
447,KV105,Parasite infection,0.00561135140332443,1,0,1,0.006146533112157982
448,KV105,Leishmania parasite growth and survival,0.005193968057436977,0,0,1,0.005689341898925352
449,KV105,Leishmania parasite growth and survival,0.00561135140332443,1,0,1,0.006146533112157982
450,KV105,Potential therapeutics for SARS,0.005193968057436977,0,0,1,0.005689341898925352
451,KV105,Potential therapeutics for SARS,0.00561135140332443,1,0,1,0.006146533112157982
452,KV105,CD22 mediated BCR regulation,0.005193968057436977,0,0,1,0.005689341898925352
453,KV105,CD22 mediated BCR regulation,0.00561135140332443,1,0,1,0.006146533112157982
454,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005193968057436977,0,0,1,0.005689341898925352
455,KV105,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00561135140332443,1,0,1,0.006146533112157982
456,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005193968057436977,0,0,1,0.005689341898925352
457,KV105,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00561135140332443,1,0,1,0.006146533112157982
458,KV105,Scavenging of heme from plasma,0.005193968057436977,0,0,1,0.005689341898925352
459,KV105,Scavenging of heme from plasma,0.00561135140332443,1,0,1,0.006146533112157982
460,KVD12,Initial triggering of complement,0.0020118038435815245,0,0,1,0.0022036793012846353
461,KVD12,Initial triggering of complement,0.002045832089242126,1,0,1,0.0022409529852277974
462,KVD12,Regulation of Complement cascade,0.0020118038435815245,0,0,1,0.0022036793012846353
463,KVD12,Regulation of Complement cascade,0.002045832089242126,1,0,1,0.0022409529852277974
464,KVD12,FCGR activation,0.0020118038435815245,0,0,1,0.0022036793012846353
465,KVD12,FCGR activation,0.002045832089242126,1,0,1,0.0022409529852277974
466,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.0020118038435815245,0,0,1,0.0022036793012846353
467,KVD12,Regulation of actin dynamics for phagocytic cup formation,0.002045832089242126,1,0,1,0.0022409529852277974
468,KVD12,Role of phospholipids in phagocytosis,0.0020118038435815245,0,0,1,0.0022036793012846353
469,KVD12,Role of phospholipids in phagocytosis,0.002045832089242126,1,0,1,0.0022409529852277974
470,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.0020118038435815245,0,0,1,0.0022036793012846353
471,KVD12,Role of LAT2/NTAL/LAB on calcium mobilization,0.002045832089242126,1,0,1,0.0022409529852277974
472,KVD12,FCERI mediated MAPK activation,0.0020118038435815245,0,0,1,0.0022036793012846353
473,KVD12,FCERI mediated MAPK activation,0.002045832089242126,1,0,1,0.0022409529852277974
474,KVD12,FCERI mediated Ca+2 mobilization,0.0020118038435815245,0,0,1,0.0022036793012846353
475,KVD12,FCERI mediated Ca+2 mobilization,0.002045832089242126,1,0,1,0.0022409529852277974
476,KVD12,FCERI mediated NF-kB activation,0.0020118038435815245,0,0,1,0.0022036793012846353
477,KVD12,FCERI mediated NF-kB activation,0.002045832089242126,1,0,1,0.0022409529852277974
478,KVD12,Parasite infection,0.0020118038435815245,0,0,1,0.0022036793012846353
479,KVD12,Parasite infection,0.002045832089242126,1,0,1,0.0022409529852277974
480,KVD12,Leishmania parasite growth and survival,0.0020118038435815245,0,0,1,0.0022036793012846353
481,KVD12,Leishmania parasite growth and survival,0.002045832089242126,1,0,1,0.0022409529852277974
482,KVD12,Potential therapeutics for SARS,0.0020118038435815245,0,0,1,0.0022036793012846353
483,KVD12,Potential therapeutics for SARS,0.002045832089242126,1,0,1,0.0022409529852277974
484,KVD12,CD22 mediated BCR regulation,0.0020118038435815245,0,0,1,0.0022036793012846353
485,KVD12,CD22 mediated BCR regulation,0.002045832089242126,1,0,1,0.0022409529852277974
486,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0020118038435815245,0,0,1,0.0022036793012846353
487,KVD12,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002045832089242126,1,0,1,0.0022409529852277974
488,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0020118038435815245,0,0,1,0.0022036793012846353
489,KVD12,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002045832089242126,1,0,1,0.0022409529852277974
490,KVD12,Scavenging of heme from plasma,0.0020118038435815245,0,0,1,0.0022036793012846353
491,KVD12,Scavenging of heme from plasma,0.002045832089242126,1,0,1,0.0022409529852277974
492,KVD40,Initial triggering of complement,0.00821627717186626,0,0,1,0.008999903243561641
493,KVD40,Initial triggering of complement,0.008985830786408086,1,0,1,0.009842852906375463
494,KVD40,Regulation of Complement cascade,0.00821627717186626,0,0,1,0.008999903243561641
495,KVD40,Regulation of Complement cascade,0.008985830786408086,1,0,1,0.009842852906375463
496,KVD40,FCGR activation,0.00821627717186626,0,0,1,0.008999903243561641
497,KVD40,FCGR activation,0.008985830786408086,1,0,1,0.009842852906375463
498,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.00821627717186626,0,0,1,0.008999903243561641
499,KVD40,Regulation of actin dynamics for phagocytic cup formation,0.008985830786408086,1,0,1,0.009842852906375463
500,KVD40,Role of phospholipids in phagocytosis,0.00821627717186626,0,0,1,0.008999903243561641
501,KVD40,Role of phospholipids in phagocytosis,0.008985830786408086,1,0,1,0.009842852906375463
502,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.00821627717186626,0,0,1,0.008999903243561641
503,KVD40,Role of LAT2/NTAL/LAB on calcium mobilization,0.008985830786408086,1,0,1,0.009842852906375463
504,KVD40,FCERI mediated MAPK activation,0.00821627717186626,0,0,1,0.008999903243561641
505,KVD40,FCERI mediated MAPK activation,0.008985830786408086,1,0,1,0.009842852906375463
506,KVD40,FCERI mediated Ca+2 mobilization,0.00821627717186626,0,0,1,0.008999903243561641
507,KVD40,FCERI mediated Ca+2 mobilization,0.008985830786408086,1,0,1,0.009842852906375463
508,KVD40,FCERI mediated NF-kB activation,0.00821627717186626,0,0,1,0.008999903243561641
509,KVD40,FCERI mediated NF-kB activation,0.008985830786408086,1,0,1,0.009842852906375463
510,KVD40,Parasite infection,0.00821627717186626,0,0,1,0.008999903243561641
511,KVD40,Parasite infection,0.008985830786408086,1,0,1,0.009842852906375463
512,KVD40,Leishmania parasite growth and survival,0.00821627717186626,0,0,1,0.008999903243561641
513,KVD40,Leishmania parasite growth and survival,0.008985830786408086,1,0,1,0.009842852906375463
514,KVD40,Potential therapeutics for SARS,0.00821627717186626,0,0,1,0.008999903243561641
515,KVD40,Potential therapeutics for SARS,0.008985830786408086,1,0,1,0.009842852906375463
516,KVD40,CD22 mediated BCR regulation,0.00821627717186626,0,0,1,0.008999903243561641
517,KVD40,CD22 mediated BCR regulation,0.008985830786408086,1,0,1,0.009842852906375463
518,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00821627717186626,0,0,1,0.008999903243561641
519,KVD40,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.008985830786408086,1,0,1,0.009842852906375463
520,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00821627717186626,0,0,1,0.008999903243561641
521,KVD40,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.008985830786408086,1,0,1,0.009842852906375463
522,KVD40,Scavenging of heme from plasma,0.00821627717186626,0,0,1,0.008999903243561641
523,KVD40,Scavenging of heme from plasma,0.008985830786408086,1,0,1,0.009842852906375463
524,KV320,Initial triggering of complement,0.005982638582549422,0,0,1,0.0065532317444828275
525,KV320,Initial triggering of complement,0.006924803603941641,1,0,1,0.007585255598428851
526,KV320,Regulation of Complement cascade,0.005982638582549422,0,0,1,0.0065532317444828275
527,KV320,Regulation of Complement cascade,0.006924803603941641,1,0,1,0.007585255598428851
528,KV320,FCGR activation,0.005982638582549422,0,0,1,0.0065532317444828275
529,KV320,FCGR activation,0.006924803603941641,1,0,1,0.007585255598428851
530,KV320,Regulation of actin dynamics for phagocytic cup formation,0.005982638582549422,0,0,1,0.0065532317444828275
531,KV320,Regulation of actin dynamics for phagocytic cup formation,0.006924803603941641,1,0,1,0.007585255598428851
532,KV320,Role of phospholipids in phagocytosis,0.005982638582549422,0,0,1,0.0065532317444828275
533,KV320,Role of phospholipids in phagocytosis,0.006924803603941641,1,0,1,0.007585255598428851
534,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.005982638582549422,0,0,1,0.0065532317444828275
535,KV320,Role of LAT2/NTAL/LAB on calcium mobilization,0.006924803603941641,1,0,1,0.007585255598428851
536,KV320,FCERI mediated MAPK activation,0.005982638582549422,0,0,1,0.0065532317444828275
537,KV320,FCERI mediated MAPK activation,0.006924803603941641,1,0,1,0.007585255598428851
538,KV320,FCERI mediated Ca+2 mobilization,0.005982638582549422,0,0,1,0.0065532317444828275
539,KV320,FCERI mediated Ca+2 mobilization,0.006924803603941641,1,0,1,0.007585255598428851
540,KV320,FCERI mediated NF-kB activation,0.005982638582549422,0,0,1,0.0065532317444828275
541,KV320,FCERI mediated NF-kB activation,0.006924803603941641,1,0,1,0.007585255598428851
542,KV320,Parasite infection,0.005982638582549422,0,0,1,0.0065532317444828275
543,KV320,Parasite infection,0.006924803603941641,1,0,1,0.007585255598428851
544,KV320,Leishmania parasite growth and survival,0.005982638582549422,0,0,1,0.0065532317444828275
545,KV320,Leishmania parasite growth and survival,0.006924803603941641,1,0,1,0.007585255598428851
546,KV320,Potential therapeutics for SARS,0.005982638582549422,0,0,1,0.0065532317444828275
547,KV320,Potential therapeutics for SARS,0.006924803603941641,1,0,1,0.007585255598428851
548,KV320,CD22 mediated BCR regulation,0.005982638582549422,0,0,1,0.0065532317444828275
549,KV320,CD22 mediated BCR regulation,0.006924803603941641,1,0,1,0.007585255598428851
550,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005982638582549422,0,0,1,0.0065532317444828275
551,KV320,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006924803603941641,1,0,1,0.007585255598428851
552,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005982638582549422,0,0,1,0.0065532317444828275
553,KV320,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006924803603941641,1,0,1,0.007585255598428851
554,KV320,Scavenging of heme from plasma,0.005982638582549422,0,0,1,0.0065532317444828275
555,KV320,Scavenging of heme from plasma,0.006924803603941641,1,0,1,0.007585255598428851
556,LV147,Initial triggering of complement,0.0061577880922894035,0,0,1,0.006745086109646489
557,LV147,Initial triggering of complement,0.006997767830130746,1,0,1,0.007665178775581616
558,LV147,Regulation of Complement cascade,0.0061577880922894035,0,0,1,0.006745086109646489
559,LV147,Regulation of Complement cascade,0.006997767830130746,1,0,1,0.007665178775581616
560,LV147,FCGR activation,0.0061577880922894035,0,0,1,0.006745086109646489
561,LV147,FCGR activation,0.006997767830130746,1,0,1,0.007665178775581616
562,LV147,Regulation of actin dynamics for phagocytic cup formation,0.0061577880922894035,0,0,1,0.006745086109646489
563,LV147,Regulation of actin dynamics for phagocytic cup formation,0.006997767830130746,1,0,1,0.007665178775581616
564,LV147,Role of phospholipids in phagocytosis,0.0061577880922894035,0,0,1,0.006745086109646489
565,LV147,Role of phospholipids in phagocytosis,0.006997767830130746,1,0,1,0.007665178775581616
566,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.0061577880922894035,0,0,1,0.006745086109646489
567,LV147,Role of LAT2/NTAL/LAB on calcium mobilization,0.006997767830130746,1,0,1,0.007665178775581616
568,LV147,FCERI mediated MAPK activation,0.0061577880922894035,0,0,1,0.006745086109646489
569,LV147,FCERI mediated MAPK activation,0.006997767830130746,1,0,1,0.007665178775581616
570,LV147,FCERI mediated Ca+2 mobilization,0.0061577880922894035,0,0,1,0.006745086109646489
571,LV147,FCERI mediated Ca+2 mobilization,0.006997767830130746,1,0,1,0.007665178775581616
572,LV147,FCERI mediated NF-kB activation,0.0061577880922894035,0,0,1,0.006745086109646489
573,LV147,FCERI mediated NF-kB activation,0.006997767830130746,1,0,1,0.007665178775581616
574,LV147,Parasite infection,0.0061577880922894035,0,0,1,0.006745086109646489
575,LV147,Parasite infection,0.006997767830130746,1,0,1,0.007665178775581616
576,LV147,Leishmania parasite growth and survival,0.0061577880922894035,0,0,1,0.006745086109646489
577,LV147,Leishmania parasite growth and survival,0.006997767830130746,1,0,1,0.007665178775581616
578,LV147,Potential therapeutics for SARS,0.0061577880922894035,0,0,1,0.006745086109646489
579,LV147,Potential therapeutics for SARS,0.006997767830130746,1,0,1,0.007665178775581616
580,LV147,CD22 mediated BCR regulation,0.0061577880922894035,0,0,1,0.006745086109646489
581,LV147,CD22 mediated BCR regulation,0.006997767830130746,1,0,1,0.007665178775581616
582,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0061577880922894035,0,0,1,0.006745086109646489
583,LV147,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006997767830130746,1,0,1,0.007665178775581616
584,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0061577880922894035,0,0,1,0.006745086109646489
585,LV147,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006997767830130746,1,0,1,0.007665178775581616
586,LV147,Scavenging of heme from plasma,0.0061577880922894035,0,0,1,0.006745086109646489
587,LV147,Scavenging of heme from plasma,0.006997767830130746,1,0,1,0.007665178775581616
588,LV319,Initial triggering of complement,0.005513021230939474,0,0,1,0.0060388247159006625
589,LV319,Initial triggering of complement,0.005935278584563329,1,0,1,0.006501354794548665
590,LV319,Regulation of Complement cascade,0.005513021230939474,0,0,1,0.0060388247159006625
591,LV319,Regulation of Complement cascade,0.005935278584563329,1,0,1,0.006501354794548665
592,LV319,FCGR activation,0.005513021230939474,0,0,1,0.0060388247159006625
593,LV319,FCGR activation,0.005935278584563329,1,0,1,0.006501354794548665
594,LV319,Regulation of actin dynamics for phagocytic cup formation,0.005513021230939474,0,0,1,0.0060388247159006625
595,LV319,Regulation of actin dynamics for phagocytic cup formation,0.005935278584563329,1,0,1,0.006501354794548665
596,LV319,Role of phospholipids in phagocytosis,0.005513021230939474,0,0,1,0.0060388247159006625
597,LV319,Role of phospholipids in phagocytosis,0.005935278584563329,1,0,1,0.006501354794548665
598,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.005513021230939474,0,0,1,0.0060388247159006625
599,LV319,Role of LAT2/NTAL/LAB on calcium mobilization,0.005935278584563329,1,0,1,0.006501354794548665
600,LV319,FCERI mediated MAPK activation,0.005513021230939474,0,0,1,0.0060388247159006625
601,LV319,FCERI mediated MAPK activation,0.005935278584563329,1,0,1,0.006501354794548665
602,LV319,FCERI mediated Ca+2 mobilization,0.005513021230939474,0,0,1,0.0060388247159006625
603,LV319,FCERI mediated Ca+2 mobilization,0.005935278584563329,1,0,1,0.006501354794548665
604,LV319,FCERI mediated NF-kB activation,0.005513021230939474,0,0,1,0.0060388247159006625
605,LV319,FCERI mediated NF-kB activation,0.005935278584563329,1,0,1,0.006501354794548665
606,LV319,Parasite infection,0.005513021230939474,0,0,1,0.0060388247159006625
607,LV319,Parasite infection,0.005935278584563329,1,0,1,0.006501354794548665
608,LV319,Leishmania parasite growth and survival,0.005513021230939474,0,0,1,0.0060388247159006625
609,LV319,Leishmania parasite growth and survival,0.005935278584563329,1,0,1,0.006501354794548665
610,LV319,Potential therapeutics for SARS,0.005513021230939474,0,0,1,0.0060388247159006625
611,LV319,Potential therapeutics for SARS,0.005935278584563329,1,0,1,0.006501354794548665
612,LV319,CD22 mediated BCR regulation,0.005513021230939474,0,0,1,0.0060388247159006625
613,LV319,CD22 mediated BCR regulation,0.005935278584563329,1,0,1,0.006501354794548665
614,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005513021230939474,0,0,1,0.0060388247159006625
615,LV319,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005935278584563329,1,0,1,0.006501354794548665
616,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005513021230939474,0,0,1,0.0060388247159006625
617,LV319,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005935278584563329,1,0,1,0.006501354794548665
618,LV319,Scavenging of heme from plasma,0.005513021230939474,0,0,1,0.0060388247159006625
619,LV319,Scavenging of heme from plasma,0.005935278584563329,1,0,1,0.006501354794548665
620,LV325,Initial triggering of complement,0.005469370445573843,0,0,1,0.005991010744125057
621,LV325,Initial triggering of complement,0.006014508610246478,1,0,1,0.006588141370782349
622,LV325,Regulation of Complement cascade,0.005469370445573843,0,0,1,0.005991010744125057
623,LV325,Regulation of Complement cascade,0.006014508610246478,1,0,1,0.006588141370782349
624,LV325,FCGR activation,0.005469370445573843,0,0,1,0.005991010744125057
625,LV325,FCGR activation,0.006014508610246478,1,0,1,0.006588141370782349
626,LV325,Regulation of actin dynamics for phagocytic cup formation,0.005469370445573843,0,0,1,0.005991010744125057
627,LV325,Regulation of actin dynamics for phagocytic cup formation,0.006014508610246478,1,0,1,0.006588141370782349
628,LV325,Role of phospholipids in phagocytosis,0.005469370445573843,0,0,1,0.005991010744125057
629,LV325,Role of phospholipids in phagocytosis,0.006014508610246478,1,0,1,0.006588141370782349
630,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.005469370445573843,0,0,1,0.005991010744125057
631,LV325,Role of LAT2/NTAL/LAB on calcium mobilization,0.006014508610246478,1,0,1,0.006588141370782349
632,LV325,FCERI mediated MAPK activation,0.005469370445573843,0,0,1,0.005991010744125057
633,LV325,FCERI mediated MAPK activation,0.006014508610246478,1,0,1,0.006588141370782349
634,LV325,FCERI mediated Ca+2 mobilization,0.005469370445573843,0,0,1,0.005991010744125057
635,LV325,FCERI mediated Ca+2 mobilization,0.006014508610246478,1,0,1,0.006588141370782349
636,LV325,FCERI mediated NF-kB activation,0.005469370445573843,0,0,1,0.005991010744125057
637,LV325,FCERI mediated NF-kB activation,0.006014508610246478,1,0,1,0.006588141370782349
638,LV325,Parasite infection,0.005469370445573843,0,0,1,0.005991010744125057
639,LV325,Parasite infection,0.006014508610246478,1,0,1,0.006588141370782349
640,LV325,Leishmania parasite growth and survival,0.005469370445573843,0,0,1,0.005991010744125057
641,LV325,Leishmania parasite growth and survival,0.006014508610246478,1,0,1,0.006588141370782349
642,LV325,Potential therapeutics for SARS,0.005469370445573843,0,0,1,0.005991010744125057
643,LV325,Potential therapeutics for SARS,0.006014508610246478,1,0,1,0.006588141370782349
644,LV325,CD22 mediated BCR regulation,0.005469370445573843,0,0,1,0.005991010744125057
645,LV325,CD22 mediated BCR regulation,0.006014508610246478,1,0,1,0.006588141370782349
646,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005469370445573843,0,0,1,0.005991010744125057
647,LV325,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006014508610246478,1,0,1,0.006588141370782349
648,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005469370445573843,0,0,1,0.005991010744125057
649,LV325,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006014508610246478,1,0,1,0.006588141370782349
650,LV325,Scavenging of heme from plasma,0.005469370445573843,0,0,1,0.005991010744125057
651,LV325,Scavenging of heme from plasma,0.006014508610246478,1,0,1,0.006588141370782349
652,HV169,Initial triggering of complement,0.004719479906003092,0,0,1,0.0051695995187943985
653,HV169,Initial triggering of complement,0.005021719306112084,1,0,1,0.005500664951529208
654,HV169,Regulation of Complement cascade,0.004719479906003092,0,0,1,0.0051695995187943985
655,HV169,Regulation of Complement cascade,0.005021719306112084,1,0,1,0.005500664951529208
656,HV169,FCGR activation,0.004719479906003092,0,0,1,0.0051695995187943985
657,HV169,FCGR activation,0.005021719306112084,1,0,1,0.005500664951529208
658,HV169,Regulation of actin dynamics for phagocytic cup formation,0.004719479906003092,0,0,1,0.0051695995187943985
659,HV169,Regulation of actin dynamics for phagocytic cup formation,0.005021719306112084,1,0,1,0.005500664951529208
660,HV169,Role of phospholipids in phagocytosis,0.004719479906003092,0,0,1,0.0051695995187943985
661,HV169,Role of phospholipids in phagocytosis,0.005021719306112084,1,0,1,0.005500664951529208
662,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.004719479906003092,0,0,1,0.0051695995187943985
663,HV169,Role of LAT2/NTAL/LAB on calcium mobilization,0.005021719306112084,1,0,1,0.005500664951529208
664,HV169,FCERI mediated MAPK activation,0.004719479906003092,0,0,1,0.0051695995187943985
665,HV169,FCERI mediated MAPK activation,0.005021719306112084,1,0,1,0.005500664951529208
666,HV169,FCERI mediated Ca+2 mobilization,0.004719479906003092,0,0,1,0.0051695995187943985
667,HV169,FCERI mediated Ca+2 mobilization,0.005021719306112084,1,0,1,0.005500664951529208
668,HV169,FCERI mediated NF-kB activation,0.004719479906003092,0,0,1,0.0051695995187943985
669,HV169,FCERI mediated NF-kB activation,0.005021719306112084,1,0,1,0.005500664951529208
670,HV169,Parasite infection,0.004719479906003092,0,0,1,0.0051695995187943985
671,HV169,Parasite infection,0.005021719306112084,1,0,1,0.005500664951529208
672,HV169,Leishmania parasite growth and survival,0.004719479906003092,0,0,1,0.0051695995187943985
673,HV169,Leishmania parasite growth and survival,0.005021719306112084,1,0,1,0.005500664951529208
674,HV169,Potential therapeutics for SARS,0.004719479906003092,0,0,1,0.0051695995187943985
675,HV169,Potential therapeutics for SARS,0.005021719306112084,1,0,1,0.005500664951529208
676,HV169,CD22 mediated BCR regulation,0.004719479906003092,0,0,1,0.0051695995187943985
677,HV169,CD22 mediated BCR regulation,0.005021719306112084,1,0,1,0.005500664951529208
678,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004719479906003092,0,0,1,0.0051695995187943985
679,HV169,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005021719306112084,1,0,1,0.005500664951529208
680,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004719479906003092,0,0,1,0.0051695995187943985
681,HV169,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005021719306112084,1,0,1,0.005500664951529208
682,HV169,Scavenging of heme from plasma,0.004719479906003092,0,0,1,0.0051695995187943985
683,HV169,Scavenging of heme from plasma,0.005021719306112084,1,0,1,0.005500664951529208
684,HV146,Initial triggering of complement,0.0037281351191646756,0,0,1,0.004083705387434608
685,HV146,Initial triggering of complement,0.004003404925085679,1,0,1,0.004385229005411617
686,HV146,Regulation of Complement cascade,0.0037281351191646756,0,0,1,0.004083705387434608
687,HV146,Regulation of Complement cascade,0.004003404925085679,1,0,1,0.004385229005411617
688,HV146,FCGR activation,0.0037281351191646756,0,0,1,0.004083705387434608
689,HV146,FCGR activation,0.004003404925085679,1,0,1,0.004385229005411617
690,HV146,Regulation of actin dynamics for phagocytic cup formation,0.0037281351191646756,0,0,1,0.004083705387434608
691,HV146,Regulation of actin dynamics for phagocytic cup formation,0.004003404925085679,1,0,1,0.004385229005411617
692,HV146,Role of phospholipids in phagocytosis,0.0037281351191646756,0,0,1,0.004083705387434608
693,HV146,Role of phospholipids in phagocytosis,0.004003404925085679,1,0,1,0.004385229005411617
694,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.0037281351191646756,0,0,1,0.004083705387434608
695,HV146,Role of LAT2/NTAL/LAB on calcium mobilization,0.004003404925085679,1,0,1,0.004385229005411617
696,HV146,FCERI mediated MAPK activation,0.0037281351191646756,0,0,1,0.004083705387434608
697,HV146,FCERI mediated MAPK activation,0.004003404925085679,1,0,1,0.004385229005411617
698,HV146,FCERI mediated Ca+2 mobilization,0.0037281351191646756,0,0,1,0.004083705387434608
699,HV146,FCERI mediated Ca+2 mobilization,0.004003404925085679,1,0,1,0.004385229005411617
700,HV146,FCERI mediated NF-kB activation,0.0037281351191646756,0,0,1,0.004083705387434608
701,HV146,FCERI mediated NF-kB activation,0.004003404925085679,1,0,1,0.004385229005411617
702,HV146,Parasite infection,0.0037281351191646756,0,0,1,0.004083705387434608
703,HV146,Parasite infection,0.004003404925085679,1,0,1,0.004385229005411617
704,HV146,Leishmania parasite growth and survival,0.0037281351191646756,0,0,1,0.004083705387434608
705,HV146,Leishmania parasite growth and survival,0.004003404925085679,1,0,1,0.004385229005411617
706,HV146,Potential therapeutics for SARS,0.0037281351191646756,0,0,1,0.004083705387434608
707,HV146,Potential therapeutics for SARS,0.004003404925085679,1,0,1,0.004385229005411617
708,HV146,CD22 mediated BCR regulation,0.0037281351191646756,0,0,1,0.004083705387434608
709,HV146,CD22 mediated BCR regulation,0.004003404925085679,1,0,1,0.004385229005411617
710,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0037281351191646756,0,0,1,0.004083705387434608
711,HV146,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004003404925085679,1,0,1,0.004385229005411617
712,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0037281351191646756,0,0,1,0.004083705387434608
713,HV146,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004003404925085679,1,0,1,0.004385229005411617
714,HV146,Scavenging of heme from plasma,0.0037281351191646756,0,0,1,0.004083705387434608
715,HV146,Scavenging of heme from plasma,0.004003404925085679,1,0,1,0.004385229005411617
716,HV348,Initial triggering of complement,0.004423732456732719,0,0,1,0.004845645205632038
717,HV348,Initial triggering of complement,0.004641445533531721,1,0,1,0.005084122630999136
718,HV348,Regulation of Complement cascade,0.004423732456732719,0,0,1,0.004845645205632038
719,HV348,Regulation of Complement cascade,0.004641445533531721,1,0,1,0.005084122630999136
720,HV348,FCGR activation,0.004423732456732719,0,0,1,0.004845645205632038
721,HV348,FCGR activation,0.004641445533531721,1,0,1,0.005084122630999136
722,HV348,Regulation of actin dynamics for phagocytic cup formation,0.004423732456732719,0,0,1,0.004845645205632038
723,HV348,Regulation of actin dynamics for phagocytic cup formation,0.004641445533531721,1,0,1,0.005084122630999136
724,HV348,Role of phospholipids in phagocytosis,0.004423732456732719,0,0,1,0.004845645205632038
725,HV348,Role of phospholipids in phagocytosis,0.004641445533531721,1,0,1,0.005084122630999136
726,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.004423732456732719,0,0,1,0.004845645205632038
727,HV348,Role of LAT2/NTAL/LAB on calcium mobilization,0.004641445533531721,1,0,1,0.005084122630999136
728,HV348,FCERI mediated MAPK activation,0.004423732456732719,0,0,1,0.004845645205632038
729,HV348,FCERI mediated MAPK activation,0.004641445533531721,1,0,1,0.005084122630999136
730,HV348,FCERI mediated Ca+2 mobilization,0.004423732456732719,0,0,1,0.004845645205632038
731,HV348,FCERI mediated Ca+2 mobilization,0.004641445533531721,1,0,1,0.005084122630999136
732,HV348,FCERI mediated NF-kB activation,0.004423732456732719,0,0,1,0.004845645205632038
733,HV348,FCERI mediated NF-kB activation,0.004641445533531721,1,0,1,0.005084122630999136
734,HV348,Parasite infection,0.004423732456732719,0,0,1,0.004845645205632038
735,HV348,Parasite infection,0.004641445533531721,1,0,1,0.005084122630999136
736,HV348,Leishmania parasite growth and survival,0.004423732456732719,0,0,1,0.004845645205632038
737,HV348,Leishmania parasite growth and survival,0.004641445533531721,1,0,1,0.005084122630999136
738,HV348,Potential therapeutics for SARS,0.004423732456732719,0,0,1,0.004845645205632038
739,HV348,Potential therapeutics for SARS,0.004641445533531721,1,0,1,0.005084122630999136
740,HV348,CD22 mediated BCR regulation,0.004423732456732719,0,0,1,0.004845645205632038
741,HV348,CD22 mediated BCR regulation,0.004641445533531721,1,0,1,0.005084122630999136
742,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004423732456732719,0,0,1,0.004845645205632038
743,HV348,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004641445533531721,1,0,1,0.005084122630999136
744,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004423732456732719,0,0,1,0.004845645205632038
745,HV348,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004641445533531721,1,0,1,0.005084122630999136
746,HV348,Scavenging of heme from plasma,0.004423732456732719,0,0,1,0.004845645205632038
747,HV348,Scavenging of heme from plasma,0.004641445533531721,1,0,1,0.005084122630999136
748,HV323,Initial triggering of complement,0.01363077756448271,0,0,1,0.014930810712534714
749,HV323,Initial triggering of complement,0.014896057285487738,1,0,1,0.01631676627694508
750,HV323,Regulation of Complement cascade,0.01363077756448271,0,0,1,0.014930810712534714
751,HV323,Regulation of Complement cascade,0.014896057285487738,1,0,1,0.01631676627694508
752,HV323,FCGR activation,0.01363077756448271,0,0,1,0.014930810712534714
753,HV323,FCGR activation,0.014896057285487738,1,0,1,0.01631676627694508
754,HV323,Regulation of actin dynamics for phagocytic cup formation,0.01363077756448271,0,0,1,0.014930810712534714
755,HV323,Regulation of actin dynamics for phagocytic cup formation,0.014896057285487738,1,0,1,0.01631676627694508
756,HV323,Role of phospholipids in phagocytosis,0.01363077756448271,0,0,1,0.014930810712534714
757,HV323,Role of phospholipids in phagocytosis,0.014896057285487738,1,0,1,0.01631676627694508
758,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.01363077756448271,0,0,1,0.014930810712534714
759,HV323,Role of LAT2/NTAL/LAB on calcium mobilization,0.014896057285487738,1,0,1,0.01631676627694508
760,HV323,FCERI mediated MAPK activation,0.01363077756448271,0,0,1,0.014930810712534714
761,HV323,FCERI mediated MAPK activation,0.014896057285487738,1,0,1,0.01631676627694508
762,HV323,FCERI mediated Ca+2 mobilization,0.01363077756448271,0,0,1,0.014930810712534714
763,HV323,FCERI mediated Ca+2 mobilization,0.014896057285487738,1,0,1,0.01631676627694508
764,HV323,FCERI mediated NF-kB activation,0.01363077756448271,0,0,1,0.014930810712534714
765,HV323,FCERI mediated NF-kB activation,0.014896057285487738,1,0,1,0.01631676627694508
766,HV323,Parasite infection,0.01363077756448271,0,0,1,0.014930810712534714
767,HV323,Parasite infection,0.014896057285487738,1,0,1,0.01631676627694508
768,HV323,Leishmania parasite growth and survival,0.01363077756448271,0,0,1,0.014930810712534714
769,HV323,Leishmania parasite growth and survival,0.014896057285487738,1,0,1,0.01631676627694508
770,HV323,Potential therapeutics for SARS,0.01363077756448271,0,0,1,0.014930810712534714
771,HV323,Potential therapeutics for SARS,0.014896057285487738,1,0,1,0.01631676627694508
772,HV323,CD22 mediated BCR regulation,0.01363077756448271,0,0,1,0.014930810712534714
773,HV323,CD22 mediated BCR regulation,0.014896057285487738,1,0,1,0.01631676627694508
774,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01363077756448271,0,0,1,0.014930810712534714
775,HV323,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.014896057285487738,1,0,1,0.01631676627694508
776,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01363077756448271,0,0,1,0.014930810712534714
777,HV323,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.014896057285487738,1,0,1,0.01631676627694508
778,HV323,Scavenging of heme from plasma,0.01363077756448271,0,0,1,0.014930810712534714
779,HV323,Scavenging of heme from plasma,0.014896057285487738,1,0,1,0.01631676627694508
780,HV313,Initial triggering of complement,0.0023212939526376136,0,0,1,0.002542686978129046
781,HV313,Initial triggering of complement,0.0023736302094285807,1,0,1,0.0026000147967257382
782,HV313,Regulation of Complement cascade,0.0023212939526376136,0,0,1,0.002542686978129046
783,HV313,Regulation of Complement cascade,0.0023736302094285807,1,0,1,0.0026000147967257382
784,HV313,FCGR activation,0.0023212939526376136,0,0,1,0.002542686978129046
785,HV313,FCGR activation,0.0023736302094285807,1,0,1,0.0026000147967257382
786,HV313,Regulation of actin dynamics for phagocytic cup formation,0.0023212939526376136,0,0,1,0.002542686978129046
787,HV313,Regulation of actin dynamics for phagocytic cup formation,0.0023736302094285807,1,0,1,0.0026000147967257382
788,HV313,Role of phospholipids in phagocytosis,0.0023212939526376136,0,0,1,0.002542686978129046
789,HV313,Role of phospholipids in phagocytosis,0.0023736302094285807,1,0,1,0.0026000147967257382
790,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.0023212939526376136,0,0,1,0.002542686978129046
791,HV313,Role of LAT2/NTAL/LAB on calcium mobilization,0.0023736302094285807,1,0,1,0.0026000147967257382
792,HV313,FCERI mediated MAPK activation,0.0023212939526376136,0,0,1,0.002542686978129046
793,HV313,FCERI mediated MAPK activation,0.0023736302094285807,1,0,1,0.0026000147967257382
794,HV313,FCERI mediated Ca+2 mobilization,0.0023212939526376136,0,0,1,0.002542686978129046
795,HV313,FCERI mediated Ca+2 mobilization,0.0023736302094285807,1,0,1,0.0026000147967257382
796,HV313,FCERI mediated NF-kB activation,0.0023212939526376136,0,0,1,0.002542686978129046
797,HV313,FCERI mediated NF-kB activation,0.0023736302094285807,1,0,1,0.0026000147967257382
798,HV313,Parasite infection,0.0023212939526376136,0,0,1,0.002542686978129046
799,HV313,Parasite infection,0.0023736302094285807,1,0,1,0.0026000147967257382
800,HV313,Leishmania parasite growth and survival,0.0023212939526376136,0,0,1,0.002542686978129046
801,HV313,Leishmania parasite growth and survival,0.0023736302094285807,1,0,1,0.0026000147967257382
802,HV313,Potential therapeutics for SARS,0.0023212939526376136,0,0,1,0.002542686978129046
803,HV313,Potential therapeutics for SARS,0.0023736302094285807,1,0,1,0.0026000147967257382
804,HV313,CD22 mediated BCR regulation,0.0023212939526376136,0,0,1,0.002542686978129046
805,HV313,CD22 mediated BCR regulation,0.0023736302094285807,1,0,1,0.0026000147967257382
806,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0023212939526376136,0,0,1,0.002542686978129046
807,HV313,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0023736302094285807,1,0,1,0.0026000147967257382
808,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0023212939526376136,0,0,1,0.002542686978129046
809,HV313,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0023736302094285807,1,0,1,0.0026000147967257382
810,HV313,Scavenging of heme from plasma,0.0023212939526376136,0,0,1,0.002542686978129046
811,HV313,Scavenging of heme from plasma,0.0023736302094285807,1,0,1,0.0026000147967257382
812,HV353,Initial triggering of complement,0.012425896636007098,0,0,1,0.013611014465467489
813,HV353,Initial triggering of complement,0.013533103299861404,1,0,1,0.014823820781135151
814,HV353,Regulation of Complement cascade,0.012425896636007098,0,0,1,0.013611014465467489
815,HV353,Regulation of Complement cascade,0.013533103299861404,1,0,1,0.014823820781135151
816,HV353,FCGR activation,0.012425896636007098,0,0,1,0.013611014465467489
817,HV353,FCGR activation,0.013533103299861404,1,0,1,0.014823820781135151
818,HV353,Regulation of actin dynamics for phagocytic cup formation,0.012425896636007098,0,0,1,0.013611014465467489
819,HV353,Regulation of actin dynamics for phagocytic cup formation,0.013533103299861404,1,0,1,0.014823820781135151
820,HV353,Role of phospholipids in phagocytosis,0.012425896636007098,0,0,1,0.013611014465467489
821,HV353,Role of phospholipids in phagocytosis,0.013533103299861404,1,0,1,0.014823820781135151
822,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.012425896636007098,0,0,1,0.013611014465467489
823,HV353,Role of LAT2/NTAL/LAB on calcium mobilization,0.013533103299861404,1,0,1,0.014823820781135151
824,HV353,FCERI mediated MAPK activation,0.012425896636007098,0,0,1,0.013611014465467489
825,HV353,FCERI mediated MAPK activation,0.013533103299861404,1,0,1,0.014823820781135151
826,HV353,FCERI mediated Ca+2 mobilization,0.012425896636007098,0,0,1,0.013611014465467489
827,HV353,FCERI mediated Ca+2 mobilization,0.013533103299861404,1,0,1,0.014823820781135151
828,HV353,FCERI mediated NF-kB activation,0.012425896636007098,0,0,1,0.013611014465467489
829,HV353,FCERI mediated NF-kB activation,0.013533103299861404,1,0,1,0.014823820781135151
830,HV353,Parasite infection,0.012425896636007098,0,0,1,0.013611014465467489
831,HV353,Parasite infection,0.013533103299861404,1,0,1,0.014823820781135151
832,HV353,Leishmania parasite growth and survival,0.012425896636007098,0,0,1,0.013611014465467489
833,HV353,Leishmania parasite growth and survival,0.013533103299861404,1,0,1,0.014823820781135151
834,HV353,Potential therapeutics for SARS,0.012425896636007098,0,0,1,0.013611014465467489
835,HV353,Potential therapeutics for SARS,0.013533103299861404,1,0,1,0.014823820781135151
836,HV353,CD22 mediated BCR regulation,0.012425896636007098,0,0,1,0.013611014465467489
837,HV353,CD22 mediated BCR regulation,0.013533103299861404,1,0,1,0.014823820781135151
838,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.012425896636007098,0,0,1,0.013611014465467489
839,HV353,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.013533103299861404,1,0,1,0.014823820781135151
840,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.012425896636007098,0,0,1,0.013611014465467489
841,HV353,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.013533103299861404,1,0,1,0.014823820781135151
842,HV353,Scavenging of heme from plasma,0.012425896636007098,0,0,1,0.013611014465467489
843,HV353,Scavenging of heme from plasma,0.013533103299861404,1,0,1,0.014823820781135151
844,HV307,Initial triggering of complement,0.006051960236955491,0,0,1,0.006629164940173271
845,HV307,Initial triggering of complement,0.006410483019142814,1,0,1,0.007021881773211355
846,HV307,Regulation of Complement cascade,0.006051960236955491,0,0,1,0.006629164940173271
847,HV307,Regulation of Complement cascade,0.006410483019142814,1,0,1,0.007021881773211355
848,HV307,FCGR activation,0.006051960236955491,0,0,1,0.006629164940173271
849,HV307,FCGR activation,0.006410483019142814,1,0,1,0.007021881773211355
850,HV307,Regulation of actin dynamics for phagocytic cup formation,0.006051960236955491,0,0,1,0.006629164940173271
851,HV307,Regulation of actin dynamics for phagocytic cup formation,0.006410483019142814,1,0,1,0.007021881773211355
852,HV307,Role of phospholipids in phagocytosis,0.006051960236955491,0,0,1,0.006629164940173271
853,HV307,Role of phospholipids in phagocytosis,0.006410483019142814,1,0,1,0.007021881773211355
854,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.006051960236955491,0,0,1,0.006629164940173271
855,HV307,Role of LAT2/NTAL/LAB on calcium mobilization,0.006410483019142814,1,0,1,0.007021881773211355
856,HV307,FCERI mediated MAPK activation,0.006051960236955491,0,0,1,0.006629164940173271
857,HV307,FCERI mediated MAPK activation,0.006410483019142814,1,0,1,0.007021881773211355
858,HV307,FCERI mediated Ca+2 mobilization,0.006051960236955491,0,0,1,0.006629164940173271
859,HV307,FCERI mediated Ca+2 mobilization,0.006410483019142814,1,0,1,0.007021881773211355
860,HV307,FCERI mediated NF-kB activation,0.006051960236955491,0,0,1,0.006629164940173271
861,HV307,FCERI mediated NF-kB activation,0.006410483019142814,1,0,1,0.007021881773211355
862,HV307,Parasite infection,0.006051960236955491,0,0,1,0.006629164940173271
863,HV307,Parasite infection,0.006410483019142814,1,0,1,0.007021881773211355
864,HV307,Leishmania parasite growth and survival,0.006051960236955491,0,0,1,0.006629164940173271
865,HV307,Leishmania parasite growth and survival,0.006410483019142814,1,0,1,0.007021881773211355
866,HV307,Potential therapeutics for SARS,0.006051960236955491,0,0,1,0.006629164940173271
867,HV307,Potential therapeutics for SARS,0.006410483019142814,1,0,1,0.007021881773211355
868,HV307,CD22 mediated BCR regulation,0.006051960236955491,0,0,1,0.006629164940173271
869,HV307,CD22 mediated BCR regulation,0.006410483019142814,1,0,1,0.007021881773211355
870,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006051960236955491,0,0,1,0.006629164940173271
871,HV307,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006410483019142814,1,0,1,0.007021881773211355
872,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006051960236955491,0,0,1,0.006629164940173271
873,HV307,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006410483019142814,1,0,1,0.007021881773211355
874,HV307,Scavenging of heme from plasma,0.006051960236955491,0,0,1,0.006629164940173271
875,HV307,Scavenging of heme from plasma,0.006410483019142814,1,0,1,0.007021881773211355
876,PIGR,Neutrophil degranulation,0.00045043804103560834,0,0,1,0.0004933984944447917
877,PIGR,Neutrophil degranulation,0.0004749500624297449,1,0,1,0.0005202483458113848
878,IGKC,Initial triggering of complement,0.00026089511936904186,0,0,1,0.0002857779480807736
879,IGKC,Initial triggering of complement,0.0003745889195513347,1,0,1,0.0004103152755868571
880,IGKC,Regulation of Complement cascade,0.00026089511936904186,0,0,1,0.0002857779480807736
881,IGKC,Regulation of Complement cascade,0.0003745889195513347,1,0,1,0.0004103152755868571
882,IGKC,FCGR activation,0.00026089511936904186,0,0,1,0.0002857779480807736
883,IGKC,FCGR activation,0.0003745889195513347,1,0,1,0.0004103152755868571
884,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.00026089511936904186,0,0,1,0.0002857779480807736
885,IGKC,Regulation of actin dynamics for phagocytic cup formation,0.0003745889195513347,1,0,1,0.0004103152755868571
886,IGKC,Role of phospholipids in phagocytosis,0.00026089511936904186,0,0,1,0.0002857779480807736
887,IGKC,Role of phospholipids in phagocytosis,0.0003745889195513347,1,0,1,0.0004103152755868571
888,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.00026089511936904186,0,0,1,0.0002857779480807736
889,IGKC,Role of LAT2/NTAL/LAB on calcium mobilization,0.0003745889195513347,1,0,1,0.0004103152755868571
890,IGKC,FCERI mediated MAPK activation,0.00026089511936904186,0,0,1,0.0002857779480807736
891,IGKC,FCERI mediated MAPK activation,0.0003745889195513347,1,0,1,0.0004103152755868571
892,IGKC,FCERI mediated Ca+2 mobilization,0.00026089511936904186,0,0,1,0.0002857779480807736
893,IGKC,FCERI mediated Ca+2 mobilization,0.0003745889195513347,1,0,1,0.0004103152755868571
894,IGKC,FCERI mediated NF-kB activation,0.00026089511936904186,0,0,1,0.0002857779480807736
895,IGKC,FCERI mediated NF-kB activation,0.0003745889195513347,1,0,1,0.0004103152755868571
896,IGKC,Parasite infection,0.00026089511936904186,0,0,1,0.0002857779480807736
897,IGKC,Parasite infection,0.0003745889195513347,1,0,1,0.0004103152755868571
898,IGKC,Leishmania parasite growth and survival,0.00026089511936904186,0,0,1,0.0002857779480807736
899,IGKC,Leishmania parasite growth and survival,0.0003745889195513347,1,0,1,0.0004103152755868571
900,IGKC,Potential therapeutics for SARS,0.00026089511936904186,0,0,1,0.0002857779480807736
901,IGKC,Potential therapeutics for SARS,0.0003745889195513347,1,0,1,0.0004103152755868571
902,IGKC,CD22 mediated BCR regulation,0.00026089511936904186,0,0,1,0.0002857779480807736
903,IGKC,CD22 mediated BCR regulation,0.0003745889195513347,1,0,1,0.0004103152755868571
904,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00026089511936904186,0,0,1,0.0002857779480807736
905,IGKC,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0003745889195513347,1,0,1,0.0004103152755868571
906,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00026089511936904186,0,0,1,0.0002857779480807736
907,IGKC,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0003745889195513347,1,0,1,0.0004103152755868571
908,IGKC,Scavenging of heme from plasma,0.00026089511936904186,0,0,1,0.0002857779480807736
909,IGKC,Scavenging of heme from plasma,0.0003745889195513347,1,0,1,0.0004103152755868571
910,IGHG1,Initial triggering of complement,0.009335188166337941,0,0,1,0.010225530188436863
911,IGHG1,Initial triggering of complement,0.009631849358243594,1,0,1,0.010550485392286698
912,IGHG1,Regulation of Complement cascade,0.009335188166337941,0,0,1,0.010225530188436863
913,IGHG1,Regulation of Complement cascade,0.009631849358243594,1,0,1,0.010550485392286698
914,IGHG1,FCGR activation,0.009335188166337941,0,0,1,0.010225530188436863
915,IGHG1,FCGR activation,0.009631849358243594,1,0,1,0.010550485392286698
916,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.009335188166337941,0,0,1,0.010225530188436863
917,IGHG1,Regulation of actin dynamics for phagocytic cup formation,0.009631849358243594,1,0,1,0.010550485392286698
918,IGHG1,Role of phospholipids in phagocytosis,0.009335188166337941,0,0,1,0.010225530188436863
919,IGHG1,Role of phospholipids in phagocytosis,0.009631849358243594,1,0,1,0.010550485392286698
920,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.009335188166337941,0,0,1,0.010225530188436863
921,IGHG1,Interleukin-4 and Interleukin-13 signaling,0.009631849358243594,1,0,1,0.010550485392286698
922,IGHG1,Parasite infection,0.009335188166337941,0,0,1,0.010225530188436863
923,IGHG1,Parasite infection,0.009631849358243594,1,0,1,0.010550485392286698
924,IGHG1,Leishmania parasite growth and survival,0.009335188166337941,0,0,1,0.010225530188436863
925,IGHG1,Leishmania parasite growth and survival,0.009631849358243594,1,0,1,0.010550485392286698
926,IGHG2,Initial triggering of complement,0.005514464942026108,0,0,1,0.006040406120692586
927,IGHG2,Initial triggering of complement,0.005657784078500858,1,0,1,0.006197394296023406
928,IGHG2,Regulation of Complement cascade,0.005514464942026108,0,0,1,0.006040406120692586
929,IGHG2,Regulation of Complement cascade,0.005657784078500858,1,0,1,0.006197394296023406
930,IGHG2,FCGR activation,0.005514464942026108,0,0,1,0.006040406120692586
931,IGHG2,FCGR activation,0.005657784078500858,1,0,1,0.006197394296023406
932,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.005514464942026108,0,0,1,0.006040406120692586
933,IGHG2,Regulation of actin dynamics for phagocytic cup formation,0.005657784078500858,1,0,1,0.006197394296023406
934,IGHG2,Role of phospholipids in phagocytosis,0.005514464942026108,0,0,1,0.006040406120692586
935,IGHG2,Role of phospholipids in phagocytosis,0.005657784078500858,1,0,1,0.006197394296023406
936,IGHG2,Parasite infection,0.005514464942026108,0,0,1,0.006040406120692586
937,IGHG2,Parasite infection,0.005657784078500858,1,0,1,0.006197394296023406
938,IGHG2,Leishmania parasite growth and survival,0.005514464942026108,0,0,1,0.006040406120692586
939,IGHG2,Leishmania parasite growth and survival,0.005657784078500858,1,0,1,0.006197394296023406
940,IGHG3,Initial triggering of complement,0.0008120341118415657,0,0,1,0.0008894817304934711
941,IGHG3,Initial triggering of complement,0.0008928764140119679,1,0,1,0.0009780343538168066
942,IGHG3,Regulation of Complement cascade,0.0008120341118415657,0,0,1,0.0008894817304934711
943,IGHG3,Regulation of Complement cascade,0.0008928764140119679,1,0,1,0.0009780343538168066
944,IGHG3,FCGR activation,0.0008120341118415657,0,0,1,0.0008894817304934711
945,IGHG3,FCGR activation,0.0008928764140119679,1,0,1,0.0009780343538168066
946,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.0008120341118415657,0,0,1,0.0008894817304934711
947,IGHG3,Regulation of actin dynamics for phagocytic cup formation,0.0008928764140119679,1,0,1,0.0009780343538168066
948,IGHG3,Role of phospholipids in phagocytosis,0.0008120341118415657,0,0,1,0.0008894817304934711
949,IGHG3,Role of phospholipids in phagocytosis,0.0008928764140119679,1,0,1,0.0009780343538168066
950,IGHG3,Parasite infection,0.0008120341118415657,0,0,1,0.0008894817304934711
951,IGHG3,Parasite infection,0.0008928764140119679,1,0,1,0.0009780343538168066
952,IGHG3,Leishmania parasite growth and survival,0.0008120341118415657,0,0,1,0.0008894817304934711
953,IGHG3,Leishmania parasite growth and survival,0.0008928764140119679,1,0,1,0.0009780343538168066
954,IGHG4,Initial triggering of complement,0.0032521082111951947,0,0,1,0.003562277492118848
955,IGHG4,Initial triggering of complement,0.0034896824495112945,1,0,1,0.0038225103339865826
956,IGHG4,Regulation of Complement cascade,0.0032521082111951947,0,0,1,0.003562277492118848
957,IGHG4,Regulation of Complement cascade,0.0034896824495112945,1,0,1,0.0038225103339865826
958,IGHG4,FCGR activation,0.0032521082111951947,0,0,1,0.003562277492118848
959,IGHG4,FCGR activation,0.0034896824495112945,1,0,1,0.0038225103339865826
960,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.0032521082111951947,0,0,1,0.003562277492118848
961,IGHG4,Regulation of actin dynamics for phagocytic cup formation,0.0034896824495112945,1,0,1,0.0038225103339865826
962,IGHG4,Role of phospholipids in phagocytosis,0.0032521082111951947,0,0,1,0.003562277492118848
963,IGHG4,Role of phospholipids in phagocytosis,0.0034896824495112945,1,0,1,0.0038225103339865826
964,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.0032521082111951947,0,0,1,0.003562277492118848
965,IGHG4,Interleukin-4 and Interleukin-13 signaling,0.0034896824495112945,1,0,1,0.0038225103339865826
966,IGHG4,Parasite infection,0.0032521082111951947,0,0,1,0.003562277492118848
967,IGHG4,Parasite infection,0.0034896824495112945,1,0,1,0.0038225103339865826
968,IGHG4,Leishmania parasite growth and survival,0.0032521082111951947,0,0,1,0.003562277492118848
969,IGHG4,Leishmania parasite growth and survival,0.0034896824495112945,1,0,1,0.0038225103339865826
970,IGHM,Potential therapeutics for SARS,0.005930176131671938,0,0,1,0.006495765696059559
971,IGHM,Potential therapeutics for SARS,0.006284426966830402,1,0,1,0.006883803145829879
972,IGHM,CD22 mediated BCR regulation,0.005930176131671938,0,0,1,0.006495765696059559
973,IGHM,CD22 mediated BCR regulation,0.006284426966830402,1,0,1,0.006883803145829879
974,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005930176131671938,0,0,1,0.006495765696059559
975,IGHM,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006284426966830402,1,0,1,0.006883803145829879
976,IGHA1,Scavenging of heme from plasma,0.001762266761961932,0,0,1,0.0019303426619186877
977,IGHA1,Scavenging of heme from plasma,0.001983477993101398,1,0,1,0.002172651877515918
978,IGHA2,Scavenging of heme from plasma,0.0004994904368446766,0,0,1,0.0005471292543634261
979,IGHA2,Scavenging of heme from plasma,0.0005604699604116389,1,0,1,0.0006139246898704405
980,IGHD,Potential therapeutics for SARS,0.0059034452503976985,0,0,1,0.00646648536142004
981,IGHD,Potential therapeutics for SARS,0.006277640465544159,1,0,1,0.006876369383109746
982,IGHD,CD22 mediated BCR regulation,0.0059034452503976985,0,0,1,0.00646648536142004
983,IGHD,CD22 mediated BCR regulation,0.006277640465544159,1,0,1,0.006876369383109746
984,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0059034452503976985,0,0,1,0.00646648536142004
985,IGHD,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.006277640465544159,1,0,1,0.006876369383109746
986,P01891,Antigen processing-Cross presentation,0.0015816196925148632,0,0,1,0.0017324664082032483
987,P01891,Antigen processing-Cross presentation,0.001595009231779176,1,0,1,0.0017471329725527703
988,P01891,Interferon gamma signaling,0.0015816196925148632,0,0,1,0.0017324664082032483
989,P01891,Interferon gamma signaling,0.001595009231779176,1,0,1,0.0017471329725527703
990,P01891,Interferon alpha/beta signaling,0.0015816196925148632,0,0,1,0.0017324664082032483
991,P01891,Interferon alpha/beta signaling,0.001595009231779176,1,0,1,0.0017471329725527703
992,P01891,SARS-CoV-2 Infection,0.0015816196925148632,0,0,1,0.0017324664082032483
993,P01891,SARS-CoV-2 Infection,0.001595009231779176,1,0,1,0.0017471329725527703
994,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0015816196925148632,0,0,1,0.0017324664082032483
995,P01891,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.001595009231779176,1,0,1,0.0017471329725527703
996,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0015816196925148632,0,0,1,0.0017324664082032483
997,P01891,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.001595009231779176,1,0,1,0.0017471329725527703
998,MYG,Intracellular oxygen transport,0.00015420839160936058,0,0,1,0.00016891599136671613
999,MYG,Intracellular oxygen transport,0.0008885586632210005,1,0,1,0.0009733047982607235
1000,CO1A1,Collagen chain trimerization,0.024798303980593846,0,0,1,0.027163438107222482
1001,CO1A1,Collagen chain trimerization,0.02276054998758712,1,0,1,0.024931333665317894
1002,CO1A1,Anchoring fibril formation,0.024798303980593846,0,0,1,0.027163438107222482
1003,CO1A1,Anchoring fibril formation,0.02276054998758712,1,0,1,0.024931333665317894
1004,CO1A1,Crosslinking of collagen fibrils,0.024798303980593846,0,0,1,0.027163438107222482
1005,CO1A1,Crosslinking of collagen fibrils,0.02276054998758712,1,0,1,0.024931333665317894
1006,CO1A1,Transcriptional regulation by RUNX2,0.024798303980593846,0,0,1,0.027163438107222482
1007,CO1A1,Transcriptional regulation by RUNX2,0.02276054998758712,1,0,1,0.024931333665317894
1008,CO1A1,MET promotes cell motility,0.024798303980593846,0,0,1,0.027163438107222482
1009,CO1A1,MET promotes cell motility,0.02276054998758712,1,0,1,0.024931333665317894
1010,CO1A1,Platelet Adhesion to exposed collagen,0.024798303980593846,0,0,1,0.027163438107222482
1011,CO1A1,Platelet Adhesion to exposed collagen,0.02276054998758712,1,0,1,0.024931333665317894
1012,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.024798303980593846,0,0,1,0.027163438107222482
1013,CO1A1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.02276054998758712,1,0,1,0.024931333665317894
1014,CO1A1,Collagen degradation,0.024798303980593846,0,0,1,0.027163438107222482
1015,CO1A1,Collagen degradation,0.02276054998758712,1,0,1,0.024931333665317894
1016,CO1A1,Integrin cell surface interactions,0.024798303980593846,0,0,1,0.027163438107222482
1017,CO1A1,Integrin cell surface interactions,0.02276054998758712,1,0,1,0.024931333665317894
1018,CO1A1,ECM proteoglycans,0.024798303980593846,0,0,1,0.027163438107222482
1019,CO1A1,ECM proteoglycans,0.02276054998758712,1,0,1,0.024931333665317894
1020,CO1A1,Scavenging by Class A Receptors,0.024798303980593846,0,0,1,0.027163438107222482
1021,CO1A1,Scavenging by Class A Receptors,0.02276054998758712,1,0,1,0.024931333665317894
1022,CO1A1,Syndecan interactions,0.024798303980593846,0,0,1,0.027163438107222482
1023,CO1A1,Syndecan interactions,0.02276054998758712,1,0,1,0.024931333665317894
1024,CO1A1,GPVI-mediated activation cascade,0.024798303980593846,0,0,1,0.027163438107222482
1025,CO1A1,GPVI-mediated activation cascade,0.02276054998758712,1,0,1,0.024931333665317894
1026,CO1A1,GP1b-IX-V activation signalling,0.024798303980593846,0,0,1,0.027163438107222482
1027,CO1A1,GP1b-IX-V activation signalling,0.02276054998758712,1,0,1,0.024931333665317894
1028,K1C14,Type I hemidesmosome assembly,0.0021708843204887762,0,0,1,0.002377932052275959
1029,K1C14,Type I hemidesmosome assembly,0.0018032786299280708,1,0,1,0.001975266029985777
1030,K1C14,Formation of the cornified envelope,0.0021708843204887762,0,0,1,0.002377932052275959
1031,K1C14,Formation of the cornified envelope,0.0018032786299280708,1,0,1,0.001975266029985777
1032,K2C6A,Formation of the cornified envelope,9.146064104672479e-05,0,0,1,0.0001001836845077704
1033,K2C6A,Formation of the cornified envelope,8.848567041485726e-05,1,0,1,9.69249765456139e-05
1034,APOA1,PPARA activates gene expression,0.02530339111668122,0,0,1,0.027716697845090052
1035,APOA1,PPARA activates gene expression,0.022235624383065995,1,0,1,0.024356343368382095
1036,APOA1,Defective ABCA1 causes TGD,0.02530339111668122,0,0,1,0.027716697845090052
1037,APOA1,Defective ABCA1 causes TGD,0.022235624383065995,1,0,1,0.024356343368382095
1038,APOA1,Platelet degranulation ,0.02530339111668122,0,0,1,0.027716697845090052
1039,APOA1,Platelet degranulation ,0.022235624383065995,1,0,1,0.024356343368382095
1040,APOA1,Chylomicron assembly,0.02530339111668122,0,0,1,0.027716697845090052
1041,APOA1,Chylomicron assembly,0.022235624383065995,1,0,1,0.024356343368382095
1042,APOA1,HDL assembly,0.02530339111668122,0,0,1,0.027716697845090052
1043,APOA1,HDL assembly,0.022235624383065995,1,0,1,0.024356343368382095
1044,APOA1,Chylomicron remodeling,0.02530339111668122,0,0,1,0.027716697845090052
1045,APOA1,Chylomicron remodeling,0.022235624383065995,1,0,1,0.024356343368382095
1046,APOA1,HDL remodeling,0.02530339111668122,0,0,1,0.027716697845090052
1047,APOA1,HDL remodeling,0.022235624383065995,1,0,1,0.024356343368382095
1048,APOA1,HDL clearance,0.02530339111668122,0,0,1,0.027716697845090052
1049,APOA1,HDL clearance,0.022235624383065995,1,0,1,0.024356343368382095
1050,APOA1,Scavenging of heme from plasma,0.02530339111668122,0,0,1,0.027716697845090052
1051,APOA1,Scavenging of heme from plasma,0.022235624383065995,1,0,1,0.024356343368382095
1052,APOA1,Scavenging by Class B Receptors,0.02530339111668122,0,0,1,0.027716697845090052
1053,APOA1,Scavenging by Class B Receptors,0.022235624383065995,1,0,1,0.024356343368382095
1054,APOA1,Scavenging by Class A Receptors,0.02530339111668122,0,0,1,0.027716697845090052
1055,APOA1,Scavenging by Class A Receptors,0.022235624383065995,1,0,1,0.024356343368382095
1056,APOA1,Retinoid metabolism and transport,0.02530339111668122,0,0,1,0.027716697845090052
1057,APOA1,Retinoid metabolism and transport,0.022235624383065995,1,0,1,0.024356343368382095
1058,APOA1,Heme signaling,0.02530339111668122,0,0,1,0.027716697845090052
1059,APOA1,Heme signaling,0.022235624383065995,1,0,1,0.024356343368382095
1060,APOA1,ABC transporters in lipid homeostasis,0.02530339111668122,0,0,1,0.027716697845090052
1061,APOA1,ABC transporters in lipid homeostasis,0.022235624383065995,1,0,1,0.024356343368382095
1062,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.02530339111668122,0,0,1,0.027716697845090052
1063,APOA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.022235624383065995,1,0,1,0.024356343368382095
1064,APOA1,Amyloid fiber formation,0.02530339111668122,0,0,1,0.027716697845090052
1065,APOA1,Amyloid fiber formation,0.022235624383065995,1,0,1,0.024356343368382095
1066,APOA1,Post-translational protein phosphorylation,0.02530339111668122,0,0,1,0.027716697845090052
1067,APOA1,Post-translational protein phosphorylation,0.022235624383065995,1,0,1,0.024356343368382095
1068,APOE,Nuclear signaling by ERBB4,0.004724315783882934,0,0,1,0.005174896617724469
1069,APOE,Nuclear signaling by ERBB4,0.005062434849651946,1,0,1,0.005545263733277042
1070,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.004724315783882934,0,0,1,0.005174896617724469
1071,APOE,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.005062434849651946,1,0,1,0.005545263733277042
1072,APOE,Chylomicron assembly,0.004724315783882934,0,0,1,0.005174896617724469
1073,APOE,Chylomicron assembly,0.005062434849651946,1,0,1,0.005545263733277042
1074,APOE,Chylomicron remodeling,0.004724315783882934,0,0,1,0.005174896617724469
1075,APOE,Chylomicron remodeling,0.005062434849651946,1,0,1,0.005545263733277042
1076,APOE,HDL remodeling,0.004724315783882934,0,0,1,0.005174896617724469
1077,APOE,HDL remodeling,0.005062434849651946,1,0,1,0.005545263733277042
1078,APOE,Chylomicron clearance,0.004724315783882934,0,0,1,0.005174896617724469
1079,APOE,Chylomicron clearance,0.005062434849651946,1,0,1,0.005545263733277042
1080,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.004724315783882934,0,0,1,0.005174896617724469
1081,APOE,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.005062434849651946,1,0,1,0.005545263733277042
1082,APOE,Scavenging by Class A Receptors,0.004724315783882934,0,0,1,0.005174896617724469
1083,APOE,Scavenging by Class A Receptors,0.005062434849651946,1,0,1,0.005545263733277042
1084,APOE,Retinoid metabolism and transport,0.004724315783882934,0,0,1,0.005174896617724469
1085,APOE,Retinoid metabolism and transport,0.005062434849651946,1,0,1,0.005545263733277042
1086,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004724315783882934,0,0,1,0.005174896617724469
1087,APOE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005062434849651946,1,0,1,0.005545263733277042
1088,APOE,Amyloid fiber formation,0.004724315783882934,0,0,1,0.005174896617724469
1089,APOE,Amyloid fiber formation,0.005062434849651946,1,0,1,0.005545263733277042
1090,APOE,Post-translational protein phosphorylation,0.004724315783882934,0,0,1,0.005174896617724469
1091,APOE,Post-translational protein phosphorylation,0.005062434849651946,1,0,1,0.005545263733277042
1092,APOA2,PPARA activates gene expression,0.0054622091071679525,0,0,1,0.0059831663942572
1093,APOA2,PPARA activates gene expression,0.005664963335054616,1,0,1,0.006205258272979511
1094,APOA2,Chylomicron assembly,0.0054622091071679525,0,0,1,0.0059831663942572
1095,APOA2,Chylomicron assembly,0.005664963335054616,1,0,1,0.006205258272979511
1096,APOA2,Chylomicron remodeling,0.0054622091071679525,0,0,1,0.0059831663942572
1097,APOA2,Chylomicron remodeling,0.005664963335054616,1,0,1,0.006205258272979511
1098,APOA2,Retinoid metabolism and transport,0.0054622091071679525,0,0,1,0.0059831663942572
1099,APOA2,Retinoid metabolism and transport,0.005664963335054616,1,0,1,0.006205258272979511
1100,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0054622091071679525,0,0,1,0.0059831663942572
1101,APOA2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005664963335054616,1,0,1,0.006205258272979511
1102,APOA2,Post-translational protein phosphorylation,0.0054622091071679525,0,0,1,0.0059831663942572
1103,APOA2,Post-translational protein phosphorylation,0.005664963335054616,1,0,1,0.006205258272979511
1104,APOC1,VLDL assembly,0.00533985177605758,0,0,1,0.005849139252998568
1105,APOC1,VLDL assembly,0.004800556768644908,1,0,1,0.005258409073755182
1106,APOC1,VLDL clearance,0.00533985177605758,0,0,1,0.005849139252998568
1107,APOC1,VLDL clearance,0.004800556768644908,1,0,1,0.005258409073755182
1108,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.00533985177605758,0,0,1,0.005849139252998568
1109,APOC1,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.004800556768644908,1,0,1,0.005258409073755182
1110,APOC2,Chylomicron assembly,0.007230787156461281,0,0,1,0.007920422281489096
1111,APOC2,Chylomicron assembly,0.006272174264198709,1,0,1,0.006870381843718144
1112,APOC2,Assembly of active LPL and LIPC lipase complexes,0.007230787156461281,0,0,1,0.007920422281489096
1113,APOC2,Assembly of active LPL and LIPC lipase complexes,0.006272174264198709,1,0,1,0.006870381843718144
1114,APOC2,Chylomicron remodeling,0.007230787156461281,0,0,1,0.007920422281489096
1115,APOC2,Chylomicron remodeling,0.006272174264198709,1,0,1,0.006870381843718144
1116,APOC2,HDL remodeling,0.007230787156461281,0,0,1,0.007920422281489096
1117,APOC2,HDL remodeling,0.006272174264198709,1,0,1,0.006870381843718144
1118,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.007230787156461281,0,0,1,0.007920422281489096
1119,APOC2,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.006272174264198709,1,0,1,0.006870381843718144
1120,APOC2,Retinoid metabolism and transport,0.007230787156461281,0,0,1,0.007920422281489096
1121,APOC2,Retinoid metabolism and transport,0.006272174264198709,1,0,1,0.006870381843718144
1122,APOC3,Chylomicron assembly,0.007315614213811049,0,0,1,0.00801333970535572
1123,APOC3,Chylomicron assembly,0.0064398265995911745,1,0,1,0.007054023992775125
1124,APOC3,Chylomicron remodeling,0.007315614213811049,0,0,1,0.00801333970535572
1125,APOC3,Chylomicron remodeling,0.0064398265995911745,1,0,1,0.007054023992775125
1126,APOC3,HDL remodeling,0.007315614213811049,0,0,1,0.00801333970535572
1127,APOC3,HDL remodeling,0.0064398265995911745,1,0,1,0.007054023992775125
1128,APOC3,Retinoid metabolism and transport,0.007315614213811049,0,0,1,0.00801333970535572
1129,APOC3,Retinoid metabolism and transport,0.0064398265995911745,1,0,1,0.007054023992775125
1130,FIBA,Antigen processing-Cross presentation,0.00875450427931152,0,0,1,0.009589463672055454
1131,FIBA,Antigen processing-Cross presentation,0.008802233193011193,1,0,1,0.009641744722978154
1132,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.00875450427931152,0,0,1,0.009589463672055454
1133,FIBA,Toll Like Receptor 4 (TLR4) Cascade,0.008802233193011193,1,0,1,0.009641744722978154
1134,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.00875450427931152,0,0,1,0.009589463672055454
1135,FIBA,Toll Like Receptor 2 (TLR2) Cascade,0.008802233193011193,1,0,1,0.009641744722978154
1136,FIBA,Regulation of TLR by endogenous ligand,0.00875450427931152,0,0,1,0.009589463672055454
1137,FIBA,Regulation of TLR by endogenous ligand,0.008802233193011193,1,0,1,0.009641744722978154
1138,FIBA,MyD88 deficiency (TLR2/4),0.00875450427931152,0,0,1,0.009589463672055454
1139,FIBA,MyD88 deficiency (TLR2/4),0.008802233193011193,1,0,1,0.009641744722978154
1140,FIBA,IRAK4 deficiency (TLR2/4),0.00875450427931152,0,0,1,0.009589463672055454
1141,FIBA,IRAK4 deficiency (TLR2/4),0.008802233193011193,1,0,1,0.009641744722978154
1142,FIBA,RAF/MAP kinase cascade,0.00875450427931152,0,0,1,0.009589463672055454
1143,FIBA,RAF/MAP kinase cascade,0.008802233193011193,1,0,1,0.009641744722978154
1144,FIBA,Signaling by RAS mutants,0.00875450427931152,0,0,1,0.009589463672055454
1145,FIBA,Signaling by RAS mutants,0.008802233193011193,1,0,1,0.009641744722978154
1146,FIBA,Signaling by moderate kinase activity BRAF mutants,0.00875450427931152,0,0,1,0.009589463672055454
1147,FIBA,Signaling by moderate kinase activity BRAF mutants,0.008802233193011193,1,0,1,0.009641744722978154
1148,FIBA,Signaling by high-kinase activity BRAF mutants,0.00875450427931152,0,0,1,0.009589463672055454
1149,FIBA,Signaling by high-kinase activity BRAF mutants,0.008802233193011193,1,0,1,0.009641744722978154
1150,FIBA,Signaling by BRAF and RAF1 fusions,0.00875450427931152,0,0,1,0.009589463672055454
1151,FIBA,Signaling by BRAF and RAF1 fusions,0.008802233193011193,1,0,1,0.009641744722978154
1152,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00875450427931152,0,0,1,0.009589463672055454
1153,FIBA,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.008802233193011193,1,0,1,0.009641744722978154
1154,FIBA,Signaling by RAF1 mutants,0.00875450427931152,0,0,1,0.009589463672055454
1155,FIBA,Signaling by RAF1 mutants,0.008802233193011193,1,0,1,0.009641744722978154
1156,FIBA,Platelet degranulation ,0.00875450427931152,0,0,1,0.009589463672055454
1157,FIBA,Platelet degranulation ,0.008802233193011193,1,0,1,0.009641744722978154
1158,FIBA,Common Pathway of Fibrin Clot Formation,0.00875450427931152,0,0,1,0.009589463672055454
1159,FIBA,Common Pathway of Fibrin Clot Formation,0.008802233193011193,1,0,1,0.009641744722978154
1160,FIBA,Integrin cell surface interactions,0.00875450427931152,0,0,1,0.009589463672055454
1161,FIBA,Integrin cell surface interactions,0.008802233193011193,1,0,1,0.009641744722978154
1162,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.00875450427931152,0,0,1,0.009589463672055454
1163,FIBA,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.008802233193011193,1,0,1,0.009641744722978154
1164,FIBA,p130Cas linkage to MAPK signaling for integrins,0.00875450427931152,0,0,1,0.009589463672055454
1165,FIBA,p130Cas linkage to MAPK signaling for integrins,0.008802233193011193,1,0,1,0.009641744722978154
1166,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00875450427931152,0,0,1,0.009589463672055454
1167,FIBA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008802233193011193,1,0,1,0.009641744722978154
1168,FIBA,Amyloid fiber formation,0.00875450427931152,0,0,1,0.009589463672055454
1169,FIBA,Amyloid fiber formation,0.008802233193011193,1,0,1,0.009641744722978154
1170,FIBA,Post-translational protein phosphorylation,0.00875450427931152,0,0,1,0.009589463672055454
1171,FIBA,Post-translational protein phosphorylation,0.008802233193011193,1,0,1,0.009641744722978154
1172,FIBB,Antigen processing-Cross presentation,0.0005585064605898869,0,0,1,0.0006117739215790508
1173,FIBB,Antigen processing-Cross presentation,0.0011537763396507743,1,0,1,0.001263817566564526
1174,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.0005585064605898869,0,0,1,0.0006117739215790508
1175,FIBB,Toll Like Receptor 4 (TLR4) Cascade,0.0011537763396507743,1,0,1,0.001263817566564526
1176,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.0005585064605898869,0,0,1,0.0006117739215790508
1177,FIBB,Toll Like Receptor 2 (TLR2) Cascade,0.0011537763396507743,1,0,1,0.001263817566564526
1178,FIBB,Regulation of TLR by endogenous ligand,0.0005585064605898869,0,0,1,0.0006117739215790508
1179,FIBB,Regulation of TLR by endogenous ligand,0.0011537763396507743,1,0,1,0.001263817566564526
1180,FIBB,MyD88 deficiency (TLR2/4),0.0005585064605898869,0,0,1,0.0006117739215790508
1181,FIBB,MyD88 deficiency (TLR2/4),0.0011537763396507743,1,0,1,0.001263817566564526
1182,FIBB,IRAK4 deficiency (TLR2/4),0.0005585064605898869,0,0,1,0.0006117739215790508
1183,FIBB,IRAK4 deficiency (TLR2/4),0.0011537763396507743,1,0,1,0.001263817566564526
1184,FIBB,RAF/MAP kinase cascade,0.0005585064605898869,0,0,1,0.0006117739215790508
1185,FIBB,RAF/MAP kinase cascade,0.0011537763396507743,1,0,1,0.001263817566564526
1186,FIBB,Signaling by RAS mutants,0.0005585064605898869,0,0,1,0.0006117739215790508
1187,FIBB,Signaling by RAS mutants,0.0011537763396507743,1,0,1,0.001263817566564526
1188,FIBB,Signaling by moderate kinase activity BRAF mutants,0.0005585064605898869,0,0,1,0.0006117739215790508
1189,FIBB,Signaling by moderate kinase activity BRAF mutants,0.0011537763396507743,1,0,1,0.001263817566564526
1190,FIBB,Signaling by high-kinase activity BRAF mutants,0.0005585064605898869,0,0,1,0.0006117739215790508
1191,FIBB,Signaling by high-kinase activity BRAF mutants,0.0011537763396507743,1,0,1,0.001263817566564526
1192,FIBB,Signaling by BRAF and RAF1 fusions,0.0005585064605898869,0,0,1,0.0006117739215790508
1193,FIBB,Signaling by BRAF and RAF1 fusions,0.0011537763396507743,1,0,1,0.001263817566564526
1194,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0005585064605898869,0,0,1,0.0006117739215790508
1195,FIBB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0011537763396507743,1,0,1,0.001263817566564526
1196,FIBB,Signaling by RAF1 mutants,0.0005585064605898869,0,0,1,0.0006117739215790508
1197,FIBB,Signaling by RAF1 mutants,0.0011537763396507743,1,0,1,0.001263817566564526
1198,FIBB,Platelet degranulation ,0.0005585064605898869,0,0,1,0.0006117739215790508
1199,FIBB,Platelet degranulation ,0.0011537763396507743,1,0,1,0.001263817566564526
1200,FIBB,Common Pathway of Fibrin Clot Formation,0.0005585064605898869,0,0,1,0.0006117739215790508
1201,FIBB,Common Pathway of Fibrin Clot Formation,0.0011537763396507743,1,0,1,0.001263817566564526
1202,FIBB,Integrin cell surface interactions,0.0005585064605898869,0,0,1,0.0006117739215790508
1203,FIBB,Integrin cell surface interactions,0.0011537763396507743,1,0,1,0.001263817566564526
1204,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0005585064605898869,0,0,1,0.0006117739215790508
1205,FIBB,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0011537763396507743,1,0,1,0.001263817566564526
1206,FIBB,p130Cas linkage to MAPK signaling for integrins,0.0005585064605898869,0,0,1,0.0006117739215790508
1207,FIBB,p130Cas linkage to MAPK signaling for integrins,0.0011537763396507743,1,0,1,0.001263817566564526
1208,FIBG,Antigen processing-Cross presentation,0.0013411073981066883,0,0,1,0.0014690152936312558
1209,FIBG,Antigen processing-Cross presentation,0.0004745480318195931,1,0,1,0.0005198079715985107
1210,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.0013411073981066883,0,0,1,0.0014690152936312558
1211,FIBG,Toll Like Receptor 4 (TLR4) Cascade,0.0004745480318195931,1,0,1,0.0005198079715985107
1212,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.0013411073981066883,0,0,1,0.0014690152936312558
1213,FIBG,Toll Like Receptor 2 (TLR2) Cascade,0.0004745480318195931,1,0,1,0.0005198079715985107
1214,FIBG,Regulation of TLR by endogenous ligand,0.0013411073981066883,0,0,1,0.0014690152936312558
1215,FIBG,Regulation of TLR by endogenous ligand,0.0004745480318195931,1,0,1,0.0005198079715985107
1216,FIBG,MyD88 deficiency (TLR2/4),0.0013411073981066883,0,0,1,0.0014690152936312558
1217,FIBG,MyD88 deficiency (TLR2/4),0.0004745480318195931,1,0,1,0.0005198079715985107
1218,FIBG,IRAK4 deficiency (TLR2/4),0.0013411073981066883,0,0,1,0.0014690152936312558
1219,FIBG,IRAK4 deficiency (TLR2/4),0.0004745480318195931,1,0,1,0.0005198079715985107
1220,FIBG,RAF/MAP kinase cascade,0.0013411073981066883,0,0,1,0.0014690152936312558
1221,FIBG,RAF/MAP kinase cascade,0.0004745480318195931,1,0,1,0.0005198079715985107
1222,FIBG,Signaling by RAS mutants,0.0013411073981066883,0,0,1,0.0014690152936312558
1223,FIBG,Signaling by RAS mutants,0.0004745480318195931,1,0,1,0.0005198079715985107
1224,FIBG,Signaling by moderate kinase activity BRAF mutants,0.0013411073981066883,0,0,1,0.0014690152936312558
1225,FIBG,Signaling by moderate kinase activity BRAF mutants,0.0004745480318195931,1,0,1,0.0005198079715985107
1226,FIBG,Signaling by high-kinase activity BRAF mutants,0.0013411073981066883,0,0,1,0.0014690152936312558
1227,FIBG,Signaling by high-kinase activity BRAF mutants,0.0004745480318195931,1,0,1,0.0005198079715985107
1228,FIBG,Signaling by BRAF and RAF1 fusions,0.0013411073981066883,0,0,1,0.0014690152936312558
1229,FIBG,Signaling by BRAF and RAF1 fusions,0.0004745480318195931,1,0,1,0.0005198079715985107
1230,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0013411073981066883,0,0,1,0.0014690152936312558
1231,FIBG,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0004745480318195931,1,0,1,0.0005198079715985107
1232,FIBG,Signaling by RAF1 mutants,0.0013411073981066883,0,0,1,0.0014690152936312558
1233,FIBG,Signaling by RAF1 mutants,0.0004745480318195931,1,0,1,0.0005198079715985107
1234,FIBG,Platelet degranulation ,0.0013411073981066883,0,0,1,0.0014690152936312558
1235,FIBG,Platelet degranulation ,0.0004745480318195931,1,0,1,0.0005198079715985107
1236,FIBG,Common Pathway of Fibrin Clot Formation,0.0013411073981066883,0,0,1,0.0014690152936312558
1237,FIBG,Common Pathway of Fibrin Clot Formation,0.0004745480318195931,1,0,1,0.0005198079715985107
1238,FIBG,Integrin cell surface interactions,0.0013411073981066883,0,0,1,0.0014690152936312558
1239,FIBG,Integrin cell surface interactions,0.0004745480318195931,1,0,1,0.0005198079715985107
1240,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0013411073981066883,0,0,1,0.0014690152936312558
1241,FIBG,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0004745480318195931,1,0,1,0.0005198079715985107
1242,FIBG,p130Cas linkage to MAPK signaling for integrins,0.0013411073981066883,0,0,1,0.0014690152936312558
1243,FIBG,p130Cas linkage to MAPK signaling for integrins,0.0004745480318195931,1,0,1,0.0005198079715985107
1244,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0013411073981066883,0,0,1,0.0014690152936312558
1245,FIBG,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0004745480318195931,1,0,1,0.0005198079715985107
1246,FIBG,Post-translational protein phosphorylation,0.0013411073981066883,0,0,1,0.0014690152936312558
1247,FIBG,Post-translational protein phosphorylation,0.0004745480318195931,1,0,1,0.0005198079715985107
1248,B3AT,Bicarbonate transporters,0.0026703233450064956,0,0,1,0.0029250049908702766
1249,B3AT,Bicarbonate transporters,0.0027765443502466764,1,0,1,0.0030413568068568273
1250,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0026703233450064956,0,0,1,0.0029250049908702766
1251,B3AT,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",0.0027765443502466764,1,0,1,0.0030413568068568273
1252,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.0026703233450064956,0,0,1,0.0029250049908702766
1253,B3AT,Erythrocytes take up carbon dioxide and release oxygen,0.0027765443502466764,1,0,1,0.0030413568068568273
1254,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.0026703233450064956,0,0,1,0.0029250049908702766
1255,B3AT,Erythrocytes take up oxygen and release carbon dioxide,0.0027765443502466764,1,0,1,0.0030413568068568273
1256,CRP,Initial triggering of complement,0.0007765958428623387,0,0,1,0.0008506635424916768
1257,CRP,Initial triggering of complement,0.0008269945578762288,1,0,1,0.0009058690265858581
1258,SAMP,Amyloid fiber formation,0.0011382350544593507,0,0,1,0.0012467940338771982
1259,SAMP,Amyloid fiber formation,0.0012077704396148048,1,0,1,0.001322961344851778
1260,C1QA,Initial triggering of complement,0.0005912099035214602,0,0,1,0.0006475964499527676
1261,C1QA,Initial triggering of complement,0.0006313064863925873,1,0,1,0.0006915172377608092
1262,C1QA,Regulation of Complement cascade,0.0005912099035214602,0,0,1,0.0006475964499527676
1263,C1QA,Regulation of Complement cascade,0.0006313064863925873,1,0,1,0.0006915172377608092
1264,C1QB,Initial triggering of complement,0.0009664873441279316,0,0,1,0.0010586659141761281
1265,C1QB,Initial triggering of complement,0.0010267139013498809,1,0,1,0.001124636569297936
1266,C1QB,Regulation of Complement cascade,0.0009664873441279316,0,0,1,0.0010586659141761281
1267,C1QB,Regulation of Complement cascade,0.0010267139013498809,1,0,1,0.001124636569297936
1268,C1QC,Initial triggering of complement,0.0008906172538791643,0,0,1,0.0009755597266612666
1269,C1QC,Initial triggering of complement,0.0009474554927082817,1,0,1,0.0010378189030858505
1270,C1QC,Regulation of Complement cascade,0.0008906172538791643,0,0,1,0.0009755597266612666
1271,C1QC,Regulation of Complement cascade,0.0009474554927082817,1,0,1,0.0010378189030858505
1272,CO9,Terminal pathway of complement,0.0003025754822348469,0,0,1,0.0003314335686376419
1273,CO9,Terminal pathway of complement,0.0004087483675738588,1,0,1,0.0004477326752954358
1274,CO9,Regulation of Complement cascade,0.0003025754822348469,0,0,1,0.0003314335686376419
1275,CO9,Regulation of Complement cascade,0.0004087483675738588,1,0,1,0.0004477326752954358
1276,APOH,Platelet degranulation ,0.003001557352229791,0,0,1,0.0032878303865609784
1277,APOH,Platelet degranulation ,0.002341684041570501,1,0,1,0.002565021768409973
1278,A2GL,Neutrophil degranulation,0.0007099280022754358,0,0,1,0.0007776372676729767
1279,A2GL,Neutrophil degranulation,0.0007471074016319819,1,0,1,0.0008183626460728692
1280,FINC,G alpha (s) signalling events,0.0023480884890720753,0,0,1,0.0025720370390291294
1281,FINC,G alpha (s) signalling events,0.0018323794157289472,1,0,1,0.0020071422984028527
1282,FINC,Interleukin-4 and Interleukin-13 signaling,0.0023480884890720753,0,0,1,0.0025720370390291294
1283,FINC,Interleukin-4 and Interleukin-13 signaling,0.0018323794157289472,1,0,1,0.0020071422984028527
1284,FINC,RAF/MAP kinase cascade,0.0023480884890720753,0,0,1,0.0025720370390291294
1285,FINC,RAF/MAP kinase cascade,0.0018323794157289472,1,0,1,0.0020071422984028527
1286,FINC,Signaling by RAS mutants,0.0023480884890720753,0,0,1,0.0025720370390291294
1287,FINC,Signaling by RAS mutants,0.0018323794157289472,1,0,1,0.0020071422984028527
1288,FINC,Signaling by moderate kinase activity BRAF mutants,0.0023480884890720753,0,0,1,0.0025720370390291294
1289,FINC,Signaling by moderate kinase activity BRAF mutants,0.0018323794157289472,1,0,1,0.0020071422984028527
1290,FINC,Signaling by high-kinase activity BRAF mutants,0.0023480884890720753,0,0,1,0.0025720370390291294
1291,FINC,Signaling by high-kinase activity BRAF mutants,0.0018323794157289472,1,0,1,0.0020071422984028527
1292,FINC,Signaling by BRAF and RAF1 fusions,0.0023480884890720753,0,0,1,0.0025720370390291294
1293,FINC,Signaling by BRAF and RAF1 fusions,0.0018323794157289472,1,0,1,0.0020071422984028527
1294,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0023480884890720753,0,0,1,0.0025720370390291294
1295,FINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0018323794157289472,1,0,1,0.0020071422984028527
1296,FINC,Signaling by RAF1 mutants,0.0023480884890720753,0,0,1,0.0025720370390291294
1297,FINC,Signaling by RAF1 mutants,0.0018323794157289472,1,0,1,0.0020071422984028527
1298,FINC,MET promotes cell motility,0.0023480884890720753,0,0,1,0.0025720370390291294
1299,FINC,MET promotes cell motility,0.0018323794157289472,1,0,1,0.0020071422984028527
1300,FINC,Platelet degranulation ,0.0023480884890720753,0,0,1,0.0025720370390291294
1301,FINC,Platelet degranulation ,0.0018323794157289472,1,0,1,0.0020071422984028527
1302,FINC,ALK mutants bind TKIs,0.0023480884890720753,0,0,1,0.0025720370390291294
1303,FINC,ALK mutants bind TKIs,0.0018323794157289472,1,0,1,0.0020071422984028527
1304,FINC,Signaling by ALK fusions and activated point mutants,0.0023480884890720753,0,0,1,0.0025720370390291294
1305,FINC,Signaling by ALK fusions and activated point mutants,0.0018323794157289472,1,0,1,0.0020071422984028527
1306,FINC,Fibronectin matrix formation,0.0023480884890720753,0,0,1,0.0025720370390291294
1307,FINC,Fibronectin matrix formation,0.0018323794157289472,1,0,1,0.0020071422984028527
1308,FINC,Integrin cell surface interactions,0.0023480884890720753,0,0,1,0.0025720370390291294
1309,FINC,Integrin cell surface interactions,0.0018323794157289472,1,0,1,0.0020071422984028527
1310,FINC,ECM proteoglycans,0.0023480884890720753,0,0,1,0.0025720370390291294
1311,FINC,ECM proteoglycans,0.0018323794157289472,1,0,1,0.0020071422984028527
1312,FINC,Molecules associated with elastic fibres,0.0023480884890720753,0,0,1,0.0025720370390291294
1313,FINC,Molecules associated with elastic fibres,0.0018323794157289472,1,0,1,0.0020071422984028527
1314,FINC,Syndecan interactions,0.0023480884890720753,0,0,1,0.0025720370390291294
1315,FINC,Syndecan interactions,0.0018323794157289472,1,0,1,0.0020071422984028527
1316,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0023480884890720753,0,0,1,0.0025720370390291294
1317,FINC,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0018323794157289472,1,0,1,0.0020071422984028527
1318,FINC,p130Cas linkage to MAPK signaling for integrins,0.0023480884890720753,0,0,1,0.0025720370390291294
1319,FINC,p130Cas linkage to MAPK signaling for integrins,0.0018323794157289472,1,0,1,0.0020071422984028527
1320,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0023480884890720753,0,0,1,0.0025720370390291294
1321,FINC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0018323794157289472,1,0,1,0.0020071422984028527
1322,FINC,Post-translational protein phosphorylation,0.0023480884890720753,0,0,1,0.0025720370390291294
1323,FINC,Post-translational protein phosphorylation,0.0018323794157289472,1,0,1,0.0020071422984028527
1324,RET4,Retinoid cycle disease events,0.0045156627814963565,0,0,1,0.0049463433698632734
1325,RET4,Retinoid cycle disease events,0.004632648380037363,1,0,1,0.005074486450450226
1326,RET4,Retinoid metabolism disease events,0.0045156627814963565,0,0,1,0.0049463433698632734
1327,RET4,Retinoid metabolism disease events,0.004632648380037363,1,0,1,0.005074486450450226
1328,RET4,The canonical retinoid cycle in rods (twilight vision),0.0045156627814963565,0,0,1,0.0049463433698632734
1329,RET4,The canonical retinoid cycle in rods (twilight vision),0.004632648380037363,1,0,1,0.005074486450450226
1330,RET4,Retinoid metabolism and transport,0.0045156627814963565,0,0,1,0.0049463433698632734
1331,RET4,Retinoid metabolism and transport,0.004632648380037363,1,0,1,0.005074486450450226
1332,AMBP,Scavenging of heme from plasma,0.0007721807952815292,0,0,1,0.0008458274104805678
1333,AMBP,Scavenging of heme from plasma,0.0008653205258071217,1,0,1,0.0009478503273475917
1334,A1AG1,Platelet degranulation ,0.0012602299054429603,0,0,1,0.0013804241235271337
1335,A1AG1,Platelet degranulation ,0.001113252998384915,1,0,1,0.001219429318350679
1336,A1AG1,Neutrophil degranulation,0.0012602299054429603,0,0,1,0.0013804241235271337
1337,A1AG1,Neutrophil degranulation,0.001113252998384915,1,0,1,0.001219429318350679
1338,FETUA,Platelet degranulation ,0.008423093562530735,0,0,1,0.009226444713162543
1339,FETUA,Platelet degranulation ,0.008531574246425347,1,0,1,0.009345271724280176
1340,FETUA,Neutrophil degranulation,0.008423093562530735,0,0,1,0.009226444713162543
1341,FETUA,Neutrophil degranulation,0.008531574246425347,1,0,1,0.009345271724280176
1342,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008423093562530735,0,0,1,0.009226444713162543
1343,FETUA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008531574246425347,1,0,1,0.009345271724280176
1344,FETUA,Post-translational protein phosphorylation,0.008423093562530735,0,0,1,0.009226444713162543
1345,FETUA,Post-translational protein phosphorylation,0.008531574246425347,1,0,1,0.009345271724280176
1346,TTHY,Retinoid cycle disease events,0.0015793392976775067,0,0,1,0.0017299685210867327
1347,TTHY,Retinoid cycle disease events,0.002137675068322932,1,0,1,0.002341555473196196
1348,TTHY,Neutrophil degranulation,0.0015793392976775067,0,0,1,0.0017299685210867327
1349,TTHY,Neutrophil degranulation,0.002137675068322932,1,0,1,0.002341555473196196
1350,TTHY,The canonical retinoid cycle in rods (twilight vision),0.0015793392976775067,0,0,1,0.0017299685210867327
1351,TTHY,The canonical retinoid cycle in rods (twilight vision),0.002137675068322932,1,0,1,0.002341555473196196
1352,TTHY,Retinoid metabolism and transport,0.0015793392976775067,0,0,1,0.0017299685210867327
1353,TTHY,Retinoid metabolism and transport,0.002137675068322932,1,0,1,0.002341555473196196
1354,TTHY,Amyloid fiber formation,0.0015793392976775067,0,0,1,0.0017299685210867327
1355,TTHY,Amyloid fiber formation,0.002137675068322932,1,0,1,0.002341555473196196
1356,ALBU,Bile acid and bile salt metabolism,0.0037510990892142327,0,0,1,0.004108859542316547
1357,ALBU,Bile acid and bile salt metabolism,0.0037696700815288793,1,0,1,0.0041292017399411655
1358,ALBU,Platelet degranulation ,0.0037510990892142327,0,0,1,0.004108859542316547
1359,ALBU,Platelet degranulation ,0.0037696700815288793,1,0,1,0.0041292017399411655
1360,ALBU,HDL remodeling,0.0037510990892142327,0,0,1,0.004108859542316547
1361,ALBU,HDL remodeling,0.0037696700815288793,1,0,1,0.0041292017399411655
1362,ALBU,Cytoprotection by HMOX1,0.0037510990892142327,0,0,1,0.004108859542316547
1363,ALBU,Cytoprotection by HMOX1,0.0037696700815288793,1,0,1,0.0041292017399411655
1364,ALBU,Heme biosynthesis,0.0037510990892142327,0,0,1,0.004108859542316547
1365,ALBU,Heme biosynthesis,0.0037696700815288793,1,0,1,0.0041292017399411655
1366,ALBU,Heme degradation,0.0037510990892142327,0,0,1,0.004108859542316547
1367,ALBU,Heme degradation,0.0037696700815288793,1,0,1,0.0041292017399411655
1368,ALBU,Scavenging of heme from plasma,0.0037510990892142327,0,0,1,0.004108859542316547
1369,ALBU,Scavenging of heme from plasma,0.0037696700815288793,1,0,1,0.0041292017399411655
1370,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0037510990892142327,0,0,1,0.004108859542316547
1371,ALBU,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0037696700815288793,1,0,1,0.0041292017399411655
1372,ALBU,Post-translational protein phosphorylation,0.0037510990892142327,0,0,1,0.004108859542316547
1373,ALBU,Post-translational protein phosphorylation,0.0037696700815288793,1,0,1,0.0041292017399411655
1374,ALBU,Aspirin ADME,0.0037510990892142327,0,0,1,0.004108859542316547
1375,ALBU,Aspirin ADME,0.0037696700815288793,1,0,1,0.0041292017399411655
1376,VTDB,Vitamin D (calciferol) metabolism,0.0020453143585729065,0,0,1,0.0022403858760819237
1377,VTDB,Vitamin D (calciferol) metabolism,0.0023647432622402186,1,0,1,0.0025902802584241618
1378,CXCL7,Class A/1 (Rhodopsin-like receptors),0.0011999962242593084,0,0,1,0.0013144456649969581
1379,CXCL7,Class A/1 (Rhodopsin-like receptors),0.0010918064291762662,1,0,1,0.001195937286163023
1380,CXCL7,G alpha (i) signalling events,0.0011999962242593084,0,0,1,0.0013144456649969581
1381,CXCL7,G alpha (i) signalling events,0.0010918064291762662,1,0,1,0.001195937286163023
1382,CXCL7,Platelet degranulation ,0.0011999962242593084,0,0,1,0.0013144456649969581
1383,CXCL7,Platelet degranulation ,0.0010918064291762662,1,0,1,0.001195937286163023
1384,CXCL7,Neutrophil degranulation,0.0011999962242593084,0,0,1,0.0013144456649969581
1385,CXCL7,Neutrophil degranulation,0.0010918064291762662,1,0,1,0.001195937286163023
1386,PLF4,Transcriptional regulation by RUNX1,0.004304129456590653,0,0,1,0.004714635089200708
1387,PLF4,Transcriptional regulation by RUNX1,0.0034123918675075327,1,0,1,0.003737848175551338
1388,PLF4,Class A/1 (Rhodopsin-like receptors),0.004304129456590653,0,0,1,0.004714635089200708
1389,PLF4,Class A/1 (Rhodopsin-like receptors),0.0034123918675075327,1,0,1,0.003737848175551338
1390,PLF4,G alpha (i) signalling events,0.004304129456590653,0,0,1,0.004714635089200708
1391,PLF4,G alpha (i) signalling events,0.0034123918675075327,1,0,1,0.003737848175551338
1392,PLF4,Platelet degranulation ,0.004304129456590653,0,0,1,0.004714635089200708
1393,PLF4,Platelet degranulation ,0.0034123918675075327,1,0,1,0.003737848175551338
1394,PLF4,Common Pathway of Fibrin Clot Formation,0.004304129456590653,0,0,1,0.004714635089200708
1395,PLF4,Common Pathway of Fibrin Clot Formation,0.0034123918675075327,1,0,1,0.003737848175551338
1396,TFR1,RHO GTPase cycle,0.0040454199188665885,0,0,1,0.0044312511722515826
1397,TFR1,RHO GTPase cycle,0.004404537578916391,1,0,1,0.004824619619529555
1398,TFR1,Golgi Associated Vesicle Biogenesis,0.0040454199188665885,0,0,1,0.0044312511722515826
1399,TFR1,Golgi Associated Vesicle Biogenesis,0.004404537578916391,1,0,1,0.004824619619529555
1400,TFR1,Cargo recognition for clathrin-mediated endocytosis,0.0040454199188665885,0,0,1,0.0044312511722515826
1401,TFR1,Cargo recognition for clathrin-mediated endocytosis,0.004404537578916391,1,0,1,0.004824619619529555
1402,TFR1,Transferrin endocytosis and recycling,0.0040454199188665885,0,0,1,0.0044312511722515826
1403,TFR1,Transferrin endocytosis and recycling,0.004404537578916391,1,0,1,0.004824619619529555
1404,TRFE,Platelet degranulation ,0.006854795532758013,0,0,1,0.007508570519074608
1405,TRFE,Platelet degranulation ,0.0070344215318013095,1,0,1,0.00770532831796597
1406,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.006854795532758013,0,0,1,0.007508570519074608
1407,TRFE,Cargo recognition for clathrin-mediated endocytosis,0.0070344215318013095,1,0,1,0.00770532831796597
1408,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006854795532758013,0,0,1,0.007508570519074608
1409,TRFE,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0070344215318013095,1,0,1,0.00770532831796597
1410,TRFE,Post-translational protein phosphorylation,0.006854795532758013,0,0,1,0.007508570519074608
1411,TRFE,Post-translational protein phosphorylation,0.0070344215318013095,1,0,1,0.00770532831796597
1412,TRFE,Transferrin endocytosis and recycling,0.006854795532758013,0,0,1,0.007508570519074608
1413,TRFE,Transferrin endocytosis and recycling,0.0070344215318013095,1,0,1,0.00770532831796597
1414,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.010260704969798173,0,0,1,0.01123931800342857
1415,TRFL,Latent infection - Other responses of Mtb to phagocytosis,0.010335400669840235,1,0,1,0.011321137793465663
1416,TRFL,Metal sequestration by antimicrobial proteins,0.010260704969798173,0,0,1,0.01123931800342857
1417,TRFL,Metal sequestration by antimicrobial proteins,0.010335400669840235,1,0,1,0.011321137793465663
1418,TRFL,Neutrophil degranulation,0.010260704969798173,0,0,1,0.01123931800342857
1419,TRFL,Neutrophil degranulation,0.010335400669840235,1,0,1,0.011321137793465663
1420,TRFL,Amyloid fiber formation,0.010260704969798173,0,0,1,0.01123931800342857
1421,TRFL,Amyloid fiber formation,0.010335400669840235,1,0,1,0.011321137793465663
1422,HEMO,Scavenging of heme from plasma,0.0007546869232918176,0,0,1,0.0008266650633531162
1423,HEMO,Scavenging of heme from plasma,0.0008477357148145012,1,0,1,0.0009285883679249209
1424,ANGI,Adherens junctions interactions,0.0005166984464992269,0,0,1,0.000565978475082942
1425,ANGI,Adherens junctions interactions,0.0008271986020753766,1,0,1,0.0009060925314666365
1426,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0005166984464992269,0,0,1,0.000565978475082942
1427,ANGI,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0008271986020753766,1,0,1,0.0009060925314666365
1428,FA11,Defective factor IX causes hemophilia B,0.001484949960863121,0,0,1,0.0016265768169385064
1429,FA11,Defective factor IX causes hemophilia B,0.0012163133115759108,1,0,1,0.0013323189918084018
1430,FA11,Intrinsic Pathway of Fibrin Clot Formation,0.001484949960863121,0,0,1,0.0016265768169385064
1431,FA11,Intrinsic Pathway of Fibrin Clot Formation,0.0012163133115759108,1,0,1,0.0013323189918084018
1432,KLKB1,Defective factor XII causes hereditary angioedema,0.0023662909994887687,0,0,1,0.0025919756108559303
1433,KLKB1,Defective factor XII causes hereditary angioedema,0.002081453680939018,1,0,1,0.0022799719803210296
1434,KLKB1,Defective SERPING1 causes hereditary angioedema,0.0023662909994887687,0,0,1,0.0025919756108559303
1435,KLKB1,Defective SERPING1 causes hereditary angioedema,0.002081453680939018,1,0,1,0.0022799719803210296
1436,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.0023662909994887687,0,0,1,0.0025919756108559303
1437,KLKB1,Intrinsic Pathway of Fibrin Clot Formation,0.002081453680939018,1,0,1,0.0022799719803210296
1438,KLKB1,Activation of Matrix Metalloproteinases,0.0023662909994887687,0,0,1,0.0025919756108559303
1439,KLKB1,Activation of Matrix Metalloproteinases,0.002081453680939018,1,0,1,0.0022799719803210296
1440,C4BPA,Regulation of Complement cascade,0.0003427278145259175,0,0,1,0.00037541542295730203
1441,C4BPA,Regulation of Complement cascade,0.00036566846827942206,1,0,1,0.0004005440377553218
1442,VTNC,Regulation of Complement cascade,0.007971744259001693,0,0,1,0.008732048044715238
1443,VTNC,Regulation of Complement cascade,0.0068221691624526775,1,0,1,0.007472832414116065
1444,VTNC,Integrin cell surface interactions,0.007971744259001693,0,0,1,0.008732048044715238
1445,VTNC,Integrin cell surface interactions,0.0068221691624526775,1,0,1,0.007472832414116065
1446,VTNC,ECM proteoglycans,0.007971744259001693,0,0,1,0.008732048044715238
1447,VTNC,ECM proteoglycans,0.0068221691624526775,1,0,1,0.007472832414116065
1448,VTNC,Molecules associated with elastic fibres,0.007971744259001693,0,0,1,0.008732048044715238
1449,VTNC,Molecules associated with elastic fibres,0.0068221691624526775,1,0,1,0.007472832414116065
1450,VTNC,Syndecan interactions,0.007971744259001693,0,0,1,0.008732048044715238
1451,VTNC,Syndecan interactions,0.0068221691624526775,1,0,1,0.007472832414116065
1452,CATA,FOXO-mediated transcription,0.0040435918469719475,0,0,1,0.004429248748303377
1453,CATA,FOXO-mediated transcription,0.003880926208726608,1,0,1,0.004251068901806337
1454,CATA,Detoxification of Reactive Oxygen Species,0.0040435918469719475,0,0,1,0.004429248748303377
1455,CATA,Detoxification of Reactive Oxygen Species,0.003880926208726608,1,0,1,0.004251068901806337
1456,CATA,Neutrophil degranulation,0.0040435918469719475,0,0,1,0.004429248748303377
1457,CATA,Neutrophil degranulation,0.003880926208726608,1,0,1,0.004251068901806337
1458,FUCO,Neutrophil degranulation,0.0016156567201824376,0,0,1,0.0017697497117358408
1459,FUCO,Neutrophil degranulation,0.0016965169843988312,1,0,1,0.0018583220102323234
1460,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0049191022196200624,0,0,1,0.005388260777443316
1461,PROC,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.004785704894861807,1,0,1,0.00524214070497483
1462,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.0049191022196200624,0,0,1,0.005388260777443316
1463,PROC,Intrinsic Pathway of Fibrin Clot Formation,0.004785704894861807,1,0,1,0.00524214070497483
1464,PROC,Common Pathway of Fibrin Clot Formation,0.0049191022196200624,0,0,1,0.005388260777443316
1465,PROC,Common Pathway of Fibrin Clot Formation,0.004785704894861807,1,0,1,0.00524214070497483
1466,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0049191022196200624,0,0,1,0.005388260777443316
1467,PROC,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004785704894861807,1,0,1,0.00524214070497483
1468,PROC,Post-translational protein phosphorylation,0.0049191022196200624,0,0,1,0.005388260777443316
1469,PROC,Post-translational protein phosphorylation,0.004785704894861807,1,0,1,0.00524214070497483
1470,ALDOA,Glycolysis,0.003285258872343492,0,0,1,0.003598589892072488
1471,ALDOA,Glycolysis,0.0032461407360370237,1,0,1,0.003555740870007827
1472,ALDOA,Gluconeogenesis,0.003285258872343492,0,0,1,0.003598589892072488
1473,ALDOA,Gluconeogenesis,0.0032461407360370237,1,0,1,0.003555740870007827
1474,ALDOA,Platelet degranulation ,0.003285258872343492,0,0,1,0.003598589892072488
1475,ALDOA,Platelet degranulation ,0.0032461407360370237,1,0,1,0.003555740870007827
1476,ALDOA,Neutrophil degranulation,0.003285258872343492,0,0,1,0.003598589892072488
1477,ALDOA,Neutrophil degranulation,0.0032461407360370237,1,0,1,0.003555740870007827
1478,APOB,Regulation of TLR by endogenous ligand,0.0401103081424522,0,0,1,0.04393582212484158
1479,APOB,Regulation of TLR by endogenous ligand,0.038583530637265426,1,0,1,0.042263428468481246
1480,APOB,Cargo recognition for clathrin-mediated endocytosis,0.0401103081424522,0,0,1,0.04393582212484158
1481,APOB,Cargo recognition for clathrin-mediated endocytosis,0.038583530637265426,1,0,1,0.042263428468481246
1482,APOB,VLDL assembly,0.0401103081424522,0,0,1,0.04393582212484158
1483,APOB,VLDL assembly,0.038583530637265426,1,0,1,0.042263428468481246
1484,APOB,Chylomicron assembly,0.0401103081424522,0,0,1,0.04393582212484158
1485,APOB,Chylomicron assembly,0.038583530637265426,1,0,1,0.042263428468481246
1486,APOB,Chylomicron remodeling,0.0401103081424522,0,0,1,0.04393582212484158
1487,APOB,Chylomicron remodeling,0.038583530637265426,1,0,1,0.042263428468481246
1488,APOB,LDL remodeling,0.0401103081424522,0,0,1,0.04393582212484158
1489,APOB,LDL remodeling,0.038583530637265426,1,0,1,0.042263428468481246
1490,APOB,Chylomicron clearance,0.0401103081424522,0,0,1,0.04393582212484158
1491,APOB,Chylomicron clearance,0.038583530637265426,1,0,1,0.042263428468481246
1492,APOB,LDL clearance,0.0401103081424522,0,0,1,0.04393582212484158
1493,APOB,LDL clearance,0.038583530637265426,1,0,1,0.042263428468481246
1494,APOB,VLDL clearance,0.0401103081424522,0,0,1,0.04393582212484158
1495,APOB,VLDL clearance,0.038583530637265426,1,0,1,0.042263428468481246
1496,APOB,Scavenging by Class B Receptors,0.0401103081424522,0,0,1,0.04393582212484158
1497,APOB,Scavenging by Class B Receptors,0.038583530637265426,1,0,1,0.042263428468481246
1498,APOB,Scavenging by Class A Receptors,0.0401103081424522,0,0,1,0.04393582212484158
1499,APOB,Scavenging by Class A Receptors,0.038583530637265426,1,0,1,0.042263428468481246
1500,APOB,Scavenging by Class F Receptors,0.0401103081424522,0,0,1,0.04393582212484158
1501,APOB,Scavenging by Class F Receptors,0.038583530637265426,1,0,1,0.042263428468481246
1502,APOB,Scavenging by Class H Receptors,0.0401103081424522,0,0,1,0.04393582212484158
1503,APOB,Scavenging by Class H Receptors,0.038583530637265426,1,0,1,0.042263428468481246
1504,APOB,Retinoid metabolism and transport,0.0401103081424522,0,0,1,0.04393582212484158
1505,APOB,Retinoid metabolism and transport,0.038583530637265426,1,0,1,0.042263428468481246
1506,APOB,Heme signaling,0.0401103081424522,0,0,1,0.04393582212484158
1507,APOB,Heme signaling,0.038583530637265426,1,0,1,0.042263428468481246
1508,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0401103081424522,0,0,1,0.04393582212484158
1509,APOB,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.038583530637265426,1,0,1,0.042263428468481246
1510,APOB,Platelet sensitization by LDL,0.0401103081424522,0,0,1,0.04393582212484158
1511,APOB,Platelet sensitization by LDL,0.038583530637265426,1,0,1,0.042263428468481246
1512,APOB,Post-translational protein phosphorylation,0.0401103081424522,0,0,1,0.04393582212484158
1513,APOB,Post-translational protein phosphorylation,0.038583530637265426,1,0,1,0.042263428468481246
1514,SODM,FOXO-mediated transcription,0.00027772237094007504,0,0,1,0.00030421009597774747
1515,SODM,FOXO-mediated transcription,0.0004107866720707146,1,0,1,0.00044996538274540273
1516,SODM,Interleukin-12 family signaling,0.00027772237094007504,0,0,1,0.00030421009597774747
1517,SODM,Interleukin-12 family signaling,0.0004107866720707146,1,0,1,0.00044996538274540273
1518,SODM,Neurodegenerative Diseases,0.00027772237094007504,0,0,1,0.00030421009597774747
1519,SODM,Neurodegenerative Diseases,0.0004107866720707146,1,0,1,0.00044996538274540273
1520,SODM,Detoxification of Reactive Oxygen Species,0.00027772237094007504,0,0,1,0.00030421009597774747
1521,SODM,Detoxification of Reactive Oxygen Species,0.0004107866720707146,1,0,1,0.00044996538274540273
1522,SODM,Transcriptional activation of mitochondrial biogenesis,0.00027772237094007504,0,0,1,0.00030421009597774747
1523,SODM,Transcriptional activation of mitochondrial biogenesis,0.0004107866720707146,1,0,1,0.00044996538274540273
1524,LCAT,HDL remodeling,0.00043029063215560434,0,0,1,0.0004713295297865163
1525,LCAT,HDL remodeling,0.0003290861710113485,1,0,1,0.0003604727099564949
1526,HRG,Platelet degranulation ,0.0023853844389787777,0,0,1,0.0026128900839685566
1527,HRG,Platelet degranulation ,0.0027149531734043018,1,0,1,0.002973891381744768
1528,HRG,Dissolution of Fibrin Clot,0.0023853844389787777,0,0,1,0.0026128900839685566
1529,HRG,Dissolution of Fibrin Clot,0.0027149531734043018,1,0,1,0.002973891381744768
1530,LV743,Initial triggering of complement,0.00873610287662306,0,0,1,0.009569307238639474
1531,LV743,Initial triggering of complement,0.009538711455820819,1,0,1,0.010448464477877494
1532,LV743,Regulation of Complement cascade,0.00873610287662306,0,0,1,0.009569307238639474
1533,LV743,Regulation of Complement cascade,0.009538711455820819,1,0,1,0.010448464477877494
1534,LV743,FCGR activation,0.00873610287662306,0,0,1,0.009569307238639474
1535,LV743,FCGR activation,0.009538711455820819,1,0,1,0.010448464477877494
1536,LV743,Regulation of actin dynamics for phagocytic cup formation,0.00873610287662306,0,0,1,0.009569307238639474
1537,LV743,Regulation of actin dynamics for phagocytic cup formation,0.009538711455820819,1,0,1,0.010448464477877494
1538,LV743,Role of phospholipids in phagocytosis,0.00873610287662306,0,0,1,0.009569307238639474
1539,LV743,Role of phospholipids in phagocytosis,0.009538711455820819,1,0,1,0.010448464477877494
1540,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.00873610287662306,0,0,1,0.009569307238639474
1541,LV743,Role of LAT2/NTAL/LAB on calcium mobilization,0.009538711455820819,1,0,1,0.010448464477877494
1542,LV743,FCERI mediated MAPK activation,0.00873610287662306,0,0,1,0.009569307238639474
1543,LV743,FCERI mediated MAPK activation,0.009538711455820819,1,0,1,0.010448464477877494
1544,LV743,FCERI mediated Ca+2 mobilization,0.00873610287662306,0,0,1,0.009569307238639474
1545,LV743,FCERI mediated Ca+2 mobilization,0.009538711455820819,1,0,1,0.010448464477877494
1546,LV743,FCERI mediated NF-kB activation,0.00873610287662306,0,0,1,0.009569307238639474
1547,LV743,FCERI mediated NF-kB activation,0.009538711455820819,1,0,1,0.010448464477877494
1548,LV743,Parasite infection,0.00873610287662306,0,0,1,0.009569307238639474
1549,LV743,Parasite infection,0.009538711455820819,1,0,1,0.010448464477877494
1550,LV743,Leishmania parasite growth and survival,0.00873610287662306,0,0,1,0.009569307238639474
1551,LV743,Leishmania parasite growth and survival,0.009538711455820819,1,0,1,0.010448464477877494
1552,LV743,Potential therapeutics for SARS,0.00873610287662306,0,0,1,0.009569307238639474
1553,LV743,Potential therapeutics for SARS,0.009538711455820819,1,0,1,0.010448464477877494
1554,LV743,CD22 mediated BCR regulation,0.00873610287662306,0,0,1,0.009569307238639474
1555,LV743,CD22 mediated BCR regulation,0.009538711455820819,1,0,1,0.010448464477877494
1556,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00873610287662306,0,0,1,0.009569307238639474
1557,LV743,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.009538711455820819,1,0,1,0.010448464477877494
1558,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00873610287662306,0,0,1,0.009569307238639474
1559,LV743,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009538711455820819,1,0,1,0.010448464477877494
1560,LV743,Scavenging of heme from plasma,0.00873610287662306,0,0,1,0.009569307238639474
1561,LV743,Scavenging of heme from plasma,0.009538711455820819,1,0,1,0.010448464477877494
1562,A1BG,Platelet degranulation ,0.004057946159970606,0,0,1,0.0044449721015220435
1563,A1BG,Platelet degranulation ,0.003743497255467455,1,0,1,0.0041005326849377684
1564,A1BG,Neutrophil degranulation,0.004057946159970606,0,0,1,0.0044449721015220435
1565,A1BG,Neutrophil degranulation,0.003743497255467455,1,0,1,0.0041005326849377684
1566,K2C6B,Formation of the cornified envelope,0.0003493033334149549,0,0,1,0.00038261808086910985
1567,K2C6B,Formation of the cornified envelope,0.00034507291585320445,1,0,1,0.00037798418793448654
1568,K2C1,Neutrophil degranulation,0.001489998765104302,0,0,1,0.0016321071500462916
1569,K2C1,Neutrophil degranulation,0.0015442314299266146,1,0,1,0.0016915122462755924
1570,K2C1,Formation of the cornified envelope,0.001489998765104302,0,0,1,0.0016321071500462916
1571,K2C1,Formation of the cornified envelope,0.0015442314299266146,1,0,1,0.0016915122462755924
1572,VWF,RAF/MAP kinase cascade,0.005845292332662839,0,0,1,0.0064027861188072615
1573,VWF,RAF/MAP kinase cascade,0.0054005765915707375,1,0,1,0.005915655687713417
1574,VWF,Signaling by RAS mutants,0.005845292332662839,0,0,1,0.0064027861188072615
1575,VWF,Signaling by RAS mutants,0.0054005765915707375,1,0,1,0.005915655687713417
1576,VWF,Signaling by moderate kinase activity BRAF mutants,0.005845292332662839,0,0,1,0.0064027861188072615
1577,VWF,Signaling by moderate kinase activity BRAF mutants,0.0054005765915707375,1,0,1,0.005915655687713417
1578,VWF,Signaling by high-kinase activity BRAF mutants,0.005845292332662839,0,0,1,0.0064027861188072615
1579,VWF,Signaling by high-kinase activity BRAF mutants,0.0054005765915707375,1,0,1,0.005915655687713417
1580,VWF,Signaling by BRAF and RAF1 fusions,0.005845292332662839,0,0,1,0.0064027861188072615
1581,VWF,Signaling by BRAF and RAF1 fusions,0.0054005765915707375,1,0,1,0.005915655687713417
1582,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005845292332662839,0,0,1,0.0064027861188072615
1583,VWF,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0054005765915707375,1,0,1,0.005915655687713417
1584,VWF,Signaling by RAF1 mutants,0.005845292332662839,0,0,1,0.0064027861188072615
1585,VWF,Signaling by RAF1 mutants,0.0054005765915707375,1,0,1,0.005915655687713417
1586,VWF,Platelet degranulation ,0.005845292332662839,0,0,1,0.0064027861188072615
1587,VWF,Platelet degranulation ,0.0054005765915707375,1,0,1,0.005915655687713417
1588,VWF,Defective factor VIII causes hemophilia A,0.005845292332662839,0,0,1,0.0064027861188072615
1589,VWF,Defective factor VIII causes hemophilia A,0.0054005765915707375,1,0,1,0.005915655687713417
1590,VWF,Platelet Adhesion to exposed collagen,0.005845292332662839,0,0,1,0.0064027861188072615
1591,VWF,Platelet Adhesion to exposed collagen,0.0054005765915707375,1,0,1,0.005915655687713417
1592,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.005845292332662839,0,0,1,0.0064027861188072615
1593,VWF,Intrinsic Pathway of Fibrin Clot Formation,0.0054005765915707375,1,0,1,0.005915655687713417
1594,VWF,Integrin cell surface interactions,0.005845292332662839,0,0,1,0.0064027861188072615
1595,VWF,Integrin cell surface interactions,0.0054005765915707375,1,0,1,0.005915655687713417
1596,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.005845292332662839,0,0,1,0.0064027861188072615
1597,VWF,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0054005765915707375,1,0,1,0.005915655687713417
1598,VWF,p130Cas linkage to MAPK signaling for integrins,0.005845292332662839,0,0,1,0.0064027861188072615
1599,VWF,p130Cas linkage to MAPK signaling for integrins,0.0054005765915707375,1,0,1,0.005915655687713417
1600,VWF,GP1b-IX-V activation signalling,0.005845292332662839,0,0,1,0.0064027861188072615
1601,VWF,GP1b-IX-V activation signalling,0.0054005765915707375,1,0,1,0.005915655687713417
1602,G3P,Glycolysis,0.00013552766863840542,0,0,1,0.00014845359754265438
1603,G3P,Glycolysis,0.0001706413274733137,1,0,1,0.00018691621576148775
1604,G3P,Gluconeogenesis,0.00013552766863840542,0,0,1,0.00014845359754265438
1605,G3P,Gluconeogenesis,0.0001706413274733137,1,0,1,0.00018691621576148775
1606,ARLY,Urea cycle,0.000825149344421006,0,0,1,0.0009038478262035747
1607,ARLY,Urea cycle,0.0005509454305939669,1,0,1,0.0006034917596020967
1608,KV116,Initial triggering of complement,0.003844282231196229,0,0,1,0.0042109300110004235
1609,KV116,Initial triggering of complement,0.00421206995480563,1,0,1,0.004613795427711111
1610,KV116,Regulation of Complement cascade,0.003844282231196229,0,0,1,0.0042109300110004235
1611,KV116,Regulation of Complement cascade,0.00421206995480563,1,0,1,0.004613795427711111
1612,KV116,FCGR activation,0.003844282231196229,0,0,1,0.0042109300110004235
1613,KV116,FCGR activation,0.00421206995480563,1,0,1,0.004613795427711111
1614,KV116,Regulation of actin dynamics for phagocytic cup formation,0.003844282231196229,0,0,1,0.0042109300110004235
1615,KV116,Regulation of actin dynamics for phagocytic cup formation,0.00421206995480563,1,0,1,0.004613795427711111
1616,KV116,Role of phospholipids in phagocytosis,0.003844282231196229,0,0,1,0.0042109300110004235
1617,KV116,Role of phospholipids in phagocytosis,0.00421206995480563,1,0,1,0.004613795427711111
1618,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.003844282231196229,0,0,1,0.0042109300110004235
1619,KV116,Role of LAT2/NTAL/LAB on calcium mobilization,0.00421206995480563,1,0,1,0.004613795427711111
1620,KV116,FCERI mediated MAPK activation,0.003844282231196229,0,0,1,0.0042109300110004235
1621,KV116,FCERI mediated MAPK activation,0.00421206995480563,1,0,1,0.004613795427711111
1622,KV116,FCERI mediated Ca+2 mobilization,0.003844282231196229,0,0,1,0.0042109300110004235
1623,KV116,FCERI mediated Ca+2 mobilization,0.00421206995480563,1,0,1,0.004613795427711111
1624,KV116,FCERI mediated NF-kB activation,0.003844282231196229,0,0,1,0.0042109300110004235
1625,KV116,FCERI mediated NF-kB activation,0.00421206995480563,1,0,1,0.004613795427711111
1626,KV116,Parasite infection,0.003844282231196229,0,0,1,0.0042109300110004235
1627,KV116,Parasite infection,0.00421206995480563,1,0,1,0.004613795427711111
1628,KV116,Leishmania parasite growth and survival,0.003844282231196229,0,0,1,0.0042109300110004235
1629,KV116,Leishmania parasite growth and survival,0.00421206995480563,1,0,1,0.004613795427711111
1630,KV116,Potential therapeutics for SARS,0.003844282231196229,0,0,1,0.0042109300110004235
1631,KV116,Potential therapeutics for SARS,0.00421206995480563,1,0,1,0.004613795427711111
1632,KV116,CD22 mediated BCR regulation,0.003844282231196229,0,0,1,0.0042109300110004235
1633,KV116,CD22 mediated BCR regulation,0.00421206995480563,1,0,1,0.004613795427711111
1634,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003844282231196229,0,0,1,0.0042109300110004235
1635,KV116,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00421206995480563,1,0,1,0.004613795427711111
1636,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003844282231196229,0,0,1,0.0042109300110004235
1637,KV116,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00421206995480563,1,0,1,0.004613795427711111
1638,KV116,Scavenging of heme from plasma,0.003844282231196229,0,0,1,0.0042109300110004235
1639,KV116,Scavenging of heme from plasma,0.00421206995480563,1,0,1,0.004613795427711111
1640,KV311,Initial triggering of complement,0.010179351684542448,0,0,1,0.011150205662092951
1641,KV311,Initial triggering of complement,0.01133439650376956,1,0,1,0.012415412689262892
1642,KV311,Regulation of Complement cascade,0.010179351684542448,0,0,1,0.011150205662092951
1643,KV311,Regulation of Complement cascade,0.01133439650376956,1,0,1,0.012415412689262892
1644,KV311,FCGR activation,0.010179351684542448,0,0,1,0.011150205662092951
1645,KV311,FCGR activation,0.01133439650376956,1,0,1,0.012415412689262892
1646,KV311,Regulation of actin dynamics for phagocytic cup formation,0.010179351684542448,0,0,1,0.011150205662092951
1647,KV311,Regulation of actin dynamics for phagocytic cup formation,0.01133439650376956,1,0,1,0.012415412689262892
1648,KV311,Role of phospholipids in phagocytosis,0.010179351684542448,0,0,1,0.011150205662092951
1649,KV311,Role of phospholipids in phagocytosis,0.01133439650376956,1,0,1,0.012415412689262892
1650,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.010179351684542448,0,0,1,0.011150205662092951
1651,KV311,Role of LAT2/NTAL/LAB on calcium mobilization,0.01133439650376956,1,0,1,0.012415412689262892
1652,KV311,FCERI mediated MAPK activation,0.010179351684542448,0,0,1,0.011150205662092951
1653,KV311,FCERI mediated MAPK activation,0.01133439650376956,1,0,1,0.012415412689262892
1654,KV311,FCERI mediated Ca+2 mobilization,0.010179351684542448,0,0,1,0.011150205662092951
1655,KV311,FCERI mediated Ca+2 mobilization,0.01133439650376956,1,0,1,0.012415412689262892
1656,KV311,FCERI mediated NF-kB activation,0.010179351684542448,0,0,1,0.011150205662092951
1657,KV311,FCERI mediated NF-kB activation,0.01133439650376956,1,0,1,0.012415412689262892
1658,KV311,Parasite infection,0.010179351684542448,0,0,1,0.011150205662092951
1659,KV311,Parasite infection,0.01133439650376956,1,0,1,0.012415412689262892
1660,KV311,Leishmania parasite growth and survival,0.010179351684542448,0,0,1,0.011150205662092951
1661,KV311,Leishmania parasite growth and survival,0.01133439650376956,1,0,1,0.012415412689262892
1662,KV311,Potential therapeutics for SARS,0.010179351684542448,0,0,1,0.011150205662092951
1663,KV311,Potential therapeutics for SARS,0.01133439650376956,1,0,1,0.012415412689262892
1664,KV311,CD22 mediated BCR regulation,0.010179351684542448,0,0,1,0.011150205662092951
1665,KV311,CD22 mediated BCR regulation,0.01133439650376956,1,0,1,0.012415412689262892
1666,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.010179351684542448,0,0,1,0.011150205662092951
1667,KV311,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.01133439650376956,1,0,1,0.012415412689262892
1668,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.010179351684542448,0,0,1,0.011150205662092951
1669,KV311,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.01133439650376956,1,0,1,0.012415412689262892
1670,KV311,Scavenging of heme from plasma,0.010179351684542448,0,0,1,0.011150205662092951
1671,KV311,Scavenging of heme from plasma,0.01133439650376956,1,0,1,0.012415412689262892
1672,MT1A,Metallothioneins bind metals,0.0011646136113201376,0,0,1,0.001275688441220804
1673,MT1A,Metallothioneins bind metals,0.0011164642626515396,1,0,1,0.0012229468564137925
1674,MT1E,Metallothioneins bind metals,0.0034150429008538044,0,0,1,0.0037407520507630456
1675,MT1E,Metallothioneins bind metals,0.003205282859466403,1,0,1,0.0035109861802400466
1676,H2A1B,Packaging Of Telomere Ends,0.008110506079504786,0,0,1,0.008884044250819937
1677,H2A1B,Packaging Of Telomere Ends,0.0049359566333519326,1,0,1,0.0054067226780877085
1678,H2A1B,Inhibition of DNA recombination at telomere,0.008110506079504786,0,0,1,0.008884044250819937
1679,H2A1B,Inhibition of DNA recombination at telomere,0.0049359566333519326,1,0,1,0.0054067226780877085
1680,H2A1B,Pre-NOTCH Transcription and Translation,0.008110506079504786,0,0,1,0.008884044250819937
1681,H2A1B,Pre-NOTCH Transcription and Translation,0.0049359566333519326,1,0,1,0.0054067226780877085
1682,H2A1B,RHO GTPase Effectors,0.008110506079504786,0,0,1,0.008884044250819937
1683,H2A1B,RHO GTPase Effectors,0.0049359566333519326,1,0,1,0.0054067226780877085
1684,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.008110506079504786,0,0,1,0.008884044250819937
1685,H2A1B,Formation of the beta-catenin:TCF transactivating complex,0.0049359566333519326,1,0,1,0.0054067226780877085
1686,H2A1B,Transcriptional regulation by RUNX1,0.008110506079504786,0,0,1,0.008884044250819937
1687,H2A1B,Transcriptional regulation by RUNX1,0.0049359566333519326,1,0,1,0.0054067226780877085
1688,H2A1B,Oxidative Stress Induced Senescence,0.008110506079504786,0,0,1,0.008884044250819937
1689,H2A1B,Oxidative Stress Induced Senescence,0.0049359566333519326,1,0,1,0.0054067226780877085
1690,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.008110506079504786,0,0,1,0.008884044250819937
1691,H2A1B,Senescence-Associated Secretory Phenotype (SASP),0.0049359566333519326,1,0,1,0.0054067226780877085
1692,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.008110506079504786,0,0,1,0.008884044250819937
1693,H2A1B,DNA Damage/Telomere Stress Induced Senescence,0.0049359566333519326,1,0,1,0.0054067226780877085
1694,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.008110506079504786,0,0,1,0.008884044250819937
1695,H2A1B,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0049359566333519326,1,0,1,0.0054067226780877085
1696,H2A1B,B-WICH complex positively regulates rRNA expression,0.008110506079504786,0,0,1,0.008884044250819937
1697,H2A1B,B-WICH complex positively regulates rRNA expression,0.0049359566333519326,1,0,1,0.0054067226780877085
1698,H2A1B,SIRT1 negatively regulates rRNA expression,0.008110506079504786,0,0,1,0.008884044250819937
1699,H2A1B,SIRT1 negatively regulates rRNA expression,0.0049359566333519326,1,0,1,0.0054067226780877085
1700,H2A1B,NoRC negatively regulates rRNA expression,0.008110506079504786,0,0,1,0.008884044250819937
1701,H2A1B,NoRC negatively regulates rRNA expression,0.0049359566333519326,1,0,1,0.0054067226780877085
1702,H2A1B,UCH proteinases,0.008110506079504786,0,0,1,0.008884044250819937
1703,H2A1B,UCH proteinases,0.0049359566333519326,1,0,1,0.0054067226780877085
1704,H2A1B,Ub-specific processing proteases,0.008110506079504786,0,0,1,0.008884044250819937
1705,H2A1B,Ub-specific processing proteases,0.0049359566333519326,1,0,1,0.0054067226780877085
1706,H2A1B,Metalloprotease DUBs,0.008110506079504786,0,0,1,0.008884044250819937
1707,H2A1B,Metalloprotease DUBs,0.0049359566333519326,1,0,1,0.0054067226780877085
1708,H2A1B,Assembly of the ORC complex at the origin of replication,0.008110506079504786,0,0,1,0.008884044250819937
1709,H2A1B,Assembly of the ORC complex at the origin of replication,0.0049359566333519326,1,0,1,0.0054067226780877085
1710,H2A1B,Mitotic Prophase,0.008110506079504786,0,0,1,0.008884044250819937
1711,H2A1B,Mitotic Prophase,0.0049359566333519326,1,0,1,0.0054067226780877085
1712,H2A1B,RNA Polymerase I Promoter Opening,0.008110506079504786,0,0,1,0.008884044250819937
1713,H2A1B,RNA Polymerase I Promoter Opening,0.0049359566333519326,1,0,1,0.0054067226780877085
1714,H2A1B,RNA Polymerase I Promoter Escape,0.008110506079504786,0,0,1,0.008884044250819937
1715,H2A1B,RNA Polymerase I Promoter Escape,0.0049359566333519326,1,0,1,0.0054067226780877085
1716,H2A1B,Depurination,0.008110506079504786,0,0,1,0.008884044250819937
1717,H2A1B,Depurination,0.0049359566333519326,1,0,1,0.0054067226780877085
1718,H2A1B,Depyrimidination,0.008110506079504786,0,0,1,0.008884044250819937
1719,H2A1B,Depyrimidination,0.0049359566333519326,1,0,1,0.0054067226780877085
1720,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.008110506079504786,0,0,1,0.008884044250819937
1721,H2A1B,Deposition of new CENPA-containing nucleosomes at the centromere,0.0049359566333519326,1,0,1,0.0054067226780877085
1722,H2A1B,Estrogen-dependent gene expression,0.008110506079504786,0,0,1,0.008884044250819937
1723,H2A1B,Estrogen-dependent gene expression,0.0049359566333519326,1,0,1,0.0054067226780877085
1724,H2A1B,HCMV Early Events,0.008110506079504786,0,0,1,0.008884044250819937
1725,H2A1B,HCMV Early Events,0.0049359566333519326,1,0,1,0.0054067226780877085
1726,H2A1B,HCMV Late Events,0.008110506079504786,0,0,1,0.008884044250819937
1727,H2A1B,HCMV Late Events,0.0049359566333519326,1,0,1,0.0054067226780877085
1728,H2A1B,Transcriptional regulation of granulopoiesis,0.008110506079504786,0,0,1,0.008884044250819937
1729,H2A1B,Transcriptional regulation of granulopoiesis,0.0049359566333519326,1,0,1,0.0054067226780877085
1730,H2A1B,Meiotic synapsis,0.008110506079504786,0,0,1,0.008884044250819937
1731,H2A1B,Meiotic synapsis,0.0049359566333519326,1,0,1,0.0054067226780877085
1732,H2A1B,Meiotic recombination,0.008110506079504786,0,0,1,0.008884044250819937
1733,H2A1B,Meiotic recombination,0.0049359566333519326,1,0,1,0.0054067226780877085
1734,H2A1B,Transcriptional regulation by small RNAs,0.008110506079504786,0,0,1,0.008884044250819937
1735,H2A1B,Transcriptional regulation by small RNAs,0.0049359566333519326,1,0,1,0.0054067226780877085
1736,H2A1B,PRC2 methylates histones and DNA,0.008110506079504786,0,0,1,0.008884044250819937
1737,H2A1B,PRC2 methylates histones and DNA,0.0049359566333519326,1,0,1,0.0054067226780877085
1738,H2A1B,DNA methylation,0.008110506079504786,0,0,1,0.008884044250819937
1739,H2A1B,DNA methylation,0.0049359566333519326,1,0,1,0.0054067226780877085
1740,H2A1B,HDACs deacetylate histones,0.008110506079504786,0,0,1,0.008884044250819937
1741,H2A1B,HDACs deacetylate histones,0.0049359566333519326,1,0,1,0.0054067226780877085
1742,H2A1B,HATs acetylate histones,0.008110506079504786,0,0,1,0.008884044250819937
1743,H2A1B,HATs acetylate histones,0.0049359566333519326,1,0,1,0.0054067226780877085
1744,H2A1B,RMTs methylate histone arginines,0.008110506079504786,0,0,1,0.008884044250819937
1745,H2A1B,RMTs methylate histone arginines,0.0049359566333519326,1,0,1,0.0054067226780877085
1746,H2A1B,Amyloid fiber formation,0.008110506079504786,0,0,1,0.008884044250819937
1747,H2A1B,Amyloid fiber formation,0.0049359566333519326,1,0,1,0.0054067226780877085
1748,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.008110506079504786,0,0,1,0.008884044250819937
1749,H2A1B,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0049359566333519326,1,0,1,0.0054067226780877085
1750,H2A1B,Defective pyroptosis,0.008110506079504786,0,0,1,0.008884044250819937
1751,H2A1B,Defective pyroptosis,0.0049359566333519326,1,0,1,0.0054067226780877085
1752,IGF1,IGF1R signaling cascade,0.0024783690855956545,0,0,1,0.0027147431258248084
1753,IGF1,IGF1R signaling cascade,0.0026367646813402093,1,0,1,0.0028882456752262055
1754,IGF1,Platelet degranulation ,0.0024783690855956545,0,0,1,0.0027147431258248084
1755,IGF1,Platelet degranulation ,0.0026367646813402093,1,0,1,0.0028882456752262055
1756,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.0024783690855956545,0,0,1,0.0027147431258248084
1757,IGF1,"Synthesis, secretion, and deacylation of Ghrelin",0.0026367646813402093,1,0,1,0.0028882456752262055
1758,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0024783690855956545,0,0,1,0.0027147431258248084
1759,IGF1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0026367646813402093,1,0,1,0.0028882456752262055
1760,ALDOB,Fructose catabolism,0.005376246381376109,0,0,1,0.005889004987759312
1761,ALDOB,Fructose catabolism,0.00685003998205964,1,0,1,0.007503361408517606
1762,ALDOB,Hereditary fructose intolerance,0.005376246381376109,0,0,1,0.005889004987759312
1763,ALDOB,Hereditary fructose intolerance,0.00685003998205964,1,0,1,0.007503361408517606
1764,ALDOB,Glycolysis,0.005376246381376109,0,0,1,0.005889004987759312
1765,ALDOB,Glycolysis,0.00685003998205964,1,0,1,0.007503361408517606
1766,ALDOB,Gluconeogenesis,0.005376246381376109,0,0,1,0.005889004987759312
1767,ALDOB,Gluconeogenesis,0.00685003998205964,1,0,1,0.007503361408517606
1768,APOD,Transport of fatty acids,0.0012070311275348855,0,0,1,0.0013221515210049325
1769,APOD,Transport of fatty acids,0.0008737582680591429,1,0,1,0.0009570928178665737
1770,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0012070311275348855,0,0,1,0.0013221515210049325
1771,APOD,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,0.0008737582680591429,1,0,1,0.0009570928178665737
1772,ALDH2,Serotonin clearance from the synaptic cleft,0.001145213051787152,0,0,1,0.0012544375565420717
1773,ALDH2,Serotonin clearance from the synaptic cleft,0.0007981560629929019,1,0,1,0.0008742800650390635
1774,ALDH2,Ethanol oxidation,0.001145213051787152,0,0,1,0.0012544375565420717
1775,ALDH2,Ethanol oxidation,0.0007981560629929019,1,0,1,0.0008742800650390635
1776,ALDH2,Smooth Muscle Contraction,0.001145213051787152,0,0,1,0.0012544375565420717
1777,ALDH2,Smooth Muscle Contraction,0.0007981560629929019,1,0,1,0.0008742800650390635
1778,ITB3,TGF-beta receptor signaling activates SMADs,0.0022396357023265912,0,0,1,0.002453240585746593
1779,ITB3,TGF-beta receptor signaling activates SMADs,0.0023974794835362793,1,0,1,0.002626138691393439
1780,ITB3,VEGFA-VEGFR2 Pathway,0.0022396357023265912,0,0,1,0.002453240585746593
1781,ITB3,VEGFA-VEGFR2 Pathway,0.0023974794835362793,1,0,1,0.002626138691393439
1782,ITB3,L1CAM interactions,0.0022396357023265912,0,0,1,0.002453240585746593
1783,ITB3,L1CAM interactions,0.0023974794835362793,1,0,1,0.002626138691393439
1784,ITB3,RAF/MAP kinase cascade,0.0022396357023265912,0,0,1,0.002453240585746593
1785,ITB3,RAF/MAP kinase cascade,0.0023974794835362793,1,0,1,0.002626138691393439
1786,ITB3,Signaling by RAS mutants,0.0022396357023265912,0,0,1,0.002453240585746593
1787,ITB3,Signaling by RAS mutants,0.0023974794835362793,1,0,1,0.002626138691393439
1788,ITB3,Signaling by moderate kinase activity BRAF mutants,0.0022396357023265912,0,0,1,0.002453240585746593
1789,ITB3,Signaling by moderate kinase activity BRAF mutants,0.0023974794835362793,1,0,1,0.002626138691393439
1790,ITB3,Signaling by high-kinase activity BRAF mutants,0.0022396357023265912,0,0,1,0.002453240585746593
1791,ITB3,Signaling by high-kinase activity BRAF mutants,0.0023974794835362793,1,0,1,0.002626138691393439
1792,ITB3,Signaling by BRAF and RAF1 fusions,0.0022396357023265912,0,0,1,0.002453240585746593
1793,ITB3,Signaling by BRAF and RAF1 fusions,0.0023974794835362793,1,0,1,0.002626138691393439
1794,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0022396357023265912,0,0,1,0.002453240585746593
1795,ITB3,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0023974794835362793,1,0,1,0.002626138691393439
1796,ITB3,Signaling by RAF1 mutants,0.0022396357023265912,0,0,1,0.002453240585746593
1797,ITB3,Signaling by RAF1 mutants,0.0023974794835362793,1,0,1,0.002626138691393439
1798,ITB3,Platelet degranulation ,0.0022396357023265912,0,0,1,0.002453240585746593
1799,ITB3,Platelet degranulation ,0.0023974794835362793,1,0,1,0.002626138691393439
1800,ITB3,Integrin cell surface interactions,0.0022396357023265912,0,0,1,0.002453240585746593
1801,ITB3,Integrin cell surface interactions,0.0023974794835362793,1,0,1,0.002626138691393439
1802,ITB3,ECM proteoglycans,0.0022396357023265912,0,0,1,0.002453240585746593
1803,ITB3,ECM proteoglycans,0.0023974794835362793,1,0,1,0.002626138691393439
1804,ITB3,Molecules associated with elastic fibres,0.0022396357023265912,0,0,1,0.002453240585746593
1805,ITB3,Molecules associated with elastic fibres,0.0023974794835362793,1,0,1,0.002626138691393439
1806,ITB3,PECAM1 interactions,0.0022396357023265912,0,0,1,0.002453240585746593
1807,ITB3,PECAM1 interactions,0.0023974794835362793,1,0,1,0.002626138691393439
1808,ITB3,Syndecan interactions,0.0022396357023265912,0,0,1,0.002453240585746593
1809,ITB3,Syndecan interactions,0.0023974794835362793,1,0,1,0.002626138691393439
1810,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0022396357023265912,0,0,1,0.002453240585746593
1811,ITB3,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0023974794835362793,1,0,1,0.002626138691393439
1812,ITB3,p130Cas linkage to MAPK signaling for integrins,0.0022396357023265912,0,0,1,0.002453240585746593
1813,ITB3,p130Cas linkage to MAPK signaling for integrins,0.0023974794835362793,1,0,1,0.002626138691393439
1814,S10A8,Antigen processing-Cross presentation,0.007123507432081012,0,0,1,0.0078029107712001755
1815,S10A8,Antigen processing-Cross presentation,0.007254557436007311,1,0,1,0.007946459647501918
1816,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.007123507432081012,0,0,1,0.0078029107712001755
1817,S10A8,Toll Like Receptor 4 (TLR4) Cascade,0.007254557436007311,1,0,1,0.007946459647501918
1818,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.007123507432081012,0,0,1,0.0078029107712001755
1819,S10A8,Toll Like Receptor 2 (TLR2) Cascade,0.007254557436007311,1,0,1,0.007946459647501918
1820,S10A8,Regulation of TLR by endogenous ligand,0.007123507432081012,0,0,1,0.0078029107712001755
1821,S10A8,Regulation of TLR by endogenous ligand,0.007254557436007311,1,0,1,0.007946459647501918
1822,S10A8,RHO GTPase Effectors,0.007123507432081012,0,0,1,0.0078029107712001755
1823,S10A8,RHO GTPase Effectors,0.007254557436007311,1,0,1,0.007946459647501918
1824,S10A8,MyD88 deficiency (TLR2/4),0.007123507432081012,0,0,1,0.0078029107712001755
1825,S10A8,MyD88 deficiency (TLR2/4),0.007254557436007311,1,0,1,0.007946459647501918
1826,S10A8,IRAK4 deficiency (TLR2/4),0.007123507432081012,0,0,1,0.0078029107712001755
1827,S10A8,IRAK4 deficiency (TLR2/4),0.007254557436007311,1,0,1,0.007946459647501918
1828,S10A8,Metal sequestration by antimicrobial proteins,0.007123507432081012,0,0,1,0.0078029107712001755
1829,S10A8,Metal sequestration by antimicrobial proteins,0.007254557436007311,1,0,1,0.007946459647501918
1830,S10A8,Neutrophil degranulation,0.007123507432081012,0,0,1,0.0078029107712001755
1831,S10A8,Neutrophil degranulation,0.007254557436007311,1,0,1,0.007946459647501918
1832,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.007532703734551401,0,0,1,0.008251134103108558
1833,PAI1,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.006470952273422124,1,0,1,0.0070881182725820915
1834,PAI1,Platelet degranulation ,0.007532703734551401,0,0,1,0.008251134103108558
1835,PAI1,Platelet degranulation ,0.006470952273422124,1,0,1,0.0070881182725820915
1836,PAI1,Dissolution of Fibrin Clot,0.007532703734551401,0,0,1,0.008251134103108558
1837,PAI1,Dissolution of Fibrin Clot,0.006470952273422124,1,0,1,0.0070881182725820915
1838,PAI1,ECM proteoglycans,0.007532703734551401,0,0,1,0.008251134103108558
1839,PAI1,ECM proteoglycans,0.006470952273422124,1,0,1,0.0070881182725820915
1840,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.007532703734551401,0,0,1,0.008251134103108558
1841,PAI1,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.006470952273422124,1,0,1,0.0070881182725820915
1842,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.002536472050723653,0,0,1,0.0027783876516091362
1843,IPSP,Intrinsic Pathway of Fibrin Clot Formation,0.002053838233117175,1,0,1,0.0022497227137462314
1844,IPSP,Common Pathway of Fibrin Clot Formation,0.002536472050723653,0,0,1,0.0027783876516091362
1845,IPSP,Common Pathway of Fibrin Clot Formation,0.002053838233117175,1,0,1,0.0022497227137462314
1846,IC1,Regulation of Complement cascade,0.00013096036587361375,0,0,1,0.00014345068903465915
1847,IC1,Regulation of Complement cascade,0.000355948126129734,1,0,1,0.00038989661958629284
1848,IC1,Platelet degranulation ,0.00013096036587361375,0,0,1,0.00014345068903465915
1849,IC1,Platelet degranulation ,0.000355948126129734,1,0,1,0.00038989661958629284
1850,IC1,Defective SERPING1 causes hereditary angioedema,0.00013096036587361375,0,0,1,0.00014345068903465915
1851,IC1,Defective SERPING1 causes hereditary angioedema,0.000355948126129734,1,0,1,0.00038989661958629284
1852,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.00013096036587361375,0,0,1,0.00014345068903465915
1853,IC1,Intrinsic Pathway of Fibrin Clot Formation,0.000355948126129734,1,0,1,0.00038989661958629284
1854,CFAI,Regulation of Complement cascade,6.887603294045719e-05,0,0,1,7.544507315150359e-05
1855,CFAI,Regulation of Complement cascade,7.340727603435382e-05,1,0,1,8.040848280347662e-05
1856,F13B,Common Pathway of Fibrin Clot Formation,0.0013395233010189333,0,0,1,0.0014672801135466526
1857,F13B,Common Pathway of Fibrin Clot Formation,0.0010160891114015973,1,0,1,0.0011129984417716226
1858,PERM,Events associated with phagocytolytic activity of PMN cells,0.004521882203454861,0,0,1,0.004953155968158896
1859,PERM,Events associated with phagocytolytic activity of PMN cells,0.005176941548334671,1,0,1,0.005670691489343129
1860,PERM,Neutrophil degranulation,0.004521882203454861,0,0,1,0.004953155968158896
1861,PERM,Neutrophil degranulation,0.005176941548334671,1,0,1,0.005670691489343129
1862,ICAM1,Interleukin-10 signaling,0.006109262207237269,0,0,1,0.006691932076360852
1863,ICAM1,Interleukin-10 signaling,0.006438414907524052,1,0,1,0.007052477660811385
1864,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.006109262207237269,0,0,1,0.006691932076360852
1865,ICAM1,Interleukin-4 and Interleukin-13 signaling,0.006438414907524052,1,0,1,0.007052477660811385
1866,ICAM1,Interferon gamma signaling,0.006109262207237269,0,0,1,0.006691932076360852
1867,ICAM1,Interferon gamma signaling,0.006438414907524052,1,0,1,0.007052477660811385
1868,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006109262207237269,0,0,1,0.006691932076360852
1869,ICAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.006438414907524052,1,0,1,0.007052477660811385
1870,ICAM1,Integrin cell surface interactions,0.006109262207237269,0,0,1,0.006691932076360852
1871,ICAM1,Integrin cell surface interactions,0.006438414907524052,1,0,1,0.007052477660811385
1872,TETN,Platelet degranulation ,0.0011363174294112773,0,0,1,0.0012446935156584134
1873,TETN,Platelet degranulation ,0.0008838005791816899,1,0,1,0.0009680929127458142
1874,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.0053855393335112325,0,0,1,0.005899184253662067
1875,HEP2,Intrinsic Pathway of Fibrin Clot Formation,0.005193507144243081,1,0,1,0.005688837026212081
1876,HEP2,Common Pathway of Fibrin Clot Formation,0.0053855393335112325,0,0,1,0.005899184253662067
1877,HEP2,Common Pathway of Fibrin Clot Formation,0.005193507144243081,1,0,1,0.005688837026212081
1878,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0053855393335112325,0,0,1,0.005899184253662067
1879,HEP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005193507144243081,1,0,1,0.005688837026212081
1880,HEP2,Post-translational protein phosphorylation,0.0053855393335112325,0,0,1,0.005899184253662067
1881,HEP2,Post-translational protein phosphorylation,0.005193507144243081,1,0,1,0.005688837026212081
1882,K2C8,Formation of the cornified envelope,7.607160057259212e-05,0,0,1,8.332691685237874e-05
1883,K2C8,Formation of the cornified envelope,7.359597396958256e-05,1,0,1,8.061517777296154e-05
1884,CHLE,Glycerophospholipid biosynthesis,9.313643279787496e-05,0,0,1,0.00010201930461907251
1885,CHLE,Glycerophospholipid biosynthesis,0.00019985805288628476,1,0,1,0.00021891948151192027
1886,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",9.313643279787496e-05,0,0,1,0.00010201930461907251
1887,CHLE,"Synthesis, secretion, and deacylation of Ghrelin",0.00019985805288628476,1,0,1,0.00021891948151192027
1888,CHLE,Aspirin ADME,9.313643279787496e-05,0,0,1,0.00010201930461907251
1889,CHLE,Aspirin ADME,0.00019985805288628476,1,0,1,0.00021891948151192027
1890,KV230,Initial triggering of complement,0.003405479131902327,0,0,1,0.003730276138935022
1891,KV230,Initial triggering of complement,0.003950517988340636,1,0,1,0.004327297985851618
1892,KV230,Regulation of Complement cascade,0.003405479131902327,0,0,1,0.003730276138935022
1893,KV230,Regulation of Complement cascade,0.003950517988340636,1,0,1,0.004327297985851618
1894,KV230,FCGR activation,0.003405479131902327,0,0,1,0.003730276138935022
1895,KV230,FCGR activation,0.003950517988340636,1,0,1,0.004327297985851618
1896,KV230,Regulation of actin dynamics for phagocytic cup formation,0.003405479131902327,0,0,1,0.003730276138935022
1897,KV230,Regulation of actin dynamics for phagocytic cup formation,0.003950517988340636,1,0,1,0.004327297985851618
1898,KV230,Role of phospholipids in phagocytosis,0.003405479131902327,0,0,1,0.003730276138935022
1899,KV230,Role of phospholipids in phagocytosis,0.003950517988340636,1,0,1,0.004327297985851618
1900,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.003405479131902327,0,0,1,0.003730276138935022
1901,KV230,Role of LAT2/NTAL/LAB on calcium mobilization,0.003950517988340636,1,0,1,0.004327297985851618
1902,KV230,FCERI mediated MAPK activation,0.003405479131902327,0,0,1,0.003730276138935022
1903,KV230,FCERI mediated MAPK activation,0.003950517988340636,1,0,1,0.004327297985851618
1904,KV230,FCERI mediated Ca+2 mobilization,0.003405479131902327,0,0,1,0.003730276138935022
1905,KV230,FCERI mediated Ca+2 mobilization,0.003950517988340636,1,0,1,0.004327297985851618
1906,KV230,FCERI mediated NF-kB activation,0.003405479131902327,0,0,1,0.003730276138935022
1907,KV230,FCERI mediated NF-kB activation,0.003950517988340636,1,0,1,0.004327297985851618
1908,KV230,Parasite infection,0.003405479131902327,0,0,1,0.003730276138935022
1909,KV230,Parasite infection,0.003950517988340636,1,0,1,0.004327297985851618
1910,KV230,Leishmania parasite growth and survival,0.003405479131902327,0,0,1,0.003730276138935022
1911,KV230,Leishmania parasite growth and survival,0.003950517988340636,1,0,1,0.004327297985851618
1912,KV230,Potential therapeutics for SARS,0.003405479131902327,0,0,1,0.003730276138935022
1913,KV230,Potential therapeutics for SARS,0.003950517988340636,1,0,1,0.004327297985851618
1914,KV230,CD22 mediated BCR regulation,0.003405479131902327,0,0,1,0.003730276138935022
1915,KV230,CD22 mediated BCR regulation,0.003950517988340636,1,0,1,0.004327297985851618
1916,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003405479131902327,0,0,1,0.003730276138935022
1917,KV230,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.003950517988340636,1,0,1,0.004327297985851618
1918,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003405479131902327,0,0,1,0.003730276138935022
1919,KV230,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003950517988340636,1,0,1,0.004327297985851618
1920,KV230,Scavenging of heme from plasma,0.003405479131902327,0,0,1,0.003730276138935022
1921,KV230,Scavenging of heme from plasma,0.003950517988340636,1,0,1,0.004327297985851618
1922,KV401,Initial triggering of complement,0.004707462968319656,0,0,1,0.005156436467673733
1923,KV401,Initial triggering of complement,0.005181222883920367,1,0,1,0.00567538115659978
1924,KV401,Regulation of Complement cascade,0.004707462968319656,0,0,1,0.005156436467673733
1925,KV401,Regulation of Complement cascade,0.005181222883920367,1,0,1,0.00567538115659978
1926,KV401,FCGR activation,0.004707462968319656,0,0,1,0.005156436467673733
1927,KV401,FCGR activation,0.005181222883920367,1,0,1,0.00567538115659978
1928,KV401,Regulation of actin dynamics for phagocytic cup formation,0.004707462968319656,0,0,1,0.005156436467673733
1929,KV401,Regulation of actin dynamics for phagocytic cup formation,0.005181222883920367,1,0,1,0.00567538115659978
1930,KV401,Role of phospholipids in phagocytosis,0.004707462968319656,0,0,1,0.005156436467673733
1931,KV401,Role of phospholipids in phagocytosis,0.005181222883920367,1,0,1,0.00567538115659978
1932,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.004707462968319656,0,0,1,0.005156436467673733
1933,KV401,Role of LAT2/NTAL/LAB on calcium mobilization,0.005181222883920367,1,0,1,0.00567538115659978
1934,KV401,FCERI mediated MAPK activation,0.004707462968319656,0,0,1,0.005156436467673733
1935,KV401,FCERI mediated MAPK activation,0.005181222883920367,1,0,1,0.00567538115659978
1936,KV401,FCERI mediated Ca+2 mobilization,0.004707462968319656,0,0,1,0.005156436467673733
1937,KV401,FCERI mediated Ca+2 mobilization,0.005181222883920367,1,0,1,0.00567538115659978
1938,KV401,FCERI mediated NF-kB activation,0.004707462968319656,0,0,1,0.005156436467673733
1939,KV401,FCERI mediated NF-kB activation,0.005181222883920367,1,0,1,0.00567538115659978
1940,KV401,Parasite infection,0.004707462968319656,0,0,1,0.005156436467673733
1941,KV401,Parasite infection,0.005181222883920367,1,0,1,0.00567538115659978
1942,KV401,Leishmania parasite growth and survival,0.004707462968319656,0,0,1,0.005156436467673733
1943,KV401,Leishmania parasite growth and survival,0.005181222883920367,1,0,1,0.00567538115659978
1944,KV401,Potential therapeutics for SARS,0.004707462968319656,0,0,1,0.005156436467673733
1945,KV401,Potential therapeutics for SARS,0.005181222883920367,1,0,1,0.00567538115659978
1946,KV401,CD22 mediated BCR regulation,0.004707462968319656,0,0,1,0.005156436467673733
1947,KV401,CD22 mediated BCR regulation,0.005181222883920367,1,0,1,0.00567538115659978
1948,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.004707462968319656,0,0,1,0.005156436467673733
1949,KV401,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.005181222883920367,1,0,1,0.00567538115659978
1950,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.004707462968319656,0,0,1,0.005156436467673733
1951,KV401,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.005181222883920367,1,0,1,0.00567538115659978
1952,KV401,Scavenging of heme from plasma,0.004707462968319656,0,0,1,0.005156436467673733
1953,KV401,Scavenging of heme from plasma,0.005181222883920367,1,0,1,0.00567538115659978
1954,HV434,Initial triggering of complement,0.002913304483520959,0,0,1,0.003191160415145466
1955,HV434,Initial triggering of complement,0.0029465669378189742,1,0,1,0.0032275952705019257
1956,HV434,Regulation of Complement cascade,0.002913304483520959,0,0,1,0.003191160415145466
1957,HV434,Regulation of Complement cascade,0.0029465669378189742,1,0,1,0.0032275952705019257
1958,HV434,FCGR activation,0.002913304483520959,0,0,1,0.003191160415145466
1959,HV434,FCGR activation,0.0029465669378189742,1,0,1,0.0032275952705019257
1960,HV434,Regulation of actin dynamics for phagocytic cup formation,0.002913304483520959,0,0,1,0.003191160415145466
1961,HV434,Regulation of actin dynamics for phagocytic cup formation,0.0029465669378189742,1,0,1,0.0032275952705019257
1962,HV434,Role of phospholipids in phagocytosis,0.002913304483520959,0,0,1,0.003191160415145466
1963,HV434,Role of phospholipids in phagocytosis,0.0029465669378189742,1,0,1,0.0032275952705019257
1964,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.002913304483520959,0,0,1,0.003191160415145466
1965,HV434,Role of LAT2/NTAL/LAB on calcium mobilization,0.0029465669378189742,1,0,1,0.0032275952705019257
1966,HV434,FCERI mediated MAPK activation,0.002913304483520959,0,0,1,0.003191160415145466
1967,HV434,FCERI mediated MAPK activation,0.0029465669378189742,1,0,1,0.0032275952705019257
1968,HV434,FCERI mediated Ca+2 mobilization,0.002913304483520959,0,0,1,0.003191160415145466
1969,HV434,FCERI mediated Ca+2 mobilization,0.0029465669378189742,1,0,1,0.0032275952705019257
1970,HV434,FCERI mediated NF-kB activation,0.002913304483520959,0,0,1,0.003191160415145466
1971,HV434,FCERI mediated NF-kB activation,0.0029465669378189742,1,0,1,0.0032275952705019257
1972,HV434,Parasite infection,0.002913304483520959,0,0,1,0.003191160415145466
1973,HV434,Parasite infection,0.0029465669378189742,1,0,1,0.0032275952705019257
1974,HV434,Leishmania parasite growth and survival,0.002913304483520959,0,0,1,0.003191160415145466
1975,HV434,Leishmania parasite growth and survival,0.0029465669378189742,1,0,1,0.0032275952705019257
1976,HV434,Potential therapeutics for SARS,0.002913304483520959,0,0,1,0.003191160415145466
1977,HV434,Potential therapeutics for SARS,0.0029465669378189742,1,0,1,0.0032275952705019257
1978,HV434,CD22 mediated BCR regulation,0.002913304483520959,0,0,1,0.003191160415145466
1979,HV434,CD22 mediated BCR regulation,0.0029465669378189742,1,0,1,0.0032275952705019257
1980,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.002913304483520959,0,0,1,0.003191160415145466
1981,HV434,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0029465669378189742,1,0,1,0.0032275952705019257
1982,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002913304483520959,0,0,1,0.003191160415145466
1983,HV434,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0029465669378189742,1,0,1,0.0032275952705019257
1984,HV434,Scavenging of heme from plasma,0.002913304483520959,0,0,1,0.003191160415145466
1985,HV434,Scavenging of heme from plasma,0.0029465669378189742,1,0,1,0.0032275952705019257
1986,GELS,Apoptotic cleavage of cellular proteins,0.0030674702449484037,0,0,1,0.003360029710483741
1987,GELS,Apoptotic cleavage of cellular proteins,0.0039645095112248825,1,0,1,0.00434262394790892
1988,GELS,Neutrophil degranulation,0.0030674702449484037,0,0,1,0.003360029710483741
1989,GELS,Neutrophil degranulation,0.0039645095112248825,1,0,1,0.00434262394790892
1990,GELS,Amyloid fiber formation,0.0030674702449484037,0,0,1,0.003360029710483741
1991,GELS,Amyloid fiber formation,0.0039645095112248825,1,0,1,0.00434262394790892
1992,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.0030674702449484037,0,0,1,0.003360029710483741
1993,GELS,Sensory processing of sound by outer hair cells of the cochlea,0.0039645095112248825,1,0,1,0.00434262394790892
1994,CO2,Initial triggering of complement,0.0007094195976873758,0,0,1,0.0007770803740817052
1995,CO2,Initial triggering of complement,0.0007825985905149394,1,0,1,0.0008572388012054298
1996,CO2,Activation of C3 and C5,0.0007094195976873758,0,0,1,0.0007770803740817052
1997,CO2,Activation of C3 and C5,0.0007825985905149394,1,0,1,0.0008572388012054298
1998,CO2,Regulation of Complement cascade,0.0007094195976873758,0,0,1,0.0007770803740817052
1999,CO2,Regulation of Complement cascade,0.0007825985905149394,1,0,1,0.0008572388012054298
2000,S10A9,Antigen processing-Cross presentation,0.002014368322920861,0,0,1,0.0022064883674153602
2001,S10A9,Antigen processing-Cross presentation,0.0027920938200992253,1,0,1,0.0030583893048159766
2002,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.002014368322920861,0,0,1,0.0022064883674153602
2003,S10A9,Toll Like Receptor 4 (TLR4) Cascade,0.0027920938200992253,1,0,1,0.0030583893048159766
2004,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.002014368322920861,0,0,1,0.0022064883674153602
2005,S10A9,Toll Like Receptor 2 (TLR2) Cascade,0.0027920938200992253,1,0,1,0.0030583893048159766
2006,S10A9,Regulation of TLR by endogenous ligand,0.002014368322920861,0,0,1,0.0022064883674153602
2007,S10A9,Regulation of TLR by endogenous ligand,0.0027920938200992253,1,0,1,0.0030583893048159766
2008,S10A9,RHO GTPase Effectors,0.002014368322920861,0,0,1,0.0022064883674153602
2009,S10A9,RHO GTPase Effectors,0.0027920938200992253,1,0,1,0.0030583893048159766
2010,S10A9,MyD88 deficiency (TLR2/4),0.002014368322920861,0,0,1,0.0022064883674153602
2011,S10A9,MyD88 deficiency (TLR2/4),0.0027920938200992253,1,0,1,0.0030583893048159766
2012,S10A9,IRAK4 deficiency (TLR2/4),0.002014368322920861,0,0,1,0.0022064883674153602
2013,S10A9,IRAK4 deficiency (TLR2/4),0.0027920938200992253,1,0,1,0.0030583893048159766
2014,S10A9,Metal sequestration by antimicrobial proteins,0.002014368322920861,0,0,1,0.0022064883674153602
2015,S10A9,Metal sequestration by antimicrobial proteins,0.0027920938200992253,1,0,1,0.0030583893048159766
2016,S10A9,Neutrophil degranulation,0.002014368322920861,0,0,1,0.0022064883674153602
2017,S10A9,Neutrophil degranulation,0.0027920938200992253,1,0,1,0.0030583893048159766
2018,APOA4,Chylomicron assembly,0.022014086747500362,0,0,1,0.024113676617590722
2019,APOA4,Chylomicron assembly,0.020032848040842176,1,0,1,0.021943477598090906
2020,APOA4,Assembly of active LPL and LIPC lipase complexes,0.022014086747500362,0,0,1,0.024113676617590722
2021,APOA4,Assembly of active LPL and LIPC lipase complexes,0.020032848040842176,1,0,1,0.021943477598090906
2022,APOA4,Chylomicron remodeling,0.022014086747500362,0,0,1,0.024113676617590722
2023,APOA4,Chylomicron remodeling,0.020032848040842176,1,0,1,0.021943477598090906
2024,APOA4,Retinoid metabolism and transport,0.022014086747500362,0,0,1,0.024113676617590722
2025,APOA4,Retinoid metabolism and transport,0.020032848040842176,1,0,1,0.021943477598090906
2026,APOA4,Amyloid fiber formation,0.022014086747500362,0,0,1,0.024113676617590722
2027,APOA4,Amyloid fiber formation,0.020032848040842176,1,0,1,0.021943477598090906
2028,ENOA,Glycolysis,0.0007932029766749193,0,0,1,0.0008688545789355165
2029,ENOA,Glycolysis,0.0011725090472157666,1,0,1,0.0012843369030046538
2030,ENOA,Gluconeogenesis,0.0007932029766749193,0,0,1,0.0008688545789355165
2031,ENOA,Gluconeogenesis,0.0011725090472157666,1,0,1,0.0012843369030046538
2032,ENOA,Response of Mtb to phagocytosis,0.0007932029766749193,0,0,1,0.0008688545789355165
2033,ENOA,Response of Mtb to phagocytosis,0.0011725090472157666,1,0,1,0.0012843369030046538
2034,PYGL,Glycogen breakdown (glycogenolysis),0.0013348285453323142,0,0,1,0.0014621375963155625
2035,PYGL,Glycogen breakdown (glycogenolysis),0.0014099737794462327,1,0,1,0.0015444497946620114
2036,PYGL,Neutrophil degranulation,0.0013348285453323142,0,0,1,0.0014621375963155625
2037,PYGL,Neutrophil degranulation,0.0014099737794462327,1,0,1,0.0015444497946620114
2038,G6PI,Transcriptional Regulation by TP53,0.0008573548049919501,0,0,1,0.0009391248772316622
2039,G6PI,Transcriptional Regulation by TP53,0.0009044838723103719,1,0,1,0.00099074887152405
2040,G6PI,Glycolysis,0.0008573548049919501,0,0,1,0.0009391248772316622
2041,G6PI,Glycolysis,0.0009044838723103719,1,0,1,0.00099074887152405
2042,G6PI,Gluconeogenesis,0.0008573548049919501,0,0,1,0.0009391248772316622
2043,G6PI,Gluconeogenesis,0.0009044838723103719,1,0,1,0.00099074887152405
2044,G6PI,Neutrophil degranulation,0.0008573548049919501,0,0,1,0.0009391248772316622
2045,G6PI,Neutrophil degranulation,0.0009044838723103719,1,0,1,0.00099074887152405
2046,TPM3,RHO GTPase cycle,0.0027813608244033105,0,0,1,0.0030466326514368095
2047,TPM3,RHO GTPase cycle,0.0041343195725534925,1,0,1,0.00452862961565511
2048,TPM3,Signaling by ALK fusions and activated point mutants,0.0027813608244033105,0,0,1,0.0030466326514368095
2049,TPM3,Signaling by ALK fusions and activated point mutants,0.0041343195725534925,1,0,1,0.00452862961565511
2050,TPM3,Striated Muscle Contraction,0.0027813608244033105,0,0,1,0.0030466326514368095
2051,TPM3,Striated Muscle Contraction,0.0041343195725534925,1,0,1,0.00452862961565511
2052,TPM3,Smooth Muscle Contraction,0.0027813608244033105,0,0,1,0.0030466326514368095
2053,TPM3,Smooth Muscle Contraction,0.0041343195725534925,1,0,1,0.00452862961565511
2054,FABPL,PPARA activates gene expression,0.003636140662640201,0,0,1,0.003982936974886489
2055,FABPL,PPARA activates gene expression,0.0039059844909254747,1,0,1,0.004278517113511254
2056,FABPL,Triglyceride catabolism,0.003636140662640201,0,0,1,0.003982936974886489
2057,FABPL,Triglyceride catabolism,0.0039059844909254747,1,0,1,0.004278517113511254
2058,FABPL,Cytoprotection by HMOX1,0.003636140662640201,0,0,1,0.003982936974886489
2059,FABPL,Cytoprotection by HMOX1,0.0039059844909254747,1,0,1,0.004278517113511254
2060,FABPL,Heme degradation,0.003636140662640201,0,0,1,0.003982936974886489
2061,FABPL,Heme degradation,0.0039059844909254747,1,0,1,0.004278517113511254
2062,LDHB,Pyruvate metabolism,0.0003884079759272486,0,0,1,0.0004254523221712166
2063,LDHB,Pyruvate metabolism,0.000636853523205277,1,0,1,0.0006975933222889242
2064,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0025381406820937638,0,0,1,0.0027802154284192453
2065,PROS,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0026133426852291836,1,0,1,0.0028625898101232
2066,PROS,Regulation of Complement cascade,0.0025381406820937638,0,0,1,0.0027802154284192453
2067,PROS,Regulation of Complement cascade,0.0026133426852291836,1,0,1,0.0028625898101232
2068,PROS,Platelet degranulation ,0.0025381406820937638,0,0,1,0.0027802154284192453
2069,PROS,Platelet degranulation ,0.0026133426852291836,1,0,1,0.0028625898101232
2070,PROS,Intrinsic Pathway of Fibrin Clot Formation,0.0025381406820937638,0,0,1,0.0027802154284192453
2071,PROS,Intrinsic Pathway of Fibrin Clot Formation,0.0026133426852291836,1,0,1,0.0028625898101232
2072,PROS,Common Pathway of Fibrin Clot Formation,0.0025381406820937638,0,0,1,0.0027802154284192453
2073,PROS,Common Pathway of Fibrin Clot Formation,0.0026133426852291836,1,0,1,0.0028625898101232
2074,PDIA1,Interleukin-12 family signaling,0.004704051534054319,0,0,1,0.0051526996684314996
2075,PDIA1,Interleukin-12 family signaling,0.004720832457586291,1,0,1,0.0051710810697603755
2076,PDIA1,VLDL assembly,0.004704051534054319,0,0,1,0.0051526996684314996
2077,PDIA1,VLDL assembly,0.004720832457586291,1,0,1,0.0051710810697603755
2078,PDIA1,Chylomicron assembly,0.004704051534054319,0,0,1,0.0051526996684314996
2079,PDIA1,Chylomicron assembly,0.004720832457586291,1,0,1,0.0051710810697603755
2080,PDIA1,LDL remodeling,0.004704051534054319,0,0,1,0.0051526996684314996
2081,PDIA1,LDL remodeling,0.004720832457586291,1,0,1,0.0051710810697603755
2082,PDIA1,Detoxification of Reactive Oxygen Species,0.004704051534054319,0,0,1,0.0051526996684314996
2083,PDIA1,Detoxification of Reactive Oxygen Species,0.004720832457586291,1,0,1,0.0051710810697603755
2084,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004704051534054319,0,0,1,0.0051526996684314996
2085,PDIA1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004720832457586291,1,0,1,0.0051710810697603755
2086,PDIA1,Hedgehog ligand biogenesis,0.004704051534054319,0,0,1,0.0051526996684314996
2087,PDIA1,Hedgehog ligand biogenesis,0.004720832457586291,1,0,1,0.0051710810697603755
2088,PDIA1,Post-translational protein phosphorylation,0.004704051534054319,0,0,1,0.0051526996684314996
2089,PDIA1,Post-translational protein phosphorylation,0.004720832457586291,1,0,1,0.0051710810697603755
2090,ADH1A,Ethanol oxidation,0.012173762871188864,0,0,1,0.013334833484673772
2091,ADH1A,Ethanol oxidation,0.011280322875260249,1,0,1,0.012356181797408551
2092,ADH1A,RA biosynthesis pathway,0.012173762871188864,0,0,1,0.013334833484673772
2093,ADH1A,RA biosynthesis pathway,0.011280322875260249,1,0,1,0.012356181797408551
2094,ADH1A,Abacavir metabolism,0.012173762871188864,0,0,1,0.013334833484673772
2095,ADH1A,Abacavir metabolism,0.011280322875260249,1,0,1,0.012356181797408551
2096,CSF1R,Transcriptional Regulation by VENTX,0.0010439605572672211,0,0,1,0.0011435281221611419
2097,CSF1R,Transcriptional Regulation by VENTX,0.0012600745065882329,1,0,1,0.0013802539035324267
2098,CSF1R,Other interleukin signaling,0.0010439605572672211,0,0,1,0.0011435281221611419
2099,CSF1R,Other interleukin signaling,0.0012600745065882329,1,0,1,0.0013802539035324267
2100,CATD,Estrogen-dependent gene expression,0.000600804938659365,0,0,1,0.0006581066099745602
2101,CATD,Estrogen-dependent gene expression,0.0005843158611740567,1,0,1,0.000640044889460614
2102,CATD,MHC class II antigen presentation,0.000600804938659365,0,0,1,0.0006581066099745602
2103,CATD,MHC class II antigen presentation,0.0005843158611740567,1,0,1,0.000640044889460614
2104,CATD,Collagen degradation,0.000600804938659365,0,0,1,0.0006581066099745602
2105,CATD,Collagen degradation,0.0005843158611740567,1,0,1,0.000640044889460614
2106,CATD,Neutrophil degranulation,0.000600804938659365,0,0,1,0.0006581066099745602
2107,CATD,Neutrophil degranulation,0.0005843158611740567,1,0,1,0.000640044889460614
2108,CATD,Metabolism of Angiotensinogen to Angiotensins,0.000600804938659365,0,0,1,0.0006581066099745602
2109,CATD,Metabolism of Angiotensinogen to Angiotensins,0.0005843158611740567,1,0,1,0.000640044889460614
2110,CO8A,Terminal pathway of complement,0.0006751216111749692,0,0,1,0.0007395112227977634
2111,CO8A,Terminal pathway of complement,0.0006788520583660993,1,0,1,0.0007435974607706432
2112,CO8A,Regulation of Complement cascade,0.0006751216111749692,0,0,1,0.0007395112227977634
2113,CO8A,Regulation of Complement cascade,0.0006788520583660993,1,0,1,0.0007435974607706432
2114,CO8B,Terminal pathway of complement,0.00019682274454147506,0,0,1,0.00021559468113746338
2115,CO8B,Terminal pathway of complement,0.00034345108848883636,1,0,1,0.00037620767905439993
2116,CO8B,Regulation of Complement cascade,0.00019682274454147506,0,0,1,0.00021559468113746338
2117,CO8B,Regulation of Complement cascade,0.00034345108848883636,1,0,1,0.00037620767905439993
2118,GP1BA,Transcriptional regulation by RUNX1,0.00031652398413174764,0,0,1,0.0003467124065880695
2119,GP1BA,Transcriptional regulation by RUNX1,0.0005523058252635892,1,0,1,0.0006049819016875635
2120,GP1BA,Defective factor IX causes hemophilia B,0.00031652398413174764,0,0,1,0.0003467124065880695
2121,GP1BA,Defective factor IX causes hemophilia B,0.0005523058252635892,1,0,1,0.0006049819016875635
2122,GP1BA,Platelet Adhesion to exposed collagen,0.00031652398413174764,0,0,1,0.0003467124065880695
2123,GP1BA,Platelet Adhesion to exposed collagen,0.0005523058252635892,1,0,1,0.0006049819016875635
2124,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.00031652398413174764,0,0,1,0.0003467124065880695
2125,GP1BA,Intrinsic Pathway of Fibrin Clot Formation,0.0005523058252635892,1,0,1,0.0006049819016875635
2126,GP1BA,GP1b-IX-V activation signalling,0.00031652398413174764,0,0,1,0.0003467124065880695
2127,GP1BA,GP1b-IX-V activation signalling,0.0005523058252635892,1,0,1,0.0006049819016875635
2128,CO8G,Terminal pathway of complement,0.000516378024987744,0,0,1,0.0005656274934229784
2129,CO8G,Terminal pathway of complement,0.0007059960903807869,1,0,1,0.0007733303503339148
2130,CO8G,Regulation of Complement cascade,0.000516378024987744,0,0,1,0.0005656274934229784
2131,CO8G,Regulation of Complement cascade,0.0007059960903807869,1,0,1,0.0007733303503339148
2132,TBB5,G2/M Transition,0.0003118881488197925,0,0,1,0.0003416344292525988
2133,TBB5,G2/M Transition,0.00021008083001157354,1,0,1,0.00023011725430896384
2134,TBB5,Mitotic Prometaphase,0.0003118881488197925,0,0,1,0.0003416344292525988
2135,TBB5,Mitotic Prometaphase,0.00021008083001157354,1,0,1,0.00023011725430896384
2136,TBB5,Potential therapeutics for SARS,0.0003118881488197925,0,0,1,0.0003416344292525988
2137,TBB5,Potential therapeutics for SARS,0.00021008083001157354,1,0,1,0.00023011725430896384
2138,TBB5,Neutrophil degranulation,0.0003118881488197925,0,0,1,0.0003416344292525988
2139,TBB5,Neutrophil degranulation,0.00021008083001157354,1,0,1,0.00023011725430896384
2140,TBB5,Anchoring of the basal body to the plasma membrane,0.0003118881488197925,0,0,1,0.0003416344292525988
2141,TBB5,Anchoring of the basal body to the plasma membrane,0.00021008083001157354,1,0,1,0.00023011725430896384
2142,CAH3,Reversible hydration of carbon dioxide,0.0016371931262883987,0,0,1,0.0017933401489999812
2143,CAH3,Reversible hydration of carbon dioxide,0.0014077547779850436,1,0,1,0.001542019156304726
2144,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.00016611393236630728,0,0,1,0.00018195702109751597
2145,TRY1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",1.1608687329085589e-05,1,0,1,1.2715863956522198e-05
2146,TRY1,Activation of Matrix Metalloproteinases,0.00016611393236630728,0,0,1,0.00018195702109751597
2147,TRY1,Activation of Matrix Metalloproteinases,1.1608687329085589e-05,1,0,1,1.2715863956522198e-05
2148,TRY2,Defensins,0.0024278359998816503,0,0,1,0.00265939045544729
2149,TRY2,Defensins,0.0020918726955356103,1,0,1,0.0022913847067056346
2150,TRY2,Collagen degradation,0.0024278359998816503,0,0,1,0.00265939045544729
2151,TRY2,Collagen degradation,0.0020918726955356103,1,0,1,0.0022913847067056346
2152,TRY2,Activation of Matrix Metalloproteinases,0.0024278359998816503,0,0,1,0.00265939045544729
2153,TRY2,Activation of Matrix Metalloproteinases,0.0020918726955356103,1,0,1,0.0022913847067056346
2154,TRY2,Neutrophil degranulation,0.0024278359998816503,0,0,1,0.00265939045544729
2155,TRY2,Neutrophil degranulation,0.0020918726955356103,1,0,1,0.0022913847067056346
2156,SAP,Class A/1 (Rhodopsin-like receptors),0.003884801680108693,0,0,1,0.004255313995628317
2157,SAP,Class A/1 (Rhodopsin-like receptors),0.0043371044806096,1,0,1,0.004750755100662935
2158,SAP,G alpha (i) signalling events,0.003884801680108693,0,0,1,0.004255313995628317
2159,SAP,G alpha (i) signalling events,0.0043371044806096,1,0,1,0.004750755100662935
2160,SAP,Glycosphingolipid metabolism,0.003884801680108693,0,0,1,0.004255313995628317
2161,SAP,Glycosphingolipid metabolism,0.0043371044806096,1,0,1,0.004750755100662935
2162,SAP,Platelet degranulation ,0.003884801680108693,0,0,1,0.004255313995628317
2163,SAP,Platelet degranulation ,0.0043371044806096,1,0,1,0.004750755100662935
2164,SAP,Neutrophil degranulation,0.003884801680108693,0,0,1,0.004255313995628317
2165,SAP,Neutrophil degranulation,0.0043371044806096,1,0,1,0.004750755100662935
2166,PROF1,RHO GTPase Effectors,0.003926279330098715,0,0,1,0.004300747569602516
2167,PROF1,RHO GTPase Effectors,0.0031982244206678126,1,0,1,0.0035032545440124574
2168,PROF1,Signaling by ROBO receptors,0.003926279330098715,0,0,1,0.004300747569602516
2169,PROF1,Signaling by ROBO receptors,0.0031982244206678126,1,0,1,0.0035032545440124574
2170,PROF1,PCP/CE pathway,0.003926279330098715,0,0,1,0.004300747569602516
2171,PROF1,PCP/CE pathway,0.0031982244206678126,1,0,1,0.0035032545440124574
2172,PROF1,Platelet degranulation ,0.003926279330098715,0,0,1,0.004300747569602516
2173,PROF1,Platelet degranulation ,0.0031982244206678126,1,0,1,0.0035032545440124574
2174,CATB,Trafficking and processing of endosomal TLR,0.004210353201387573,0,0,1,0.0046119149392207185
2175,CATB,Trafficking and processing of endosomal TLR,0.0038688991875931392,1,0,1,0.0042378948055282655
2176,CATB,MHC class II antigen presentation,0.004210353201387573,0,0,1,0.0046119149392207185
2177,CATB,MHC class II antigen presentation,0.0038688991875931392,1,0,1,0.0042378948055282655
2178,CATB,Collagen degradation,0.004210353201387573,0,0,1,0.0046119149392207185
2179,CATB,Collagen degradation,0.0038688991875931392,1,0,1,0.0042378948055282655
2180,CATB,Neutrophil degranulation,0.004210353201387573,0,0,1,0.0046119149392207185
2181,CATB,Neutrophil degranulation,0.0038688991875931392,1,0,1,0.0042378948055282655
2182,HS90A,Downregulation of ERBB2 signaling,0.007395456382546214,0,0,1,0.008100796807683414
2183,HS90A,Downregulation of ERBB2 signaling,0.007379147458140772,1,0,1,0.008082932422319429
2184,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.007395456382546214,0,0,1,0.008100796807683414
2185,HS90A,Drug-mediated inhibition of ERBB2 signaling,0.007379147458140772,1,0,1,0.008082932422319429
2186,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.007395456382546214,0,0,1,0.008100796807683414
2187,HS90A,Constitutive Signaling by Overexpressed ERBB2,0.007379147458140772,1,0,1,0.008082932422319429
2188,HS90A,Signaling by ERBB2 KD Mutants,0.007395456382546214,0,0,1,0.008100796807683414
2189,HS90A,Signaling by ERBB2 KD Mutants,0.007379147458140772,1,0,1,0.008082932422319429
2190,HS90A,Drug resistance in ERBB2 KD mutants,0.007395456382546214,0,0,1,0.008100796807683414
2191,HS90A,Drug resistance in ERBB2 KD mutants,0.007379147458140772,1,0,1,0.008082932422319429
2192,HS90A,Signaling by ERBB2 ECD mutants,0.007395456382546214,0,0,1,0.008100796807683414
2193,HS90A,Signaling by ERBB2 ECD mutants,0.007379147458140772,1,0,1,0.008082932422319429
2194,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.007395456382546214,0,0,1,0.008100796807683414
2195,HS90A,Signaling by ERBB2 TMD/JMD mutants,0.007379147458140772,1,0,1,0.008082932422319429
2196,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.007395456382546214,0,0,1,0.008100796807683414
2197,HS90A,Drug resistance in ERBB2 TMD/JMD mutants,0.007379147458140772,1,0,1,0.008082932422319429
2198,HS90A,Signaling by EGFRvIII in Cancer,0.007395456382546214,0,0,1,0.008100796807683414
2199,HS90A,Signaling by EGFRvIII in Cancer,0.007379147458140772,1,0,1,0.008082932422319429
2200,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.007395456382546214,0,0,1,0.008100796807683414
2201,HS90A,Signaling by Ligand-Responsive EGFR Variants in Cancer,0.007379147458140772,1,0,1,0.008082932422319429
2202,HS90A,Influenza Viral RNA Transcription and Replication,0.007395456382546214,0,0,1,0.008100796807683414
2203,HS90A,Influenza Viral RNA Transcription and Replication,0.007379147458140772,1,0,1,0.008082932422319429
2204,HS90A,VEGFA-VEGFR2 Pathway,0.007395456382546214,0,0,1,0.008100796807683414
2205,HS90A,VEGFA-VEGFR2 Pathway,0.007379147458140772,1,0,1,0.008082932422319429
2206,HS90A,RHO GTPase cycle,0.007395456382546214,0,0,1,0.008100796807683414
2207,HS90A,RHO GTPase cycle,0.007379147458140772,1,0,1,0.008082932422319429
2208,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.007395456382546214,0,0,1,0.008100796807683414
2209,HS90A,Regulation of actin dynamics for phagocytic cup formation,0.007379147458140772,1,0,1,0.008082932422319429
2210,HS90A,HSF1 activation,0.007395456382546214,0,0,1,0.008100796807683414
2211,HS90A,HSF1 activation,0.007379147458140772,1,0,1,0.008082932422319429
2212,HS90A,HSF1-dependent transactivation,0.007395456382546214,0,0,1,0.008100796807683414
2213,HS90A,HSF1-dependent transactivation,0.007379147458140772,1,0,1,0.008082932422319429
2214,HS90A,Semaphorin interactions,0.007395456382546214,0,0,1,0.008100796807683414
2215,HS90A,Semaphorin interactions,0.007379147458140772,1,0,1,0.008082932422319429
2216,HS90A,Interleukin-4 and Interleukin-13 signaling,0.007395456382546214,0,0,1,0.008100796807683414
2217,HS90A,Interleukin-4 and Interleukin-13 signaling,0.007379147458140772,1,0,1,0.008082932422319429
2218,HS90A,G2/M Transition,0.007395456382546214,0,0,1,0.008100796807683414
2219,HS90A,G2/M Transition,0.007379147458140772,1,0,1,0.008082932422319429
2220,HS90A,Regulation of necroptotic cell death,0.007395456382546214,0,0,1,0.008100796807683414
2221,HS90A,Regulation of necroptotic cell death,0.007379147458140772,1,0,1,0.008082932422319429
2222,HS90A,Uptake and function of diphtheria toxin,0.007395456382546214,0,0,1,0.008100796807683414
2223,HS90A,Uptake and function of diphtheria toxin,0.007379147458140772,1,0,1,0.008082932422319429
2224,HS90A,Mitotic Prometaphase,0.007395456382546214,0,0,1,0.008100796807683414
2225,HS90A,Mitotic Prometaphase,0.007379147458140772,1,0,1,0.008082932422319429
2226,HS90A,Extra-nuclear estrogen signaling,0.007395456382546214,0,0,1,0.008100796807683414
2227,HS90A,Extra-nuclear estrogen signaling,0.007379147458140772,1,0,1,0.008082932422319429
2228,HS90A,Estrogen-dependent gene expression,0.007395456382546214,0,0,1,0.008100796807683414
2229,HS90A,Estrogen-dependent gene expression,0.007379147458140772,1,0,1,0.008082932422319429
2230,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.007395456382546214,0,0,1,0.008100796807683414
2231,HS90A,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",0.007379147458140772,1,0,1,0.008082932422319429
2232,HS90A,Aggrephagy,0.007395456382546214,0,0,1,0.008100796807683414
2233,HS90A,Aggrephagy,0.007379147458140772,1,0,1,0.008082932422319429
2234,HS90A,Potential therapeutics for SARS,0.007395456382546214,0,0,1,0.008100796807683414
2235,HS90A,Potential therapeutics for SARS,0.007379147458140772,1,0,1,0.008082932422319429
2236,HS90A,SARS-CoV-2 Infection,0.007395456382546214,0,0,1,0.008100796807683414
2237,HS90A,SARS-CoV-2 Infection,0.007379147458140772,1,0,1,0.008082932422319429
2238,HS90A,Neutrophil degranulation,0.007395456382546214,0,0,1,0.008100796807683414
2239,HS90A,Neutrophil degranulation,0.007379147458140772,1,0,1,0.008082932422319429
2240,HS90A,eNOS activation,0.007395456382546214,0,0,1,0.008100796807683414
2241,HS90A,eNOS activation,0.007379147458140772,1,0,1,0.008082932422319429
2242,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.007395456382546214,0,0,1,0.008100796807683414
2243,HS90A,PIWI-interacting RNA (piRNA) biogenesis,0.007379147458140772,1,0,1,0.008082932422319429
2244,HS90A,Scavenging by Class F Receptors,0.007395456382546214,0,0,1,0.008100796807683414
2245,HS90A,Scavenging by Class F Receptors,0.007379147458140772,1,0,1,0.008082932422319429
2246,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.007395456382546214,0,0,1,0.008100796807683414
2247,HS90A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.007379147458140772,1,0,1,0.008082932422319429
2248,HS90A,Anchoring of the basal body to the plasma membrane,0.007395456382546214,0,0,1,0.008100796807683414
2249,HS90A,Anchoring of the basal body to the plasma membrane,0.007379147458140772,1,0,1,0.008082932422319429
2250,HS90A,Chaperone Mediated Autophagy,0.007395456382546214,0,0,1,0.008100796807683414
2251,HS90A,Chaperone Mediated Autophagy,0.007379147458140772,1,0,1,0.008082932422319429
2252,FUMH,Citric acid cycle (TCA cycle),0.0014399737565834927,0,0,1,0.0015773110146399484
2253,FUMH,Citric acid cycle (TCA cycle),0.001562540396943991,1,0,1,0.0017115674279836995
2254,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.0044357950632521875,0,0,1,0.004858858281246394
2255,PSPB,Defective pro-SFTPB causes SMDP1 and RDS,0.005110059773814179,1,0,1,0.005597430876677427
2256,PSPB,Defective CSF2RB causes SMDP5,0.0044357950632521875,0,0,1,0.004858858281246394
2257,PSPB,Defective CSF2RB causes SMDP5,0.005110059773814179,1,0,1,0.005597430876677427
2258,PSPB,Defective CSF2RA causes SMDP4,0.0044357950632521875,0,0,1,0.004858858281246394
2259,PSPB,Defective CSF2RA causes SMDP4,0.005110059773814179,1,0,1,0.005597430876677427
2260,PSPB,Surfactant metabolism,0.0044357950632521875,0,0,1,0.004858858281246394
2261,PSPB,Surfactant metabolism,0.005110059773814179,1,0,1,0.005597430876677427
2262,TSP1,Transcriptional regulation by RUNX1,0.003832151262705444,0,0,1,0.004197642053403083
2263,TSP1,Transcriptional regulation by RUNX1,0.003206126423369108,1,0,1,0.003511910198909974
2264,TSP1,Diseases associated with O-glycosylation of proteins,0.003832151262705444,0,0,1,0.004197642053403083
2265,TSP1,Diseases associated with O-glycosylation of proteins,0.003206126423369108,1,0,1,0.003511910198909974
2266,TSP1,O-glycosylation of TSR domain-containing proteins,0.003832151262705444,0,0,1,0.004197642053403083
2267,TSP1,O-glycosylation of TSR domain-containing proteins,0.003206126423369108,1,0,1,0.003511910198909974
2268,TSP1,Platelet degranulation ,0.003832151262705444,0,0,1,0.004197642053403083
2269,TSP1,Platelet degranulation ,0.003206126423369108,1,0,1,0.003511910198909974
2270,TSP1,Integrin cell surface interactions,0.003832151262705444,0,0,1,0.004197642053403083
2271,TSP1,Integrin cell surface interactions,0.003206126423369108,1,0,1,0.003511910198909974
2272,TSP1,Syndecan interactions,0.003832151262705444,0,0,1,0.004197642053403083
2273,TSP1,Syndecan interactions,0.003206126423369108,1,0,1,0.003511910198909974
2274,TSP1,Signaling by PDGF,0.003832151262705444,0,0,1,0.004197642053403083
2275,TSP1,Signaling by PDGF,0.003206126423369108,1,0,1,0.003511910198909974
2276,RNAS1,Chaperone Mediated Autophagy,0.009163099369755118,0,0,1,0.010037028451439767
2277,RNAS1,Chaperone Mediated Autophagy,0.011155215703036049,1,0,1,0.012219142549396225
2278,RNAS1,Late endosomal microautophagy,0.009163099369755118,0,0,1,0.010037028451439767
2279,RNAS1,Late endosomal microautophagy,0.011155215703036049,1,0,1,0.012219142549396225
2280,CO1A2,Collagen chain trimerization,0.002986488421709805,0,0,1,0.0032713242592934846
2281,CO1A2,Collagen chain trimerization,0.003651597641253617,1,0,1,0.003999868160269923
2282,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.002986488421709805,0,0,1,0.0032713242592934846
2283,CO1A2,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,0.003651597641253617,1,0,1,0.003999868160269923
2284,CO1A2,Anchoring fibril formation,0.002986488421709805,0,0,1,0.0032713242592934846
2285,CO1A2,Anchoring fibril formation,0.003651597641253617,1,0,1,0.003999868160269923
2286,CO1A2,Crosslinking of collagen fibrils,0.002986488421709805,0,0,1,0.0032713242592934846
2287,CO1A2,Crosslinking of collagen fibrils,0.003651597641253617,1,0,1,0.003999868160269923
2288,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.002986488421709805,0,0,1,0.0032713242592934846
2289,CO1A2,Interleukin-4 and Interleukin-13 signaling,0.003651597641253617,1,0,1,0.003999868160269923
2290,CO1A2,MET promotes cell motility,0.002986488421709805,0,0,1,0.0032713242592934846
2291,CO1A2,MET promotes cell motility,0.003651597641253617,1,0,1,0.003999868160269923
2292,CO1A2,Platelet Adhesion to exposed collagen,0.002986488421709805,0,0,1,0.0032713242592934846
2293,CO1A2,Platelet Adhesion to exposed collagen,0.003651597641253617,1,0,1,0.003999868160269923
2294,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.002986488421709805,0,0,1,0.0032713242592934846
2295,CO1A2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003651597641253617,1,0,1,0.003999868160269923
2296,CO1A2,Collagen degradation,0.002986488421709805,0,0,1,0.0032713242592934846
2297,CO1A2,Collagen degradation,0.003651597641253617,1,0,1,0.003999868160269923
2298,CO1A2,Integrin cell surface interactions,0.002986488421709805,0,0,1,0.0032713242592934846
2299,CO1A2,Integrin cell surface interactions,0.003651597641253617,1,0,1,0.003999868160269923
2300,CO1A2,ECM proteoglycans,0.002986488421709805,0,0,1,0.0032713242592934846
2301,CO1A2,ECM proteoglycans,0.003651597641253617,1,0,1,0.003999868160269923
2302,CO1A2,Scavenging by Class A Receptors,0.002986488421709805,0,0,1,0.0032713242592934846
2303,CO1A2,Scavenging by Class A Receptors,0.003651597641253617,1,0,1,0.003999868160269923
2304,CO1A2,Syndecan interactions,0.002986488421709805,0,0,1,0.0032713242592934846
2305,CO1A2,Syndecan interactions,0.003651597641253617,1,0,1,0.003999868160269923
2306,CO1A2,GPVI-mediated activation cascade,0.002986488421709805,0,0,1,0.0032713242592934846
2307,CO1A2,GPVI-mediated activation cascade,0.003651597641253617,1,0,1,0.003999868160269923
2308,CO1A2,GP1b-IX-V activation signalling,0.002986488421709805,0,0,1,0.0032713242592934846
2309,CO1A2,GP1b-IX-V activation signalling,0.003651597641253617,1,0,1,0.003999868160269923
2310,CBG,Metabolism of steroid hormones,0.0014523697895194362,0,0,1,0.001590889317159915
2311,CBG,Metabolism of steroid hormones,0.0011963726696544216,1,0,1,0.0013104765144729945
2312,4F2,Amino acid transport across the plasma membrane,0.0018262966833819594,0,0,1,0.00200047942646776
2313,4F2,Amino acid transport across the plasma membrane,0.001979154804697837,1,0,1,0.0021679163657358424
2314,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.0018262966833819594,0,0,1,0.00200047942646776
2315,4F2,Defective SLC7A7 causes lysinuric protein intolerance (LPI),0.001979154804697837,1,0,1,0.0021679163657358424
2316,4F2,Basigin interactions,0.0018262966833819594,0,0,1,0.00200047942646776
2317,4F2,Basigin interactions,0.001979154804697837,1,0,1,0.0021679163657358424
2318,4F2,Tryptophan catabolism,0.0018262966833819594,0,0,1,0.00200047942646776
2319,4F2,Tryptophan catabolism,0.001979154804697837,1,0,1,0.0021679163657358424
2320,HS90B,Inflammasomes,0.012025743442809747,0,0,1,0.013172696727878267
2321,HS90B,Inflammasomes,0.012930465582049059,1,0,1,0.014163706591000061
2322,HS90B,RHO GTPase cycle,0.012025743442809747,0,0,1,0.013172696727878267
2323,HS90B,RHO GTPase cycle,0.012930465582049059,1,0,1,0.014163706591000061
2324,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.012025743442809747,0,0,1,0.013172696727878267
2325,HS90B,Regulation of actin dynamics for phagocytic cup formation,0.012930465582049059,1,0,1,0.014163706591000061
2326,HS90B,Aryl hydrocarbon receptor signalling,0.012025743442809747,0,0,1,0.013172696727878267
2327,HS90B,Aryl hydrocarbon receptor signalling,0.012930465582049059,1,0,1,0.014163706591000061
2328,HS90B,HSF1 activation,0.012025743442809747,0,0,1,0.013172696727878267
2329,HS90B,HSF1 activation,0.012930465582049059,1,0,1,0.014163706591000061
2330,HS90B,HSF1-dependent transactivation,0.012025743442809747,0,0,1,0.013172696727878267
2331,HS90B,HSF1-dependent transactivation,0.012930465582049059,1,0,1,0.014163706591000061
2332,HS90B,Semaphorin interactions,0.012025743442809747,0,0,1,0.013172696727878267
2333,HS90B,Semaphorin interactions,0.012930465582049059,1,0,1,0.014163706591000061
2334,HS90B,G2/M Transition,0.012025743442809747,0,0,1,0.013172696727878267
2335,HS90B,G2/M Transition,0.012930465582049059,1,0,1,0.014163706591000061
2336,HS90B,Uptake and function of diphtheria toxin,0.012025743442809747,0,0,1,0.013172696727878267
2337,HS90B,Uptake and function of diphtheria toxin,0.012930465582049059,1,0,1,0.014163706591000061
2338,HS90B,Estrogen-dependent gene expression,0.012025743442809747,0,0,1,0.013172696727878267
2339,HS90B,Estrogen-dependent gene expression,0.012930465582049059,1,0,1,0.014163706591000061
2340,HS90B,Cell recruitment (pro-inflammatory response),0.012025743442809747,0,0,1,0.013172696727878267
2341,HS90B,Cell recruitment (pro-inflammatory response),0.012930465582049059,1,0,1,0.014163706591000061
2342,HS90B,Potential therapeutics for SARS,0.012025743442809747,0,0,1,0.013172696727878267
2343,HS90B,Potential therapeutics for SARS,0.012930465582049059,1,0,1,0.014163706591000061
2344,HS90B,SARS-CoV-2 Infection,0.012025743442809747,0,0,1,0.013172696727878267
2345,HS90B,SARS-CoV-2 Infection,0.012930465582049059,1,0,1,0.014163706591000061
2346,HS90B,Neutrophil degranulation,0.012025743442809747,0,0,1,0.013172696727878267
2347,HS90B,Neutrophil degranulation,0.012930465582049059,1,0,1,0.014163706591000061
2348,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.012025743442809747,0,0,1,0.013172696727878267
2349,HS90B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.012930465582049059,1,0,1,0.014163706591000061
2350,HS90B,Chaperone Mediated Autophagy,0.012025743442809747,0,0,1,0.013172696727878267
2351,HS90B,Chaperone Mediated Autophagy,0.012930465582049059,1,0,1,0.014163706591000061
2352,SODE,Detoxification of Reactive Oxygen Species,0.0003086684127496769,0,0,1,0.0003381076113891425
2353,SODE,Detoxification of Reactive Oxygen Species,0.00022776238480942706,1,0,1,0.00024948518446123614
2354,ITA2B,Transcriptional regulation by RUNX1,0.0013554124821238646,0,0,1,0.001484684722662502
2355,ITA2B,Transcriptional regulation by RUNX1,0.0017150654425007778,1,0,1,0.0018786395244474454
2356,ITA2B,L1CAM interactions,0.0013554124821238646,0,0,1,0.001484684722662502
2357,ITA2B,L1CAM interactions,0.0017150654425007778,1,0,1,0.0018786395244474454
2358,ITA2B,RAF/MAP kinase cascade,0.0013554124821238646,0,0,1,0.001484684722662502
2359,ITA2B,RAF/MAP kinase cascade,0.0017150654425007778,1,0,1,0.0018786395244474454
2360,ITA2B,Signaling by RAS mutants,0.0013554124821238646,0,0,1,0.001484684722662502
2361,ITA2B,Signaling by RAS mutants,0.0017150654425007778,1,0,1,0.0018786395244474454
2362,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.0013554124821238646,0,0,1,0.001484684722662502
2363,ITA2B,Signaling by moderate kinase activity BRAF mutants,0.0017150654425007778,1,0,1,0.0018786395244474454
2364,ITA2B,Signaling by high-kinase activity BRAF mutants,0.0013554124821238646,0,0,1,0.001484684722662502
2365,ITA2B,Signaling by high-kinase activity BRAF mutants,0.0017150654425007778,1,0,1,0.0018786395244474454
2366,ITA2B,Signaling by BRAF and RAF1 fusions,0.0013554124821238646,0,0,1,0.001484684722662502
2367,ITA2B,Signaling by BRAF and RAF1 fusions,0.0017150654425007778,1,0,1,0.0018786395244474454
2368,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0013554124821238646,0,0,1,0.001484684722662502
2369,ITA2B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0017150654425007778,1,0,1,0.0018786395244474454
2370,ITA2B,Signaling by RAF1 mutants,0.0013554124821238646,0,0,1,0.001484684722662502
2371,ITA2B,Signaling by RAF1 mutants,0.0017150654425007778,1,0,1,0.0018786395244474454
2372,ITA2B,Platelet degranulation ,0.0013554124821238646,0,0,1,0.001484684722662502
2373,ITA2B,Platelet degranulation ,0.0017150654425007778,1,0,1,0.0018786395244474454
2374,ITA2B,Integrin cell surface interactions,0.0013554124821238646,0,0,1,0.001484684722662502
2375,ITA2B,Integrin cell surface interactions,0.0017150654425007778,1,0,1,0.0018786395244474454
2376,ITA2B,ECM proteoglycans,0.0013554124821238646,0,0,1,0.001484684722662502
2377,ITA2B,ECM proteoglycans,0.0017150654425007778,1,0,1,0.0018786395244474454
2378,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0013554124821238646,0,0,1,0.001484684722662502
2379,ITA2B,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.0017150654425007778,1,0,1,0.0018786395244474454
2380,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.0013554124821238646,0,0,1,0.001484684722662502
2381,ITA2B,p130Cas linkage to MAPK signaling for integrins,0.0017150654425007778,1,0,1,0.0018786395244474454
2382,APOA,LDL remodeling,0.0005178346668060674,0,0,1,0.0005672230622129805
2383,APOA,LDL remodeling,0.0004077227831585956,1,0,1,0.0004466092759367726
2384,PLEK,Platelet degranulation ,0.0013566585078889854,0,0,1,0.001486049587928181
2385,PLEK,Platelet degranulation ,0.0010577807955498226,1,0,1,0.001158666463376343
2386,CD14,Antigen processing-Cross presentation,0.028047507967437525,0,0,1,0.030722534385074267
2387,CD14,Antigen processing-Cross presentation,0.03301652314298435,1,0,1,0.036165468558332324
2388,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.028047507967437525,0,0,1,0.030722534385074267
2389,CD14,Toll Like Receptor 4 (TLR4) Cascade,0.03301652314298435,1,0,1,0.036165468558332324
2390,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.028047507967437525,0,0,1,0.030722534385074267
2391,CD14,Toll Like Receptor 9 (TLR9) Cascade,0.03301652314298435,1,0,1,0.036165468558332324
2392,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.028047507967437525,0,0,1,0.030722534385074267
2393,CD14,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.03301652314298435,1,0,1,0.036165468558332324
2394,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.028047507967437525,0,0,1,0.030722534385074267
2395,CD14,Toll Like Receptor 2 (TLR2) Cascade,0.03301652314298435,1,0,1,0.036165468558332324
2396,CD14,Regulation of TLR by endogenous ligand,0.028047507967437525,0,0,1,0.030722534385074267
2397,CD14,Regulation of TLR by endogenous ligand,0.03301652314298435,1,0,1,0.036165468558332324
2398,CD14,Caspase activation via Death Receptors in the presence of ligand,0.028047507967437525,0,0,1,0.030722534385074267
2399,CD14,Caspase activation via Death Receptors in the presence of ligand,0.03301652314298435,1,0,1,0.036165468558332324
2400,CD14,MyD88 deficiency (TLR2/4),0.028047507967437525,0,0,1,0.030722534385074267
2401,CD14,MyD88 deficiency (TLR2/4),0.03301652314298435,1,0,1,0.036165468558332324
2402,CD14,IRAK4 deficiency (TLR2/4),0.028047507967437525,0,0,1,0.030722534385074267
2403,CD14,IRAK4 deficiency (TLR2/4),0.03301652314298435,1,0,1,0.036165468558332324
2404,CD14,Neutrophil degranulation,0.028047507967437525,0,0,1,0.030722534385074267
2405,CD14,Neutrophil degranulation,0.03301652314298435,1,0,1,0.036165468558332324
2406,CFAH,Regulation of Complement cascade,0.0008026968209683241,0,0,1,0.0008792538970528085
2407,CFAH,Regulation of Complement cascade,0.000859359129503785,1,0,1,0.0009413203638611762
2408,FCG3A,FCGR activation,0.0002532385029221148,0,0,1,0.0002773910831109111
2409,FCG3A,FCGR activation,0.00021335357335000327,1,0,1,0.00023370213500015265
2410,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.0002532385029221148,0,0,1,0.0002773910831109111
2411,FCG3A,Regulation of actin dynamics for phagocytic cup formation,0.00021335357335000327,1,0,1,0.00023370213500015265
2412,FCG3A,Role of phospholipids in phagocytosis,0.0002532385029221148,0,0,1,0.0002773910831109111
2413,FCG3A,Role of phospholipids in phagocytosis,0.00021335357335000327,1,0,1,0.00023370213500015265
2414,FCG3A,Parasite infection,0.0002532385029221148,0,0,1,0.0002773910831109111
2415,FCG3A,Parasite infection,0.00021335357335000327,1,0,1,0.00023370213500015265
2416,FCG3A,Leishmania parasite growth and survival,0.0002532385029221148,0,0,1,0.0002773910831109111
2417,FCG3A,Leishmania parasite growth and survival,0.00021335357335000327,1,0,1,0.00023370213500015265
2418,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0002532385029221148,0,0,1,0.0002773910831109111
2419,FCG3A,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00021335357335000327,1,0,1,0.00023370213500015265
2420,A2AP,Platelet degranulation ,0.00017258432131751563,0,0,1,0.00018904452232112166
2421,A2AP,Platelet degranulation ,0.0002415712382696307,1,0,1,0.0002646110550284927
2422,A2AP,Dissolution of Fibrin Clot,0.00017258432131751563,0,0,1,0.00018904452232112166
2423,A2AP,Dissolution of Fibrin Clot,0.0002415712382696307,1,0,1,0.0002646110550284927
2424,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.001049888020549454,0,0,1,0.0011500209162701974
2425,FA7,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.000657369092509102,1,0,1,0.0007200655606103427
2426,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.001049888020549454,0,0,1,0.0011500209162701974
2427,FA7,Extrinsic Pathway of Fibrin Clot Formation,0.000657369092509102,1,0,1,0.0007200655606103427
2428,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.001049888020549454,0,0,1,0.0011500209162701974
2429,FA7,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.000657369092509102,1,0,1,0.0007200655606103427
2430,K1C16,Formation of the cornified envelope,0.00028575657726029704,0,0,1,0.0003130105633924057
2431,K1C16,Formation of the cornified envelope,0.00027552471697232377,1,0,1,0.0003018028411275441
2432,ENOG,Glycolysis,0.0003355857491807015,0,0,1,0.00036759218431508145
2433,ENOG,Glycolysis,0.00040065711952136065,1,0,1,0.0004388697258027522
2434,ENOG,Gluconeogenesis,0.0003355857491807015,0,0,1,0.00036759218431508145
2435,ENOG,Gluconeogenesis,0.00040065711952136065,1,0,1,0.0004388697258027522
2436,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,0.0010772841544656395,0,0,1,0.0011800299519119832
2437,THIK,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,0.0007933859508319138,1,0,1,0.000869055004222368
2438,THIK,Peroxisomal lipid metabolism,0.0010772841544656395,0,0,1,0.0011800299519119832
2439,THIK,Peroxisomal lipid metabolism,0.0007933859508319138,1,0,1,0.000869055004222368
2440,THIK,Neutrophil degranulation,0.0010772841544656395,0,0,1,0.0011800299519119832
2441,THIK,Neutrophil degranulation,0.0007933859508319138,1,0,1,0.000869055004222368
2442,THIK,TYSND1 cleaves peroxisomal proteins,0.0010772841544656395,0,0,1,0.0011800299519119832
2443,THIK,TYSND1 cleaves peroxisomal proteins,0.0007933859508319138,1,0,1,0.000869055004222368
2444,DOPO,Catecholamine biosynthesis,0.0002742468712700789,0,0,1,0.0003004031211035185
2445,DOPO,Catecholamine biosynthesis,6.183268938972096e-05,1,0,1,6.772997187852747e-05
2446,F16P1,Gluconeogenesis,0.00010622295886250083,0,0,1,0.00011635395593527541
2447,F16P1,Gluconeogenesis,0.00015454121058624176,1,0,1,0.0001692805528982828
2448,C1S,Initial triggering of complement,0.00040078341723718153,0,0,1,0.00043900806914225915
2449,C1S,Initial triggering of complement,0.00042819575854285497,1,0,1,0.00046903485795061567
2450,C1S,Regulation of Complement cascade,0.00040078341723718153,0,0,1,0.00043900806914225915
2451,C1S,Regulation of Complement cascade,0.00042819575854285497,1,0,1,0.00046903485795061567
2452,LKHA4,Arachidonic acid metabolism,0.0014756439514588186,0,0,1,0.0016163832484316918
2453,LKHA4,Arachidonic acid metabolism,0.0012280239198719704,1,0,1,0.0013451464974272081
2454,LKHA4,Biosynthesis of DHA-derived SPMs,0.0014756439514588186,0,0,1,0.0016163832484316918
2455,LKHA4,Biosynthesis of DHA-derived SPMs,0.0012280239198719704,1,0,1,0.0013451464974272081
2456,LKHA4,Biosynthesis of EPA-derived SPMs,0.0014756439514588186,0,0,1,0.0016163832484316918
2457,LKHA4,Biosynthesis of EPA-derived SPMs,0.0012280239198719704,1,0,1,0.0013451464974272081
2458,LKHA4,Neutrophil degranulation,0.0014756439514588186,0,0,1,0.0016163832484316918
2459,LKHA4,Neutrophil degranulation,0.0012280239198719704,1,0,1,0.0013451464974272081
2460,CO4A,Initial triggering of complement,0.0007803347350915363,0,0,1,0.0008547590309467284
2461,CO4A,Initial triggering of complement,0.0005631416034243488,1,0,1,0.0006168511403921023
2462,CO4A,Activation of C3 and C5,0.0007803347350915363,0,0,1,0.0008547590309467284
2463,CO4A,Activation of C3 and C5,0.0005631416034243488,1,0,1,0.0006168511403921023
2464,CO4A,Regulation of Complement cascade,0.0007803347350915363,0,0,1,0.0008547590309467284
2465,CO4A,Regulation of Complement cascade,0.0005631416034243488,1,0,1,0.0006168511403921023
2466,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0007803347350915363,0,0,1,0.0008547590309467284
2467,CO4A,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005631416034243488,1,0,1,0.0006168511403921023
2468,CO4A,Post-translational protein phosphorylation,0.0007803347350915363,0,0,1,0.0008547590309467284
2469,CO4A,Post-translational protein phosphorylation,0.0005631416034243488,1,0,1,0.0006168511403921023
2470,CO4B,Initial triggering of complement,0.00024621578103711626,0,0,1,0.00026969857029162
2471,CO4B,Initial triggering of complement,0.0002110207039362739,1,0,1,0.00023114676855325126
2472,CO4B,Activation of C3 and C5,0.00024621578103711626,0,0,1,0.00026969857029162
2473,CO4B,Activation of C3 and C5,0.0002110207039362739,1,0,1,0.00023114676855325126
2474,CO4B,Regulation of Complement cascade,0.00024621578103711626,0,0,1,0.00026969857029162
2475,CO4B,Regulation of Complement cascade,0.0002110207039362739,1,0,1,0.00023114676855325126
2476,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.0014546748144833694,0,0,1,0.001593414183497242
2477,SAA1,Toll Like Receptor 4 (TLR4) Cascade,0.000970186374572019,1,0,1,0.0010627177390349302
2478,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.0014546748144833694,0,0,1,0.001593414183497242
2479,SAA1,Toll Like Receptor 9 (TLR9) Cascade,0.000970186374572019,1,0,1,0.0010627177390349302
2480,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.0014546748144833694,0,0,1,0.001593414183497242
2481,SAA1,Toll Like Receptor 10 (TLR10) Cascade,0.000970186374572019,1,0,1,0.0010627177390349302
2482,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.0014546748144833694,0,0,1,0.001593414183497242
2483,SAA1,Toll Like Receptor 3 (TLR3) Cascade,0.000970186374572019,1,0,1,0.0010627177390349302
2484,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.0014546748144833694,0,0,1,0.001593414183497242
2485,SAA1,Toll Like Receptor 5 (TLR5) Cascade,0.000970186374572019,1,0,1,0.0010627177390349302
2486,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0014546748144833694,0,0,1,0.001593414183497242
2487,SAA1,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.000970186374572019,1,0,1,0.0010627177390349302
2488,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.0014546748144833694,0,0,1,0.001593414183497242
2489,SAA1,Toll Like Receptor 2 (TLR2) Cascade,0.000970186374572019,1,0,1,0.0010627177390349302
2490,SAA1,TRAF6 mediated NF-kB activation,0.0014546748144833694,0,0,1,0.001593414183497242
2491,SAA1,TRAF6 mediated NF-kB activation,0.000970186374572019,1,0,1,0.0010627177390349302
2492,SAA1,Class A/1 (Rhodopsin-like receptors),0.0014546748144833694,0,0,1,0.001593414183497242
2493,SAA1,Class A/1 (Rhodopsin-like receptors),0.000970186374572019,1,0,1,0.0010627177390349302
2494,SAA1,G alpha (q) signalling events,0.0014546748144833694,0,0,1,0.001593414183497242
2495,SAA1,G alpha (q) signalling events,0.000970186374572019,1,0,1,0.0010627177390349302
2496,SAA1,G alpha (i) signalling events,0.0014546748144833694,0,0,1,0.001593414183497242
2497,SAA1,G alpha (i) signalling events,0.000970186374572019,1,0,1,0.0010627177390349302
2498,SAA1,Interleukin-1 family signaling,0.0014546748144833694,0,0,1,0.001593414183497242
2499,SAA1,Interleukin-1 family signaling,0.000970186374572019,1,0,1,0.0010627177390349302
2500,SAA1,Interleukin-4 and Interleukin-13 signaling,0.0014546748144833694,0,0,1,0.001593414183497242
2501,SAA1,Interleukin-4 and Interleukin-13 signaling,0.000970186374572019,1,0,1,0.0010627177390349302
2502,SAA1,Advanced glycosylation endproduct receptor signaling,0.0014546748144833694,0,0,1,0.001593414183497242
2503,SAA1,Advanced glycosylation endproduct receptor signaling,0.000970186374572019,1,0,1,0.0010627177390349302
2504,SAA1,Scavenging by Class B Receptors,0.0014546748144833694,0,0,1,0.001593414183497242
2505,SAA1,Scavenging by Class B Receptors,0.000970186374572019,1,0,1,0.0010627177390349302
2506,SAA1,Amyloid fiber formation,0.0014546748144833694,0,0,1,0.001593414183497242
2507,SAA1,Amyloid fiber formation,0.000970186374572019,1,0,1,0.0010627177390349302
2508,OSTP,Transcriptional regulation by RUNX3,0.01754619941696865,0,0,1,0.01921966527439904
2509,OSTP,Transcriptional regulation by RUNX3,0.016747379758239245,1,0,1,0.018344658323290238
2510,OSTP,Integrin cell surface interactions,0.01754619941696865,0,0,1,0.01921966527439904
2511,OSTP,Integrin cell surface interactions,0.016747379758239245,1,0,1,0.018344658323290238
2512,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01754619941696865,0,0,1,0.01921966527439904
2513,OSTP,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.016747379758239245,1,0,1,0.018344658323290238
2514,OSTP,Post-translational protein phosphorylation,0.01754619941696865,0,0,1,0.01921966527439904
2515,OSTP,Post-translational protein phosphorylation,0.016747379758239245,1,0,1,0.018344658323290238
2516,OSTP,Signaling by PDGF,0.01754619941696865,0,0,1,0.01921966527439904
2517,OSTP,Signaling by PDGF,0.016747379758239245,1,0,1,0.018344658323290238
2518,CO7,Terminal pathway of complement,0.0008717811175061835,0,0,1,0.0009549270969077533
2519,CO7,Terminal pathway of complement,0.001041746188065684,1,0,1,0.0011411025578645041
2520,CO7,Regulation of Complement cascade,0.0008717811175061835,0,0,1,0.0009549270969077533
2521,CO7,Regulation of Complement cascade,0.001041746188065684,1,0,1,0.0011411025578645041
2522,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.0005202481336935972,0,0,1,0.0005698667131043701
2523,CH60,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,0.0002328630522649019,1,0,1,0.00025507232722877133
2524,CH60,Mitochondrial protein import,0.0005202481336935972,0,0,1,0.0005698667131043701
2525,CH60,Mitochondrial protein import,0.0002328630522649019,1,0,1,0.00025507232722877133
2526,CLUS,Terminal pathway of complement,0.002799040144003959,0,0,1,0.0030659981332103146
2527,CLUS,Terminal pathway of complement,0.0022086484341632294,1,0,1,0.0024192979120247894
2528,CLUS,Regulation of Complement cascade,0.002799040144003959,0,0,1,0.0030659981332103146
2529,CLUS,Regulation of Complement cascade,0.0022086484341632294,1,0,1,0.0024192979120247894
2530,CLUS,Platelet degranulation ,0.002799040144003959,0,0,1,0.0030659981332103146
2531,CLUS,Platelet degranulation ,0.0022086484341632294,1,0,1,0.0024192979120247894
2532,BIP,Regulation of HSF1-mediated heat shock response,0.004627031809209003,0,0,1,0.0050683342001112365
2533,BIP,Regulation of HSF1-mediated heat shock response,0.0033270035121381277,1,0,1,0.003644315919959607
2534,BIP,ATF6 (ATF6-alpha) activates chaperones,0.004627031809209003,0,0,1,0.0050683342001112365
2535,BIP,ATF6 (ATF6-alpha) activates chaperones,0.0033270035121381277,1,0,1,0.003644315919959607
2536,BIP,IRE1alpha activates chaperones,0.004627031809209003,0,0,1,0.0050683342001112365
2537,BIP,IRE1alpha activates chaperones,0.0033270035121381277,1,0,1,0.003644315919959607
2538,BIP,PERK regulates gene expression,0.004627031809209003,0,0,1,0.0050683342001112365
2539,BIP,PERK regulates gene expression,0.0033270035121381277,1,0,1,0.003644315919959607
2540,BIP,Platelet degranulation ,0.004627031809209003,0,0,1,0.0050683342001112365
2541,BIP,Platelet degranulation ,0.0033270035121381277,1,0,1,0.003644315919959607
2542,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.004627031809209003,0,0,1,0.0050683342001112365
2543,BIP,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0033270035121381277,1,0,1,0.003644315919959607
2544,LAMC1,L1CAM interactions,0.011070484590957764,0,0,1,0.012126330221565427
2545,LAMC1,L1CAM interactions,0.011238854662113383,1,0,1,0.012310758560314859
2546,LAMC1,MET promotes cell motility,0.011070484590957764,0,0,1,0.012126330221565427
2547,LAMC1,MET promotes cell motility,0.011238854662113383,1,0,1,0.012310758560314859
2548,LAMC1,Laminin interactions,0.011070484590957764,0,0,1,0.012126330221565427
2549,LAMC1,Laminin interactions,0.011238854662113383,1,0,1,0.012310758560314859
2550,LAMC1,ECM proteoglycans,0.011070484590957764,0,0,1,0.012126330221565427
2551,LAMC1,ECM proteoglycans,0.011238854662113383,1,0,1,0.012310758560314859
2552,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.011070484590957764,0,0,1,0.012126330221565427
2553,LAMC1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.011238854662113383,1,0,1,0.012310758560314859
2554,LAMC1,Post-translational protein phosphorylation,0.011070484590957764,0,0,1,0.012126330221565427
2555,LAMC1,Post-translational protein phosphorylation,0.011238854662113383,1,0,1,0.012310758560314859
2556,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.011070484590957764,0,0,1,0.012126330221565427
2557,LAMC1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.011238854662113383,1,0,1,0.012310758560314859
2558,HSP7C,"GABA synthesis, release, reuptake and degradation",0.016679332827969552,0,0,1,0.018270121428339125
2559,HSP7C,"GABA synthesis, release, reuptake and degradation",0.01990046252160886,1,0,1,0.021798465831931377
2560,HSP7C,Lysosome Vesicle Biogenesis,0.016679332827969552,0,0,1,0.018270121428339125
2561,HSP7C,Lysosome Vesicle Biogenesis,0.01990046252160886,1,0,1,0.021798465831931377
2562,HSP7C,Golgi Associated Vesicle Biogenesis,0.016679332827969552,0,0,1,0.018270121428339125
2563,HSP7C,Golgi Associated Vesicle Biogenesis,0.01990046252160886,1,0,1,0.021798465831931377
2564,HSP7C,Regulation of HSF1-mediated heat shock response,0.016679332827969552,0,0,1,0.018270121428339125
2565,HSP7C,Regulation of HSF1-mediated heat shock response,0.01990046252160886,1,0,1,0.021798465831931377
2566,HSP7C,HSF1-dependent transactivation,0.016679332827969552,0,0,1,0.018270121428339125
2567,HSP7C,HSF1-dependent transactivation,0.01990046252160886,1,0,1,0.021798465831931377
2568,HSP7C,L1CAM interactions,0.016679332827969552,0,0,1,0.018270121428339125
2569,HSP7C,L1CAM interactions,0.01990046252160886,1,0,1,0.021798465831931377
2570,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.016679332827969552,0,0,1,0.018270121428339125
2571,HSP7C,Interleukin-4 and Interleukin-13 signaling,0.01990046252160886,1,0,1,0.021798465831931377
2572,HSP7C,mRNA Splicing - Major Pathway,0.016679332827969552,0,0,1,0.018270121428339125
2573,HSP7C,mRNA Splicing - Major Pathway,0.01990046252160886,1,0,1,0.021798465831931377
2574,HSP7C,Lipophagy,0.016679332827969552,0,0,1,0.018270121428339125
2575,HSP7C,Lipophagy,0.01990046252160886,1,0,1,0.021798465831931377
2576,HSP7C,Neutrophil degranulation,0.016679332827969552,0,0,1,0.018270121428339125
2577,HSP7C,Neutrophil degranulation,0.01990046252160886,1,0,1,0.021798465831931377
2578,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.016679332827969552,0,0,1,0.018270121428339125
2579,HSP7C,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.01990046252160886,1,0,1,0.021798465831931377
2580,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.016679332827969552,0,0,1,0.018270121428339125
2581,HSP7C,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.01990046252160886,1,0,1,0.021798465831931377
2582,HSP7C,Protein methylation,0.016679332827969552,0,0,1,0.018270121428339125
2583,HSP7C,Protein methylation,0.01990046252160886,1,0,1,0.021798465831931377
2584,HSP7C,Chaperone Mediated Autophagy,0.016679332827969552,0,0,1,0.018270121428339125
2585,HSP7C,Chaperone Mediated Autophagy,0.01990046252160886,1,0,1,0.021798465831931377
2586,HSP7C,Late endosomal microautophagy,0.016679332827969552,0,0,1,0.018270121428339125
2587,HSP7C,Late endosomal microautophagy,0.01990046252160886,1,0,1,0.021798465831931377
2588,PYGB,Glycogen breakdown (glycogenolysis),0.001211246671326468,0,0,1,0.0013267691215860266
2589,PYGB,Glycogen breakdown (glycogenolysis),0.0012766344669696917,1,0,1,0.00139839326738698
2590,PYGB,Neutrophil degranulation,0.001211246671326468,0,0,1,0.0013267691215860266
2591,PYGB,Neutrophil degranulation,0.0012766344669696917,1,0,1,0.00139839326738698
2592,C1TC,Metabolism of folate and pterines,0.00029563327781740234,0,0,1,0.0003238292526260101
2593,C1TC,Metabolism of folate and pterines,0.0004059722387278571,1,0,1,0.0004446917736214723
2594,CO6A1,Collagen chain trimerization,0.012214704178838617,0,0,1,0.013379679562746013
2595,CO6A1,Collagen chain trimerization,0.010514998908963073,1,0,1,0.011517865184838761
2596,CO6A1,NCAM signaling for neurite out-growth,0.012214704178838617,0,0,1,0.013379679562746013
2597,CO6A1,NCAM signaling for neurite out-growth,0.010514998908963073,1,0,1,0.011517865184838761
2598,CO6A1,Collagen degradation,0.012214704178838617,0,0,1,0.013379679562746013
2599,CO6A1,Collagen degradation,0.010514998908963073,1,0,1,0.011517865184838761
2600,CO6A1,Integrin cell surface interactions,0.012214704178838617,0,0,1,0.013379679562746013
2601,CO6A1,Integrin cell surface interactions,0.010514998908963073,1,0,1,0.011517865184838761
2602,CO6A1,ECM proteoglycans,0.012214704178838617,0,0,1,0.013379679562746013
2603,CO6A1,ECM proteoglycans,0.010514998908963073,1,0,1,0.011517865184838761
2604,CO6A1,Signaling by PDGF,0.012214704178838617,0,0,1,0.013379679562746013
2605,CO6A1,Signaling by PDGF,0.010514998908963073,1,0,1,0.011517865184838761
2606,CO6A3,Collagen chain trimerization,0.004515824725421212,0,0,1,0.004946520759163085
2607,CO6A3,Collagen chain trimerization,0.0035620538105947076,1,0,1,0.003901784101622593
2608,CO6A3,NCAM signaling for neurite out-growth,0.004515824725421212,0,0,1,0.004946520759163085
2609,CO6A3,NCAM signaling for neurite out-growth,0.0035620538105947076,1,0,1,0.003901784101622593
2610,CO6A3,Collagen degradation,0.004515824725421212,0,0,1,0.004946520759163085
2611,CO6A3,Collagen degradation,0.0035620538105947076,1,0,1,0.003901784101622593
2612,CO6A3,Integrin cell surface interactions,0.004515824725421212,0,0,1,0.004946520759163085
2613,CO6A3,Integrin cell surface interactions,0.0035620538105947076,1,0,1,0.003901784101622593
2614,CO6A3,ECM proteoglycans,0.004515824725421212,0,0,1,0.004946520759163085
2615,CO6A3,ECM proteoglycans,0.0035620538105947076,1,0,1,0.003901784101622593
2616,CO6A3,Signaling by PDGF,0.004515824725421212,0,0,1,0.004946520759163085
2617,CO6A3,Signaling by PDGF,0.0035620538105947076,1,0,1,0.003901784101622593
2618,FA5,COPII-mediated vesicle transport,0.0032358543654380195,0,0,1,0.0035444734385200664
2619,FA5,COPII-mediated vesicle transport,0.003917560631565591,1,0,1,0.004291197326643749
2620,FA5,Cargo concentration in the ER,0.0032358543654380195,0,0,1,0.0035444734385200664
2621,FA5,Cargo concentration in the ER,0.003917560631565591,1,0,1,0.004291197326643749
2622,FA5,Platelet degranulation ,0.0032358543654380195,0,0,1,0.0035444734385200664
2623,FA5,Platelet degranulation ,0.003917560631565591,1,0,1,0.004291197326643749
2624,FA5,Common Pathway of Fibrin Clot Formation,0.0032358543654380195,0,0,1,0.0035444734385200664
2625,FA5,Common Pathway of Fibrin Clot Formation,0.003917560631565591,1,0,1,0.004291197326643749
2626,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0032358543654380195,0,0,1,0.0035444734385200664
2627,FA5,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003917560631565591,1,0,1,0.004291197326643749
2628,FA5,Post-translational protein phosphorylation,0.0032358543654380195,0,0,1,0.0035444734385200664
2629,FA5,Post-translational protein phosphorylation,0.003917560631565591,1,0,1,0.004291197326643749
2630,ACTN1,RHO GTPase cycle,0.003728282887862078,0,0,1,0.004083867249547002
2631,ACTN1,RHO GTPase cycle,0.0024013591387786614,1,0,1,0.002630388368110697
2632,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.003728282887862078,0,0,1,0.004083867249547002
2633,ACTN1,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,0.0024013591387786614,1,0,1,0.002630388368110697
2634,ACTN1,Platelet degranulation ,0.003728282887862078,0,0,1,0.004083867249547002
2635,ACTN1,Platelet degranulation ,0.0024013591387786614,1,0,1,0.002630388368110697
2636,ACTN1,Nephrin family interactions,0.003728282887862078,0,0,1,0.004083867249547002
2637,ACTN1,Nephrin family interactions,0.0024013591387786614,1,0,1,0.002630388368110697
2638,ACTN1,Syndecan interactions,0.003728282887862078,0,0,1,0.004083867249547002
2639,ACTN1,Syndecan interactions,0.0024013591387786614,1,0,1,0.002630388368110697
2640,ICAM2,CD209 (DC-SIGN) signaling,0.0009756707599644223,0,0,1,0.001068725196773947
2641,ICAM2,CD209 (DC-SIGN) signaling,0.0015677905119695526,1,0,1,0.0017173182718585162
2642,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0009756707599644223,0,0,1,0.001068725196773947
2643,ICAM2,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0015677905119695526,1,0,1,0.0017173182718585162
2644,ICAM2,Integrin cell surface interactions,0.0009756707599644223,0,0,1,0.001068725196773947
2645,ICAM2,Integrin cell surface interactions,0.0015677905119695526,1,0,1,0.0017173182718585162
2646,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.01224977118294062,0,0,1,0.013418091076544533
2647,CSPG2,Heparan sulfate/heparin (HS-GAG) metabolism,0.013755766889978635,1,0,1,0.015067720874206615
2648,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.01224977118294062,0,0,1,0.013418091076544533
2649,CSPG2,Chondroitin sulfate/dermatan sulfate metabolism,0.013755766889978635,1,0,1,0.015067720874206615
2650,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.01224977118294062,0,0,1,0.013418091076544533
2651,CSPG2,Diseases associated with glycosaminoglycan metabolism,0.013755766889978635,1,0,1,0.015067720874206615
2652,CSPG2,ECM proteoglycans,0.01224977118294062,0,0,1,0.013418091076544533
2653,CSPG2,ECM proteoglycans,0.013755766889978635,1,0,1,0.015067720874206615
2654,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01224977118294062,0,0,1,0.013418091076544533
2655,CSPG2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.013755766889978635,1,0,1,0.015067720874206615
2656,CSPG2,Post-translational protein phosphorylation,0.01224977118294062,0,0,1,0.013418091076544533
2657,CSPG2,Post-translational protein phosphorylation,0.013755766889978635,1,0,1,0.015067720874206615
2658,K1C10,Formation of the cornified envelope,0.00015025758010649831,0,0,1,0.0001645883718724441
2659,K1C10,Formation of the cornified envelope,0.00014864638141894311,1,0,1,0.00016282350537745745
2660,K2C5,Type I hemidesmosome assembly,0.002399898572797712,0,0,1,0.00262878850089171
2661,K2C5,Type I hemidesmosome assembly,0.002012602915026503,1,0,1,0.002204554584036065
2662,K2C5,Formation of the cornified envelope,0.002399898572797712,0,0,1,0.00262878850089171
2663,K2C5,Formation of the cornified envelope,0.002012602915026503,1,0,1,0.002204554584036065
2664,CO6,Terminal pathway of complement,0.0010817023778045825,0,0,1,0.0011848695625686309
2665,CO6,Terminal pathway of complement,0.0012518531691592973,1,0,1,0.0013712484574106175
2666,CO6,Regulation of Complement cascade,0.0010817023778045825,0,0,1,0.0011848695625686309
2667,CO6,Regulation of Complement cascade,0.0012518531691592973,1,0,1,0.0013712484574106175
2668,PRG2,Neutrophil degranulation,0.0021201213059455232,0,0,1,0.0023223275236452607
2669,PRG2,Neutrophil degranulation,0.0022280667019123923,1,0,1,0.002440568193837878
2670,PLSL,Interleukin-12 family signaling,0.00026621339309472,0,0,1,0.00029160345128041883
2671,PLSL,Interleukin-12 family signaling,0.0003631314290813986,1,0,1,0.0003977650288648332
2672,CD59,Regulation of Complement cascade,0.00021590315955569194,0,0,1,0.00023649488756708012
2673,CD59,Regulation of Complement cascade,0.0002493113273069677,1,0,1,0.00027308935377322243
2674,CD59,COPII-mediated vesicle transport,0.00021590315955569194,0,0,1,0.00023649488756708012
2675,CD59,COPII-mediated vesicle transport,0.0002493113273069677,1,0,1,0.00027308935377322243
2676,CD59,Cargo concentration in the ER,0.00021590315955569194,0,0,1,0.00023649488756708012
2677,CD59,Cargo concentration in the ER,0.0002493113273069677,1,0,1,0.00027308935377322243
2678,CD59,COPI-mediated anterograde transport,0.00021590315955569194,0,0,1,0.00023649488756708012
2679,CD59,COPI-mediated anterograde transport,0.0002493113273069677,1,0,1,0.00027308935377322243
2680,CD59,Neutrophil degranulation,0.00021590315955569194,0,0,1,0.00023649488756708012
2681,CD59,Neutrophil degranulation,0.0002493113273069677,1,0,1,0.00027308935377322243
2682,GFAP,Nuclear signaling by ERBB4,0.0001683976062785345,0,0,1,0.0001844585000301239
2683,GFAP,Nuclear signaling by ERBB4,3.3165145213259045e-05,1,0,1,3.6328265433894186e-05
2684,GFAP,Chaperone Mediated Autophagy,0.0001683976062785345,0,0,1,0.0001844585000301239
2685,GFAP,Chaperone Mediated Autophagy,3.3165145213259045e-05,1,0,1,3.6328265433894186e-05
2686,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0018032798886848966,0,0,1,0.0019752674087963264
2687,LYAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0019444104272510886,1,0,1,0.002129858249056279
2688,LYAM1,Neutrophil degranulation,0.0018032798886848966,0,0,1,0.0019752674087963264
2689,LYAM1,Neutrophil degranulation,0.0019444104272510886,1,0,1,0.002129858249056279
2690,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.006474677496353344,0,0,1,0.007092198788032139
2691,GLU2B,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0066404999653350205,1,0,1,0.007273836547473087
2692,GLU2B,SARS-CoV-1 Infection,0.006474677496353344,0,0,1,0.007092198788032139
2693,GLU2B,SARS-CoV-1 Infection,0.0066404999653350205,1,0,1,0.007273836547473087
2694,GLU2B,SARS-CoV-2 Infection,0.006474677496353344,0,0,1,0.007092198788032139
2695,GLU2B,SARS-CoV-2 Infection,0.0066404999653350205,1,0,1,0.007273836547473087
2696,GLU2B,Advanced glycosylation endproduct receptor signaling,0.006474677496353344,0,0,1,0.007092198788032139
2697,GLU2B,Advanced glycosylation endproduct receptor signaling,0.0066404999653350205,1,0,1,0.007273836547473087
2698,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006474677496353344,0,0,1,0.007092198788032139
2699,GLU2B,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0066404999653350205,1,0,1,0.007273836547473087
2700,GLU2B,Post-translational protein phosphorylation,0.006474677496353344,0,0,1,0.007092198788032139
2701,GLU2B,Post-translational protein phosphorylation,0.0066404999653350205,1,0,1,0.007273836547473087
2702,NID1,Laminin interactions,6.989109458353489e-05,0,0,1,7.655694613033046e-05
2703,NID1,Laminin interactions,0.00012545980981545644,1,0,1,0.00013742551835532602
2704,PA2GA,Glycerophospholipid biosynthesis,0.0009429752102788292,0,0,1,0.0010329113144632357
2705,PA2GA,Glycerophospholipid biosynthesis,0.000439213728443554,1,0,1,0.00048110366490205424
2706,KPYM,Neutrophil degranulation,0.0011263060731267283,0,0,1,0.001233727327929708
2707,KPYM,Neutrophil degranulation,0.0011856599820501213,1,0,1,0.001298742106066309
2708,ENPL,Trafficking and processing of endosomal TLR,0.0017587594958903478,0,0,1,0.001926500890927591
2709,ENPL,Trafficking and processing of endosomal TLR,0.0012540147044843525,1,0,1,0.0013736161488085718
2710,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.0017587594958903478,0,0,1,0.001926500890927591
2711,ENPL,ATF6 (ATF6-alpha) activates chaperones,0.0012540147044843525,1,0,1,0.0013736161488085718
2712,ENPL,Interleukin-4 and Interleukin-13 signaling,0.0017587594958903478,0,0,1,0.001926500890927591
2713,ENPL,Interleukin-4 and Interleukin-13 signaling,0.0012540147044843525,1,0,1,0.0013736161488085718
2714,ENPL,Scavenging by Class A Receptors,0.0017587594958903478,0,0,1,0.001926500890927591
2715,ENPL,Scavenging by Class A Receptors,0.0012540147044843525,1,0,1,0.0013736161488085718
2716,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0017587594958903478,0,0,1,0.001926500890927591
2717,ENPL,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0012540147044843525,1,0,1,0.0013736161488085718
2718,ENPL,Post-translational protein phosphorylation,0.0017587594958903478,0,0,1,0.001926500890927591
2719,ENPL,Post-translational protein phosphorylation,0.0012540147044843525,1,0,1,0.0013736161488085718
2720,GPIX,Defective factor IX causes hemophilia B,0.0003300211408963252,0,0,1,0.00036149685243908383
2721,GPIX,Defective factor IX causes hemophilia B,0.00039579318573362745,1,0,1,0.0004335418951372312
2722,GPIX,Platelet Adhesion to exposed collagen,0.0003300211408963252,0,0,1,0.00036149685243908383
2723,GPIX,Platelet Adhesion to exposed collagen,0.00039579318573362745,1,0,1,0.0004335418951372312
2724,GPIX,Intrinsic Pathway of Fibrin Clot Formation,0.0003300211408963252,0,0,1,0.00036149685243908383
2725,GPIX,Intrinsic Pathway of Fibrin Clot Formation,0.00039579318573362745,1,0,1,0.0004335418951372312
2726,GPIX,GP1b-IX-V activation signalling,0.0003300211408963252,0,0,1,0.00036149685243908383
2727,GPIX,GP1b-IX-V activation signalling,0.00039579318573362745,1,0,1,0.0004335418951372312
2728,MMP9,EPH-Ephrin signaling,0.008309231871304097,0,0,1,0.009101723482031622
2729,MMP9,EPH-Ephrin signaling,0.008213082938289581,1,0,1,0.008996404360487702
2730,MMP9,Interleukin-4 and Interleukin-13 signaling,0.008309231871304097,0,0,1,0.009101723482031622
2731,MMP9,Interleukin-4 and Interleukin-13 signaling,0.008213082938289581,1,0,1,0.008996404360487702
2732,MMP9,Extra-nuclear estrogen signaling,0.008309231871304097,0,0,1,0.009101723482031622
2733,MMP9,Extra-nuclear estrogen signaling,0.008213082938289581,1,0,1,0.008996404360487702
2734,MMP9,Collagen degradation,0.008309231871304097,0,0,1,0.009101723482031622
2735,MMP9,Collagen degradation,0.008213082938289581,1,0,1,0.008996404360487702
2736,MMP9,Activation of Matrix Metalloproteinases,0.008309231871304097,0,0,1,0.009101723482031622
2737,MMP9,Activation of Matrix Metalloproteinases,0.008213082938289581,1,0,1,0.008996404360487702
2738,MMP9,Neutrophil degranulation,0.008309231871304097,0,0,1,0.009101723482031622
2739,MMP9,Neutrophil degranulation,0.008213082938289581,1,0,1,0.008996404360487702
2740,MMP9,Signaling by SCF-KIT,0.008309231871304097,0,0,1,0.009101723482031622
2741,MMP9,Signaling by SCF-KIT,0.008213082938289581,1,0,1,0.008996404360487702
2742,AMPN,Neutrophil degranulation,0.000296291325710091,0,0,1,0.0003245500617272545
2743,AMPN,Neutrophil degranulation,0.0002537628473606295,1,0,1,0.00027796543681322906
2744,AMPN,Metabolism of Angiotensinogen to Angiotensins,0.000296291325710091,0,0,1,0.0003245500617272545
2745,AMPN,Metabolism of Angiotensinogen to Angiotensins,0.0002537628473606295,1,0,1,0.00027796543681322906
2746,PVR,Adherens junctions interactions,0.0007919079365782992,0,0,1,0.0008674360246046058
2747,PVR,Adherens junctions interactions,0.0005229975203093751,1,0,1,0.0005728783220123403
2748,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0007919079365782992,0,0,1,0.0008674360246046058
2749,PVR,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0005229975203093751,1,0,1,0.0005728783220123403
2750,CBPN,Regulation of Complement cascade,0.001634761582835875,0,0,1,0.0017906766974942114
2751,CBPN,Regulation of Complement cascade,0.0017436475480010856,1,0,1,0.0019099476435163656
2752,B4GT1,Keratan sulfate/keratin metabolism,0.009287244821788023,0,0,1,0.010173014255357162
2753,B4GT1,Keratan sulfate/keratin metabolism,0.008742432424327406,1,0,1,0.009576240465905671
2754,B4GT1,Pre-NOTCH Processing in Golgi,0.009287244821788023,0,0,1,0.010173014255357162
2755,B4GT1,Pre-NOTCH Processing in Golgi,0.008742432424327406,1,0,1,0.009576240465905671
2756,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.009287244821788023,0,0,1,0.010173014255357162
2757,B4GT1,Diseases associated with glycosaminoglycan metabolism,0.008742432424327406,1,0,1,0.009576240465905671
2758,B4GT1,Diseases associated with N-glycosylation of proteins,0.009287244821788023,0,0,1,0.010173014255357162
2759,B4GT1,Diseases associated with N-glycosylation of proteins,0.008742432424327406,1,0,1,0.009576240465905671
2760,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.009287244821788023,0,0,1,0.010173014255357162
2761,B4GT1,Interaction With Cumulus Cells And The Zona Pellucida,0.008742432424327406,1,0,1,0.009576240465905671
2762,B4GT1,Neutrophil degranulation,0.009287244821788023,0,0,1,0.010173014255357162
2763,B4GT1,Neutrophil degranulation,0.008742432424327406,1,0,1,0.009576240465905671
2764,B4GT1,Lactose synthesis,0.009287244821788023,0,0,1,0.010173014255357162
2765,B4GT1,Lactose synthesis,0.008742432424327406,1,0,1,0.009576240465905671
2766,EZRI,L1CAM interactions,0.00024842591325428603,0,0,1,0.00027211949350220934
2767,EZRI,L1CAM interactions,7.266957084488387e-05,1,0,1,7.960041910399035e-05
2768,EZRI,Netrin-1 signaling,0.00024842591325428603,0,0,1,0.00027211949350220934
2769,EZRI,Netrin-1 signaling,7.266957084488387e-05,1,0,1,7.960041910399035e-05
2770,EZRI,Sensory processing of sound by inner hair cells of the cochlea,0.00024842591325428603,0,0,1,0.00027211949350220934
2771,EZRI,Sensory processing of sound by inner hair cells of the cochlea,7.266957084488387e-05,1,0,1,7.960041910399035e-05
2772,EZRI,Sensory processing of sound by outer hair cells of the cochlea,0.00024842591325428603,0,0,1,0.00027211949350220934
2773,EZRI,Sensory processing of sound by outer hair cells of the cochlea,7.266957084488387e-05,1,0,1,7.960041910399035e-05
2774,TIMP2,Activation of Matrix Metalloproteinases,0.0012518194670136545,0,0,1,0.0013712115409284273
2775,TIMP2,Activation of Matrix Metalloproteinases,0.0012628064471058226,1,0,1,0.0013832464024234894
2776,TIMP2,Neutrophil degranulation,0.0012518194670136545,0,0,1,0.0013712115409284273
2777,TIMP2,Neutrophil degranulation,0.0012628064471058226,1,0,1,0.0013832464024234894
2778,CD44,Hyaluronan metabolism,0.007807172339535608,0,0,1,0.008551780105742392
2779,CD44,Hyaluronan metabolism,0.008936561708508307,1,0,1,0.009788884798347676
2780,CD44,Interferon gamma signaling,0.007807172339535608,0,0,1,0.008551780105742392
2781,CD44,Interferon gamma signaling,0.008936561708508307,1,0,1,0.009788884798347676
2782,CD44,Integrin cell surface interactions,0.007807172339535608,0,0,1,0.008551780105742392
2783,CD44,Integrin cell surface interactions,0.008936561708508307,1,0,1,0.009788884798347676
2784,CD44,Neutrophil degranulation,0.007807172339535608,0,0,1,0.008551780105742392
2785,CD44,Neutrophil degranulation,0.008936561708508307,1,0,1,0.009788884798347676
2786,CD36,Antigen processing-Cross presentation,0.0021433833444923596,0,0,1,0.0023478081752579395
2787,CD36,Antigen processing-Cross presentation,0.0020707513134498715,1,0,1,0.0022682488763087682
2788,CD36,Toll Like Receptor 4 (TLR4) Cascade,0.0021433833444923596,0,0,1,0.0023478081752579395
2789,CD36,Toll Like Receptor 4 (TLR4) Cascade,0.0020707513134498715,1,0,1,0.0022682488763087682
2790,CD36,Toll Like Receptor 2 (TLR2) Cascade,0.0021433833444923596,0,0,1,0.0023478081752579395
2791,CD36,Toll Like Receptor 2 (TLR2) Cascade,0.0020707513134498715,1,0,1,0.0022682488763087682
2792,CD36,Regulation of TLR by endogenous ligand,0.0021433833444923596,0,0,1,0.0023478081752579395
2793,CD36,Regulation of TLR by endogenous ligand,0.0020707513134498715,1,0,1,0.0022682488763087682
2794,CD36,PPARA activates gene expression,0.0021433833444923596,0,0,1,0.0023478081752579395
2795,CD36,PPARA activates gene expression,0.0020707513134498715,1,0,1,0.0022682488763087682
2796,CD36,Free fatty acids regulate insulin secretion,0.0021433833444923596,0,0,1,0.0023478081752579395
2797,CD36,Free fatty acids regulate insulin secretion,0.0020707513134498715,1,0,1,0.0022682488763087682
2798,CD36,Interleukin-4 and Interleukin-13 signaling,0.0021433833444923596,0,0,1,0.0023478081752579395
2799,CD36,Interleukin-4 and Interleukin-13 signaling,0.0020707513134498715,1,0,1,0.0022682488763087682
2800,CD36,MyD88 deficiency (TLR2/4),0.0021433833444923596,0,0,1,0.0023478081752579395
2801,CD36,MyD88 deficiency (TLR2/4),0.0020707513134498715,1,0,1,0.0022682488763087682
2802,CD36,IRAK4 deficiency (TLR2/4),0.0021433833444923596,0,0,1,0.0023478081752579395
2803,CD36,IRAK4 deficiency (TLR2/4),0.0020707513134498715,1,0,1,0.0022682488763087682
2804,CD36,Platelet degranulation ,0.0021433833444923596,0,0,1,0.0023478081752579395
2805,CD36,Platelet degranulation ,0.0020707513134498715,1,0,1,0.0022682488763087682
2806,CD36,Transcriptional regulation of white adipocyte differentiation,0.0021433833444923596,0,0,1,0.0023478081752579395
2807,CD36,Transcriptional regulation of white adipocyte differentiation,0.0020707513134498715,1,0,1,0.0022682488763087682
2808,CD36,Neutrophil degranulation,0.0021433833444923596,0,0,1,0.0023478081752579395
2809,CD36,Neutrophil degranulation,0.0020707513134498715,1,0,1,0.0022682488763087682
2810,CD36,Scavenging by Class B Receptors,0.0021433833444923596,0,0,1,0.0023478081752579395
2811,CD36,Scavenging by Class B Receptors,0.0020707513134498715,1,0,1,0.0022682488763087682
2812,FAAA,Tyrosine catabolism,0.00029626630655422493,0,0,1,0.00032452265637354985
2813,FAAA,Tyrosine catabolism,0.0002837435354818153,1,0,1,0.00031080552808838524
2814,HSP76,Regulation of HSF1-mediated heat shock response,0.000548140108358538,0,0,1,0.0006004188802240343
2815,HSP76,Regulation of HSF1-mediated heat shock response,0.0005689549587542562,1,0,1,0.0006232189435218167
2816,HSP76,Neutrophil degranulation,0.000548140108358538,0,0,1,0.0006004188802240343
2817,HSP76,Neutrophil degranulation,0.0005689549587542562,1,0,1,0.0006232189435218167
2818,AATC,Methionine salvage pathway,0.0008479856033094445,0,0,1,0.0009288620894935981
2819,AATC,Methionine salvage pathway,0.001951338333871953,1,0,1,0.0021374469036213547
2820,AATC,Gluconeogenesis,0.0008479856033094445,0,0,1,0.0009288620894935981
2821,AATC,Gluconeogenesis,0.001951338333871953,1,0,1,0.0021374469036213547
2822,AATC,Aspartate and asparagine metabolism,0.0008479856033094445,0,0,1,0.0009288620894935981
2823,AATC,Aspartate and asparagine metabolism,0.001951338333871953,1,0,1,0.0021374469036213547
2824,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0002293672556232491,0,0,1,0.00025124311956258244
2825,CTRB1,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0001939694083361948,1,0,1,0.00021246920846514346
2826,CTRB1,Activation of Matrix Metalloproteinases,0.0002293672556232491,0,0,1,0.00025124311956258244
2827,CTRB1,Activation of Matrix Metalloproteinases,0.0001939694083361948,1,0,1,0.00021246920846514346
2828,IBP3,Transcriptional Regulation by TP53,0.001529831629604214,0,0,1,0.0016757390673872302
2829,IBP3,Transcriptional Regulation by TP53,0.0016926319767489662,1,0,1,0.0018540664706226072
2830,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001529831629604214,0,0,1,0.0016757390673872302
2831,IBP3,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0016926319767489662,1,0,1,0.0018540664706226072
2832,IBP3,Post-translational protein phosphorylation,0.001529831629604214,0,0,1,0.0016757390673872302
2833,IBP3,Post-translational protein phosphorylation,0.0016926319767489662,1,0,1,0.0018540664706226072
2834,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),2.707246818190803e-06,0,0,1,2.9654500341817267e-06
2835,IBP2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),3.1127091656959743e-06,1,0,1,3.4095832857897707e-06
2836,VINC,RAF/MAP kinase cascade,0.0102531520099034,0,0,1,0.011231044681237323
2837,VINC,RAF/MAP kinase cascade,0.010583747776348126,1,0,1,0.01159317096404112
2838,VINC,Signaling by RAS mutants,0.0102531520099034,0,0,1,0.011231044681237323
2839,VINC,Signaling by RAS mutants,0.010583747776348126,1,0,1,0.01159317096404112
2840,VINC,Signaling by moderate kinase activity BRAF mutants,0.0102531520099034,0,0,1,0.011231044681237323
2841,VINC,Signaling by moderate kinase activity BRAF mutants,0.010583747776348126,1,0,1,0.01159317096404112
2842,VINC,Signaling by high-kinase activity BRAF mutants,0.0102531520099034,0,0,1,0.011231044681237323
2843,VINC,Signaling by high-kinase activity BRAF mutants,0.010583747776348126,1,0,1,0.01159317096404112
2844,VINC,Signaling by BRAF and RAF1 fusions,0.0102531520099034,0,0,1,0.011231044681237323
2845,VINC,Signaling by BRAF and RAF1 fusions,0.010583747776348126,1,0,1,0.01159317096404112
2846,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0102531520099034,0,0,1,0.011231044681237323
2847,VINC,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.010583747776348126,1,0,1,0.01159317096404112
2848,VINC,Signaling by RAF1 mutants,0.0102531520099034,0,0,1,0.011231044681237323
2849,VINC,Signaling by RAF1 mutants,0.010583747776348126,1,0,1,0.01159317096404112
2850,VINC,Platelet degranulation ,0.0102531520099034,0,0,1,0.011231044681237323
2851,VINC,Platelet degranulation ,0.010583747776348126,1,0,1,0.01159317096404112
2852,VINC,Signaling by ALK fusions and activated point mutants,0.0102531520099034,0,0,1,0.011231044681237323
2853,VINC,Signaling by ALK fusions and activated point mutants,0.010583747776348126,1,0,1,0.01159317096404112
2854,VINC,Neutrophil degranulation,0.0102531520099034,0,0,1,0.011231044681237323
2855,VINC,Neutrophil degranulation,0.010583747776348126,1,0,1,0.01159317096404112
2856,VINC,Smooth Muscle Contraction,0.0102531520099034,0,0,1,0.011231044681237323
2857,VINC,Smooth Muscle Contraction,0.010583747776348126,1,0,1,0.01159317096404112
2858,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.00194605442252188,0,0,1,0.002131659040103185
2859,LBP,Toll Like Receptor 4 (TLR4) Cascade,0.0025550026079939102,1,0,1,0.0027986855577037174
2860,LBP,Regulation of TLR by endogenous ligand,0.00194605442252188,0,0,1,0.002131659040103185
2861,LBP,Regulation of TLR by endogenous ligand,0.0025550026079939102,1,0,1,0.0027986855577037174
2862,LBP,Interleukin-4 and Interleukin-13 signaling,0.00194605442252188,0,0,1,0.002131659040103185
2863,LBP,Interleukin-4 and Interleukin-13 signaling,0.0025550026079939102,1,0,1,0.0027986855577037174
2864,ML12A,EPH-Ephrin signaling,0.0015296647065144203,0,0,1,0.0016755562240354503
2865,ML12A,EPH-Ephrin signaling,0.0020560616099034546,1,0,1,0.0022521581447245112
2866,ML12A,Smooth Muscle Contraction,0.0015296647065144203,0,0,1,0.0016755562240354503
2867,ML12A,Smooth Muscle Contraction,0.0020560616099034546,1,0,1,0.0022521581447245112
2868,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.003690558292559965,0,0,1,0.004042544677228714
2869,VCAM1,Interleukin-4 and Interleukin-13 signaling,0.0038998736921629306,1,0,1,0.004271823498330879
2870,VCAM1,Interferon gamma signaling,0.003690558292559965,0,0,1,0.004042544677228714
2871,VCAM1,Interferon gamma signaling,0.0038998736921629306,1,0,1,0.004271823498330879
2872,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003690558292559965,0,0,1,0.004042544677228714
2873,VCAM1,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0038998736921629306,1,0,1,0.004271823498330879
2874,VCAM1,Integrin cell surface interactions,0.003690558292559965,0,0,1,0.004042544677228714
2875,VCAM1,Integrin cell surface interactions,0.0038998736921629306,1,0,1,0.004271823498330879
2876,A1AG2,Platelet degranulation ,0.0029539272778160482,0,0,1,0.0032356576017047007
2877,A1AG2,Platelet degranulation ,0.0025526717169488647,1,0,1,0.0027961323583120846
2878,A1AG2,Neutrophil degranulation,0.0029539272778160482,0,0,1,0.0032356576017047007
2879,A1AG2,Neutrophil degranulation,0.0025526717169488647,1,0,1,0.0027961323583120846
2880,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009651913820469852,0,0,1,0.01057246349926789
2881,ITIH2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01062112945595255,1,0,1,0.01163411791513396
2882,ITIH2,Post-translational protein phosphorylation,0.009651913820469852,0,0,1,0.01057246349926789
2883,ITIH2,Post-translational protein phosphorylation,0.01062112945595255,1,0,1,0.01163411791513396
2884,TYPH,Pyrimidine catabolism,0.0009415438547931365,0,0,1,0.0010313434436856426
2885,TYPH,Pyrimidine catabolism,0.0005847830084556723,1,0,1,0.000640556590836686
2886,TYPH,Pyrimidine salvage,0.0009415438547931365,0,0,1,0.0010313434436856426
2887,TYPH,Pyrimidine salvage,0.0005847830084556723,1,0,1,0.000640556590836686
2888,C4BPB,Regulation of Complement cascade,0.001005415706300323,0,0,1,0.00110130706243017
2889,C4BPB,Regulation of Complement cascade,0.0010735254753724683,1,0,1,0.0011759127894240902
2890,FLNA,Antiviral mechanism by IFN-stimulated genes,0.00245166061502801,0,0,1,0.002685487339309306
2891,FLNA,Antiviral mechanism by IFN-stimulated genes,0.0018883429634323353,1,0,1,0.0020684433601807547
2892,FLNA,RHO GTPase Effectors,0.00245166061502801,0,0,1,0.002685487339309306
2893,FLNA,RHO GTPase Effectors,0.0018883429634323353,1,0,1,0.0020684433601807547
2894,FLNA,Platelet degranulation ,0.00245166061502801,0,0,1,0.002685487339309306
2895,FLNA,Platelet degranulation ,0.0018883429634323353,1,0,1,0.0020684433601807547
2896,FLNA,GP1b-IX-V activation signalling,0.00245166061502801,0,0,1,0.002685487339309306
2897,FLNA,GP1b-IX-V activation signalling,0.0018883429634323353,1,0,1,0.0020684433601807547
2898,TENX,ECM proteoglycans,0.002928951740688006,0,0,1,0.0032083000268680055
2899,TENX,ECM proteoglycans,0.0022857475701984265,1,0,1,0.0025037503653639903
2900,GPX3,Detoxification of Reactive Oxygen Species,0.001421444510185954,0,0,1,0.0015570145444423538
2901,GPX3,Detoxification of Reactive Oxygen Species,0.0010466505559472658,1,0,1,0.0011464746790188643
2902,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0017437345037934636,0,0,1,0.0019100428927030107
2903,IBP4,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.001832534040736414,1,0,1,0.0020073116707447452
2904,IBP4,Post-translational protein phosphorylation,0.0017437345037934636,0,0,1,0.0019100428927030107
2905,IBP4,Post-translational protein phosphorylation,0.001832534040736414,1,0,1,0.0020073116707447452
2906,CPN2,Regulation of Complement cascade,0.00010570146371564941,0,0,1,0.00011578272327534024
2907,CPN2,Regulation of Complement cascade,0.0001127616240041725,1,0,1,0.00012351624517967873
2908,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0012677341292054258,0,0,1,0.0013886440613855452
2909,PROZ,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins",0.0012878881406089618,1,0,1,0.0014107202582819387
2910,MMP8,Collagen degradation,0.0021150911662391942,0,0,1,0.0023168176351992414
2911,MMP8,Collagen degradation,0.0020161644534354432,1,0,1,0.0022084558035796857
2912,MMP8,Activation of Matrix Metalloproteinases,0.0021150911662391942,0,0,1,0.0023168176351992414
2913,MMP8,Activation of Matrix Metalloproteinases,0.0020161644534354432,1,0,1,0.0022084558035796857
2914,MMP8,Neutrophil degranulation,0.0021150911662391942,0,0,1,0.0023168176351992414
2915,MMP8,Neutrophil degranulation,0.0020161644534354432,1,0,1,0.0022084558035796857
2916,MRC1,Antigen processing-Cross presentation,0.0026409033210806282,0,0,1,0.0028927790370450197
2917,MRC1,Antigen processing-Cross presentation,0.0029336676352567557,1,0,1,0.0032134656990986006
2918,MRC1,Modulation by Mtb of host immune system,0.0026409033210806282,0,0,1,0.0028927790370450197
2919,MRC1,Modulation by Mtb of host immune system,0.0029336676352567557,1,0,1,0.0032134656990986006
2920,HV102,Initial triggering of complement,0.0017293168406246281,0,0,1,0.0018942501473021992
2921,HV102,Initial triggering of complement,0.0017514849617940725,1,0,1,0.0019185325493491633
2922,HV102,Regulation of Complement cascade,0.0017293168406246281,0,0,1,0.0018942501473021992
2923,HV102,Regulation of Complement cascade,0.0017514849617940725,1,0,1,0.0019185325493491633
2924,HV102,FCGR activation,0.0017293168406246281,0,0,1,0.0018942501473021992
2925,HV102,FCGR activation,0.0017514849617940725,1,0,1,0.0019185325493491633
2926,HV102,Regulation of actin dynamics for phagocytic cup formation,0.0017293168406246281,0,0,1,0.0018942501473021992
2927,HV102,Regulation of actin dynamics for phagocytic cup formation,0.0017514849617940725,1,0,1,0.0019185325493491633
2928,HV102,Role of phospholipids in phagocytosis,0.0017293168406246281,0,0,1,0.0018942501473021992
2929,HV102,Role of phospholipids in phagocytosis,0.0017514849617940725,1,0,1,0.0019185325493491633
2930,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.0017293168406246281,0,0,1,0.0018942501473021992
2931,HV102,Role of LAT2/NTAL/LAB on calcium mobilization,0.0017514849617940725,1,0,1,0.0019185325493491633
2932,HV102,FCERI mediated MAPK activation,0.0017293168406246281,0,0,1,0.0018942501473021992
2933,HV102,FCERI mediated MAPK activation,0.0017514849617940725,1,0,1,0.0019185325493491633
2934,HV102,FCERI mediated Ca+2 mobilization,0.0017293168406246281,0,0,1,0.0018942501473021992
2935,HV102,FCERI mediated Ca+2 mobilization,0.0017514849617940725,1,0,1,0.0019185325493491633
2936,HV102,FCERI mediated NF-kB activation,0.0017293168406246281,0,0,1,0.0018942501473021992
2937,HV102,FCERI mediated NF-kB activation,0.0017514849617940725,1,0,1,0.0019185325493491633
2938,HV102,Parasite infection,0.0017293168406246281,0,0,1,0.0018942501473021992
2939,HV102,Parasite infection,0.0017514849617940725,1,0,1,0.0019185325493491633
2940,HV102,Leishmania parasite growth and survival,0.0017293168406246281,0,0,1,0.0018942501473021992
2941,HV102,Leishmania parasite growth and survival,0.0017514849617940725,1,0,1,0.0019185325493491633
2942,HV102,Potential therapeutics for SARS,0.0017293168406246281,0,0,1,0.0018942501473021992
2943,HV102,Potential therapeutics for SARS,0.0017514849617940725,1,0,1,0.0019185325493491633
2944,HV102,CD22 mediated BCR regulation,0.0017293168406246281,0,0,1,0.0018942501473021992
2945,HV102,CD22 mediated BCR regulation,0.0017514849617940725,1,0,1,0.0019185325493491633
2946,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0017293168406246281,0,0,1,0.0018942501473021992
2947,HV102,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.0017514849617940725,1,0,1,0.0019185325493491633
2948,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0017293168406246281,0,0,1,0.0018942501473021992
2949,HV102,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0017514849617940725,1,0,1,0.0019185325493491633
2950,HV102,Scavenging of heme from plasma,0.0017293168406246281,0,0,1,0.0018942501473021992
2951,HV102,Scavenging of heme from plasma,0.0017514849617940725,1,0,1,0.0019185325493491633
2952,EST1,Metabolism of Angiotensinogen to Angiotensins,0.0030678872552081034,0,0,1,0.0033604864930277525
2953,EST1,Metabolism of Angiotensinogen to Angiotensins,0.004374187978027095,1,0,1,0.004791375430492255
2954,EST1,Physiological factors,0.0030678872552081034,0,0,1,0.0033604864930277525
2955,EST1,Physiological factors,0.004374187978027095,1,0,1,0.004791375430492255
2956,EST1,Aspirin ADME,0.0030678872552081034,0,0,1,0.0033604864930277525
2957,EST1,Aspirin ADME,0.004374187978027095,1,0,1,0.004791375430492255
2958,FBLN1,Molecules associated with elastic fibres,0.00018477167300336522,0,0,1,0.00020239424065139923
2959,FBLN1,Molecules associated with elastic fibres,0.00019013150761519612,1,0,1,0.0002082652685998166
2960,SAHH,Methylation,0.0004123956782239262,0,0,1,0.0004517278475934466
2961,SAHH,Methylation,0.0003822780689809632,1,0,1,0.0004187377763672471
2962,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0004123956782239262,0,0,1,0.0004517278475934466
2963,SAHH,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0003822780689809632,1,0,1,0.0004187377763672471
2964,SAHH,Defective AHCY causes HMAHCHD,0.0004123956782239262,0,0,1,0.0004517278475934466
2965,SAHH,Defective AHCY causes HMAHCHD,0.0003822780689809632,1,0,1,0.0004187377763672471
2966,PRTN3,Other interleukin signaling,0.0015357250390872171,0,0,1,0.001682194559821606
2967,PRTN3,Other interleukin signaling,0.0009228911587832109,1,0,1,0.0010109117498893672
2968,PRTN3,Common Pathway of Fibrin Clot Formation,0.0015357250390872171,0,0,1,0.001682194559821606
2969,PRTN3,Common Pathway of Fibrin Clot Formation,0.0009228911587832109,1,0,1,0.0010109117498893672
2970,PRTN3,Neutrophil degranulation,0.0015357250390872171,0,0,1,0.001682194559821606
2971,PRTN3,Neutrophil degranulation,0.0009228911587832109,1,0,1,0.0010109117498893672
2972,ALAT1,Alanine metabolism,0.0005600164807815256,0,0,1,0.0006134279596958645
2973,ALAT1,Alanine metabolism,0.0007076197728422485,1,0,1,0.0007751088912406722
2974,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0017710745062497044,0,0,1,0.0019399904433561753
2975,IBP6,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0020125279010115146,1,0,1,0.0022044724155718463
2976,THIL,Utilization of Ketone Bodies,0.0007688508314071082,0,0,1,0.000842179851854264
2977,THIL,Utilization of Ketone Bodies,0.0008402502495614661,1,0,1,0.0009203889776656636
2978,THIL,Synthesis of Ketone Bodies,0.0007688508314071082,0,0,1,0.000842179851854264
2979,THIL,Synthesis of Ketone Bodies,0.0008402502495614661,1,0,1,0.0009203889776656636
2980,THIL,Branched-chain amino acid catabolism,0.0007688508314071082,0,0,1,0.000842179851854264
2981,THIL,Branched-chain amino acid catabolism,0.0008402502495614661,1,0,1,0.0009203889776656636
2982,TENA,Integrin cell surface interactions,0.0048173759030686394,0,0,1,0.005276832330333276
2983,TENA,Integrin cell surface interactions,0.005578770996074353,1,0,1,0.006110845353973464
2984,TENA,ECM proteoglycans,0.0048173759030686394,0,0,1,0.005276832330333276
2985,TENA,ECM proteoglycans,0.005578770996074353,1,0,1,0.006110845353973464
2986,TENA,Syndecan interactions,0.0048173759030686394,0,0,1,0.005276832330333276
2987,TENA,Syndecan interactions,0.005578770996074353,1,0,1,0.006110845353973464
2988,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0048173759030686394,0,0,1,0.005276832330333276
2989,TENA,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.005578770996074353,1,0,1,0.006110845353973464
2990,TENA,Post-translational protein phosphorylation,0.0048173759030686394,0,0,1,0.005276832330333276
2991,TENA,Post-translational protein phosphorylation,0.005578770996074353,1,0,1,0.006110845353973464
2992,ZA2G,Miscellaneous transport and binding events,0.0005920376228930551,0,0,1,0.0006485031129220602
2993,ZA2G,Miscellaneous transport and binding events,0.00010717250804651799,1,0,1,0.00011739406821513124
2994,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.009019987077362419,0,0,1,0.009880266847910995
2995,PSA1,Downstream signaling events of B Cell Receptor (BCR),0.00856743408792515,1,0,1,0.009384551692211732
2996,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.009019987077362419,0,0,1,0.009880266847910995
2997,PSA1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00856743408792515,1,0,1,0.009384551692211732
2998,PSA1,Antigen processing-Cross presentation,0.009019987077362419,0,0,1,0.009880266847910995
2999,PSA1,Antigen processing-Cross presentation,0.00856743408792515,1,0,1,0.009384551692211732
3000,PSA1,PTEN Regulation,0.009019987077362419,0,0,1,0.009880266847910995
3001,PSA1,PTEN Regulation,0.00856743408792515,1,0,1,0.009384551692211732
3002,PSA1,Host Interactions of HIV factors,0.009019987077362419,0,0,1,0.009880266847910995
3003,PSA1,Host Interactions of HIV factors,0.00856743408792515,1,0,1,0.009384551692211732
3004,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.009019987077362419,0,0,1,0.009880266847910995
3005,PSA1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.00856743408792515,1,0,1,0.009384551692211732
3006,PSA1,APC/C-mediated degradation of cell cycle proteins,0.009019987077362419,0,0,1,0.009880266847910995
3007,PSA1,APC/C-mediated degradation of cell cycle proteins,0.00856743408792515,1,0,1,0.009384551692211732
3008,PSA1,Degradation of AXIN,0.009019987077362419,0,0,1,0.009880266847910995
3009,PSA1,Degradation of AXIN,0.00856743408792515,1,0,1,0.009384551692211732
3010,PSA1,Degradation of DVL,0.009019987077362419,0,0,1,0.009880266847910995
3011,PSA1,Degradation of DVL,0.00856743408792515,1,0,1,0.009384551692211732
3012,PSA1,Downstream TCR signaling,0.009019987077362419,0,0,1,0.009880266847910995
3013,PSA1,Downstream TCR signaling,0.00856743408792515,1,0,1,0.009384551692211732
3014,PSA1,Transcriptional regulation by RUNX3,0.009019987077362419,0,0,1,0.009880266847910995
3015,PSA1,Transcriptional regulation by RUNX3,0.00856743408792515,1,0,1,0.009384551692211732
3016,PSA1,Transcriptional regulation by RUNX2,0.009019987077362419,0,0,1,0.009880266847910995
3017,PSA1,Transcriptional regulation by RUNX2,0.00856743408792515,1,0,1,0.009384551692211732
3018,PSA1,Transcriptional regulation by RUNX1,0.009019987077362419,0,0,1,0.009880266847910995
3019,PSA1,Transcriptional regulation by RUNX1,0.00856743408792515,1,0,1,0.009384551692211732
3020,PSA1,FCERI mediated NF-kB activation,0.009019987077362419,0,0,1,0.009880266847910995
3021,PSA1,FCERI mediated NF-kB activation,0.00856743408792515,1,0,1,0.009384551692211732
3022,PSA1,Mitotic Metaphase and Anaphase,0.009019987077362419,0,0,1,0.009880266847910995
3023,PSA1,Mitotic Metaphase and Anaphase,0.00856743408792515,1,0,1,0.009384551692211732
3024,PSA1,Regulation of ornithine decarboxylase (ODC),0.009019987077362419,0,0,1,0.009880266847910995
3025,PSA1,Regulation of ornithine decarboxylase (ODC),0.00856743408792515,1,0,1,0.009384551692211732
3026,PSA1,Signaling by ROBO receptors,0.009019987077362419,0,0,1,0.009880266847910995
3027,PSA1,Signaling by ROBO receptors,0.00856743408792515,1,0,1,0.009384551692211732
3028,PSA1,PCP/CE pathway,0.009019987077362419,0,0,1,0.009880266847910995
3029,PSA1,PCP/CE pathway,0.00856743408792515,1,0,1,0.009384551692211732
3030,PSA1,Interleukin-1 family signaling,0.009019987077362419,0,0,1,0.009880266847910995
3031,PSA1,Interleukin-1 family signaling,0.00856743408792515,1,0,1,0.009384551692211732
3032,PSA1,G2/M Transition,0.009019987077362419,0,0,1,0.009880266847910995
3033,PSA1,G2/M Transition,0.00856743408792515,1,0,1,0.009384551692211732
3034,PSA1,G1/S Transition,0.009019987077362419,0,0,1,0.009880266847910995
3035,PSA1,G1/S Transition,0.00856743408792515,1,0,1,0.009384551692211732
3036,PSA1,Hh mutants are degraded by ERAD,0.009019987077362419,0,0,1,0.009880266847910995
3037,PSA1,Hh mutants are degraded by ERAD,0.00856743408792515,1,0,1,0.009384551692211732
3038,PSA1,CLEC7A (Dectin-1) signaling,0.009019987077362419,0,0,1,0.009880266847910995
3039,PSA1,CLEC7A (Dectin-1) signaling,0.00856743408792515,1,0,1,0.009384551692211732
3040,PSA1,Degradation of GLI1 by the proteasome,0.009019987077362419,0,0,1,0.009880266847910995
3041,PSA1,Degradation of GLI1 by the proteasome,0.00856743408792515,1,0,1,0.009384551692211732
3042,PSA1,Degradation of GLI2 by the proteasome,0.009019987077362419,0,0,1,0.009880266847910995
3043,PSA1,Degradation of GLI2 by the proteasome,0.00856743408792515,1,0,1,0.009384551692211732
3044,PSA1,GLI3 is processed to GLI3R by the proteasome,0.009019987077362419,0,0,1,0.009880266847910995
3045,PSA1,GLI3 is processed to GLI3R by the proteasome,0.00856743408792515,1,0,1,0.009384551692211732
3046,PSA1,Defective CFTR causes cystic fibrosis,0.009019987077362419,0,0,1,0.009880266847910995
3047,PSA1,Defective CFTR causes cystic fibrosis,0.00856743408792515,1,0,1,0.009384551692211732
3048,PSA1,NIK-->noncanonical NF-kB signaling,0.009019987077362419,0,0,1,0.009880266847910995
3049,PSA1,NIK-->noncanonical NF-kB signaling,0.00856743408792515,1,0,1,0.009384551692211732
3050,PSA1,RAF/MAP kinase cascade,0.009019987077362419,0,0,1,0.009880266847910995
3051,PSA1,RAF/MAP kinase cascade,0.00856743408792515,1,0,1,0.009384551692211732
3052,PSA1,UCH proteinases,0.009019987077362419,0,0,1,0.009880266847910995
3053,PSA1,UCH proteinases,0.00856743408792515,1,0,1,0.009384551692211732
3054,PSA1,Ub-specific processing proteases,0.009019987077362419,0,0,1,0.009880266847910995
3055,PSA1,Ub-specific processing proteases,0.00856743408792515,1,0,1,0.009384551692211732
3056,PSA1,Orc1 removal from chromatin,0.009019987077362419,0,0,1,0.009880266847910995
3057,PSA1,Orc1 removal from chromatin,0.00856743408792515,1,0,1,0.009384551692211732
3058,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.009019987077362419,0,0,1,0.009880266847910995
3059,PSA1,CDK-mediated phosphorylation and removal of Cdc6,0.00856743408792515,1,0,1,0.009384551692211732
3060,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.009019987077362419,0,0,1,0.009880266847910995
3061,PSA1,Cyclin A:Cdk2-associated events at S phase entry,0.00856743408792515,1,0,1,0.009384551692211732
3062,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.009019987077362419,0,0,1,0.009880266847910995
3063,PSA1,Ubiquitin-dependent degradation of Cyclin D,0.00856743408792515,1,0,1,0.009384551692211732
3064,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.009019987077362419,0,0,1,0.009880266847910995
3065,PSA1,p53-Dependent G1/S DNA damage checkpoint,0.00856743408792515,1,0,1,0.009384551692211732
3066,PSA1,p53-Independent G1/S DNA damage checkpoint,0.009019987077362419,0,0,1,0.009880266847910995
3067,PSA1,p53-Independent G1/S DNA damage checkpoint,0.00856743408792515,1,0,1,0.009384551692211732
3068,PSA1,Negative regulation of NOTCH4 signaling,0.009019987077362419,0,0,1,0.009880266847910995
3069,PSA1,Negative regulation of NOTCH4 signaling,0.00856743408792515,1,0,1,0.009384551692211732
3070,PSA1,KEAP1-NFE2L2 pathway,0.009019987077362419,0,0,1,0.009880266847910995
3071,PSA1,KEAP1-NFE2L2 pathway,0.00856743408792515,1,0,1,0.009384551692211732
3072,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.009019987077362419,0,0,1,0.009880266847910995
3073,PSA1,Antigen processing: Ubiquitination & Proteasome degradation,0.00856743408792515,1,0,1,0.009384551692211732
3074,PSA1,Degradation of beta-catenin by the destruction complex,0.009019987077362419,0,0,1,0.009880266847910995
3075,PSA1,Degradation of beta-catenin by the destruction complex,0.00856743408792515,1,0,1,0.009384551692211732
3076,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.009019987077362419,0,0,1,0.009880266847910995
3077,PSA1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00856743408792515,1,0,1,0.009384551692211732
3078,PSA1,Hedgehog ligand biogenesis,0.009019987077362419,0,0,1,0.009880266847910995
3079,PSA1,Hedgehog ligand biogenesis,0.00856743408792515,1,0,1,0.009384551692211732
3080,PSA1,Hedgehog 'on' state,0.009019987077362419,0,0,1,0.009880266847910995
3081,PSA1,Hedgehog 'on' state,0.00856743408792515,1,0,1,0.009384551692211732
3082,PSA1,MAPK6/MAPK4 signaling,0.009019987077362419,0,0,1,0.009880266847910995
3083,PSA1,MAPK6/MAPK4 signaling,0.00856743408792515,1,0,1,0.009384551692211732
3084,PSA1,Neddylation,0.009019987077362419,0,0,1,0.009880266847910995
3085,PSA1,Neddylation,0.00856743408792515,1,0,1,0.009384551692211732
3086,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.0055020729476954735,0,0,1,0.006026832241959239
3087,PSA3,Downstream signaling events of B Cell Receptor (BCR),0.004790926267047824,1,0,1,0.005247860064666551
3088,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0055020729476954735,0,0,1,0.006026832241959239
3089,PSA3,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.004790926267047824,1,0,1,0.005247860064666551
3090,PSA3,Antigen processing-Cross presentation,0.0055020729476954735,0,0,1,0.006026832241959239
3091,PSA3,Antigen processing-Cross presentation,0.004790926267047824,1,0,1,0.005247860064666551
3092,PSA3,PTEN Regulation,0.0055020729476954735,0,0,1,0.006026832241959239
3093,PSA3,PTEN Regulation,0.004790926267047824,1,0,1,0.005247860064666551
3094,PSA3,Host Interactions of HIV factors,0.0055020729476954735,0,0,1,0.006026832241959239
3095,PSA3,Host Interactions of HIV factors,0.004790926267047824,1,0,1,0.005247860064666551
3096,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0055020729476954735,0,0,1,0.006026832241959239
3097,PSA3,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.004790926267047824,1,0,1,0.005247860064666551
3098,PSA3,APC/C-mediated degradation of cell cycle proteins,0.0055020729476954735,0,0,1,0.006026832241959239
3099,PSA3,APC/C-mediated degradation of cell cycle proteins,0.004790926267047824,1,0,1,0.005247860064666551
3100,PSA3,Degradation of AXIN,0.0055020729476954735,0,0,1,0.006026832241959239
3101,PSA3,Degradation of AXIN,0.004790926267047824,1,0,1,0.005247860064666551
3102,PSA3,Degradation of DVL,0.0055020729476954735,0,0,1,0.006026832241959239
3103,PSA3,Degradation of DVL,0.004790926267047824,1,0,1,0.005247860064666551
3104,PSA3,Downstream TCR signaling,0.0055020729476954735,0,0,1,0.006026832241959239
3105,PSA3,Downstream TCR signaling,0.004790926267047824,1,0,1,0.005247860064666551
3106,PSA3,Transcriptional regulation by RUNX3,0.0055020729476954735,0,0,1,0.006026832241959239
3107,PSA3,Transcriptional regulation by RUNX3,0.004790926267047824,1,0,1,0.005247860064666551
3108,PSA3,Transcriptional regulation by RUNX2,0.0055020729476954735,0,0,1,0.006026832241959239
3109,PSA3,Transcriptional regulation by RUNX2,0.004790926267047824,1,0,1,0.005247860064666551
3110,PSA3,Transcriptional regulation by RUNX1,0.0055020729476954735,0,0,1,0.006026832241959239
3111,PSA3,Transcriptional regulation by RUNX1,0.004790926267047824,1,0,1,0.005247860064666551
3112,PSA3,FCERI mediated NF-kB activation,0.0055020729476954735,0,0,1,0.006026832241959239
3113,PSA3,FCERI mediated NF-kB activation,0.004790926267047824,1,0,1,0.005247860064666551
3114,PSA3,Mitotic Metaphase and Anaphase,0.0055020729476954735,0,0,1,0.006026832241959239
3115,PSA3,Mitotic Metaphase and Anaphase,0.004790926267047824,1,0,1,0.005247860064666551
3116,PSA3,Regulation of ornithine decarboxylase (ODC),0.0055020729476954735,0,0,1,0.006026832241959239
3117,PSA3,Regulation of ornithine decarboxylase (ODC),0.004790926267047824,1,0,1,0.005247860064666551
3118,PSA3,Signaling by ROBO receptors,0.0055020729476954735,0,0,1,0.006026832241959239
3119,PSA3,Signaling by ROBO receptors,0.004790926267047824,1,0,1,0.005247860064666551
3120,PSA3,PCP/CE pathway,0.0055020729476954735,0,0,1,0.006026832241959239
3121,PSA3,PCP/CE pathway,0.004790926267047824,1,0,1,0.005247860064666551
3122,PSA3,Interleukin-1 family signaling,0.0055020729476954735,0,0,1,0.006026832241959239
3123,PSA3,Interleukin-1 family signaling,0.004790926267047824,1,0,1,0.005247860064666551
3124,PSA3,G2/M Transition,0.0055020729476954735,0,0,1,0.006026832241959239
3125,PSA3,G2/M Transition,0.004790926267047824,1,0,1,0.005247860064666551
3126,PSA3,G1/S Transition,0.0055020729476954735,0,0,1,0.006026832241959239
3127,PSA3,G1/S Transition,0.004790926267047824,1,0,1,0.005247860064666551
3128,PSA3,Hh mutants are degraded by ERAD,0.0055020729476954735,0,0,1,0.006026832241959239
3129,PSA3,Hh mutants are degraded by ERAD,0.004790926267047824,1,0,1,0.005247860064666551
3130,PSA3,CLEC7A (Dectin-1) signaling,0.0055020729476954735,0,0,1,0.006026832241959239
3131,PSA3,CLEC7A (Dectin-1) signaling,0.004790926267047824,1,0,1,0.005247860064666551
3132,PSA3,Degradation of GLI1 by the proteasome,0.0055020729476954735,0,0,1,0.006026832241959239
3133,PSA3,Degradation of GLI1 by the proteasome,0.004790926267047824,1,0,1,0.005247860064666551
3134,PSA3,Degradation of GLI2 by the proteasome,0.0055020729476954735,0,0,1,0.006026832241959239
3135,PSA3,Degradation of GLI2 by the proteasome,0.004790926267047824,1,0,1,0.005247860064666551
3136,PSA3,GLI3 is processed to GLI3R by the proteasome,0.0055020729476954735,0,0,1,0.006026832241959239
3137,PSA3,GLI3 is processed to GLI3R by the proteasome,0.004790926267047824,1,0,1,0.005247860064666551
3138,PSA3,Defective CFTR causes cystic fibrosis,0.0055020729476954735,0,0,1,0.006026832241959239
3139,PSA3,Defective CFTR causes cystic fibrosis,0.004790926267047824,1,0,1,0.005247860064666551
3140,PSA3,NIK-->noncanonical NF-kB signaling,0.0055020729476954735,0,0,1,0.006026832241959239
3141,PSA3,NIK-->noncanonical NF-kB signaling,0.004790926267047824,1,0,1,0.005247860064666551
3142,PSA3,RAF/MAP kinase cascade,0.0055020729476954735,0,0,1,0.006026832241959239
3143,PSA3,RAF/MAP kinase cascade,0.004790926267047824,1,0,1,0.005247860064666551
3144,PSA3,UCH proteinases,0.0055020729476954735,0,0,1,0.006026832241959239
3145,PSA3,UCH proteinases,0.004790926267047824,1,0,1,0.005247860064666551
3146,PSA3,Ub-specific processing proteases,0.0055020729476954735,0,0,1,0.006026832241959239
3147,PSA3,Ub-specific processing proteases,0.004790926267047824,1,0,1,0.005247860064666551
3148,PSA3,Orc1 removal from chromatin,0.0055020729476954735,0,0,1,0.006026832241959239
3149,PSA3,Orc1 removal from chromatin,0.004790926267047824,1,0,1,0.005247860064666551
3150,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.0055020729476954735,0,0,1,0.006026832241959239
3151,PSA3,CDK-mediated phosphorylation and removal of Cdc6,0.004790926267047824,1,0,1,0.005247860064666551
3152,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.0055020729476954735,0,0,1,0.006026832241959239
3153,PSA3,Cyclin A:Cdk2-associated events at S phase entry,0.004790926267047824,1,0,1,0.005247860064666551
3154,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.0055020729476954735,0,0,1,0.006026832241959239
3155,PSA3,Ubiquitin-dependent degradation of Cyclin D,0.004790926267047824,1,0,1,0.005247860064666551
3156,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.0055020729476954735,0,0,1,0.006026832241959239
3157,PSA3,p53-Dependent G1/S DNA damage checkpoint,0.004790926267047824,1,0,1,0.005247860064666551
3158,PSA3,p53-Independent G1/S DNA damage checkpoint,0.0055020729476954735,0,0,1,0.006026832241959239
3159,PSA3,p53-Independent G1/S DNA damage checkpoint,0.004790926267047824,1,0,1,0.005247860064666551
3160,PSA3,Negative regulation of NOTCH4 signaling,0.0055020729476954735,0,0,1,0.006026832241959239
3161,PSA3,Negative regulation of NOTCH4 signaling,0.004790926267047824,1,0,1,0.005247860064666551
3162,PSA3,KEAP1-NFE2L2 pathway,0.0055020729476954735,0,0,1,0.006026832241959239
3163,PSA3,KEAP1-NFE2L2 pathway,0.004790926267047824,1,0,1,0.005247860064666551
3164,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.0055020729476954735,0,0,1,0.006026832241959239
3165,PSA3,Antigen processing: Ubiquitination & Proteasome degradation,0.004790926267047824,1,0,1,0.005247860064666551
3166,PSA3,Degradation of beta-catenin by the destruction complex,0.0055020729476954735,0,0,1,0.006026832241959239
3167,PSA3,Degradation of beta-catenin by the destruction complex,0.004790926267047824,1,0,1,0.005247860064666551
3168,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0055020729476954735,0,0,1,0.006026832241959239
3169,PSA3,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.004790926267047824,1,0,1,0.005247860064666551
3170,PSA3,Hedgehog ligand biogenesis,0.0055020729476954735,0,0,1,0.006026832241959239
3171,PSA3,Hedgehog ligand biogenesis,0.004790926267047824,1,0,1,0.005247860064666551
3172,PSA3,Hedgehog 'on' state,0.0055020729476954735,0,0,1,0.006026832241959239
3173,PSA3,Hedgehog 'on' state,0.004790926267047824,1,0,1,0.005247860064666551
3174,PSA3,MAPK6/MAPK4 signaling,0.0055020729476954735,0,0,1,0.006026832241959239
3175,PSA3,MAPK6/MAPK4 signaling,0.004790926267047824,1,0,1,0.005247860064666551
3176,PSA3,Neddylation,0.0055020729476954735,0,0,1,0.006026832241959239
3177,PSA3,Neddylation,0.004790926267047824,1,0,1,0.005247860064666551
3178,PTX3,Neutrophil degranulation,0.0007790795145946351,0,0,1,0.0008533840940032515
3179,PTX3,Neutrophil degranulation,0.0008190700902218274,1,0,1,0.0008971887641440609
3180,HGFL,Signaling by MST1,0.0008861271532581954,0,0,1,0.0009706413834387487
3181,HGFL,Signaling by MST1,0.0006358686997225562,1,0,1,0.00069651457142998
3182,STOM,RHO GTPase cycle,0.0002937056367234729,0,0,1,0.000321717763082658
3183,STOM,RHO GTPase cycle,0.00033965728941212793,1,0,1,0.0003720520470203684
3184,STOM,Neutrophil degranulation,0.0002937056367234729,0,0,1,0.000321717763082658
3185,STOM,Neutrophil degranulation,0.00033965728941212793,1,0,1,0.0003720520470203684
3186,STOM,Stimuli-sensing channels,0.0002937056367234729,0,0,1,0.000321717763082658
3187,STOM,Stimuli-sensing channels,0.00033965728941212793,1,0,1,0.0003720520470203684
3188,PON1,Arachidonic acid metabolism,0.006085545735627674,0,0,1,0.006665953650207472
3189,PON1,Arachidonic acid metabolism,0.007121749062234074,1,0,1,0.007800984697120905
3190,PON1,Atorvastatin ADME,0.006085545735627674,0,0,1,0.006665953650207472
3191,PON1,Atorvastatin ADME,0.007121749062234074,1,0,1,0.007800984697120905
3192,1433T,Activation of BH3-only proteins,0.002476944329292717,0,0,1,0.0027131824836259307
3193,1433T,Activation of BH3-only proteins,0.0025010216100079946,1,0,1,0.002739556130993568
3194,1433T,RHO GTPase Effectors,0.002476944329292717,0,0,1,0.0027131824836259307
3195,1433T,RHO GTPase Effectors,0.0025010216100079946,1,0,1,0.002739556130993568
3196,1433T,Transcriptional Regulation by TP53,0.002476944329292717,0,0,1,0.0027131824836259307
3197,1433T,Transcriptional Regulation by TP53,0.0025010216100079946,1,0,1,0.002739556130993568
3198,1433T,FOXO-mediated transcription,0.002476944329292717,0,0,1,0.0027131824836259307
3199,1433T,FOXO-mediated transcription,0.0025010216100079946,1,0,1,0.002739556130993568
3200,1433T,G2/M DNA damage checkpoint,0.002476944329292717,0,0,1,0.0027131824836259307
3201,1433T,G2/M DNA damage checkpoint,0.0025010216100079946,1,0,1,0.002739556130993568
3202,1433T,SARS-CoV-2 Infection,0.002476944329292717,0,0,1,0.0027131824836259307
3203,1433T,SARS-CoV-2 Infection,0.0025010216100079946,1,0,1,0.002739556130993568
3204,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.002476944329292717,0,0,1,0.0027131824836259307
3205,1433T,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0025010216100079946,1,0,1,0.002739556130993568
3206,CALR,Antigen processing-Cross presentation,0.03020053649047002,0,0,1,0.0330809076461749
3207,CALR,Antigen processing-Cross presentation,0.02841968204693746,1,0,1,0.031130204505640593
3208,CALR,Virus Assembly and Release,0.03020053649047002,0,0,1,0.0330809076461749
3209,CALR,Virus Assembly and Release,0.02841968204693746,1,0,1,0.031130204505640593
3210,CALR,ATF6 (ATF6-alpha) activates chaperones,0.03020053649047002,0,0,1,0.0330809076461749
3211,CALR,ATF6 (ATF6-alpha) activates chaperones,0.02841968204693746,1,0,1,0.031130204505640593
3212,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.03020053649047002,0,0,1,0.0330809076461749
3213,CALR,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.02841968204693746,1,0,1,0.031130204505640593
3214,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.03020053649047002,0,0,1,0.0330809076461749
3215,CALR,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.02841968204693746,1,0,1,0.031130204505640593
3216,CALR,Scavenging by Class A Receptors,0.03020053649047002,0,0,1,0.0330809076461749
3217,CALR,Scavenging by Class A Receptors,0.02841968204693746,1,0,1,0.031130204505640593
3218,CALR,Scavenging by Class F Receptors,0.03020053649047002,0,0,1,0.0330809076461749
3219,CALR,Scavenging by Class F Receptors,0.02841968204693746,1,0,1,0.031130204505640593
3220,PROP,Initial triggering of complement,0.0021976501674668774,0,0,1,0.002407250687467543
3221,PROP,Initial triggering of complement,0.002406667128285372,1,0,1,0.0026362026062356973
3222,PROP,Activation of C3 and C5,0.0021976501674668774,0,0,1,0.002407250687467543
3223,PROP,Activation of C3 and C5,0.002406667128285372,1,0,1,0.0026362026062356973
3224,PROP,Regulation of Complement cascade,0.0021976501674668774,0,0,1,0.002407250687467543
3225,PROP,Regulation of Complement cascade,0.002406667128285372,1,0,1,0.0026362026062356973
3226,PROP,Diseases associated with O-glycosylation of proteins,0.0021976501674668774,0,0,1,0.002407250687467543
3227,PROP,Diseases associated with O-glycosylation of proteins,0.002406667128285372,1,0,1,0.0026362026062356973
3228,PROP,O-glycosylation of TSR domain-containing proteins,0.0021976501674668774,0,0,1,0.002407250687467543
3229,PROP,O-glycosylation of TSR domain-containing proteins,0.002406667128285372,1,0,1,0.0026362026062356973
3230,PROP,Neutrophil degranulation,0.0021976501674668774,0,0,1,0.002407250687467543
3231,PROP,Neutrophil degranulation,0.002406667128285372,1,0,1,0.0026362026062356973
3232,IL1R2,Interleukin-1 family signaling,0.0005035998056434996,0,0,1,0.000551630553529447
3233,IL1R2,Interleukin-1 family signaling,0.0005144779267820599,1,0,1,0.0005635461736662671
3234,IL1R2,Interleukin-10 signaling,0.0005035998056434996,0,0,1,0.000551630553529447
3235,IL1R2,Interleukin-10 signaling,0.0005144779267820599,1,0,1,0.0005635461736662671
3236,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.010453293094680962,0,0,1,0.011450274188760176
3237,PSA5,Downstream signaling events of B Cell Receptor (BCR),0.010467064935066335,1,0,1,0.011465359516136732
3238,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.010453293094680962,0,0,1,0.011450274188760176
3239,PSA5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.010467064935066335,1,0,1,0.011465359516136732
3240,PSA5,Antigen processing-Cross presentation,0.010453293094680962,0,0,1,0.011450274188760176
3241,PSA5,Antigen processing-Cross presentation,0.010467064935066335,1,0,1,0.011465359516136732
3242,PSA5,PTEN Regulation,0.010453293094680962,0,0,1,0.011450274188760176
3243,PSA5,PTEN Regulation,0.010467064935066335,1,0,1,0.011465359516136732
3244,PSA5,Host Interactions of HIV factors,0.010453293094680962,0,0,1,0.011450274188760176
3245,PSA5,Host Interactions of HIV factors,0.010467064935066335,1,0,1,0.011465359516136732
3246,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.010453293094680962,0,0,1,0.011450274188760176
3247,PSA5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.010467064935066335,1,0,1,0.011465359516136732
3248,PSA5,APC/C-mediated degradation of cell cycle proteins,0.010453293094680962,0,0,1,0.011450274188760176
3249,PSA5,APC/C-mediated degradation of cell cycle proteins,0.010467064935066335,1,0,1,0.011465359516136732
3250,PSA5,Degradation of AXIN,0.010453293094680962,0,0,1,0.011450274188760176
3251,PSA5,Degradation of AXIN,0.010467064935066335,1,0,1,0.011465359516136732
3252,PSA5,Degradation of DVL,0.010453293094680962,0,0,1,0.011450274188760176
3253,PSA5,Degradation of DVL,0.010467064935066335,1,0,1,0.011465359516136732
3254,PSA5,Downstream TCR signaling,0.010453293094680962,0,0,1,0.011450274188760176
3255,PSA5,Downstream TCR signaling,0.010467064935066335,1,0,1,0.011465359516136732
3256,PSA5,Transcriptional regulation by RUNX3,0.010453293094680962,0,0,1,0.011450274188760176
3257,PSA5,Transcriptional regulation by RUNX3,0.010467064935066335,1,0,1,0.011465359516136732
3258,PSA5,Transcriptional regulation by RUNX2,0.010453293094680962,0,0,1,0.011450274188760176
3259,PSA5,Transcriptional regulation by RUNX2,0.010467064935066335,1,0,1,0.011465359516136732
3260,PSA5,Transcriptional regulation by RUNX1,0.010453293094680962,0,0,1,0.011450274188760176
3261,PSA5,Transcriptional regulation by RUNX1,0.010467064935066335,1,0,1,0.011465359516136732
3262,PSA5,FCERI mediated NF-kB activation,0.010453293094680962,0,0,1,0.011450274188760176
3263,PSA5,FCERI mediated NF-kB activation,0.010467064935066335,1,0,1,0.011465359516136732
3264,PSA5,Mitotic Metaphase and Anaphase,0.010453293094680962,0,0,1,0.011450274188760176
3265,PSA5,Mitotic Metaphase and Anaphase,0.010467064935066335,1,0,1,0.011465359516136732
3266,PSA5,Regulation of ornithine decarboxylase (ODC),0.010453293094680962,0,0,1,0.011450274188760176
3267,PSA5,Regulation of ornithine decarboxylase (ODC),0.010467064935066335,1,0,1,0.011465359516136732
3268,PSA5,Signaling by ROBO receptors,0.010453293094680962,0,0,1,0.011450274188760176
3269,PSA5,Signaling by ROBO receptors,0.010467064935066335,1,0,1,0.011465359516136732
3270,PSA5,PCP/CE pathway,0.010453293094680962,0,0,1,0.011450274188760176
3271,PSA5,PCP/CE pathway,0.010467064935066335,1,0,1,0.011465359516136732
3272,PSA5,Interleukin-1 family signaling,0.010453293094680962,0,0,1,0.011450274188760176
3273,PSA5,Interleukin-1 family signaling,0.010467064935066335,1,0,1,0.011465359516136732
3274,PSA5,G2/M Transition,0.010453293094680962,0,0,1,0.011450274188760176
3275,PSA5,G2/M Transition,0.010467064935066335,1,0,1,0.011465359516136732
3276,PSA5,G1/S Transition,0.010453293094680962,0,0,1,0.011450274188760176
3277,PSA5,G1/S Transition,0.010467064935066335,1,0,1,0.011465359516136732
3278,PSA5,Hh mutants are degraded by ERAD,0.010453293094680962,0,0,1,0.011450274188760176
3279,PSA5,Hh mutants are degraded by ERAD,0.010467064935066335,1,0,1,0.011465359516136732
3280,PSA5,CLEC7A (Dectin-1) signaling,0.010453293094680962,0,0,1,0.011450274188760176
3281,PSA5,CLEC7A (Dectin-1) signaling,0.010467064935066335,1,0,1,0.011465359516136732
3282,PSA5,Degradation of GLI1 by the proteasome,0.010453293094680962,0,0,1,0.011450274188760176
3283,PSA5,Degradation of GLI1 by the proteasome,0.010467064935066335,1,0,1,0.011465359516136732
3284,PSA5,Degradation of GLI2 by the proteasome,0.010453293094680962,0,0,1,0.011450274188760176
3285,PSA5,Degradation of GLI2 by the proteasome,0.010467064935066335,1,0,1,0.011465359516136732
3286,PSA5,GLI3 is processed to GLI3R by the proteasome,0.010453293094680962,0,0,1,0.011450274188760176
3287,PSA5,GLI3 is processed to GLI3R by the proteasome,0.010467064935066335,1,0,1,0.011465359516136732
3288,PSA5,Defective CFTR causes cystic fibrosis,0.010453293094680962,0,0,1,0.011450274188760176
3289,PSA5,Defective CFTR causes cystic fibrosis,0.010467064935066335,1,0,1,0.011465359516136732
3290,PSA5,NIK-->noncanonical NF-kB signaling,0.010453293094680962,0,0,1,0.011450274188760176
3291,PSA5,NIK-->noncanonical NF-kB signaling,0.010467064935066335,1,0,1,0.011465359516136732
3292,PSA5,RAF/MAP kinase cascade,0.010453293094680962,0,0,1,0.011450274188760176
3293,PSA5,RAF/MAP kinase cascade,0.010467064935066335,1,0,1,0.011465359516136732
3294,PSA5,UCH proteinases,0.010453293094680962,0,0,1,0.011450274188760176
3295,PSA5,UCH proteinases,0.010467064935066335,1,0,1,0.011465359516136732
3296,PSA5,Ub-specific processing proteases,0.010453293094680962,0,0,1,0.011450274188760176
3297,PSA5,Ub-specific processing proteases,0.010467064935066335,1,0,1,0.011465359516136732
3298,PSA5,Orc1 removal from chromatin,0.010453293094680962,0,0,1,0.011450274188760176
3299,PSA5,Orc1 removal from chromatin,0.010467064935066335,1,0,1,0.011465359516136732
3300,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.010453293094680962,0,0,1,0.011450274188760176
3301,PSA5,CDK-mediated phosphorylation and removal of Cdc6,0.010467064935066335,1,0,1,0.011465359516136732
3302,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.010453293094680962,0,0,1,0.011450274188760176
3303,PSA5,Cyclin A:Cdk2-associated events at S phase entry,0.010467064935066335,1,0,1,0.011465359516136732
3304,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.010453293094680962,0,0,1,0.011450274188760176
3305,PSA5,Ubiquitin-dependent degradation of Cyclin D,0.010467064935066335,1,0,1,0.011465359516136732
3306,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.010453293094680962,0,0,1,0.011450274188760176
3307,PSA5,p53-Dependent G1/S DNA damage checkpoint,0.010467064935066335,1,0,1,0.011465359516136732
3308,PSA5,p53-Independent G1/S DNA damage checkpoint,0.010453293094680962,0,0,1,0.011450274188760176
3309,PSA5,p53-Independent G1/S DNA damage checkpoint,0.010467064935066335,1,0,1,0.011465359516136732
3310,PSA5,Negative regulation of NOTCH4 signaling,0.010453293094680962,0,0,1,0.011450274188760176
3311,PSA5,Negative regulation of NOTCH4 signaling,0.010467064935066335,1,0,1,0.011465359516136732
3312,PSA5,KEAP1-NFE2L2 pathway,0.010453293094680962,0,0,1,0.011450274188760176
3313,PSA5,KEAP1-NFE2L2 pathway,0.010467064935066335,1,0,1,0.011465359516136732
3314,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.010453293094680962,0,0,1,0.011450274188760176
3315,PSA5,Antigen processing: Ubiquitination & Proteasome degradation,0.010467064935066335,1,0,1,0.011465359516136732
3316,PSA5,Neutrophil degranulation,0.010453293094680962,0,0,1,0.011450274188760176
3317,PSA5,Neutrophil degranulation,0.010467064935066335,1,0,1,0.011465359516136732
3318,PSA5,Degradation of beta-catenin by the destruction complex,0.010453293094680962,0,0,1,0.011450274188760176
3319,PSA5,Degradation of beta-catenin by the destruction complex,0.010467064935066335,1,0,1,0.011465359516136732
3320,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.010453293094680962,0,0,1,0.011450274188760176
3321,PSA5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.010467064935066335,1,0,1,0.011465359516136732
3322,PSA5,Hedgehog ligand biogenesis,0.010453293094680962,0,0,1,0.011450274188760176
3323,PSA5,Hedgehog ligand biogenesis,0.010467064935066335,1,0,1,0.011465359516136732
3324,PSA5,Hedgehog 'on' state,0.010453293094680962,0,0,1,0.011450274188760176
3325,PSA5,Hedgehog 'on' state,0.010467064935066335,1,0,1,0.011465359516136732
3326,PSA5,MAPK6/MAPK4 signaling,0.010453293094680962,0,0,1,0.011450274188760176
3327,PSA5,MAPK6/MAPK4 signaling,0.010467064935066335,1,0,1,0.011465359516136732
3328,PSA5,Neddylation,0.010453293094680962,0,0,1,0.011450274188760176
3329,PSA5,Neddylation,0.010467064935066335,1,0,1,0.011465359516136732
3330,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.007237404548246319,0,0,1,0.007927670805917412
3331,PSB6,Downstream signaling events of B Cell Receptor (BCR),0.00726729407161947,1,0,1,0.007960411037621818
3332,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.007237404548246319,0,0,1,0.007927670805917412
3333,PSB6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00726729407161947,1,0,1,0.007960411037621818
3334,PSB6,Antigen processing-Cross presentation,0.007237404548246319,0,0,1,0.007927670805917412
3335,PSB6,Antigen processing-Cross presentation,0.00726729407161947,1,0,1,0.007960411037621818
3336,PSB6,PTEN Regulation,0.007237404548246319,0,0,1,0.007927670805917412
3337,PSB6,PTEN Regulation,0.00726729407161947,1,0,1,0.007960411037621818
3338,PSB6,Host Interactions of HIV factors,0.007237404548246319,0,0,1,0.007927670805917412
3339,PSB6,Host Interactions of HIV factors,0.00726729407161947,1,0,1,0.007960411037621818
3340,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.007237404548246319,0,0,1,0.007927670805917412
3341,PSB6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.00726729407161947,1,0,1,0.007960411037621818
3342,PSB6,APC/C-mediated degradation of cell cycle proteins,0.007237404548246319,0,0,1,0.007927670805917412
3343,PSB6,APC/C-mediated degradation of cell cycle proteins,0.00726729407161947,1,0,1,0.007960411037621818
3344,PSB6,Degradation of AXIN,0.007237404548246319,0,0,1,0.007927670805917412
3345,PSB6,Degradation of AXIN,0.00726729407161947,1,0,1,0.007960411037621818
3346,PSB6,Degradation of DVL,0.007237404548246319,0,0,1,0.007927670805917412
3347,PSB6,Degradation of DVL,0.00726729407161947,1,0,1,0.007960411037621818
3348,PSB6,Downstream TCR signaling,0.007237404548246319,0,0,1,0.007927670805917412
3349,PSB6,Downstream TCR signaling,0.00726729407161947,1,0,1,0.007960411037621818
3350,PSB6,Transcriptional regulation by RUNX3,0.007237404548246319,0,0,1,0.007927670805917412
3351,PSB6,Transcriptional regulation by RUNX3,0.00726729407161947,1,0,1,0.007960411037621818
3352,PSB6,Transcriptional regulation by RUNX2,0.007237404548246319,0,0,1,0.007927670805917412
3353,PSB6,Transcriptional regulation by RUNX2,0.00726729407161947,1,0,1,0.007960411037621818
3354,PSB6,Transcriptional regulation by RUNX1,0.007237404548246319,0,0,1,0.007927670805917412
3355,PSB6,Transcriptional regulation by RUNX1,0.00726729407161947,1,0,1,0.007960411037621818
3356,PSB6,FCERI mediated NF-kB activation,0.007237404548246319,0,0,1,0.007927670805917412
3357,PSB6,FCERI mediated NF-kB activation,0.00726729407161947,1,0,1,0.007960411037621818
3358,PSB6,Mitotic Metaphase and Anaphase,0.007237404548246319,0,0,1,0.007927670805917412
3359,PSB6,Mitotic Metaphase and Anaphase,0.00726729407161947,1,0,1,0.007960411037621818
3360,PSB6,Regulation of ornithine decarboxylase (ODC),0.007237404548246319,0,0,1,0.007927670805917412
3361,PSB6,Regulation of ornithine decarboxylase (ODC),0.00726729407161947,1,0,1,0.007960411037621818
3362,PSB6,Signaling by ROBO receptors,0.007237404548246319,0,0,1,0.007927670805917412
3363,PSB6,Signaling by ROBO receptors,0.00726729407161947,1,0,1,0.007960411037621818
3364,PSB6,PCP/CE pathway,0.007237404548246319,0,0,1,0.007927670805917412
3365,PSB6,PCP/CE pathway,0.00726729407161947,1,0,1,0.007960411037621818
3366,PSB6,Interleukin-1 family signaling,0.007237404548246319,0,0,1,0.007927670805917412
3367,PSB6,Interleukin-1 family signaling,0.00726729407161947,1,0,1,0.007960411037621818
3368,PSB6,G2/M Transition,0.007237404548246319,0,0,1,0.007927670805917412
3369,PSB6,G2/M Transition,0.00726729407161947,1,0,1,0.007960411037621818
3370,PSB6,G1/S Transition,0.007237404548246319,0,0,1,0.007927670805917412
3371,PSB6,G1/S Transition,0.00726729407161947,1,0,1,0.007960411037621818
3372,PSB6,Hh mutants are degraded by ERAD,0.007237404548246319,0,0,1,0.007927670805917412
3373,PSB6,Hh mutants are degraded by ERAD,0.00726729407161947,1,0,1,0.007960411037621818
3374,PSB6,CLEC7A (Dectin-1) signaling,0.007237404548246319,0,0,1,0.007927670805917412
3375,PSB6,CLEC7A (Dectin-1) signaling,0.00726729407161947,1,0,1,0.007960411037621818
3376,PSB6,Degradation of GLI1 by the proteasome,0.007237404548246319,0,0,1,0.007927670805917412
3377,PSB6,Degradation of GLI1 by the proteasome,0.00726729407161947,1,0,1,0.007960411037621818
3378,PSB6,Degradation of GLI2 by the proteasome,0.007237404548246319,0,0,1,0.007927670805917412
3379,PSB6,Degradation of GLI2 by the proteasome,0.00726729407161947,1,0,1,0.007960411037621818
3380,PSB6,GLI3 is processed to GLI3R by the proteasome,0.007237404548246319,0,0,1,0.007927670805917412
3381,PSB6,GLI3 is processed to GLI3R by the proteasome,0.00726729407161947,1,0,1,0.007960411037621818
3382,PSB6,Defective CFTR causes cystic fibrosis,0.007237404548246319,0,0,1,0.007927670805917412
3383,PSB6,Defective CFTR causes cystic fibrosis,0.00726729407161947,1,0,1,0.007960411037621818
3384,PSB6,NIK-->noncanonical NF-kB signaling,0.007237404548246319,0,0,1,0.007927670805917412
3385,PSB6,NIK-->noncanonical NF-kB signaling,0.00726729407161947,1,0,1,0.007960411037621818
3386,PSB6,RAF/MAP kinase cascade,0.007237404548246319,0,0,1,0.007927670805917412
3387,PSB6,RAF/MAP kinase cascade,0.00726729407161947,1,0,1,0.007960411037621818
3388,PSB6,UCH proteinases,0.007237404548246319,0,0,1,0.007927670805917412
3389,PSB6,UCH proteinases,0.00726729407161947,1,0,1,0.007960411037621818
3390,PSB6,Ub-specific processing proteases,0.007237404548246319,0,0,1,0.007927670805917412
3391,PSB6,Ub-specific processing proteases,0.00726729407161947,1,0,1,0.007960411037621818
3392,PSB6,Orc1 removal from chromatin,0.007237404548246319,0,0,1,0.007927670805917412
3393,PSB6,Orc1 removal from chromatin,0.00726729407161947,1,0,1,0.007960411037621818
3394,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.007237404548246319,0,0,1,0.007927670805917412
3395,PSB6,CDK-mediated phosphorylation and removal of Cdc6,0.00726729407161947,1,0,1,0.007960411037621818
3396,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.007237404548246319,0,0,1,0.007927670805917412
3397,PSB6,Cyclin A:Cdk2-associated events at S phase entry,0.00726729407161947,1,0,1,0.007960411037621818
3398,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.007237404548246319,0,0,1,0.007927670805917412
3399,PSB6,Ubiquitin-dependent degradation of Cyclin D,0.00726729407161947,1,0,1,0.007960411037621818
3400,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.007237404548246319,0,0,1,0.007927670805917412
3401,PSB6,p53-Dependent G1/S DNA damage checkpoint,0.00726729407161947,1,0,1,0.007960411037621818
3402,PSB6,p53-Independent G1/S DNA damage checkpoint,0.007237404548246319,0,0,1,0.007927670805917412
3403,PSB6,p53-Independent G1/S DNA damage checkpoint,0.00726729407161947,1,0,1,0.007960411037621818
3404,PSB6,Negative regulation of NOTCH4 signaling,0.007237404548246319,0,0,1,0.007927670805917412
3405,PSB6,Negative regulation of NOTCH4 signaling,0.00726729407161947,1,0,1,0.007960411037621818
3406,PSB6,KEAP1-NFE2L2 pathway,0.007237404548246319,0,0,1,0.007927670805917412
3407,PSB6,KEAP1-NFE2L2 pathway,0.00726729407161947,1,0,1,0.007960411037621818
3408,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.007237404548246319,0,0,1,0.007927670805917412
3409,PSB6,Antigen processing: Ubiquitination & Proteasome degradation,0.00726729407161947,1,0,1,0.007960411037621818
3410,PSB6,Degradation of beta-catenin by the destruction complex,0.007237404548246319,0,0,1,0.007927670805917412
3411,PSB6,Degradation of beta-catenin by the destruction complex,0.00726729407161947,1,0,1,0.007960411037621818
3412,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.007237404548246319,0,0,1,0.007927670805917412
3413,PSB6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00726729407161947,1,0,1,0.007960411037621818
3414,PSB6,Hedgehog ligand biogenesis,0.007237404548246319,0,0,1,0.007927670805917412
3415,PSB6,Hedgehog ligand biogenesis,0.00726729407161947,1,0,1,0.007960411037621818
3416,PSB6,Hedgehog 'on' state,0.007237404548246319,0,0,1,0.007927670805917412
3417,PSB6,Hedgehog 'on' state,0.00726729407161947,1,0,1,0.007960411037621818
3418,PSB6,MAPK6/MAPK4 signaling,0.007237404548246319,0,0,1,0.007927670805917412
3419,PSB6,MAPK6/MAPK4 signaling,0.00726729407161947,1,0,1,0.007960411037621818
3420,PSB6,Neddylation,0.007237404548246319,0,0,1,0.007927670805917412
3421,PSB6,Neddylation,0.00726729407161947,1,0,1,0.007960411037621818
3422,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.005530783921352536,0,0,1,0.0060582815199639786
3423,PSB5,Downstream signaling events of B Cell Receptor (BCR),0.005274067747496484,1,0,1,0.00577708108363096
3424,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.005530783921352536,0,0,1,0.0060582815199639786
3425,PSB5,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.005274067747496484,1,0,1,0.00577708108363096
3426,PSB5,Antigen processing-Cross presentation,0.005530783921352536,0,0,1,0.0060582815199639786
3427,PSB5,Antigen processing-Cross presentation,0.005274067747496484,1,0,1,0.00577708108363096
3428,PSB5,PTEN Regulation,0.005530783921352536,0,0,1,0.0060582815199639786
3429,PSB5,PTEN Regulation,0.005274067747496484,1,0,1,0.00577708108363096
3430,PSB5,Host Interactions of HIV factors,0.005530783921352536,0,0,1,0.0060582815199639786
3431,PSB5,Host Interactions of HIV factors,0.005274067747496484,1,0,1,0.00577708108363096
3432,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.005530783921352536,0,0,1,0.0060582815199639786
3433,PSB5,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.005274067747496484,1,0,1,0.00577708108363096
3434,PSB5,APC/C-mediated degradation of cell cycle proteins,0.005530783921352536,0,0,1,0.0060582815199639786
3435,PSB5,APC/C-mediated degradation of cell cycle proteins,0.005274067747496484,1,0,1,0.00577708108363096
3436,PSB5,Degradation of AXIN,0.005530783921352536,0,0,1,0.0060582815199639786
3437,PSB5,Degradation of AXIN,0.005274067747496484,1,0,1,0.00577708108363096
3438,PSB5,Degradation of DVL,0.005530783921352536,0,0,1,0.0060582815199639786
3439,PSB5,Degradation of DVL,0.005274067747496484,1,0,1,0.00577708108363096
3440,PSB5,Downstream TCR signaling,0.005530783921352536,0,0,1,0.0060582815199639786
3441,PSB5,Downstream TCR signaling,0.005274067747496484,1,0,1,0.00577708108363096
3442,PSB5,Transcriptional regulation by RUNX3,0.005530783921352536,0,0,1,0.0060582815199639786
3443,PSB5,Transcriptional regulation by RUNX3,0.005274067747496484,1,0,1,0.00577708108363096
3444,PSB5,Transcriptional regulation by RUNX2,0.005530783921352536,0,0,1,0.0060582815199639786
3445,PSB5,Transcriptional regulation by RUNX2,0.005274067747496484,1,0,1,0.00577708108363096
3446,PSB5,Transcriptional regulation by RUNX1,0.005530783921352536,0,0,1,0.0060582815199639786
3447,PSB5,Transcriptional regulation by RUNX1,0.005274067747496484,1,0,1,0.00577708108363096
3448,PSB5,FCERI mediated NF-kB activation,0.005530783921352536,0,0,1,0.0060582815199639786
3449,PSB5,FCERI mediated NF-kB activation,0.005274067747496484,1,0,1,0.00577708108363096
3450,PSB5,Mitotic Metaphase and Anaphase,0.005530783921352536,0,0,1,0.0060582815199639786
3451,PSB5,Mitotic Metaphase and Anaphase,0.005274067747496484,1,0,1,0.00577708108363096
3452,PSB5,Regulation of ornithine decarboxylase (ODC),0.005530783921352536,0,0,1,0.0060582815199639786
3453,PSB5,Regulation of ornithine decarboxylase (ODC),0.005274067747496484,1,0,1,0.00577708108363096
3454,PSB5,Signaling by ROBO receptors,0.005530783921352536,0,0,1,0.0060582815199639786
3455,PSB5,Signaling by ROBO receptors,0.005274067747496484,1,0,1,0.00577708108363096
3456,PSB5,PCP/CE pathway,0.005530783921352536,0,0,1,0.0060582815199639786
3457,PSB5,PCP/CE pathway,0.005274067747496484,1,0,1,0.00577708108363096
3458,PSB5,Interleukin-1 family signaling,0.005530783921352536,0,0,1,0.0060582815199639786
3459,PSB5,Interleukin-1 family signaling,0.005274067747496484,1,0,1,0.00577708108363096
3460,PSB5,G2/M Transition,0.005530783921352536,0,0,1,0.0060582815199639786
3461,PSB5,G2/M Transition,0.005274067747496484,1,0,1,0.00577708108363096
3462,PSB5,G1/S Transition,0.005530783921352536,0,0,1,0.0060582815199639786
3463,PSB5,G1/S Transition,0.005274067747496484,1,0,1,0.00577708108363096
3464,PSB5,Hh mutants are degraded by ERAD,0.005530783921352536,0,0,1,0.0060582815199639786
3465,PSB5,Hh mutants are degraded by ERAD,0.005274067747496484,1,0,1,0.00577708108363096
3466,PSB5,CLEC7A (Dectin-1) signaling,0.005530783921352536,0,0,1,0.0060582815199639786
3467,PSB5,CLEC7A (Dectin-1) signaling,0.005274067747496484,1,0,1,0.00577708108363096
3468,PSB5,Degradation of GLI1 by the proteasome,0.005530783921352536,0,0,1,0.0060582815199639786
3469,PSB5,Degradation of GLI1 by the proteasome,0.005274067747496484,1,0,1,0.00577708108363096
3470,PSB5,Degradation of GLI2 by the proteasome,0.005530783921352536,0,0,1,0.0060582815199639786
3471,PSB5,Degradation of GLI2 by the proteasome,0.005274067747496484,1,0,1,0.00577708108363096
3472,PSB5,GLI3 is processed to GLI3R by the proteasome,0.005530783921352536,0,0,1,0.0060582815199639786
3473,PSB5,GLI3 is processed to GLI3R by the proteasome,0.005274067747496484,1,0,1,0.00577708108363096
3474,PSB5,Defective CFTR causes cystic fibrosis,0.005530783921352536,0,0,1,0.0060582815199639786
3475,PSB5,Defective CFTR causes cystic fibrosis,0.005274067747496484,1,0,1,0.00577708108363096
3476,PSB5,NIK-->noncanonical NF-kB signaling,0.005530783921352536,0,0,1,0.0060582815199639786
3477,PSB5,NIK-->noncanonical NF-kB signaling,0.005274067747496484,1,0,1,0.00577708108363096
3478,PSB5,RAF/MAP kinase cascade,0.005530783921352536,0,0,1,0.0060582815199639786
3479,PSB5,RAF/MAP kinase cascade,0.005274067747496484,1,0,1,0.00577708108363096
3480,PSB5,UCH proteinases,0.005530783921352536,0,0,1,0.0060582815199639786
3481,PSB5,UCH proteinases,0.005274067747496484,1,0,1,0.00577708108363096
3482,PSB5,Ub-specific processing proteases,0.005530783921352536,0,0,1,0.0060582815199639786
3483,PSB5,Ub-specific processing proteases,0.005274067747496484,1,0,1,0.00577708108363096
3484,PSB5,Orc1 removal from chromatin,0.005530783921352536,0,0,1,0.0060582815199639786
3485,PSB5,Orc1 removal from chromatin,0.005274067747496484,1,0,1,0.00577708108363096
3486,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.005530783921352536,0,0,1,0.0060582815199639786
3487,PSB5,CDK-mediated phosphorylation and removal of Cdc6,0.005274067747496484,1,0,1,0.00577708108363096
3488,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.005530783921352536,0,0,1,0.0060582815199639786
3489,PSB5,Cyclin A:Cdk2-associated events at S phase entry,0.005274067747496484,1,0,1,0.00577708108363096
3490,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.005530783921352536,0,0,1,0.0060582815199639786
3491,PSB5,Ubiquitin-dependent degradation of Cyclin D,0.005274067747496484,1,0,1,0.00577708108363096
3492,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.005530783921352536,0,0,1,0.0060582815199639786
3493,PSB5,p53-Dependent G1/S DNA damage checkpoint,0.005274067747496484,1,0,1,0.00577708108363096
3494,PSB5,p53-Independent G1/S DNA damage checkpoint,0.005530783921352536,0,0,1,0.0060582815199639786
3495,PSB5,p53-Independent G1/S DNA damage checkpoint,0.005274067747496484,1,0,1,0.00577708108363096
3496,PSB5,Negative regulation of NOTCH4 signaling,0.005530783921352536,0,0,1,0.0060582815199639786
3497,PSB5,Negative regulation of NOTCH4 signaling,0.005274067747496484,1,0,1,0.00577708108363096
3498,PSB5,KEAP1-NFE2L2 pathway,0.005530783921352536,0,0,1,0.0060582815199639786
3499,PSB5,KEAP1-NFE2L2 pathway,0.005274067747496484,1,0,1,0.00577708108363096
3500,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.005530783921352536,0,0,1,0.0060582815199639786
3501,PSB5,Antigen processing: Ubiquitination & Proteasome degradation,0.005274067747496484,1,0,1,0.00577708108363096
3502,PSB5,Degradation of beta-catenin by the destruction complex,0.005530783921352536,0,0,1,0.0060582815199639786
3503,PSB5,Degradation of beta-catenin by the destruction complex,0.005274067747496484,1,0,1,0.00577708108363096
3504,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.005530783921352536,0,0,1,0.0060582815199639786
3505,PSB5,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.005274067747496484,1,0,1,0.00577708108363096
3506,PSB5,Hedgehog ligand biogenesis,0.005530783921352536,0,0,1,0.0060582815199639786
3507,PSB5,Hedgehog ligand biogenesis,0.005274067747496484,1,0,1,0.00577708108363096
3508,PSB5,Hedgehog 'on' state,0.005530783921352536,0,0,1,0.0060582815199639786
3509,PSB5,Hedgehog 'on' state,0.005274067747496484,1,0,1,0.00577708108363096
3510,PSB5,MAPK6/MAPK4 signaling,0.005530783921352536,0,0,1,0.0060582815199639786
3511,PSB5,MAPK6/MAPK4 signaling,0.005274067747496484,1,0,1,0.00577708108363096
3512,PSB5,Neddylation,0.005530783921352536,0,0,1,0.0060582815199639786
3513,PSB5,Neddylation,0.005274067747496484,1,0,1,0.00577708108363096
3514,GRN,Neutrophil degranulation,0.00012143850561160018,0,0,1,0.00013302068293040165
3515,GRN,Neutrophil degranulation,0.00012844490284635125,1,0,1,0.00014069531413863712
3516,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0011453435761141378,0,0,1,0.001254580529605082
3517,CCN2,YAP1- and WWTR1 (TAZ)-stimulated gene expression,0.0010693131760324158,1,0,1,0.0011712987427335525
3518,CCN2,Transcriptional regulation by RUNX3,0.0011453435761141378,0,0,1,0.001254580529605082
3519,CCN2,Transcriptional regulation by RUNX3,0.0010693131760324158,1,0,1,0.0011712987427335525
3520,TKT,KEAP1-NFE2L2 pathway,0.001672564308261877,0,0,1,0.0018320848515839872
3521,TKT,KEAP1-NFE2L2 pathway,0.0009503326223493048,1,0,1,0.0010409704384888986
3522,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.001672564308261877,0,0,1,0.0018320848515839872
3523,TKT,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0009503326223493048,1,0,1,0.0010409704384888986
3524,TKT,Pentose phosphate pathway,0.001672564308261877,0,0,1,0.0018320848515839872
3525,TKT,Pentose phosphate pathway,0.0009503326223493048,1,0,1,0.0010409704384888986
3526,KAIN,Platelet degranulation ,0.0008381751660340457,0,0,1,0.0009181159833911958
3527,KAIN,Platelet degranulation ,0.0006555470289222839,1,0,1,0.0007180697180113211
3528,PRDX6,Detoxification of Reactive Oxygen Species,0.00023615753850536207,0,0,1,0.00025868102454766324
3529,PRDX6,Detoxification of Reactive Oxygen Species,0.00021378870949747164,1,0,1,0.0002341787721854707
3530,PRDX6,Neutrophil degranulation,0.00023615753850536207,0,0,1,0.00025868102454766324
3531,PRDX6,Neutrophil degranulation,0.00021378870949747164,1,0,1,0.0002341787721854707
3532,BLVRB,Cytoprotection by HMOX1,0.00133346820215879,0,0,1,0.0014606475106376255
3533,BLVRB,Cytoprotection by HMOX1,0.001214315063204276,1,0,1,0.0013301301608299506
3534,BLVRB,Heme degradation,0.00133346820215879,0,0,1,0.0014606475106376255
3535,BLVRB,Heme degradation,0.001214315063204276,1,0,1,0.0013301301608299506
3536,PEBP1,RAF/MAP kinase cascade,0.00022398089686941078,0,0,1,0.0002453430377365156
3537,PEBP1,RAF/MAP kinase cascade,0.0003958866655565668,1,0,1,0.0004336442905827695
3538,PEBP1,Signaling by RAS mutants,0.00022398089686941078,0,0,1,0.0002453430377365156
3539,PEBP1,Signaling by RAS mutants,0.0003958866655565668,1,0,1,0.0004336442905827695
3540,PEBP1,Signaling by moderate kinase activity BRAF mutants,0.00022398089686941078,0,0,1,0.0002453430377365156
3541,PEBP1,Signaling by moderate kinase activity BRAF mutants,0.0003958866655565668,1,0,1,0.0004336442905827695
3542,PEBP1,Signaling by high-kinase activity BRAF mutants,0.00022398089686941078,0,0,1,0.0002453430377365156
3543,PEBP1,Signaling by high-kinase activity BRAF mutants,0.0003958866655565668,1,0,1,0.0004336442905827695
3544,PEBP1,Signaling by BRAF and RAF1 fusions,0.00022398089686941078,0,0,1,0.0002453430377365156
3545,PEBP1,Signaling by BRAF and RAF1 fusions,0.0003958866655565668,1,0,1,0.0004336442905827695
3546,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.00022398089686941078,0,0,1,0.0002453430377365156
3547,PEBP1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0003958866655565668,1,0,1,0.0004336442905827695
3548,PDIA3,Antigen processing-Cross presentation,0.00032816993543608727,0,0,1,0.00035946908856530137
3549,PDIA3,Antigen processing-Cross presentation,0.0003314038907506605,1,0,1,0.00036301148183129556
3550,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.00032816993543608727,0,0,1,0.00035946908856530137
3551,PDIA3,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.0003314038907506605,1,0,1,0.00036301148183129556
3552,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.00032816993543608727,0,0,1,0.00035946908856530137
3553,PDIA3,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0003314038907506605,1,0,1,0.00036301148183129556
3554,P30443,Antigen processing-Cross presentation,0.0029870026885546025,0,0,1,0.003271887574253257
3555,P30443,Antigen processing-Cross presentation,0.003125488884253002,1,0,1,0.0034235818678832563
3556,P30443,Interferon gamma signaling,0.0029870026885546025,0,0,1,0.003271887574253257
3557,P30443,Interferon gamma signaling,0.003125488884253002,1,0,1,0.0034235818678832563
3558,P30443,Interferon alpha/beta signaling,0.0029870026885546025,0,0,1,0.003271887574253257
3559,P30443,Interferon alpha/beta signaling,0.003125488884253002,1,0,1,0.0034235818678832563
3560,P30443,SARS-CoV-2 Infection,0.0029870026885546025,0,0,1,0.003271887574253257
3561,P30443,SARS-CoV-2 Infection,0.003125488884253002,1,0,1,0.0034235818678832563
3562,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.0029870026885546025,0,0,1,0.003271887574253257
3563,P30443,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.003125488884253002,1,0,1,0.0034235818678832563
3564,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0029870026885546025,0,0,1,0.003271887574253257
3565,P30443,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.003125488884253002,1,0,1,0.0034235818678832563
3566,ILEU,Neutrophil degranulation,0.00029424957213491947,0,0,1,0.0003223135762436999
3567,ILEU,Neutrophil degranulation,0.0003059510623634058,1,0,1,0.0003351310941607516
3568,CPSM,Urea cycle,0.0008113204850519766,0,0,1,0.0008887000416672583
3569,CPSM,Urea cycle,0.0004954376185713525,1,0,1,0.0005426898992198884
3570,1433B,Activation of BH3-only proteins,0.000152981547564754,0,0,1,0.0001675721372749619
3571,1433B,Activation of BH3-only proteins,0.0003415995533087802,1,0,1,0.0003741795540138262
3572,1433B,Signaling by NTRK1 (TRKA),0.000152981547564754,0,0,1,0.0001675721372749619
3573,1433B,Signaling by NTRK1 (TRKA),0.0003415995533087802,1,0,1,0.0003741795540138262
3574,1433B,RHO GTPase Effectors,0.000152981547564754,0,0,1,0.0001675721372749619
3575,1433B,RHO GTPase Effectors,0.0003415995533087802,1,0,1,0.0003741795540138262
3576,1433B,Transcriptional Regulation by TP53,0.000152981547564754,0,0,1,0.0001675721372749619
3577,1433B,Transcriptional Regulation by TP53,0.0003415995533087802,1,0,1,0.0003741795540138262
3578,1433B,FOXO-mediated transcription,0.000152981547564754,0,0,1,0.0001675721372749619
3579,1433B,FOXO-mediated transcription,0.0003415995533087802,1,0,1,0.0003741795540138262
3580,1433B,RAF/MAP kinase cascade,0.000152981547564754,0,0,1,0.0001675721372749619
3581,1433B,RAF/MAP kinase cascade,0.0003415995533087802,1,0,1,0.0003741795540138262
3582,1433B,Signaling by RAS mutants,0.000152981547564754,0,0,1,0.0001675721372749619
3583,1433B,Signaling by RAS mutants,0.0003415995533087802,1,0,1,0.0003741795540138262
3584,1433B,Signaling by moderate kinase activity BRAF mutants,0.000152981547564754,0,0,1,0.0001675721372749619
3585,1433B,Signaling by moderate kinase activity BRAF mutants,0.0003415995533087802,1,0,1,0.0003741795540138262
3586,1433B,Signaling by high-kinase activity BRAF mutants,0.000152981547564754,0,0,1,0.0001675721372749619
3587,1433B,Signaling by high-kinase activity BRAF mutants,0.0003415995533087802,1,0,1,0.0003741795540138262
3588,1433B,Signaling by BRAF and RAF1 fusions,0.000152981547564754,0,0,1,0.0001675721372749619
3589,1433B,Signaling by BRAF and RAF1 fusions,0.0003415995533087802,1,0,1,0.0003741795540138262
3590,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.000152981547564754,0,0,1,0.0001675721372749619
3591,1433B,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.0003415995533087802,1,0,1,0.0003741795540138262
3592,1433B,Signaling by RAF1 mutants,0.000152981547564754,0,0,1,0.0001675721372749619
3593,1433B,Signaling by RAF1 mutants,0.0003415995533087802,1,0,1,0.0003741795540138262
3594,1433B,Signaling by MRAS-complex mutants,0.000152981547564754,0,0,1,0.0001675721372749619
3595,1433B,Signaling by MRAS-complex mutants,0.0003415995533087802,1,0,1,0.0003741795540138262
3596,1433B,G2/M DNA damage checkpoint,0.000152981547564754,0,0,1,0.0001675721372749619
3597,1433B,G2/M DNA damage checkpoint,0.0003415995533087802,1,0,1,0.0003741795540138262
3598,1433B,SARS-CoV-2 Infection,0.000152981547564754,0,0,1,0.0001675721372749619
3599,1433B,SARS-CoV-2 Infection,0.0003415995533087802,1,0,1,0.0003741795540138262
3600,1433B,Rap1 signalling,0.000152981547564754,0,0,1,0.0001675721372749619
3601,1433B,Rap1 signalling,0.0003415995533087802,1,0,1,0.0003741795540138262
3602,1433B,Signaling by Hippo,0.000152981547564754,0,0,1,0.0001675721372749619
3603,1433B,Signaling by Hippo,0.0003415995533087802,1,0,1,0.0003741795540138262
3604,1433B,mTORC1-mediated signalling,0.000152981547564754,0,0,1,0.0001675721372749619
3605,1433B,mTORC1-mediated signalling,0.0003415995533087802,1,0,1,0.0003741795540138262
3606,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.000152981547564754,0,0,1,0.0001675721372749619
3607,1433B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0003415995533087802,1,0,1,0.0003741795540138262
3608,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.000152981547564754,0,0,1,0.0001675721372749619
3609,1433B,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0003415995533087802,1,0,1,0.0003741795540138262
3610,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.000152981547564754,0,0,1,0.0001675721372749619
3611,1433B,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0003415995533087802,1,0,1,0.0003741795540138262
3612,PRDX2,Transcriptional Regulation by TP53,0.0011028506397280746,0,0,1,0.0012080348364633155
3613,PRDX2,Transcriptional Regulation by TP53,0.0014557912143453014,1,0,1,0.0015946370598107283
3614,PRDX2,Neurodegenerative Diseases,0.0011028506397280746,0,0,1,0.0012080348364633155
3615,PRDX2,Neurodegenerative Diseases,0.0014557912143453014,1,0,1,0.0015946370598107283
3616,PRDX2,Detoxification of Reactive Oxygen Species,0.0011028506397280746,0,0,1,0.0012080348364633155
3617,PRDX2,Detoxification of Reactive Oxygen Species,0.0014557912143453014,1,0,1,0.0015946370598107283
3618,HPPD,Tyrosine catabolism,0.0007313815078332898,0,0,1,0.0008011368977629923
3619,HPPD,Tyrosine catabolism,0.0006838800385742103,1,0,1,0.0007491049837566606
3620,CADH5,VEGFA-VEGFR2 Pathway,0.005511317575860977,0,0,1,0.006036958575001791
3621,CADH5,VEGFA-VEGFR2 Pathway,0.004287027747389213,1,0,1,0.004695902307322375
3622,CADH5,Adherens junctions interactions,0.005511317575860977,0,0,1,0.006036958575001791
3623,CADH5,Adherens junctions interactions,0.004287027747389213,1,0,1,0.004695902307322375
3624,MA1A1,Intra-Golgi traffic,0.001307402197614331,0,0,1,0.0014320954652356466
3625,MA1A1,Intra-Golgi traffic,0.0011735310497915912,1,0,1,0.0012854563789065363
3626,HS71L,Regulation of HSF1-mediated heat shock response,0.0006550221615600953,0,0,1,0.0007174947915115705
3627,HS71L,Regulation of HSF1-mediated heat shock response,0.00048415209057381576,1,0,1,0.0005303280158625301
3628,HS71L,HSF1-dependent transactivation,0.0006550221615600953,0,0,1,0.0007174947915115705
3629,HS71L,HSF1-dependent transactivation,0.00048415209057381576,1,0,1,0.0005303280158625301
3630,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0006550221615600953,0,0,1,0.0007174947915115705
3631,HS71L,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00048415209057381576,1,0,1,0.0005303280158625301
3632,TRY3,Defensins,0.0002448875715030974,0,0,1,0.0002682436829937234
3633,TRY3,Defensins,0.00029227820953468294,1,0,1,0.0003201541952626327
3634,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0002448875715030974,0,0,1,0.0002682436829937234
3635,TRY3,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.00029227820953468294,1,0,1,0.0003201541952626327
3636,TRY3,Neutrophil degranulation,0.0002448875715030974,0,0,1,0.0002682436829937234
3637,TRY3,Neutrophil degranulation,0.00029227820953468294,1,0,1,0.0003201541952626327
3638,CBS,Cysteine formation from homocysteine,0.0002099155030803646,0,0,1,0.00022993615934912849
3639,CBS,Cysteine formation from homocysteine,0.00014583450812203182,1,0,1,0.00015974345013151106
3640,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.0002099155030803646,0,0,1,0.00022993615934912849
3641,CBS,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",0.00014583450812203182,1,0,1,0.00015974345013151106
3642,K1C9,Formation of the cornified envelope,0.00019638003636989802,0,0,1,0.0002151097497474939
3643,K1C9,Formation of the cornified envelope,0.00019243320253865142,1,0,1,0.00021078648729460777
3644,FBN1,TGF-beta receptor signaling activates SMADs,0.004122490706548643,0,0,1,0.004515672573518164
3645,FBN1,TGF-beta receptor signaling activates SMADs,0.004443686260182297,1,0,1,0.004867502099774091
3646,FBN1,Integrin cell surface interactions,0.004122490706548643,0,0,1,0.004515672573518164
3647,FBN1,Integrin cell surface interactions,0.004443686260182297,1,0,1,0.004867502099774091
3648,FBN1,Molecules associated with elastic fibres,0.004122490706548643,0,0,1,0.004515672573518164
3649,FBN1,Molecules associated with elastic fibres,0.004443686260182297,1,0,1,0.004867502099774091
3650,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004122490706548643,0,0,1,0.004515672573518164
3651,FBN1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.004443686260182297,1,0,1,0.004867502099774091
3652,FBN1,Post-translational protein phosphorylation,0.004122490706548643,0,0,1,0.004515672573518164
3653,FBN1,Post-translational protein phosphorylation,0.004443686260182297,1,0,1,0.004867502099774091
3654,MYH9,RHO GTPase Effectors,0.007991669723187303,0,0,1,0.008753873896740727
3655,MYH9,RHO GTPase Effectors,0.007336342245160702,1,0,1,0.008036044669255327
3656,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.007991669723187303,0,0,1,0.008753873896740727
3657,MYH9,Regulation of actin dynamics for phagocytic cup formation,0.007336342245160702,1,0,1,0.008036044669255327
3658,MYH9,EPH-Ephrin signaling,0.007991669723187303,0,0,1,0.008753873896740727
3659,MYH9,EPH-Ephrin signaling,0.007336342245160702,1,0,1,0.008036044669255327
3660,MYH9,Semaphorin interactions,0.007991669723187303,0,0,1,0.008753873896740727
3661,MYH9,Semaphorin interactions,0.007336342245160702,1,0,1,0.008036044669255327
3662,MYH9,Parasite infection,0.007991669723187303,0,0,1,0.008753873896740727
3663,MYH9,Parasite infection,0.007336342245160702,1,0,1,0.008036044669255327
3664,MYH9,Leishmania parasite growth and survival,0.007991669723187303,0,0,1,0.008753873896740727
3665,MYH9,Leishmania parasite growth and survival,0.007336342245160702,1,0,1,0.008036044669255327
3666,MYH9,Signaling by ALK fusions and activated point mutants,0.007991669723187303,0,0,1,0.008753873896740727
3667,MYH9,Signaling by ALK fusions and activated point mutants,0.007336342245160702,1,0,1,0.008036044669255327
3668,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.007991669723187303,0,0,1,0.008753873896740727
3669,MYH9,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.007336342245160702,1,0,1,0.008036044669255327
3670,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.007991669723187303,0,0,1,0.008753873896740727
3671,MYH9,Sensory processing of sound by inner hair cells of the cochlea,0.007336342245160702,1,0,1,0.008036044669255327
3672,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.007991669723187303,0,0,1,0.008753873896740727
3673,MYH9,Sensory processing of sound by outer hair cells of the cochlea,0.007336342245160702,1,0,1,0.008036044669255327
3674,MYH10,RHO GTPase Effectors,0.00031045061846524905,0,0,1,0.000340059794679063
3675,MYH10,RHO GTPase Effectors,0.0002465917265728449,1,0,1,0.000270110371570427
3676,MYH10,EPH-Ephrin signaling,0.00031045061846524905,0,0,1,0.000340059794679063
3677,MYH10,EPH-Ephrin signaling,0.0002465917265728449,1,0,1,0.000270110371570427
3678,MYH10,Semaphorin interactions,0.00031045061846524905,0,0,1,0.000340059794679063
3679,MYH10,Semaphorin interactions,0.0002465917265728449,1,0,1,0.000270110371570427
3680,MYH11,RHO GTPase Effectors,0.00023114376436038342,0,0,1,0.000253189062525692
3681,MYH11,RHO GTPase Effectors,0.0004905392607507948,1,0,1,0.0005373243613351253
3682,MYH11,EPH-Ephrin signaling,0.00023114376436038342,0,0,1,0.000253189062525692
3683,MYH11,EPH-Ephrin signaling,0.0004905392607507948,1,0,1,0.0005373243613351253
3684,MYH11,Semaphorin interactions,0.00023114376436038342,0,0,1,0.000253189062525692
3685,MYH11,Semaphorin interactions,0.0004905392607507948,1,0,1,0.0005373243613351253
3686,MYH11,Smooth Muscle Contraction,0.00023114376436038342,0,0,1,0.000253189062525692
3687,MYH11,Smooth Muscle Contraction,0.0004905392607507948,1,0,1,0.0005373243613351253
3688,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002721871560563417,0,0,1,0.00298146960893101
3689,ALS,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.003105893701667164,1,0,1,0.0034021177980103055
3690,K1C20,Formation of the cornified envelope,0.0006873291802798223,0,0,1,0.0007528830867800265
3691,K1C20,Formation of the cornified envelope,0.0006772546429449437,1,0,1,0.0007418476921188016
3692,K22E,Formation of the cornified envelope,5.1226607177936626e-05,0,0,1,5.611233633597705e-05
3693,K22E,Formation of the cornified envelope,5.063095084339236e-05,1,0,1,5.54598693773806e-05
3694,CH3L1,Neutrophil degranulation,0.0016809938328345376,0,0,1,0.0018413183406638036
3695,CH3L1,Neutrophil degranulation,0.0017624651953497628,1,0,1,0.0019305600208579506
3696,PGM1,Diseases associated with glycosylation precursor biosynthesis,0.0010697318678000837,0,0,1,0.0011717573671590758
3697,PGM1,Diseases associated with glycosylation precursor biosynthesis,0.0014524634628052006,1,0,1,0.0015909919245197632
3698,PGM1,Glycogen synthesis,0.0010697318678000837,0,0,1,0.0011717573671590758
3699,PGM1,Glycogen synthesis,0.0014524634628052006,1,0,1,0.0015909919245197632
3700,PGM1,Glycogen breakdown (glycogenolysis),0.0010697318678000837,0,0,1,0.0011717573671590758
3701,PGM1,Glycogen breakdown (glycogenolysis),0.0014524634628052006,1,0,1,0.0015909919245197632
3702,PGM1,Neutrophil degranulation,0.0010697318678000837,0,0,1,0.0011717573671590758
3703,PGM1,Neutrophil degranulation,0.0014524634628052006,1,0,1,0.0015909919245197632
3704,PGM1,Galactose catabolism,0.0010697318678000837,0,0,1,0.0011717573671590758
3705,PGM1,Galactose catabolism,0.0014524634628052006,1,0,1,0.0015909919245197632
3706,FHR2,Regulation of Complement cascade,0.0002191591064323165,0,0,1,0.00024006136983670663
3707,FHR2,Regulation of Complement cascade,0.0002350238928865535,1,0,1,0.00025743925766610036
3708,TAGL2,Platelet degranulation ,0.0005523270221860242,0,0,1,0.0006050051202629578
3709,TAGL2,Platelet degranulation ,0.0004269859712848057,1,0,1,0.000467709687433606
3710,TALDO,Interleukin-12 family signaling,0.0031220688104043304,0,0,1,0.0034198356050588624
3711,TALDO,Interleukin-12 family signaling,0.0027954233653706305,1,0,1,0.0030620364049150717
3712,TALDO,Pentose phosphate pathway disease,0.0031220688104043304,0,0,1,0.0034198356050588624
3713,TALDO,Pentose phosphate pathway disease,0.0027954233653706305,1,0,1,0.0030620364049150717
3714,TALDO,KEAP1-NFE2L2 pathway,0.0031220688104043304,0,0,1,0.0034198356050588624
3715,TALDO,KEAP1-NFE2L2 pathway,0.0027954233653706305,1,0,1,0.0030620364049150717
3716,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0031220688104043304,0,0,1,0.0034198356050588624
3717,TALDO,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0027954233653706305,1,0,1,0.0030620364049150717
3718,TALDO,Pentose phosphate pathway,0.0031220688104043304,0,0,1,0.0034198356050588624
3719,TALDO,Pentose phosphate pathway,0.0027954233653706305,1,0,1,0.0030620364049150717
3720,GRP75,Regulation of HSF1-mediated heat shock response,0.001717277847881651,0,0,1,0.001881062937624349
3721,GRP75,Regulation of HSF1-mediated heat shock response,0.0008181598205013002,1,0,1,0.0008961916776000067
3722,GRP75,Interleukin-12 family signaling,0.001717277847881651,0,0,1,0.001881062937624349
3723,GRP75,Interleukin-12 family signaling,0.0008181598205013002,1,0,1,0.0008961916776000067
3724,GRP75,Cristae formation,0.001717277847881651,0,0,1,0.001881062937624349
3725,GRP75,Cristae formation,0.0008181598205013002,1,0,1,0.0008961916776000067
3726,GRP75,Mitochondrial protein import,0.001717277847881651,0,0,1,0.001881062937624349
3727,GRP75,Mitochondrial protein import,0.0008181598205013002,1,0,1,0.0008961916776000067
3728,COIA1,Collagen chain trimerization,0.004853503527131575,0,0,1,0.005316405620545483
3729,COIA1,Collagen chain trimerization,0.004614792170586906,1,0,1,0.005054927207986845
3730,COIA1,Collagen degradation,0.004853503527131575,0,0,1,0.005316405620545483
3731,COIA1,Collagen degradation,0.004614792170586906,1,0,1,0.005054927207986845
3732,COIA1,Activation of Matrix Metalloproteinases,0.004853503527131575,0,0,1,0.005316405620545483
3733,COIA1,Activation of Matrix Metalloproteinases,0.004614792170586906,1,0,1,0.005054927207986845
3734,COIA1,Integrin cell surface interactions,0.004853503527131575,0,0,1,0.005316405620545483
3735,COIA1,Integrin cell surface interactions,0.004614792170586906,1,0,1,0.005054927207986845
3736,COIA1,Laminin interactions,0.004853503527131575,0,0,1,0.005316405620545483
3737,COIA1,Laminin interactions,0.004614792170586906,1,0,1,0.005054927207986845
3738,MDHC,Gluconeogenesis,5.061435932396949e-05,0,0,1,5.5441695444546304e-05
3739,MDHC,Gluconeogenesis,7.443459615360136e-05,1,0,1,8.15337834086036e-05
3740,MDHM,Gluconeogenesis,0.001241974964360281,0,0,1,0.0013604281204682793
3741,MDHM,Gluconeogenesis,0.0014894844940213515,1,0,1,0.0016315438304441532
3742,MDHM,Citric acid cycle (TCA cycle),0.001241974964360281,0,0,1,0.0013604281204682793
3743,MDHM,Citric acid cycle (TCA cycle),0.0014894844940213515,1,0,1,0.0016315438304441532
3744,PTGDS,Arachidonic acid metabolism,0.0019468268689665196,0,0,1,0.0021325051584992873
3745,PTGDS,Arachidonic acid metabolism,0.002327305682836152,1,0,1,0.0025492720760975644
3746,PTGDS,Transcriptional regulation of testis differentiation,0.0019468268689665196,0,0,1,0.0021325051584992873
3747,PTGDS,Transcriptional regulation of testis differentiation,0.002327305682836152,1,0,1,0.0025492720760975644
3748,THIM,Mitochondrial Fatty Acid Beta-Oxidation,0.0001659670159256743,0,0,1,0.00018179609252573983
3749,THIM,Mitochondrial Fatty Acid Beta-Oxidation,0.00016971502837495698,1,0,1,0.00018590157104035363
3750,MUC18,RHO GTPase cycle,0.0003823309745924691,0,0,1,0.0004187957278426702
3751,MUC18,RHO GTPase cycle,0.00024290670255030066,1,0,1,0.0002660738889932982
3752,BTD,Biotin transport and metabolism,0.004216236865639463,0,0,1,0.00461835975697418
3753,BTD,Biotin transport and metabolism,0.004734729406585489,1,0,1,0.005186303437964038
3754,BTD,Defects in biotin (Btn) metabolism,0.004216236865639463,0,0,1,0.00461835975697418
3755,BTD,Defects in biotin (Btn) metabolism,0.004734729406585489,1,0,1,0.005186303437964038
3756,GSHB,Glutathione conjugation,8.3698614270624e-06,0,0,1,9.168135571608308e-06
3757,GSHB,Glutathione conjugation,4.800599899819903e-05,1,0,1,5.258456318558833e-05
3758,GSHB,Defective GSS causes GSS deficiency,8.3698614270624e-06,0,0,1,9.168135571608308e-06
3759,GSHB,Defective GSS causes GSS deficiency,4.800599899819903e-05,1,0,1,5.258456318558833e-05
3760,MASP1,Initial triggering of complement,0.0011478212405577532,0,0,1,0.0012572945008838146
3761,MASP1,Initial triggering of complement,0.0012119690890090699,1,0,1,0.0013275604397352144
3762,MASP1,SARS-CoV-2 Infection,0.0011478212405577532,0,0,1,0.0012572945008838146
3763,MASP1,SARS-CoV-2 Infection,0.0012119690890090699,1,0,1,0.0013275604397352144
3764,MASP1,Scavenging by Class A Receptors,0.0011478212405577532,0,0,1,0.0012572945008838146
3765,MASP1,Scavenging by Class A Receptors,0.0012119690890090699,1,0,1,0.0013275604397352144
3766,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.00712490392621928,0,0,1,0.00780444045573512
3767,PSB2,Downstream signaling events of B Cell Receptor (BCR),0.006773683042170925,1,0,1,0.007419721938159185
3768,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.00712490392621928,0,0,1,0.00780444045573512
3769,PSB2,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.006773683042170925,1,0,1,0.007419721938159185
3770,PSB2,Antigen processing-Cross presentation,0.00712490392621928,0,0,1,0.00780444045573512
3771,PSB2,Antigen processing-Cross presentation,0.006773683042170925,1,0,1,0.007419721938159185
3772,PSB2,PTEN Regulation,0.00712490392621928,0,0,1,0.00780444045573512
3773,PSB2,PTEN Regulation,0.006773683042170925,1,0,1,0.007419721938159185
3774,PSB2,Host Interactions of HIV factors,0.00712490392621928,0,0,1,0.00780444045573512
3775,PSB2,Host Interactions of HIV factors,0.006773683042170925,1,0,1,0.007419721938159185
3776,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.00712490392621928,0,0,1,0.00780444045573512
3777,PSB2,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.006773683042170925,1,0,1,0.007419721938159185
3778,PSB2,APC/C-mediated degradation of cell cycle proteins,0.00712490392621928,0,0,1,0.00780444045573512
3779,PSB2,APC/C-mediated degradation of cell cycle proteins,0.006773683042170925,1,0,1,0.007419721938159185
3780,PSB2,Degradation of AXIN,0.00712490392621928,0,0,1,0.00780444045573512
3781,PSB2,Degradation of AXIN,0.006773683042170925,1,0,1,0.007419721938159185
3782,PSB2,Degradation of DVL,0.00712490392621928,0,0,1,0.00780444045573512
3783,PSB2,Degradation of DVL,0.006773683042170925,1,0,1,0.007419721938159185
3784,PSB2,Downstream TCR signaling,0.00712490392621928,0,0,1,0.00780444045573512
3785,PSB2,Downstream TCR signaling,0.006773683042170925,1,0,1,0.007419721938159185
3786,PSB2,Transcriptional regulation by RUNX3,0.00712490392621928,0,0,1,0.00780444045573512
3787,PSB2,Transcriptional regulation by RUNX3,0.006773683042170925,1,0,1,0.007419721938159185
3788,PSB2,Transcriptional regulation by RUNX2,0.00712490392621928,0,0,1,0.00780444045573512
3789,PSB2,Transcriptional regulation by RUNX2,0.006773683042170925,1,0,1,0.007419721938159185
3790,PSB2,Transcriptional regulation by RUNX1,0.00712490392621928,0,0,1,0.00780444045573512
3791,PSB2,Transcriptional regulation by RUNX1,0.006773683042170925,1,0,1,0.007419721938159185
3792,PSB2,FCERI mediated NF-kB activation,0.00712490392621928,0,0,1,0.00780444045573512
3793,PSB2,FCERI mediated NF-kB activation,0.006773683042170925,1,0,1,0.007419721938159185
3794,PSB2,Mitotic Metaphase and Anaphase,0.00712490392621928,0,0,1,0.00780444045573512
3795,PSB2,Mitotic Metaphase and Anaphase,0.006773683042170925,1,0,1,0.007419721938159185
3796,PSB2,Regulation of ornithine decarboxylase (ODC),0.00712490392621928,0,0,1,0.00780444045573512
3797,PSB2,Regulation of ornithine decarboxylase (ODC),0.006773683042170925,1,0,1,0.007419721938159185
3798,PSB2,Signaling by ROBO receptors,0.00712490392621928,0,0,1,0.00780444045573512
3799,PSB2,Signaling by ROBO receptors,0.006773683042170925,1,0,1,0.007419721938159185
3800,PSB2,PCP/CE pathway,0.00712490392621928,0,0,1,0.00780444045573512
3801,PSB2,PCP/CE pathway,0.006773683042170925,1,0,1,0.007419721938159185
3802,PSB2,Interleukin-1 family signaling,0.00712490392621928,0,0,1,0.00780444045573512
3803,PSB2,Interleukin-1 family signaling,0.006773683042170925,1,0,1,0.007419721938159185
3804,PSB2,G2/M Transition,0.00712490392621928,0,0,1,0.00780444045573512
3805,PSB2,G2/M Transition,0.006773683042170925,1,0,1,0.007419721938159185
3806,PSB2,G1/S Transition,0.00712490392621928,0,0,1,0.00780444045573512
3807,PSB2,G1/S Transition,0.006773683042170925,1,0,1,0.007419721938159185
3808,PSB2,Hh mutants are degraded by ERAD,0.00712490392621928,0,0,1,0.00780444045573512
3809,PSB2,Hh mutants are degraded by ERAD,0.006773683042170925,1,0,1,0.007419721938159185
3810,PSB2,CLEC7A (Dectin-1) signaling,0.00712490392621928,0,0,1,0.00780444045573512
3811,PSB2,CLEC7A (Dectin-1) signaling,0.006773683042170925,1,0,1,0.007419721938159185
3812,PSB2,Degradation of GLI1 by the proteasome,0.00712490392621928,0,0,1,0.00780444045573512
3813,PSB2,Degradation of GLI1 by the proteasome,0.006773683042170925,1,0,1,0.007419721938159185
3814,PSB2,Degradation of GLI2 by the proteasome,0.00712490392621928,0,0,1,0.00780444045573512
3815,PSB2,Degradation of GLI2 by the proteasome,0.006773683042170925,1,0,1,0.007419721938159185
3816,PSB2,GLI3 is processed to GLI3R by the proteasome,0.00712490392621928,0,0,1,0.00780444045573512
3817,PSB2,GLI3 is processed to GLI3R by the proteasome,0.006773683042170925,1,0,1,0.007419721938159185
3818,PSB2,Defective CFTR causes cystic fibrosis,0.00712490392621928,0,0,1,0.00780444045573512
3819,PSB2,Defective CFTR causes cystic fibrosis,0.006773683042170925,1,0,1,0.007419721938159185
3820,PSB2,NIK-->noncanonical NF-kB signaling,0.00712490392621928,0,0,1,0.00780444045573512
3821,PSB2,NIK-->noncanonical NF-kB signaling,0.006773683042170925,1,0,1,0.007419721938159185
3822,PSB2,RAF/MAP kinase cascade,0.00712490392621928,0,0,1,0.00780444045573512
3823,PSB2,RAF/MAP kinase cascade,0.006773683042170925,1,0,1,0.007419721938159185
3824,PSB2,UCH proteinases,0.00712490392621928,0,0,1,0.00780444045573512
3825,PSB2,UCH proteinases,0.006773683042170925,1,0,1,0.007419721938159185
3826,PSB2,Ub-specific processing proteases,0.00712490392621928,0,0,1,0.00780444045573512
3827,PSB2,Ub-specific processing proteases,0.006773683042170925,1,0,1,0.007419721938159185
3828,PSB2,Orc1 removal from chromatin,0.00712490392621928,0,0,1,0.00780444045573512
3829,PSB2,Orc1 removal from chromatin,0.006773683042170925,1,0,1,0.007419721938159185
3830,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.00712490392621928,0,0,1,0.00780444045573512
3831,PSB2,CDK-mediated phosphorylation and removal of Cdc6,0.006773683042170925,1,0,1,0.007419721938159185
3832,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.00712490392621928,0,0,1,0.00780444045573512
3833,PSB2,Cyclin A:Cdk2-associated events at S phase entry,0.006773683042170925,1,0,1,0.007419721938159185
3834,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.00712490392621928,0,0,1,0.00780444045573512
3835,PSB2,Ubiquitin-dependent degradation of Cyclin D,0.006773683042170925,1,0,1,0.007419721938159185
3836,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.00712490392621928,0,0,1,0.00780444045573512
3837,PSB2,p53-Dependent G1/S DNA damage checkpoint,0.006773683042170925,1,0,1,0.007419721938159185
3838,PSB2,p53-Independent G1/S DNA damage checkpoint,0.00712490392621928,0,0,1,0.00780444045573512
3839,PSB2,p53-Independent G1/S DNA damage checkpoint,0.006773683042170925,1,0,1,0.007419721938159185
3840,PSB2,Negative regulation of NOTCH4 signaling,0.00712490392621928,0,0,1,0.00780444045573512
3841,PSB2,Negative regulation of NOTCH4 signaling,0.006773683042170925,1,0,1,0.007419721938159185
3842,PSB2,KEAP1-NFE2L2 pathway,0.00712490392621928,0,0,1,0.00780444045573512
3843,PSB2,KEAP1-NFE2L2 pathway,0.006773683042170925,1,0,1,0.007419721938159185
3844,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.00712490392621928,0,0,1,0.00780444045573512
3845,PSB2,Antigen processing: Ubiquitination & Proteasome degradation,0.006773683042170925,1,0,1,0.007419721938159185
3846,PSB2,Degradation of beta-catenin by the destruction complex,0.00712490392621928,0,0,1,0.00780444045573512
3847,PSB2,Degradation of beta-catenin by the destruction complex,0.006773683042170925,1,0,1,0.007419721938159185
3848,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.00712490392621928,0,0,1,0.00780444045573512
3849,PSB2,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.006773683042170925,1,0,1,0.007419721938159185
3850,PSB2,Hedgehog ligand biogenesis,0.00712490392621928,0,0,1,0.00780444045573512
3851,PSB2,Hedgehog ligand biogenesis,0.006773683042170925,1,0,1,0.007419721938159185
3852,PSB2,Hedgehog 'on' state,0.00712490392621928,0,0,1,0.00780444045573512
3853,PSB2,Hedgehog 'on' state,0.006773683042170925,1,0,1,0.007419721938159185
3854,PSB2,MAPK6/MAPK4 signaling,0.00712490392621928,0,0,1,0.00780444045573512
3855,PSB2,MAPK6/MAPK4 signaling,0.006773683042170925,1,0,1,0.007419721938159185
3856,PSB2,Neddylation,0.00712490392621928,0,0,1,0.00780444045573512
3857,PSB2,Neddylation,0.006773683042170925,1,0,1,0.007419721938159185
3858,COMP,Integrin cell surface interactions,0.0016899040105143165,0,0,1,0.0018510783250610605
3859,COMP,Integrin cell surface interactions,0.0015096742344897333,1,0,1,0.0016536591640590225
3860,COMP,ECM proteoglycans,0.0016899040105143165,0,0,1,0.0018510783250610605
3861,COMP,ECM proteoglycans,0.0015096742344897333,1,0,1,0.0016536591640590225
3862,SEPP1,Platelet degranulation ,0.0005328884237781212,0,0,1,0.0005837125687579262
3863,SEPP1,Platelet degranulation ,0.00041245259416229353,1,0,1,0.0004517901918799899
3864,CAMP,Neutrophil degranulation,0.0022442084415059366,0,0,1,0.0024582494491662775
3865,CAMP,Neutrophil degranulation,0.002356777111834227,1,0,1,0.00258155433774526
3866,MMP14,Collagen degradation,0.0012321783502132343,0,0,1,0.0013496971558728018
3867,MMP14,Collagen degradation,0.001009258967268796,1,0,1,0.0011055168737756844
3868,MMP14,Activation of Matrix Metalloproteinases,0.0012321783502132343,0,0,1,0.0013496971558728018
3869,MMP14,Activation of Matrix Metalloproteinases,0.001009258967268796,1,0,1,0.0011055168737756844
3870,LUM,Keratan sulfate/keratin metabolism,0.005414602445682415,0,0,1,0.0059310192553332685
3871,LUM,Keratan sulfate/keratin metabolism,0.005423042050835813,1,0,1,0.005940263786427538
3872,LUM,Diseases associated with glycosaminoglycan metabolism,0.005414602445682415,0,0,1,0.0059310192553332685
3873,LUM,Diseases associated with glycosaminoglycan metabolism,0.005423042050835813,1,0,1,0.005940263786427538
3874,LUM,Integrin cell surface interactions,0.005414602445682415,0,0,1,0.0059310192553332685
3875,LUM,Integrin cell surface interactions,0.005423042050835813,1,0,1,0.005940263786427538
3876,LUM,ECM proteoglycans,0.005414602445682415,0,0,1,0.0059310192553332685
3877,LUM,ECM proteoglycans,0.005423042050835813,1,0,1,0.005940263786427538
3878,RIDA,Threonine catabolism,0.0001589721685811271,0,0,1,0.00017413411277656963
3879,RIDA,Threonine catabolism,1.8563853873128922e-06,1,0,1,2.0334378355425915e-06
3880,CRIS3,Neutrophil degranulation,0.00010491583900383268,0,0,1,0.00011492216973701608
3881,CRIS3,Neutrophil degranulation,0.0001107839076910682,1,0,1,0.00012134990450143341
3882,HSP72,Regulation of HSF1-mediated heat shock response,0.004617391065528928,0,0,1,0.005057773972102651
3883,HSP72,Regulation of HSF1-mediated heat shock response,0.004239375447159454,1,0,1,0.004643705176866567
3884,HSP72,HSF1-dependent transactivation,0.004617391065528928,0,0,1,0.005057773972102651
3885,HSP72,HSF1-dependent transactivation,0.004239375447159454,1,0,1,0.004643705176866567
3886,HSP72,Meiotic synapsis,0.004617391065528928,0,0,1,0.005057773972102651
3887,HSP72,Meiotic synapsis,0.004239375447159454,1,0,1,0.004643705176866567
3888,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.004617391065528928,0,0,1,0.005057773972102651
3889,HSP72,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.004239375447159454,1,0,1,0.004643705176866567
3890,MFAP4,Molecules associated with elastic fibres,0.00016806014093790833,0,0,1,0.00018408884898864117
3891,MFAP4,Molecules associated with elastic fibres,0.00017217072593385052,1,0,1,0.00018859148034637967
3892,CAD13,Adherens junctions interactions,6.640474849671148e-05,0,0,1,7.273809036406941e-05
3893,CAD13,Adherens junctions interactions,4.3497558430419006e-05,1,0,1,4.764613084687599e-05
3894,DEF1,Defensins,0.002409126014061784,0,0,1,0.0026388960078349583
3895,DEF1,Defensins,0.002929717673359292,1,0,1,0.003209139010240701
3896,DEF1,Neutrophil degranulation,0.002409126014061784,0,0,1,0.0026388960078349583
3897,DEF1,Neutrophil degranulation,0.002929717673359292,1,0,1,0.003209139010240701
3898,TPIS,Glycolysis,0.0001672097718126559,0,0,1,0.00018315737604919486
3899,TPIS,Glycolysis,0.00021113246067460783,1,0,1,0.00023126918407195666
3900,TPIS,Gluconeogenesis,0.0001672097718126559,0,0,1,0.00018315737604919486
3901,TPIS,Gluconeogenesis,0.00021113246067460783,1,0,1,0.00023126918407195666
3902,MYL6,RHO GTPase Effectors,0.00033976414963109364,0,0,1,0.0003721690990149835
3903,MYL6,RHO GTPase Effectors,0.0004407366775709759,1,0,1,0.0004827718650497558
3904,MYL6,EPH-Ephrin signaling,0.00033976414963109364,0,0,1,0.0003721690990149835
3905,MYL6,EPH-Ephrin signaling,0.0004407366775709759,1,0,1,0.0004827718650497558
3906,MYL6,Semaphorin interactions,0.00033976414963109364,0,0,1,0.0003721690990149835
3907,MYL6,Semaphorin interactions,0.0004407366775709759,1,0,1,0.0004827718650497558
3908,MYL6,Smooth Muscle Contraction,0.00033976414963109364,0,0,1,0.0003721690990149835
3909,MYL6,Smooth Muscle Contraction,0.0004407366775709759,1,0,1,0.0004827718650497558
3910,ACTB,Gap junction trafficking,0.026196758315222148,0,0,1,0.028695269791928813
3911,ACTB,Gap junction trafficking,0.02196962254532677,1,0,1,0.02406497164951409
3912,ACTB,VEGFA-VEGFR2 Pathway,0.026196758315222148,0,0,1,0.028695269791928813
3913,ACTB,VEGFA-VEGFR2 Pathway,0.02196962254532677,1,0,1,0.02406497164951409
3914,ACTB,RHO GTPase Effectors,0.026196758315222148,0,0,1,0.028695269791928813
3915,ACTB,RHO GTPase Effectors,0.02196962254532677,1,0,1,0.02406497164951409
3916,ACTB,RHO GTPase cycle,0.026196758315222148,0,0,1,0.028695269791928813
3917,ACTB,RHO GTPase cycle,0.02196962254532677,1,0,1,0.02406497164951409
3918,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.026196758315222148,0,0,1,0.028695269791928813
3919,ACTB,Regulation of actin dynamics for phagocytic cup formation,0.02196962254532677,1,0,1,0.02406497164951409
3920,ACTB,EPH-Ephrin signaling,0.026196758315222148,0,0,1,0.028695269791928813
3921,ACTB,EPH-Ephrin signaling,0.02196962254532677,1,0,1,0.02406497164951409
3922,ACTB,L1CAM interactions,0.026196758315222148,0,0,1,0.028695269791928813
3923,ACTB,L1CAM interactions,0.02196962254532677,1,0,1,0.02406497164951409
3924,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.026196758315222148,0,0,1,0.028695269791928813
3925,ACTB,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.02196962254532677,1,0,1,0.02406497164951409
3926,ACTB,Adherens junctions interactions,0.026196758315222148,0,0,1,0.028695269791928813
3927,ACTB,Adherens junctions interactions,0.02196962254532677,1,0,1,0.02406497164951409
3928,ACTB,B-WICH complex positively regulates rRNA expression,0.026196758315222148,0,0,1,0.028695269791928813
3929,ACTB,B-WICH complex positively regulates rRNA expression,0.02196962254532677,1,0,1,0.02406497164951409
3930,ACTB,RAF/MAP kinase cascade,0.026196758315222148,0,0,1,0.028695269791928813
3931,ACTB,RAF/MAP kinase cascade,0.02196962254532677,1,0,1,0.02406497164951409
3932,ACTB,UCH proteinases,0.026196758315222148,0,0,1,0.028695269791928813
3933,ACTB,UCH proteinases,0.02196962254532677,1,0,1,0.02406497164951409
3934,ACTB,DNA Damage Recognition in GG-NER,0.026196758315222148,0,0,1,0.028695269791928813
3935,ACTB,DNA Damage Recognition in GG-NER,0.02196962254532677,1,0,1,0.02406497164951409
3936,ACTB,Signaling by RAS mutants,0.026196758315222148,0,0,1,0.028695269791928813
3937,ACTB,Signaling by RAS mutants,0.02196962254532677,1,0,1,0.02406497164951409
3938,ACTB,Signaling by moderate kinase activity BRAF mutants,0.026196758315222148,0,0,1,0.028695269791928813
3939,ACTB,Signaling by moderate kinase activity BRAF mutants,0.02196962254532677,1,0,1,0.02406497164951409
3940,ACTB,Signaling by high-kinase activity BRAF mutants,0.026196758315222148,0,0,1,0.028695269791928813
3941,ACTB,Signaling by high-kinase activity BRAF mutants,0.02196962254532677,1,0,1,0.02406497164951409
3942,ACTB,Signaling by BRAF and RAF1 fusions,0.026196758315222148,0,0,1,0.028695269791928813
3943,ACTB,Signaling by BRAF and RAF1 fusions,0.02196962254532677,1,0,1,0.02406497164951409
3944,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.026196758315222148,0,0,1,0.028695269791928813
3945,ACTB,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.02196962254532677,1,0,1,0.02406497164951409
3946,ACTB,Signaling by RAF1 mutants,0.026196758315222148,0,0,1,0.028695269791928813
3947,ACTB,Signaling by RAF1 mutants,0.02196962254532677,1,0,1,0.02406497164951409
3948,ACTB,Parasite infection,0.026196758315222148,0,0,1,0.028695269791928813
3949,ACTB,Parasite infection,0.02196962254532677,1,0,1,0.02406497164951409
3950,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.026196758315222148,0,0,1,0.028695269791928813
3951,ACTB,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.02196962254532677,1,0,1,0.02406497164951409
3952,ACTB,HATs acetylate histones,0.026196758315222148,0,0,1,0.028695269791928813
3953,ACTB,HATs acetylate histones,0.02196962254532677,1,0,1,0.02406497164951409
3954,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.026196758315222148,0,0,1,0.028695269791928813
3955,ACTB,Sensory processing of sound by inner hair cells of the cochlea,0.02196962254532677,1,0,1,0.02406497164951409
3956,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.026196758315222148,0,0,1,0.028695269791928813
3957,ACTB,Sensory processing of sound by outer hair cells of the cochlea,0.02196962254532677,1,0,1,0.02406497164951409
3958,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.009481900116324727,0,0,1,0.010386234766305357
3959,PSA6,Downstream signaling events of B Cell Receptor (BCR),0.012004029427106648,1,0,1,0.013148911741531136
3960,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.009481900116324727,0,0,1,0.010386234766305357
3961,PSA6,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.012004029427106648,1,0,1,0.013148911741531136
3962,PSA6,Antigen processing-Cross presentation,0.009481900116324727,0,0,1,0.010386234766305357
3963,PSA6,Antigen processing-Cross presentation,0.012004029427106648,1,0,1,0.013148911741531136
3964,PSA6,PTEN Regulation,0.009481900116324727,0,0,1,0.010386234766305357
3965,PSA6,PTEN Regulation,0.012004029427106648,1,0,1,0.013148911741531136
3966,PSA6,Host Interactions of HIV factors,0.009481900116324727,0,0,1,0.010386234766305357
3967,PSA6,Host Interactions of HIV factors,0.012004029427106648,1,0,1,0.013148911741531136
3968,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.009481900116324727,0,0,1,0.010386234766305357
3969,PSA6,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.012004029427106648,1,0,1,0.013148911741531136
3970,PSA6,APC/C-mediated degradation of cell cycle proteins,0.009481900116324727,0,0,1,0.010386234766305357
3971,PSA6,APC/C-mediated degradation of cell cycle proteins,0.012004029427106648,1,0,1,0.013148911741531136
3972,PSA6,Degradation of AXIN,0.009481900116324727,0,0,1,0.010386234766305357
3973,PSA6,Degradation of AXIN,0.012004029427106648,1,0,1,0.013148911741531136
3974,PSA6,Degradation of DVL,0.009481900116324727,0,0,1,0.010386234766305357
3975,PSA6,Degradation of DVL,0.012004029427106648,1,0,1,0.013148911741531136
3976,PSA6,Downstream TCR signaling,0.009481900116324727,0,0,1,0.010386234766305357
3977,PSA6,Downstream TCR signaling,0.012004029427106648,1,0,1,0.013148911741531136
3978,PSA6,Transcriptional regulation by RUNX3,0.009481900116324727,0,0,1,0.010386234766305357
3979,PSA6,Transcriptional regulation by RUNX3,0.012004029427106648,1,0,1,0.013148911741531136
3980,PSA6,Transcriptional regulation by RUNX2,0.009481900116324727,0,0,1,0.010386234766305357
3981,PSA6,Transcriptional regulation by RUNX2,0.012004029427106648,1,0,1,0.013148911741531136
3982,PSA6,Transcriptional regulation by RUNX1,0.009481900116324727,0,0,1,0.010386234766305357
3983,PSA6,Transcriptional regulation by RUNX1,0.012004029427106648,1,0,1,0.013148911741531136
3984,PSA6,FCERI mediated NF-kB activation,0.009481900116324727,0,0,1,0.010386234766305357
3985,PSA6,FCERI mediated NF-kB activation,0.012004029427106648,1,0,1,0.013148911741531136
3986,PSA6,Mitotic Metaphase and Anaphase,0.009481900116324727,0,0,1,0.010386234766305357
3987,PSA6,Mitotic Metaphase and Anaphase,0.012004029427106648,1,0,1,0.013148911741531136
3988,PSA6,Regulation of ornithine decarboxylase (ODC),0.009481900116324727,0,0,1,0.010386234766305357
3989,PSA6,Regulation of ornithine decarboxylase (ODC),0.012004029427106648,1,0,1,0.013148911741531136
3990,PSA6,Signaling by ROBO receptors,0.009481900116324727,0,0,1,0.010386234766305357
3991,PSA6,Signaling by ROBO receptors,0.012004029427106648,1,0,1,0.013148911741531136
3992,PSA6,PCP/CE pathway,0.009481900116324727,0,0,1,0.010386234766305357
3993,PSA6,PCP/CE pathway,0.012004029427106648,1,0,1,0.013148911741531136
3994,PSA6,Interleukin-1 family signaling,0.009481900116324727,0,0,1,0.010386234766305357
3995,PSA6,Interleukin-1 family signaling,0.012004029427106648,1,0,1,0.013148911741531136
3996,PSA6,G2/M Transition,0.009481900116324727,0,0,1,0.010386234766305357
3997,PSA6,G2/M Transition,0.012004029427106648,1,0,1,0.013148911741531136
3998,PSA6,G1/S Transition,0.009481900116324727,0,0,1,0.010386234766305357
3999,PSA6,G1/S Transition,0.012004029427106648,1,0,1,0.013148911741531136
4000,PSA6,Hh mutants are degraded by ERAD,0.009481900116324727,0,0,1,0.010386234766305357
4001,PSA6,Hh mutants are degraded by ERAD,0.012004029427106648,1,0,1,0.013148911741531136
4002,PSA6,CLEC7A (Dectin-1) signaling,0.009481900116324727,0,0,1,0.010386234766305357
4003,PSA6,CLEC7A (Dectin-1) signaling,0.012004029427106648,1,0,1,0.013148911741531136
4004,PSA6,Degradation of GLI1 by the proteasome,0.009481900116324727,0,0,1,0.010386234766305357
4005,PSA6,Degradation of GLI1 by the proteasome,0.012004029427106648,1,0,1,0.013148911741531136
4006,PSA6,Degradation of GLI2 by the proteasome,0.009481900116324727,0,0,1,0.010386234766305357
4007,PSA6,Degradation of GLI2 by the proteasome,0.012004029427106648,1,0,1,0.013148911741531136
4008,PSA6,GLI3 is processed to GLI3R by the proteasome,0.009481900116324727,0,0,1,0.010386234766305357
4009,PSA6,GLI3 is processed to GLI3R by the proteasome,0.012004029427106648,1,0,1,0.013148911741531136
4010,PSA6,Defective CFTR causes cystic fibrosis,0.009481900116324727,0,0,1,0.010386234766305357
4011,PSA6,Defective CFTR causes cystic fibrosis,0.012004029427106648,1,0,1,0.013148911741531136
4012,PSA6,NIK-->noncanonical NF-kB signaling,0.009481900116324727,0,0,1,0.010386234766305357
4013,PSA6,NIK-->noncanonical NF-kB signaling,0.012004029427106648,1,0,1,0.013148911741531136
4014,PSA6,RAF/MAP kinase cascade,0.009481900116324727,0,0,1,0.010386234766305357
4015,PSA6,RAF/MAP kinase cascade,0.012004029427106648,1,0,1,0.013148911741531136
4016,PSA6,UCH proteinases,0.009481900116324727,0,0,1,0.010386234766305357
4017,PSA6,UCH proteinases,0.012004029427106648,1,0,1,0.013148911741531136
4018,PSA6,Ub-specific processing proteases,0.009481900116324727,0,0,1,0.010386234766305357
4019,PSA6,Ub-specific processing proteases,0.012004029427106648,1,0,1,0.013148911741531136
4020,PSA6,Orc1 removal from chromatin,0.009481900116324727,0,0,1,0.010386234766305357
4021,PSA6,Orc1 removal from chromatin,0.012004029427106648,1,0,1,0.013148911741531136
4022,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.009481900116324727,0,0,1,0.010386234766305357
4023,PSA6,CDK-mediated phosphorylation and removal of Cdc6,0.012004029427106648,1,0,1,0.013148911741531136
4024,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.009481900116324727,0,0,1,0.010386234766305357
4025,PSA6,Cyclin A:Cdk2-associated events at S phase entry,0.012004029427106648,1,0,1,0.013148911741531136
4026,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.009481900116324727,0,0,1,0.010386234766305357
4027,PSA6,Ubiquitin-dependent degradation of Cyclin D,0.012004029427106648,1,0,1,0.013148911741531136
4028,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.009481900116324727,0,0,1,0.010386234766305357
4029,PSA6,p53-Dependent G1/S DNA damage checkpoint,0.012004029427106648,1,0,1,0.013148911741531136
4030,PSA6,p53-Independent G1/S DNA damage checkpoint,0.009481900116324727,0,0,1,0.010386234766305357
4031,PSA6,p53-Independent G1/S DNA damage checkpoint,0.012004029427106648,1,0,1,0.013148911741531136
4032,PSA6,Negative regulation of NOTCH4 signaling,0.009481900116324727,0,0,1,0.010386234766305357
4033,PSA6,Negative regulation of NOTCH4 signaling,0.012004029427106648,1,0,1,0.013148911741531136
4034,PSA6,KEAP1-NFE2L2 pathway,0.009481900116324727,0,0,1,0.010386234766305357
4035,PSA6,KEAP1-NFE2L2 pathway,0.012004029427106648,1,0,1,0.013148911741531136
4036,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.009481900116324727,0,0,1,0.010386234766305357
4037,PSA6,Antigen processing: Ubiquitination & Proteasome degradation,0.012004029427106648,1,0,1,0.013148911741531136
4038,PSA6,Degradation of beta-catenin by the destruction complex,0.009481900116324727,0,0,1,0.010386234766305357
4039,PSA6,Degradation of beta-catenin by the destruction complex,0.012004029427106648,1,0,1,0.013148911741531136
4040,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.009481900116324727,0,0,1,0.010386234766305357
4041,PSA6,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.012004029427106648,1,0,1,0.013148911741531136
4042,PSA6,Hedgehog ligand biogenesis,0.009481900116324727,0,0,1,0.010386234766305357
4043,PSA6,Hedgehog ligand biogenesis,0.012004029427106648,1,0,1,0.013148911741531136
4044,PSA6,Hedgehog 'on' state,0.009481900116324727,0,0,1,0.010386234766305357
4045,PSA6,Hedgehog 'on' state,0.012004029427106648,1,0,1,0.013148911741531136
4046,PSA6,MAPK6/MAPK4 signaling,0.009481900116324727,0,0,1,0.010386234766305357
4047,PSA6,MAPK6/MAPK4 signaling,0.012004029427106648,1,0,1,0.013148911741531136
4048,PSA6,Neddylation,0.009481900116324727,0,0,1,0.010386234766305357
4049,PSA6,Neddylation,0.012004029427106648,1,0,1,0.013148911741531136
4050,RAB10,RAB GEFs exchange GTP for GDP on RABs,0.00016661489601846818,0,0,1,0.0001825057640748619
4051,RAB10,RAB GEFs exchange GTP for GDP on RABs,6.044722825409709e-05,1,0,1,6.621237261702428e-05
4052,RAB10,Neutrophil degranulation,0.00016661489601846818,0,0,1,0.0001825057640748619
4053,RAB10,Neutrophil degranulation,6.044722825409709e-05,1,0,1,6.621237261702428e-05
4054,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00016661489601846818,0,0,1,0.0001825057640748619
4055,RAB10,Translocation of SLC2A4 (GLUT4) to the plasma membrane,6.044722825409709e-05,1,0,1,6.621237261702428e-05
4056,RAB10,RAB geranylgeranylation,0.00016661489601846818,0,0,1,0.0001825057640748619
4057,RAB10,RAB geranylgeranylation,6.044722825409709e-05,1,0,1,6.621237261702428e-05
4058,LYSC,Neutrophil degranulation,0.005425685232666677,0,0,1,0.005943159061286858
4059,LYSC,Neutrophil degranulation,0.005772669938619286,1,0,1,0.006323237375984199
4060,LYSC,Amyloid fiber formation,0.005425685232666677,0,0,1,0.005943159061286858
4061,LYSC,Amyloid fiber formation,0.005772669938619286,1,0,1,0.006323237375984199
4062,B2MG,Antigen processing-Cross presentation,0.009163780090048807,0,0,1,0.010037774095318495
4063,B2MG,Antigen processing-Cross presentation,0.009539257598377386,1,0,1,0.010449062708689756
4064,B2MG,Host Interactions of HIV factors,0.009163780090048807,0,0,1,0.010037774095318495
4065,B2MG,Host Interactions of HIV factors,0.009539257598377386,1,0,1,0.010449062708689756
4066,B2MG,DAP12 signaling,0.009163780090048807,0,0,1,0.010037774095318495
4067,B2MG,DAP12 signaling,0.009539257598377386,1,0,1,0.010449062708689756
4068,B2MG,Interferon gamma signaling,0.009163780090048807,0,0,1,0.010037774095318495
4069,B2MG,Interferon gamma signaling,0.009539257598377386,1,0,1,0.010449062708689756
4070,B2MG,Modulation by Mtb of host immune system,0.009163780090048807,0,0,1,0.010037774095318495
4071,B2MG,Modulation by Mtb of host immune system,0.009539257598377386,1,0,1,0.010449062708689756
4072,B2MG,SARS-CoV-2 Infection,0.009163780090048807,0,0,1,0.010037774095318495
4073,B2MG,SARS-CoV-2 Infection,0.009539257598377386,1,0,1,0.010449062708689756
4074,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.009163780090048807,0,0,1,0.010037774095318495
4075,B2MG,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",0.009539257598377386,1,0,1,0.010449062708689756
4076,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009163780090048807,0,0,1,0.010037774095318495
4077,B2MG,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.009539257598377386,1,0,1,0.010449062708689756
4078,B2MG,Neutrophil degranulation,0.009163780090048807,0,0,1,0.010037774095318495
4079,B2MG,Neutrophil degranulation,0.009539257598377386,1,0,1,0.010449062708689756
4080,B2MG,Amyloid fiber formation,0.009163780090048807,0,0,1,0.010037774095318495
4081,B2MG,Amyloid fiber formation,0.009539257598377386,1,0,1,0.010449062708689756
4082,NPC2,LDL clearance,0.0014603426025501986,0,0,1,0.0015996225359103204
4083,NPC2,LDL clearance,0.001199795831577512,1,0,1,0.0013142261598963923
4084,NPC2,Neutrophil degranulation,0.0014603426025501986,0,0,1,0.0015996225359103204
4085,NPC2,Neutrophil degranulation,0.001199795831577512,1,0,1,0.0013142261598963923
4086,1433G,Activation of BH3-only proteins,0.005298360831784982,0,0,1,0.005803691116801798
4087,1433G,Activation of BH3-only proteins,0.005523408335860497,1,0,1,0.0060502024892296865
4088,1433G,RHO GTPase Effectors,0.005298360831784982,0,0,1,0.005803691116801798
4089,1433G,RHO GTPase Effectors,0.005523408335860497,1,0,1,0.0060502024892296865
4090,1433G,Transcriptional Regulation by TP53,0.005298360831784982,0,0,1,0.005803691116801798
4091,1433G,Transcriptional Regulation by TP53,0.005523408335860497,1,0,1,0.0060502024892296865
4092,1433G,FOXO-mediated transcription,0.005298360831784982,0,0,1,0.005803691116801798
4093,1433G,FOXO-mediated transcription,0.005523408335860497,1,0,1,0.0060502024892296865
4094,1433G,G2/M Transition,0.005298360831784982,0,0,1,0.005803691116801798
4095,1433G,G2/M Transition,0.005523408335860497,1,0,1,0.0060502024892296865
4096,1433G,Mitotic Prometaphase,0.005298360831784982,0,0,1,0.005803691116801798
4097,1433G,Mitotic Prometaphase,0.005523408335860497,1,0,1,0.0060502024892296865
4098,1433G,G2/M DNA damage checkpoint,0.005298360831784982,0,0,1,0.005803691116801798
4099,1433G,G2/M DNA damage checkpoint,0.005523408335860497,1,0,1,0.0060502024892296865
4100,1433G,SARS-CoV-2 Infection,0.005298360831784982,0,0,1,0.005803691116801798
4101,1433G,SARS-CoV-2 Infection,0.005523408335860497,1,0,1,0.0060502024892296865
4102,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.005298360831784982,0,0,1,0.005803691116801798
4103,1433G,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.005523408335860497,1,0,1,0.0060502024892296865
4104,1433G,Anchoring of the basal body to the plasma membrane,0.005298360831784982,0,0,1,0.005803691116801798
4105,1433G,Anchoring of the basal body to the plasma membrane,0.005523408335860497,1,0,1,0.0060502024892296865
4106,1433E,Activation of BH3-only proteins,0.004538700321386686,0,0,1,0.0049715781112973385
4107,1433E,Activation of BH3-only proteins,0.00406816646191977,1,0,1,0.00445616716307345
4108,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.004538700321386686,0,0,1,0.0049715781112973385
4109,1433E,"Cell death signalling via NRAGE, NRIF and NADE",0.00406816646191977,1,0,1,0.00445616716307345
4110,1433E,RHO GTPase Effectors,0.004538700321386686,0,0,1,0.0049715781112973385
4111,1433E,RHO GTPase Effectors,0.00406816646191977,1,0,1,0.00445616716307345
4112,1433E,Transcriptional Regulation by TP53,0.004538700321386686,0,0,1,0.0049715781112973385
4113,1433E,Transcriptional Regulation by TP53,0.00406816646191977,1,0,1,0.00445616716307345
4114,1433E,Regulation of HSF1-mediated heat shock response,0.004538700321386686,0,0,1,0.0049715781112973385
4115,1433E,Regulation of HSF1-mediated heat shock response,0.00406816646191977,1,0,1,0.00445616716307345
4116,1433E,HSF1 activation,0.004538700321386686,0,0,1,0.0049715781112973385
4117,1433E,HSF1 activation,0.00406816646191977,1,0,1,0.00445616716307345
4118,1433E,G2/M Transition,0.004538700321386686,0,0,1,0.0049715781112973385
4119,1433E,G2/M Transition,0.00406816646191977,1,0,1,0.00445616716307345
4120,1433E,Mitotic Prometaphase,0.004538700321386686,0,0,1,0.0049715781112973385
4121,1433E,Mitotic Prometaphase,0.00406816646191977,1,0,1,0.00445616716307345
4122,1433E,G2/M DNA damage checkpoint,0.004538700321386686,0,0,1,0.0049715781112973385
4123,1433E,G2/M DNA damage checkpoint,0.00406816646191977,1,0,1,0.00445616716307345
4124,1433E,Neurodegenerative Diseases,0.004538700321386686,0,0,1,0.0049715781112973385
4125,1433E,Neurodegenerative Diseases,0.00406816646191977,1,0,1,0.00445616716307345
4126,1433E,RAB GEFs exchange GTP for GDP on RABs,0.004538700321386686,0,0,1,0.0049715781112973385
4127,1433E,RAB GEFs exchange GTP for GDP on RABs,0.00406816646191977,1,0,1,0.00445616716307345
4128,1433E,SARS-CoV-2 Infection,0.004538700321386686,0,0,1,0.0049715781112973385
4129,1433E,SARS-CoV-2 Infection,0.00406816646191977,1,0,1,0.00445616716307345
4130,1433E,Signaling by Hippo,0.004538700321386686,0,0,1,0.0049715781112973385
4131,1433E,Signaling by Hippo,0.00406816646191977,1,0,1,0.00445616716307345
4132,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.004538700321386686,0,0,1,0.0049715781112973385
4133,1433E,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00406816646191977,1,0,1,0.00445616716307345
4134,1433E,Anchoring of the basal body to the plasma membrane,0.004538700321386686,0,0,1,0.0049715781112973385
4135,1433E,Anchoring of the basal body to the plasma membrane,0.00406816646191977,1,0,1,0.00445616716307345
4136,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.004080143842227625,0,0,1,0.004469286884040404
4137,ACTA,NOTCH4 Intracellular Domain Regulates Transcription,0.004208064376586944,1,0,1,0.004609407818134582
4138,ACTA,Smooth Muscle Contraction,0.004080143842227625,0,0,1,0.004469286884040404
4139,ACTA,Smooth Muscle Contraction,0.004208064376586944,1,0,1,0.004609407818134582
4140,H4,Packaging Of Telomere Ends,0.0004089670512793266,0,0,1,0.0004479722159230199
4141,H4,Packaging Of Telomere Ends,0.0005623928264206227,1,0,1,0.0006160309489059128
4142,H4,Inhibition of DNA recombination at telomere,0.0004089670512793266,0,0,1,0.0004479722159230199
4143,H4,Inhibition of DNA recombination at telomere,0.0005623928264206227,1,0,1,0.0006160309489059128
4144,H4,Pre-NOTCH Transcription and Translation,0.0004089670512793266,0,0,1,0.0004479722159230199
4145,H4,Pre-NOTCH Transcription and Translation,0.0005623928264206227,1,0,1,0.0006160309489059128
4146,H4,RHO GTPase Effectors,0.0004089670512793266,0,0,1,0.0004479722159230199
4147,H4,RHO GTPase Effectors,0.0005623928264206227,1,0,1,0.0006160309489059128
4148,H4,Formation of the beta-catenin:TCF transactivating complex,0.0004089670512793266,0,0,1,0.0004479722159230199
4149,H4,Formation of the beta-catenin:TCF transactivating complex,0.0005623928264206227,1,0,1,0.0006160309489059128
4150,H4,Transcriptional regulation by RUNX1,0.0004089670512793266,0,0,1,0.0004479722159230199
4151,H4,Transcriptional regulation by RUNX1,0.0005623928264206227,1,0,1,0.0006160309489059128
4152,H4,Oxidative Stress Induced Senescence,0.0004089670512793266,0,0,1,0.0004479722159230199
4153,H4,Oxidative Stress Induced Senescence,0.0005623928264206227,1,0,1,0.0006160309489059128
4154,H4,Senescence-Associated Secretory Phenotype (SASP),0.0004089670512793266,0,0,1,0.0004479722159230199
4155,H4,Senescence-Associated Secretory Phenotype (SASP),0.0005623928264206227,1,0,1,0.0006160309489059128
4156,H4,DNA Damage/Telomere Stress Induced Senescence,0.0004089670512793266,0,0,1,0.0004479722159230199
4157,H4,DNA Damage/Telomere Stress Induced Senescence,0.0005623928264206227,1,0,1,0.0006160309489059128
4158,H4,SUMO E3 ligases SUMOylate target proteins,0.0004089670512793266,0,0,1,0.0004479722159230199
4159,H4,SUMO E3 ligases SUMOylate target proteins,0.0005623928264206227,1,0,1,0.0006160309489059128
4160,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0004089670512793266,0,0,1,0.0004479722159230199
4161,H4,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0005623928264206227,1,0,1,0.0006160309489059128
4162,H4,B-WICH complex positively regulates rRNA expression,0.0004089670512793266,0,0,1,0.0004479722159230199
4163,H4,B-WICH complex positively regulates rRNA expression,0.0005623928264206227,1,0,1,0.0006160309489059128
4164,H4,SIRT1 negatively regulates rRNA expression,0.0004089670512793266,0,0,1,0.0004479722159230199
4165,H4,SIRT1 negatively regulates rRNA expression,0.0005623928264206227,1,0,1,0.0006160309489059128
4166,H4,NoRC negatively regulates rRNA expression,0.0004089670512793266,0,0,1,0.0004479722159230199
4167,H4,NoRC negatively regulates rRNA expression,0.0005623928264206227,1,0,1,0.0006160309489059128
4168,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0004089670512793266,0,0,1,0.0004479722159230199
4169,H4,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0005623928264206227,1,0,1,0.0006160309489059128
4170,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0004089670512793266,0,0,1,0.0004479722159230199
4171,H4,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0005623928264206227,1,0,1,0.0006160309489059128
4172,H4,Assembly of the ORC complex at the origin of replication,0.0004089670512793266,0,0,1,0.0004479722159230199
4173,H4,Assembly of the ORC complex at the origin of replication,0.0005623928264206227,1,0,1,0.0006160309489059128
4174,H4,Mitotic Prophase,0.0004089670512793266,0,0,1,0.0004479722159230199
4175,H4,Mitotic Prophase,0.0005623928264206227,1,0,1,0.0006160309489059128
4176,H4,G2/M DNA damage checkpoint,0.0004089670512793266,0,0,1,0.0004479722159230199
4177,H4,G2/M DNA damage checkpoint,0.0005623928264206227,1,0,1,0.0006160309489059128
4178,H4,RNA Polymerase I Promoter Opening,0.0004089670512793266,0,0,1,0.0004479722159230199
4179,H4,RNA Polymerase I Promoter Opening,0.0005623928264206227,1,0,1,0.0006160309489059128
4180,H4,RNA Polymerase I Promoter Escape,0.0004089670512793266,0,0,1,0.0004479722159230199
4181,H4,RNA Polymerase I Promoter Escape,0.0005623928264206227,1,0,1,0.0006160309489059128
4182,H4,Depurination,0.0004089670512793266,0,0,1,0.0004479722159230199
4183,H4,Depurination,0.0005623928264206227,1,0,1,0.0006160309489059128
4184,H4,Depyrimidination,0.0004089670512793266,0,0,1,0.0004479722159230199
4185,H4,Depyrimidination,0.0005623928264206227,1,0,1,0.0006160309489059128
4186,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.0004089670512793266,0,0,1,0.0004479722159230199
4187,H4,Deposition of new CENPA-containing nucleosomes at the centromere,0.0005623928264206227,1,0,1,0.0006160309489059128
4188,H4,Estrogen-dependent gene expression,0.0004089670512793266,0,0,1,0.0004479722159230199
4189,H4,Estrogen-dependent gene expression,0.0005623928264206227,1,0,1,0.0006160309489059128
4190,H4,HCMV Early Events,0.0004089670512793266,0,0,1,0.0004479722159230199
4191,H4,HCMV Early Events,0.0005623928264206227,1,0,1,0.0006160309489059128
4192,H4,HCMV Late Events,0.0004089670512793266,0,0,1,0.0004479722159230199
4193,H4,HCMV Late Events,0.0005623928264206227,1,0,1,0.0006160309489059128
4194,H4,Transcriptional regulation of granulopoiesis,0.0004089670512793266,0,0,1,0.0004479722159230199
4195,H4,Transcriptional regulation of granulopoiesis,0.0005623928264206227,1,0,1,0.0006160309489059128
4196,H4,Meiotic synapsis,0.0004089670512793266,0,0,1,0.0004479722159230199
4197,H4,Meiotic synapsis,0.0005623928264206227,1,0,1,0.0006160309489059128
4198,H4,Meiotic recombination,0.0004089670512793266,0,0,1,0.0004479722159230199
4199,H4,Meiotic recombination,0.0005623928264206227,1,0,1,0.0006160309489059128
4200,H4,Transcriptional regulation by small RNAs,0.0004089670512793266,0,0,1,0.0004479722159230199
4201,H4,Transcriptional regulation by small RNAs,0.0005623928264206227,1,0,1,0.0006160309489059128
4202,H4,PRC2 methylates histones and DNA,0.0004089670512793266,0,0,1,0.0004479722159230199
4203,H4,PRC2 methylates histones and DNA,0.0005623928264206227,1,0,1,0.0006160309489059128
4204,H4,DNA methylation,0.0004089670512793266,0,0,1,0.0004479722159230199
4205,H4,DNA methylation,0.0005623928264206227,1,0,1,0.0006160309489059128
4206,H4,HDACs deacetylate histones,0.0004089670512793266,0,0,1,0.0004479722159230199
4207,H4,HDACs deacetylate histones,0.0005623928264206227,1,0,1,0.0006160309489059128
4208,H4,PKMTs methylate histone lysines,0.0004089670512793266,0,0,1,0.0004479722159230199
4209,H4,PKMTs methylate histone lysines,0.0005623928264206227,1,0,1,0.0006160309489059128
4210,H4,HDMs demethylate histones,0.0004089670512793266,0,0,1,0.0004479722159230199
4211,H4,HDMs demethylate histones,0.0005623928264206227,1,0,1,0.0006160309489059128
4212,H4,HATs acetylate histones,0.0004089670512793266,0,0,1,0.0004479722159230199
4213,H4,HATs acetylate histones,0.0005623928264206227,1,0,1,0.0006160309489059128
4214,H4,RMTs methylate histone arginines,0.0004089670512793266,0,0,1,0.0004479722159230199
4215,H4,RMTs methylate histone arginines,0.0005623928264206227,1,0,1,0.0006160309489059128
4216,H4,Amyloid fiber formation,0.0004089670512793266,0,0,1,0.0004479722159230199
4217,H4,Amyloid fiber formation,0.0005623928264206227,1,0,1,0.0006160309489059128
4218,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0004089670512793266,0,0,1,0.0004479722159230199
4219,H4,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0005623928264206227,1,0,1,0.0006160309489059128
4220,H4,Nonhomologous End-Joining (NHEJ),0.0004089670512793266,0,0,1,0.0004479722159230199
4221,H4,Nonhomologous End-Joining (NHEJ),0.0005623928264206227,1,0,1,0.0006160309489059128
4222,H4,Defective pyroptosis,0.0004089670512793266,0,0,1,0.0004479722159230199
4223,H4,Defective pyroptosis,0.0005623928264206227,1,0,1,0.0006160309489059128
4224,RAP1A,Signaling by NTRK1 (TRKA),0.005873052866628327,0,0,1,0.006433194309092578
4225,RAP1A,Signaling by NTRK1 (TRKA),0.004638873008765318,1,0,1,0.005081304752110073
4226,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.005873052866628327,0,0,1,0.006433194309092578
4227,RAP1A,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,0.004638873008765318,1,0,1,0.005081304752110073
4228,RAP1A,RAF/MAP kinase cascade,0.005873052866628327,0,0,1,0.006433194309092578
4229,RAP1A,RAF/MAP kinase cascade,0.004638873008765318,1,0,1,0.005081304752110073
4230,RAP1A,Signaling by RAS mutants,0.005873052866628327,0,0,1,0.006433194309092578
4231,RAP1A,Signaling by RAS mutants,0.004638873008765318,1,0,1,0.005081304752110073
4232,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.005873052866628327,0,0,1,0.006433194309092578
4233,RAP1A,Signaling by moderate kinase activity BRAF mutants,0.004638873008765318,1,0,1,0.005081304752110073
4234,RAP1A,Signaling by high-kinase activity BRAF mutants,0.005873052866628327,0,0,1,0.006433194309092578
4235,RAP1A,Signaling by high-kinase activity BRAF mutants,0.004638873008765318,1,0,1,0.005081304752110073
4236,RAP1A,Signaling by BRAF and RAF1 fusions,0.005873052866628327,0,0,1,0.006433194309092578
4237,RAP1A,Signaling by BRAF and RAF1 fusions,0.004638873008765318,1,0,1,0.005081304752110073
4238,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.005873052866628327,0,0,1,0.006433194309092578
4239,RAP1A,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.004638873008765318,1,0,1,0.005081304752110073
4240,RAP1A,Signaling by RAF1 mutants,0.005873052866628327,0,0,1,0.006433194309092578
4241,RAP1A,Signaling by RAF1 mutants,0.004638873008765318,1,0,1,0.005081304752110073
4242,RAP1A,MET promotes cell motility,0.005873052866628327,0,0,1,0.006433194309092578
4243,RAP1A,MET promotes cell motility,0.004638873008765318,1,0,1,0.005081304752110073
4244,RAP1A,Rap1 signalling,0.005873052866628327,0,0,1,0.006433194309092578
4245,RAP1A,Rap1 signalling,0.004638873008765318,1,0,1,0.005081304752110073
4246,RAP1A,Neutrophil degranulation,0.005873052866628327,0,0,1,0.006433194309092578
4247,RAP1A,Neutrophil degranulation,0.004638873008765318,1,0,1,0.005081304752110073
4248,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.005873052866628327,0,0,1,0.006433194309092578
4249,RAP1A,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.004638873008765318,1,0,1,0.005081304752110073
4250,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.005873052866628327,0,0,1,0.006433194309092578
4251,RAP1A,p130Cas linkage to MAPK signaling for integrins,0.004638873008765318,1,0,1,0.005081304752110073
4252,PPIA,Downstream signaling events of B Cell Receptor (BCR),0.0004694945774705038,0,0,1,0.000514272544879547
4253,PPIA,Downstream signaling events of B Cell Receptor (BCR),0.0005809859292750687,1,0,1,0.0006363973658593947
4254,PPIA,HIV Life Cycle,0.0004694945774705038,0,0,1,0.000514272544879547
4255,PPIA,HIV Life Cycle,0.0005809859292750687,1,0,1,0.0006363973658593947
4256,PPIA,Host Interactions of HIV factors,0.0004694945774705038,0,0,1,0.000514272544879547
4257,PPIA,Host Interactions of HIV factors,0.0005809859292750687,1,0,1,0.0006363973658593947
4258,PPIA,Interleukin-12 family signaling,0.0004694945774705038,0,0,1,0.000514272544879547
4259,PPIA,Interleukin-12 family signaling,0.0005809859292750687,1,0,1,0.0006363973658593947
4260,PPIA,Platelet degranulation ,0.0004694945774705038,0,0,1,0.000514272544879547
4261,PPIA,Platelet degranulation ,0.0005809859292750687,1,0,1,0.0006363973658593947
4262,PPIA,Neutrophil degranulation,0.0004694945774705038,0,0,1,0.000514272544879547
4263,PPIA,Neutrophil degranulation,0.0005809859292750687,1,0,1,0.0006363973658593947
4264,PPIA,Basigin interactions,0.0004694945774705038,0,0,1,0.000514272544879547
4265,PPIA,Basigin interactions,0.0005809859292750687,1,0,1,0.0006363973658593947
4266,1433Z,Activation of BH3-only proteins,0.0013951244753780852,0,0,1,0.001528184240682751
4267,1433Z,Activation of BH3-only proteins,0.0020261734169040664,1,0,1,0.0022194193702780437
4268,1433Z,RHO GTPase Effectors,0.0013951244753780852,0,0,1,0.001528184240682751
4269,1433Z,RHO GTPase Effectors,0.0020261734169040664,1,0,1,0.0022194193702780437
4270,1433Z,Deactivation of the beta-catenin transactivating complex,0.0013951244753780852,0,0,1,0.001528184240682751
4271,1433Z,Deactivation of the beta-catenin transactivating complex,0.0020261734169040664,1,0,1,0.0022194193702780437
4272,1433Z,Transcriptional Regulation by TP53,0.0013951244753780852,0,0,1,0.001528184240682751
4273,1433Z,Transcriptional Regulation by TP53,0.0020261734169040664,1,0,1,0.0022194193702780437
4274,1433Z,FOXO-mediated transcription,0.0013951244753780852,0,0,1,0.001528184240682751
4275,1433Z,FOXO-mediated transcription,0.0020261734169040664,1,0,1,0.0022194193702780437
4276,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.0013951244753780852,0,0,1,0.001528184240682751
4277,1433Z,"Interleukin-3, Interleukin-5 and GM-CSF signaling",0.0020261734169040664,1,0,1,0.0022194193702780437
4278,1433Z,G2/M DNA damage checkpoint,0.0013951244753780852,0,0,1,0.001528184240682751
4279,1433Z,G2/M DNA damage checkpoint,0.0020261734169040664,1,0,1,0.0022194193702780437
4280,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.0013951244753780852,0,0,1,0.001528184240682751
4281,1433Z,NOTCH4 Activation and Transmission of Signal to the Nucleus,0.0020261734169040664,1,0,1,0.0022194193702780437
4282,1433Z,Negative regulation of NOTCH4 signaling,0.0013951244753780852,0,0,1,0.001528184240682751
4283,1433Z,Negative regulation of NOTCH4 signaling,0.0020261734169040664,1,0,1,0.0022194193702780437
4284,1433Z,SARS-CoV-2 Infection,0.0013951244753780852,0,0,1,0.001528184240682751
4285,1433Z,SARS-CoV-2 Infection,0.0020261734169040664,1,0,1,0.0022194193702780437
4286,1433Z,Rap1 signalling,0.0013951244753780852,0,0,1,0.001528184240682751
4287,1433Z,Rap1 signalling,0.0020261734169040664,1,0,1,0.0022194193702780437
4288,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0013951244753780852,0,0,1,0.001528184240682751
4289,1433Z,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0020261734169040664,1,0,1,0.0022194193702780437
4290,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.0013951244753780852,0,0,1,0.001528184240682751
4291,1433Z,KSRP (KHSRP) binds and destabilizes mRNA,0.0020261734169040664,1,0,1,0.0022194193702780437
4292,1433Z,GP1b-IX-V activation signalling,0.0013951244753780852,0,0,1,0.001528184240682751
4293,1433Z,GP1b-IX-V activation signalling,0.0020261734169040664,1,0,1,0.0022194193702780437
4294,TPM4,RHO GTPase cycle,0.0021693674740523366,0,0,1,0.002376270536862379
4295,TPM4,RHO GTPase cycle,0.0026946090106251958,1,0,1,0.002951606897816917
4296,TPM4,Signaling by ALK fusions and activated point mutants,0.0021693674740523366,0,0,1,0.002376270536862379
4297,TPM4,Signaling by ALK fusions and activated point mutants,0.0026946090106251958,1,0,1,0.002951606897816917
4298,TPM4,Striated Muscle Contraction,0.0021693674740523366,0,0,1,0.002376270536862379
4299,TPM4,Striated Muscle Contraction,0.0026946090106251958,1,0,1,0.002951606897816917
4300,TPM4,Smooth Muscle Contraction,0.0021693674740523366,0,0,1,0.002376270536862379
4301,TPM4,Smooth Muscle Contraction,0.0026946090106251958,1,0,1,0.002951606897816917
4302,TBA1B,Activation of NMDA receptors and postsynaptic events,0.004457260854305879,0,0,1,0.004882371368559373
4303,TBA1B,Activation of NMDA receptors and postsynaptic events,0.004540155192619653,1,0,1,0.0049731717406326995
4304,TBA1B,Gap junction trafficking,0.004457260854305879,0,0,1,0.004882371368559373
4305,TBA1B,Gap junction trafficking,0.004540155192619653,1,0,1,0.0049731717406326995
4306,TBA1B,RHO GTPase Effectors,0.004457260854305879,0,0,1,0.004882371368559373
4307,TBA1B,RHO GTPase Effectors,0.004540155192619653,1,0,1,0.0049731717406326995
4308,TBA1B,RHO GTPase cycle,0.004457260854305879,0,0,1,0.004882371368559373
4309,TBA1B,RHO GTPase cycle,0.004540155192619653,1,0,1,0.0049731717406326995
4310,TBA1B,COPI-mediated anterograde transport,0.004457260854305879,0,0,1,0.004882371368559373
4311,TBA1B,COPI-mediated anterograde transport,0.004540155192619653,1,0,1,0.0049731717406326995
4312,TBA1B,Mitotic Metaphase and Anaphase,0.004457260854305879,0,0,1,0.004882371368559373
4313,TBA1B,Mitotic Metaphase and Anaphase,0.004540155192619653,1,0,1,0.0049731717406326995
4314,TBA1B,L1CAM interactions,0.004457260854305879,0,0,1,0.004882371368559373
4315,TBA1B,L1CAM interactions,0.004540155192619653,1,0,1,0.0049731717406326995
4316,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.004457260854305879,0,0,1,0.004882371368559373
4317,TBA1B,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.004540155192619653,1,0,1,0.0049731717406326995
4318,TBA1B,G2/M Transition,0.004457260854305879,0,0,1,0.004882371368559373
4319,TBA1B,G2/M Transition,0.004540155192619653,1,0,1,0.0049731717406326995
4320,TBA1B,Golgi-to-ER retrograde transport,0.004457260854305879,0,0,1,0.004882371368559373
4321,TBA1B,Golgi-to-ER retrograde transport,0.004540155192619653,1,0,1,0.0049731717406326995
4322,TBA1B,Mitotic Prometaphase,0.004457260854305879,0,0,1,0.004882371368559373
4323,TBA1B,Mitotic Prometaphase,0.004540155192619653,1,0,1,0.0049731717406326995
4324,TBA1B,HCMV Early Events,0.004457260854305879,0,0,1,0.004882371368559373
4325,TBA1B,HCMV Early Events,0.004540155192619653,1,0,1,0.0049731717406326995
4326,TBA1B,Aggrephagy,0.004457260854305879,0,0,1,0.004882371368559373
4327,TBA1B,Aggrephagy,0.004540155192619653,1,0,1,0.0049731717406326995
4328,TBA1B,MHC class II antigen presentation,0.004457260854305879,0,0,1,0.004882371368559373
4329,TBA1B,MHC class II antigen presentation,0.004540155192619653,1,0,1,0.0049731717406326995
4330,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.004457260854305879,0,0,1,0.004882371368559373
4331,TBA1B,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.004540155192619653,1,0,1,0.0049731717406326995
4332,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.004457260854305879,0,0,1,0.004882371368559373
4333,TBA1B,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.004540155192619653,1,0,1,0.0049731717406326995
4334,TBA1B,Post-chaperonin tubulin folding pathway,0.004457260854305879,0,0,1,0.004882371368559373
4335,TBA1B,Post-chaperonin tubulin folding pathway,0.004540155192619653,1,0,1,0.0049731717406326995
4336,TBA1B,Intraflagellar transport,0.004457260854305879,0,0,1,0.004882371368559373
4337,TBA1B,Intraflagellar transport,0.004540155192619653,1,0,1,0.0049731717406326995
4338,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.004457260854305879,0,0,1,0.004882371368559373
4339,TBA1B,Carboxyterminal post-translational modifications of tubulin,0.004540155192619653,1,0,1,0.0049731717406326995
4340,TBA1B,Kinesins,0.004457260854305879,0,0,1,0.004882371368559373
4341,TBA1B,Kinesins,0.004540155192619653,1,0,1,0.0049731717406326995
4342,TBA4A,Activation of NMDA receptors and postsynaptic events,0.00014369077259662998,0,0,1,0.00015739525618614785
4343,TBA4A,Activation of NMDA receptors and postsynaptic events,0.00011815742785820291,1,0,1,0.00012942667293080098
4344,TBA4A,Gap junction trafficking,0.00014369077259662998,0,0,1,0.00015739525618614785
4345,TBA4A,Gap junction trafficking,0.00011815742785820291,1,0,1,0.00012942667293080098
4346,TBA4A,RHO GTPase Effectors,0.00014369077259662998,0,0,1,0.00015739525618614785
4347,TBA4A,RHO GTPase Effectors,0.00011815742785820291,1,0,1,0.00012942667293080098
4348,TBA4A,COPI-mediated anterograde transport,0.00014369077259662998,0,0,1,0.00015739525618614785
4349,TBA4A,COPI-mediated anterograde transport,0.00011815742785820291,1,0,1,0.00012942667293080098
4350,TBA4A,Mitotic Metaphase and Anaphase,0.00014369077259662998,0,0,1,0.00015739525618614785
4351,TBA4A,Mitotic Metaphase and Anaphase,0.00011815742785820291,1,0,1,0.00012942667293080098
4352,TBA4A,L1CAM interactions,0.00014369077259662998,0,0,1,0.00015739525618614785
4353,TBA4A,L1CAM interactions,0.00011815742785820291,1,0,1,0.00012942667293080098
4354,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.00014369077259662998,0,0,1,0.00015739525618614785
4355,TBA4A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.00011815742785820291,1,0,1,0.00012942667293080098
4356,TBA4A,G2/M Transition,0.00014369077259662998,0,0,1,0.00015739525618614785
4357,TBA4A,G2/M Transition,0.00011815742785820291,1,0,1,0.00012942667293080098
4358,TBA4A,Golgi-to-ER retrograde transport,0.00014369077259662998,0,0,1,0.00015739525618614785
4359,TBA4A,Golgi-to-ER retrograde transport,0.00011815742785820291,1,0,1,0.00012942667293080098
4360,TBA4A,Mitotic Prometaphase,0.00014369077259662998,0,0,1,0.00015739525618614785
4361,TBA4A,Mitotic Prometaphase,0.00011815742785820291,1,0,1,0.00012942667293080098
4362,TBA4A,Platelet degranulation ,0.00014369077259662998,0,0,1,0.00015739525618614785
4363,TBA4A,Platelet degranulation ,0.00011815742785820291,1,0,1,0.00012942667293080098
4364,TBA4A,HCMV Early Events,0.00014369077259662998,0,0,1,0.00015739525618614785
4365,TBA4A,HCMV Early Events,0.00011815742785820291,1,0,1,0.00012942667293080098
4366,TBA4A,Aggrephagy,0.00014369077259662998,0,0,1,0.00015739525618614785
4367,TBA4A,Aggrephagy,0.00011815742785820291,1,0,1,0.00012942667293080098
4368,TBA4A,MHC class II antigen presentation,0.00014369077259662998,0,0,1,0.00015739525618614785
4369,TBA4A,MHC class II antigen presentation,0.00011815742785820291,1,0,1,0.00012942667293080098
4370,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00014369077259662998,0,0,1,0.00015739525618614785
4371,TBA4A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.00011815742785820291,1,0,1,0.00012942667293080098
4372,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00014369077259662998,0,0,1,0.00015739525618614785
4373,TBA4A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.00011815742785820291,1,0,1,0.00012942667293080098
4374,TBA4A,Post-chaperonin tubulin folding pathway,0.00014369077259662998,0,0,1,0.00015739525618614785
4375,TBA4A,Post-chaperonin tubulin folding pathway,0.00011815742785820291,1,0,1,0.00012942667293080098
4376,TBA4A,Anchoring of the basal body to the plasma membrane,0.00014369077259662998,0,0,1,0.00015739525618614785
4377,TBA4A,Anchoring of the basal body to the plasma membrane,0.00011815742785820291,1,0,1,0.00012942667293080098
4378,TBA4A,Intraflagellar transport,0.00014369077259662998,0,0,1,0.00015739525618614785
4379,TBA4A,Intraflagellar transport,0.00011815742785820291,1,0,1,0.00012942667293080098
4380,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.00014369077259662998,0,0,1,0.00015739525618614785
4381,TBA4A,Carboxyterminal post-translational modifications of tubulin,0.00011815742785820291,1,0,1,0.00012942667293080098
4382,TBA4A,Kinesins,0.00014369077259662998,0,0,1,0.00015739525618614785
4383,TBA4A,Kinesins,0.00011815742785820291,1,0,1,0.00012942667293080098
4384,HBB,Cytoprotection by HMOX1,0.016687057425192945,0,0,1,0.018278582757740726
4385,HBB,Cytoprotection by HMOX1,0.01882372446947889,1,0,1,0.020619034066774698
4386,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.016687057425192945,0,0,1,0.018278582757740726
4387,HBB,Erythrocytes take up carbon dioxide and release oxygen,0.01882372446947889,1,0,1,0.020619034066774698
4388,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.016687057425192945,0,0,1,0.018278582757740726
4389,HBB,Erythrocytes take up oxygen and release carbon dioxide,0.01882372446947889,1,0,1,0.020619034066774698
4390,HBB,Neutrophil degranulation,0.016687057425192945,0,0,1,0.018278582757740726
4391,HBB,Neutrophil degranulation,0.01882372446947889,1,0,1,0.020619034066774698
4392,HBB,Scavenging of heme from plasma,0.016687057425192945,0,0,1,0.018278582757740726
4393,HBB,Scavenging of heme from plasma,0.01882372446947889,1,0,1,0.020619034066774698
4394,HBB,Heme signaling,0.016687057425192945,0,0,1,0.018278582757740726
4395,HBB,Heme signaling,0.01882372446947889,1,0,1,0.020619034066774698
4396,HBB,Chaperone Mediated Autophagy,0.016687057425192945,0,0,1,0.018278582757740726
4397,HBB,Chaperone Mediated Autophagy,0.01882372446947889,1,0,1,0.020619034066774698
4398,HBB,Late endosomal microautophagy,0.016687057425192945,0,0,1,0.018278582757740726
4399,HBB,Late endosomal microautophagy,0.01882372446947889,1,0,1,0.020619034066774698
4400,HBA,Cytoprotection by HMOX1,0.0015227591334154439,0,0,1,0.001667992033048206
4401,HBA,Cytoprotection by HMOX1,0.0009698316069047825,1,0,1,0.0010623291354603082
4402,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.0015227591334154439,0,0,1,0.001667992033048206
4403,HBA,Erythrocytes take up carbon dioxide and release oxygen,0.0009698316069047825,1,0,1,0.0010623291354603082
4404,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.0015227591334154439,0,0,1,0.001667992033048206
4405,HBA,Erythrocytes take up oxygen and release carbon dioxide,0.0009698316069047825,1,0,1,0.0010623291354603082
4406,HBA,Scavenging of heme from plasma,0.0015227591334154439,0,0,1,0.001667992033048206
4407,HBA,Scavenging of heme from plasma,0.0009698316069047825,1,0,1,0.0010623291354603082
4408,HBA,Heme signaling,0.0015227591334154439,0,0,1,0.001667992033048206
4409,HBA,Heme signaling,0.0009698316069047825,1,0,1,0.0010623291354603082
4410,GSTO1,Methylation,0.0002546723545183248,0,0,1,0.0002789616880651479
4411,GSTO1,Methylation,0.00018186165621022717,1,0,1,0.0001992066814895613
4412,GSTO1,Glutathione conjugation,0.0002546723545183248,0,0,1,0.0002789616880651479
4413,GSTO1,Glutathione conjugation,0.00018186165621022717,1,0,1,0.0001992066814895613
4414,GSTO1,Vitamin C (ascorbate) metabolism,0.0002546723545183248,0,0,1,0.0002789616880651479
4415,GSTO1,Vitamin C (ascorbate) metabolism,0.00018186165621022717,1,0,1,0.0001992066814895613
4416,GSTO1,Interleukin-12 family signaling,0.0002546723545183248,0,0,1,0.0002789616880651479
4417,GSTO1,Interleukin-12 family signaling,0.00018186165621022717,1,0,1,0.0001992066814895613
4418,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.0010833431883769534,0,0,1,0.001186666865177033
4419,PHLD,Post-translational modification: synthesis of GPI-anchored proteins,0.00035734279557175054,1,0,1,0.0003914243053948827
4420,NGAL,Interleukin-4 and Interleukin-13 signaling,0.00508252201655934,0,0,1,0.005567266710394567
4421,NGAL,Interleukin-4 and Interleukin-13 signaling,0.005648370798668933,1,0,1,0.0061870832261897366
4422,NGAL,Metal sequestration by antimicrobial proteins,0.00508252201655934,0,0,1,0.005567266710394567
4423,NGAL,Metal sequestration by antimicrobial proteins,0.005648370798668933,1,0,1,0.0061870832261897366
4424,NGAL,Neutrophil degranulation,0.00508252201655934,0,0,1,0.005567266710394567
4425,NGAL,Neutrophil degranulation,0.005648370798668933,1,0,1,0.0061870832261897366
4426,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.0038334242708515376,0,0,1,0.004199036474489842
4427,S10AC,Toll Like Receptor 4 (TLR4) Cascade,0.004455343233941473,1,0,1,0.00488027085547096
4428,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.0038334242708515376,0,0,1,0.004199036474489842
4429,S10AC,Toll Like Receptor 9 (TLR9) Cascade,0.004455343233941473,1,0,1,0.00488027085547096
4430,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.0038334242708515376,0,0,1,0.004199036474489842
4431,S10AC,Toll Like Receptor 10 (TLR10) Cascade,0.004455343233941473,1,0,1,0.00488027085547096
4432,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.0038334242708515376,0,0,1,0.004199036474489842
4433,S10AC,Toll Like Receptor 3 (TLR3) Cascade,0.004455343233941473,1,0,1,0.00488027085547096
4434,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.0038334242708515376,0,0,1,0.004199036474489842
4435,S10AC,Toll Like Receptor 5 (TLR5) Cascade,0.004455343233941473,1,0,1,0.00488027085547096
4436,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.0038334242708515376,0,0,1,0.004199036474489842
4437,S10AC,Toll Like Receptor 7/8 (TLR7/8) Cascade,0.004455343233941473,1,0,1,0.00488027085547096
4438,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.0038334242708515376,0,0,1,0.004199036474489842
4439,S10AC,Toll Like Receptor 2 (TLR2) Cascade,0.004455343233941473,1,0,1,0.00488027085547096
4440,S10AC,TRAF6 mediated NF-kB activation,0.0038334242708515376,0,0,1,0.004199036474489842
4441,S10AC,TRAF6 mediated NF-kB activation,0.004455343233941473,1,0,1,0.00488027085547096
4442,S10AC,Interleukin-1 family signaling,0.0038334242708515376,0,0,1,0.004199036474489842
4443,S10AC,Interleukin-1 family signaling,0.004455343233941473,1,0,1,0.00488027085547096
4444,S10AC,Neutrophil degranulation,0.0038334242708515376,0,0,1,0.004199036474489842
4445,S10AC,Neutrophil degranulation,0.004455343233941473,1,0,1,0.00488027085547096
4446,S10AC,Advanced glycosylation endproduct receptor signaling,0.0038334242708515376,0,0,1,0.004199036474489842
4447,S10AC,Advanced glycosylation endproduct receptor signaling,0.004455343233941473,1,0,1,0.00488027085547096
4448,BASP1,RHO GTPase cycle,0.00046884777041525594,0,0,1,0.0005135640487087488
4449,BASP1,RHO GTPase cycle,0.00030006087364582815,1,0,1,0.0003286791296717693
4450,LV321,Initial triggering of complement,0.007522377010087984,0,0,1,0.008239822469013263
4451,LV321,Initial triggering of complement,0.00833029253956318,1,0,1,0.009124792808030692
4452,LV321,Regulation of Complement cascade,0.007522377010087984,0,0,1,0.008239822469013263
4453,LV321,Regulation of Complement cascade,0.00833029253956318,1,0,1,0.009124792808030692
4454,LV321,FCGR activation,0.007522377010087984,0,0,1,0.008239822469013263
4455,LV321,FCGR activation,0.00833029253956318,1,0,1,0.009124792808030692
4456,LV321,Regulation of actin dynamics for phagocytic cup formation,0.007522377010087984,0,0,1,0.008239822469013263
4457,LV321,Regulation of actin dynamics for phagocytic cup formation,0.00833029253956318,1,0,1,0.009124792808030692
4458,LV321,Role of phospholipids in phagocytosis,0.007522377010087984,0,0,1,0.008239822469013263
4459,LV321,Role of phospholipids in phagocytosis,0.00833029253956318,1,0,1,0.009124792808030692
4460,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.007522377010087984,0,0,1,0.008239822469013263
4461,LV321,Role of LAT2/NTAL/LAB on calcium mobilization,0.00833029253956318,1,0,1,0.009124792808030692
4462,LV321,FCERI mediated MAPK activation,0.007522377010087984,0,0,1,0.008239822469013263
4463,LV321,FCERI mediated MAPK activation,0.00833029253956318,1,0,1,0.009124792808030692
4464,LV321,FCERI mediated Ca+2 mobilization,0.007522377010087984,0,0,1,0.008239822469013263
4465,LV321,FCERI mediated Ca+2 mobilization,0.00833029253956318,1,0,1,0.009124792808030692
4466,LV321,FCERI mediated NF-kB activation,0.007522377010087984,0,0,1,0.008239822469013263
4467,LV321,FCERI mediated NF-kB activation,0.00833029253956318,1,0,1,0.009124792808030692
4468,LV321,Parasite infection,0.007522377010087984,0,0,1,0.008239822469013263
4469,LV321,Parasite infection,0.00833029253956318,1,0,1,0.009124792808030692
4470,LV321,Leishmania parasite growth and survival,0.007522377010087984,0,0,1,0.008239822469013263
4471,LV321,Leishmania parasite growth and survival,0.00833029253956318,1,0,1,0.009124792808030692
4472,LV321,Potential therapeutics for SARS,0.007522377010087984,0,0,1,0.008239822469013263
4473,LV321,Potential therapeutics for SARS,0.00833029253956318,1,0,1,0.009124792808030692
4474,LV321,CD22 mediated BCR regulation,0.007522377010087984,0,0,1,0.008239822469013263
4475,LV321,CD22 mediated BCR regulation,0.00833029253956318,1,0,1,0.009124792808030692
4476,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.007522377010087984,0,0,1,0.008239822469013263
4477,LV321,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,0.00833029253956318,1,0,1,0.009124792808030692
4478,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.007522377010087984,0,0,1,0.008239822469013263
4479,LV321,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00833029253956318,1,0,1,0.009124792808030692
4480,LV321,Scavenging of heme from plasma,0.007522377010087984,0,0,1,0.008239822469013263
4481,LV321,Scavenging of heme from plasma,0.00833029253956318,1,0,1,0.009124792808030692
4482,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.0038139911846855777,0,0,1,0.004177749960955914
4483,PGBM,Heparan sulfate/heparin (HS-GAG) metabolism,0.004204124237084525,1,0,1,0.004605091888481024
4484,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.0038139911846855777,0,0,1,0.004177749960955914
4485,PGBM,Chondroitin sulfate/dermatan sulfate metabolism,0.004204124237084525,1,0,1,0.004605091888481024
4486,PGBM,Diseases associated with glycosaminoglycan metabolism,0.0038139911846855777,0,0,1,0.004177749960955914
4487,PGBM,Diseases associated with glycosaminoglycan metabolism,0.004204124237084525,1,0,1,0.004605091888481024
4488,PGBM,SARS-CoV-2 Infection,0.0038139911846855777,0,0,1,0.004177749960955914
4489,PGBM,SARS-CoV-2 Infection,0.004204124237084525,1,0,1,0.004605091888481024
4490,PGBM,Integrin cell surface interactions,0.0038139911846855777,0,0,1,0.004177749960955914
4491,PGBM,Integrin cell surface interactions,0.004204124237084525,1,0,1,0.004605091888481024
4492,PGBM,Laminin interactions,0.0038139911846855777,0,0,1,0.004177749960955914
4493,PGBM,Laminin interactions,0.004204124237084525,1,0,1,0.004605091888481024
4494,PGBM,ECM proteoglycans,0.0038139911846855777,0,0,1,0.004177749960955914
4495,PGBM,ECM proteoglycans,0.004204124237084525,1,0,1,0.004605091888481024
4496,PGBM,Retinoid metabolism and transport,0.0038139911846855777,0,0,1,0.004177749960955914
4497,PGBM,Retinoid metabolism and transport,0.004204124237084525,1,0,1,0.004605091888481024
4498,PGBM,Amyloid fiber formation,0.0038139911846855777,0,0,1,0.004177749960955914
4499,PGBM,Amyloid fiber formation,0.004204124237084525,1,0,1,0.004605091888481024
4500,DHSO,Fructose biosynthesis,0.0012786627092947096,0,0,1,0.00140061495298714
4501,DHSO,Fructose biosynthesis,0.0011087694089519343,1,0,1,0.0012145181073196232
4502,DHSO,Formation of xylulose-5-phosphate,0.0012786627092947096,0,0,1,0.00140061495298714
4503,DHSO,Formation of xylulose-5-phosphate,0.0011087694089519343,1,0,1,0.0012145181073196232
4504,CAP1,Signaling by ROBO receptors,0.00018287222087911423,0,0,1,0.0002003136285960304
4505,CAP1,Signaling by ROBO receptors,0.00017195191233943931,1,0,1,0.00018835179744171573
4506,CAP1,Platelet degranulation ,0.00018287222087911423,0,0,1,0.0002003136285960304
4507,CAP1,Platelet degranulation ,0.00017195191233943931,1,0,1,0.00018835179744171573
4508,CAP1,Neutrophil degranulation,0.00018287222087911423,0,0,1,0.0002003136285960304
4509,CAP1,Neutrophil degranulation,0.00017195191233943931,1,0,1,0.00018835179744171573
4510,DSC2,Formation of the cornified envelope,0.0003185479382146386,0,0,1,0.0003489293949557213
4511,DSC2,Formation of the cornified envelope,0.0003076087810713112,1,0,1,0.0003369469175153089
4512,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002700387037519914,0,0,1,0.0029579360030677995
4513,NUCB1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.002865313579798747,1,0,1,0.0031385923869453073
4514,NUCB1,Post-translational protein phosphorylation,0.002700387037519914,0,0,1,0.0029579360030677995
4515,NUCB1,Post-translational protein phosphorylation,0.002865313579798747,1,0,1,0.0031385923869453073
4516,FHR3,Regulation of Complement cascade,0.001748964239161835,0,0,1,0.0019157714132142147
4517,FHR3,Regulation of Complement cascade,0.0018612264534683075,1,0,1,0.0020387406175791573
4518,ACY1,Defective ACY1 causes encephalopathy,0.00047650950595022645,0,0,1,0.0005219565209988275
4519,ACY1,Defective ACY1 causes encephalopathy,0.00012693615191458632,1,0,1,0.00013904266633714705
4520,ACY1,Aflatoxin activation and detoxification,0.00047650950595022645,0,0,1,0.0005219565209988275
4521,ACY1,Aflatoxin activation and detoxification,0.00012693615191458632,1,0,1,0.00013904266633714705
4522,ACY1,Paracetamol ADME,0.00047650950595022645,0,0,1,0.0005219565209988275
4523,ACY1,Paracetamol ADME,0.00012693615191458632,1,0,1,0.00013904266633714705
4524,FHR1,Regulation of Complement cascade,0.0003891106988908985,0,0,1,0.0004262220672209009
4525,FHR1,Regulation of Complement cascade,0.00041575007387991303,1,0,1,0.0004554021681784284
4526,HGFA,MET Receptor Activation,0.005955715564157587,0,0,1,0.006523740947680008
4527,HGFA,MET Receptor Activation,0.005298563841085345,1,0,1,0.005803913488080492
4528,AK1C1,Bile acid and bile salt metabolism,0.0011918558040338327,0,0,1,0.00130552885354346
4529,AK1C1,Bile acid and bile salt metabolism,0.0009625161033854135,1,0,1,0.0010543159170068586
4530,AK1C1,Retinoid metabolism and transport,0.0011918558040338327,0,0,1,0.00130552885354346
4531,AK1C1,Retinoid metabolism and transport,0.0009625161033854135,1,0,1,0.0010543159170068586
4532,1433F,Activation of BH3-only proteins,0.0023695874547344743,0,0,1,0.0025955864649736165
4533,1433F,Activation of BH3-only proteins,0.0028028748447883893,1,0,1,0.0030701985679456537
4534,1433F,RHO GTPase Effectors,0.0023695874547344743,0,0,1,0.0025955864649736165
4535,1433F,RHO GTPase Effectors,0.0028028748447883893,1,0,1,0.0030701985679456537
4536,1433F,Transcriptional Regulation by TP53,0.0023695874547344743,0,0,1,0.0025955864649736165
4537,1433F,Transcriptional Regulation by TP53,0.0028028748447883893,1,0,1,0.0030701985679456537
4538,1433F,G2/M DNA damage checkpoint,0.0023695874547344743,0,0,1,0.0025955864649736165
4539,1433F,G2/M DNA damage checkpoint,0.0028028748447883893,1,0,1,0.0030701985679456537
4540,1433F,SARS-CoV-2 Infection,0.0023695874547344743,0,0,1,0.0025955864649736165
4541,1433F,SARS-CoV-2 Infection,0.0028028748447883893,1,0,1,0.0030701985679456537
4542,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0023695874547344743,0,0,1,0.0025955864649736165
4543,1433F,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0028028748447883893,1,0,1,0.0030701985679456537
4544,EF1A2,Eukaryotic Translation Elongation,5.668617388649639e-06,0,0,1,6.209260831329734e-06
4545,EF1A2,Eukaryotic Translation Elongation,1.8015372946133468e-05,1,0,1,1.9733586151044032e-05
4546,ITIH3,Platelet degranulation ,0.0012638199774915053,0,0,1,0.0013843565981015013
4547,ITIH3,Platelet degranulation ,0.000987433099638152,1,0,1,0.0010816093676419833
4548,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.0024149342957732792,0,0,1,0.0026452582534507467
4549,PSME1,Downstream signaling events of B Cell Receptor (BCR),0.002479365109087814,1,0,1,0.002715834144892233
4550,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0024149342957732792,0,0,1,0.0026452582534507467
4551,PSME1,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.002479365109087814,1,0,1,0.002715834144892233
4552,PSME1,Antigen processing-Cross presentation,0.0024149342957732792,0,0,1,0.0026452582534507467
4553,PSME1,Antigen processing-Cross presentation,0.002479365109087814,1,0,1,0.002715834144892233
4554,PSME1,PTEN Regulation,0.0024149342957732792,0,0,1,0.0026452582534507467
4555,PSME1,PTEN Regulation,0.002479365109087814,1,0,1,0.002715834144892233
4556,PSME1,Host Interactions of HIV factors,0.0024149342957732792,0,0,1,0.0026452582534507467
4557,PSME1,Host Interactions of HIV factors,0.002479365109087814,1,0,1,0.002715834144892233
4558,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0024149342957732792,0,0,1,0.0026452582534507467
4559,PSME1,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.002479365109087814,1,0,1,0.002715834144892233
4560,PSME1,APC/C-mediated degradation of cell cycle proteins,0.0024149342957732792,0,0,1,0.0026452582534507467
4561,PSME1,APC/C-mediated degradation of cell cycle proteins,0.002479365109087814,1,0,1,0.002715834144892233
4562,PSME1,Degradation of AXIN,0.0024149342957732792,0,0,1,0.0026452582534507467
4563,PSME1,Degradation of AXIN,0.002479365109087814,1,0,1,0.002715834144892233
4564,PSME1,Degradation of DVL,0.0024149342957732792,0,0,1,0.0026452582534507467
4565,PSME1,Degradation of DVL,0.002479365109087814,1,0,1,0.002715834144892233
4566,PSME1,Downstream TCR signaling,0.0024149342957732792,0,0,1,0.0026452582534507467
4567,PSME1,Downstream TCR signaling,0.002479365109087814,1,0,1,0.002715834144892233
4568,PSME1,Transcriptional regulation by RUNX3,0.0024149342957732792,0,0,1,0.0026452582534507467
4569,PSME1,Transcriptional regulation by RUNX3,0.002479365109087814,1,0,1,0.002715834144892233
4570,PSME1,Transcriptional regulation by RUNX2,0.0024149342957732792,0,0,1,0.0026452582534507467
4571,PSME1,Transcriptional regulation by RUNX2,0.002479365109087814,1,0,1,0.002715834144892233
4572,PSME1,Transcriptional regulation by RUNX1,0.0024149342957732792,0,0,1,0.0026452582534507467
4573,PSME1,Transcriptional regulation by RUNX1,0.002479365109087814,1,0,1,0.002715834144892233
4574,PSME1,FCERI mediated NF-kB activation,0.0024149342957732792,0,0,1,0.0026452582534507467
4575,PSME1,FCERI mediated NF-kB activation,0.002479365109087814,1,0,1,0.002715834144892233
4576,PSME1,Mitotic Metaphase and Anaphase,0.0024149342957732792,0,0,1,0.0026452582534507467
4577,PSME1,Mitotic Metaphase and Anaphase,0.002479365109087814,1,0,1,0.002715834144892233
4578,PSME1,Regulation of ornithine decarboxylase (ODC),0.0024149342957732792,0,0,1,0.0026452582534507467
4579,PSME1,Regulation of ornithine decarboxylase (ODC),0.002479365109087814,1,0,1,0.002715834144892233
4580,PSME1,Signaling by ROBO receptors,0.0024149342957732792,0,0,1,0.0026452582534507467
4581,PSME1,Signaling by ROBO receptors,0.002479365109087814,1,0,1,0.002715834144892233
4582,PSME1,PCP/CE pathway,0.0024149342957732792,0,0,1,0.0026452582534507467
4583,PSME1,PCP/CE pathway,0.002479365109087814,1,0,1,0.002715834144892233
4584,PSME1,Interleukin-1 family signaling,0.0024149342957732792,0,0,1,0.0026452582534507467
4585,PSME1,Interleukin-1 family signaling,0.002479365109087814,1,0,1,0.002715834144892233
4586,PSME1,G2/M Transition,0.0024149342957732792,0,0,1,0.0026452582534507467
4587,PSME1,G2/M Transition,0.002479365109087814,1,0,1,0.002715834144892233
4588,PSME1,G1/S Transition,0.0024149342957732792,0,0,1,0.0026452582534507467
4589,PSME1,G1/S Transition,0.002479365109087814,1,0,1,0.002715834144892233
4590,PSME1,Hh mutants are degraded by ERAD,0.0024149342957732792,0,0,1,0.0026452582534507467
4591,PSME1,Hh mutants are degraded by ERAD,0.002479365109087814,1,0,1,0.002715834144892233
4592,PSME1,CLEC7A (Dectin-1) signaling,0.0024149342957732792,0,0,1,0.0026452582534507467
4593,PSME1,CLEC7A (Dectin-1) signaling,0.002479365109087814,1,0,1,0.002715834144892233
4594,PSME1,Degradation of GLI1 by the proteasome,0.0024149342957732792,0,0,1,0.0026452582534507467
4595,PSME1,Degradation of GLI1 by the proteasome,0.002479365109087814,1,0,1,0.002715834144892233
4596,PSME1,Degradation of GLI2 by the proteasome,0.0024149342957732792,0,0,1,0.0026452582534507467
4597,PSME1,Degradation of GLI2 by the proteasome,0.002479365109087814,1,0,1,0.002715834144892233
4598,PSME1,GLI3 is processed to GLI3R by the proteasome,0.0024149342957732792,0,0,1,0.0026452582534507467
4599,PSME1,GLI3 is processed to GLI3R by the proteasome,0.002479365109087814,1,0,1,0.002715834144892233
4600,PSME1,Defective CFTR causes cystic fibrosis,0.0024149342957732792,0,0,1,0.0026452582534507467
4601,PSME1,Defective CFTR causes cystic fibrosis,0.002479365109087814,1,0,1,0.002715834144892233
4602,PSME1,NIK-->noncanonical NF-kB signaling,0.0024149342957732792,0,0,1,0.0026452582534507467
4603,PSME1,NIK-->noncanonical NF-kB signaling,0.002479365109087814,1,0,1,0.002715834144892233
4604,PSME1,RAF/MAP kinase cascade,0.0024149342957732792,0,0,1,0.0026452582534507467
4605,PSME1,RAF/MAP kinase cascade,0.002479365109087814,1,0,1,0.002715834144892233
4606,PSME1,UCH proteinases,0.0024149342957732792,0,0,1,0.0026452582534507467
4607,PSME1,UCH proteinases,0.002479365109087814,1,0,1,0.002715834144892233
4608,PSME1,Ub-specific processing proteases,0.0024149342957732792,0,0,1,0.0026452582534507467
4609,PSME1,Ub-specific processing proteases,0.002479365109087814,1,0,1,0.002715834144892233
4610,PSME1,Orc1 removal from chromatin,0.0024149342957732792,0,0,1,0.0026452582534507467
4611,PSME1,Orc1 removal from chromatin,0.002479365109087814,1,0,1,0.002715834144892233
4612,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.0024149342957732792,0,0,1,0.0026452582534507467
4613,PSME1,CDK-mediated phosphorylation and removal of Cdc6,0.002479365109087814,1,0,1,0.002715834144892233
4614,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.0024149342957732792,0,0,1,0.0026452582534507467
4615,PSME1,Cyclin A:Cdk2-associated events at S phase entry,0.002479365109087814,1,0,1,0.002715834144892233
4616,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.0024149342957732792,0,0,1,0.0026452582534507467
4617,PSME1,Ubiquitin-dependent degradation of Cyclin D,0.002479365109087814,1,0,1,0.002715834144892233
4618,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.0024149342957732792,0,0,1,0.0026452582534507467
4619,PSME1,p53-Dependent G1/S DNA damage checkpoint,0.002479365109087814,1,0,1,0.002715834144892233
4620,PSME1,p53-Independent G1/S DNA damage checkpoint,0.0024149342957732792,0,0,1,0.0026452582534507467
4621,PSME1,p53-Independent G1/S DNA damage checkpoint,0.002479365109087814,1,0,1,0.002715834144892233
4622,PSME1,Negative regulation of NOTCH4 signaling,0.0024149342957732792,0,0,1,0.0026452582534507467
4623,PSME1,Negative regulation of NOTCH4 signaling,0.002479365109087814,1,0,1,0.002715834144892233
4624,PSME1,KEAP1-NFE2L2 pathway,0.0024149342957732792,0,0,1,0.0026452582534507467
4625,PSME1,KEAP1-NFE2L2 pathway,0.002479365109087814,1,0,1,0.002715834144892233
4626,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.0024149342957732792,0,0,1,0.0026452582534507467
4627,PSME1,Antigen processing: Ubiquitination & Proteasome degradation,0.002479365109087814,1,0,1,0.002715834144892233
4628,PSME1,Degradation of beta-catenin by the destruction complex,0.0024149342957732792,0,0,1,0.0026452582534507467
4629,PSME1,Degradation of beta-catenin by the destruction complex,0.002479365109087814,1,0,1,0.002715834144892233
4630,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0024149342957732792,0,0,1,0.0026452582534507467
4631,PSME1,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.002479365109087814,1,0,1,0.002715834144892233
4632,PSME1,Hedgehog ligand biogenesis,0.0024149342957732792,0,0,1,0.0026452582534507467
4633,PSME1,Hedgehog ligand biogenesis,0.002479365109087814,1,0,1,0.002715834144892233
4634,PSME1,Hedgehog 'on' state,0.0024149342957732792,0,0,1,0.0026452582534507467
4635,PSME1,Hedgehog 'on' state,0.002479365109087814,1,0,1,0.002715834144892233
4636,PSME1,MAPK6/MAPK4 signaling,0.0024149342957732792,0,0,1,0.0026452582534507467
4637,PSME1,MAPK6/MAPK4 signaling,0.002479365109087814,1,0,1,0.002715834144892233
4638,PSME1,Neddylation,0.0024149342957732792,0,0,1,0.0026452582534507467
4639,PSME1,Neddylation,0.002479365109087814,1,0,1,0.002715834144892233
4640,LRP1,Scavenging of heme from plasma,0.0016871459101359856,0,0,1,0.00184805717131688
4641,LRP1,Scavenging of heme from plasma,0.0018759026854868676,1,0,1,0.0020548165927908235
4642,LRP1,Retinoid metabolism and transport,0.0016871459101359856,0,0,1,0.00184805717131688
4643,LRP1,Retinoid metabolism and transport,0.0018759026854868676,1,0,1,0.0020548165927908235
4644,LG3BP,Platelet degranulation ,0.004469638844403299,0,0,1,0.004895929907408086
4645,LG3BP,Platelet degranulation ,0.0034949072091668837,1,0,1,0.003828233404227224
4646,BST1,Nicotinate metabolism,0.00041543747462996467,0,0,1,0.00045505975482689517
4647,BST1,Nicotinate metabolism,4.818230037925542e-05,1,0,1,5.2777679281604035e-05
4648,BST1,Neutrophil degranulation,0.00041543747462996467,0,0,1,0.00045505975482689517
4649,BST1,Neutrophil degranulation,4.818230037925542e-05,1,0,1,5.2777679281604035e-05
4650,BST1,Post-translational modification: synthesis of GPI-anchored proteins,0.00041543747462996467,0,0,1,0.00045505975482689517
4651,BST1,Post-translational modification: synthesis of GPI-anchored proteins,4.818230037925542e-05,1,0,1,5.2777679281604035e-05
4652,FBLN3,Molecules associated with elastic fibres,0.0027497715711045753,0,0,1,0.003012030578347252
4653,FBLN3,Molecules associated with elastic fibres,0.0028123486958259673,1,0,1,0.0030805759859536624
4654,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0051664049314041885,0,0,1,0.0056591499443215555
4655,FSTL1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0047509264553126495,1,0,1,0.005204045277525493
4656,FSTL1,Post-translational protein phosphorylation,0.0051664049314041885,0,0,1,0.0056591499443215555
4657,FSTL1,Post-translational protein phosphorylation,0.0047509264553126495,1,0,1,0.005204045277525493
4658,FSTL1,Signaling by BMP,0.0051664049314041885,0,0,1,0.0056591499443215555
4659,FSTL1,Signaling by BMP,0.0047509264553126495,1,0,1,0.005204045277525493
4660,LMAN2,COPII-mediated vesicle transport,0.0019778859729791144,0,0,1,0.0021665265194025216
4661,LMAN2,COPII-mediated vesicle transport,0.0019731619927162297,1,0,1,0.002161351990306055
4662,LMAN2,Cargo concentration in the ER,0.0019778859729791144,0,0,1,0.0021665265194025216
4663,LMAN2,Cargo concentration in the ER,0.0019731619927162297,1,0,1,0.002161351990306055
4664,TRAP1,Respiratory electron transport,0.0004286947119437385,0,0,1,0.0004695813989493023
4665,TRAP1,Respiratory electron transport,3.276601136104513e-05,1,0,1,3.589106425676553e-05
4666,SPP24,Platelet degranulation ,0.0004307630052495037,0,0,1,0.00047184695538585137
4667,SPP24,Platelet degranulation ,0.0005737138201438569,1,0,1,0.000628431680526671
4668,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0004307630052495037,0,0,1,0.00047184695538585137
4669,SPP24,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0005737138201438569,1,0,1,0.000628431680526671
4670,SPP24,Post-translational protein phosphorylation,0.0004307630052495037,0,0,1,0.00047184695538585137
4671,SPP24,Post-translational protein phosphorylation,0.0005737138201438569,1,0,1,0.000628431680526671
4672,MMRN1,Platelet degranulation ,0.00032972057936045336,0,0,1,0.00036116762489660936
4673,MMRN1,Platelet degranulation ,0.00024723636963087676,1,0,1,0.0002708164973531338
4674,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.000106251814802559,0,0,1,0.0001163855640058277
4675,ILK,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,0.00014361005592520993,1,0,1,0.00015730684117558686
4676,APOF,LDL remodeling,0.00017649885717565403,0,0,1,0.00019333240638707457
4677,APOF,LDL remodeling,0.00013858602119225583,1,0,1,0.0001518036399637648
4678,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,9.34123871296935e-05,0,0,1,0.00010232157804949095
4679,BLMH,Antigen processing: Ubiquitination & Proteasome degradation,0.00011011861914334178,1,0,1,0.00012062116416887872
4680,TBB2A,Activation of NMDA receptors and postsynaptic events,0.0027320823126335434,0,0,1,0.0029926542097852508
4681,TBB2A,Activation of NMDA receptors and postsynaptic events,0.0035991342504849175,1,0,1,0.00394240108231347
4682,TBB2A,Gap junction trafficking,0.0027320823126335434,0,0,1,0.0029926542097852508
4683,TBB2A,Gap junction trafficking,0.0035991342504849175,1,0,1,0.00394240108231347
4684,TBB2A,RHO GTPase Effectors,0.0027320823126335434,0,0,1,0.0029926542097852508
4685,TBB2A,RHO GTPase Effectors,0.0035991342504849175,1,0,1,0.00394240108231347
4686,TBB2A,COPI-mediated anterograde transport,0.0027320823126335434,0,0,1,0.0029926542097852508
4687,TBB2A,COPI-mediated anterograde transport,0.0035991342504849175,1,0,1,0.00394240108231347
4688,TBB2A,Mitotic Metaphase and Anaphase,0.0027320823126335434,0,0,1,0.0029926542097852508
4689,TBB2A,Mitotic Metaphase and Anaphase,0.0035991342504849175,1,0,1,0.00394240108231347
4690,TBB2A,L1CAM interactions,0.0027320823126335434,0,0,1,0.0029926542097852508
4691,TBB2A,L1CAM interactions,0.0035991342504849175,1,0,1,0.00394240108231347
4692,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0027320823126335434,0,0,1,0.0029926542097852508
4693,TBB2A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0035991342504849175,1,0,1,0.00394240108231347
4694,TBB2A,G2/M Transition,0.0027320823126335434,0,0,1,0.0029926542097852508
4695,TBB2A,G2/M Transition,0.0035991342504849175,1,0,1,0.00394240108231347
4696,TBB2A,Golgi-to-ER retrograde transport,0.0027320823126335434,0,0,1,0.0029926542097852508
4697,TBB2A,Golgi-to-ER retrograde transport,0.0035991342504849175,1,0,1,0.00394240108231347
4698,TBB2A,Mitotic Prometaphase,0.0027320823126335434,0,0,1,0.0029926542097852508
4699,TBB2A,Mitotic Prometaphase,0.0035991342504849175,1,0,1,0.00394240108231347
4700,TBB2A,HCMV Early Events,0.0027320823126335434,0,0,1,0.0029926542097852508
4701,TBB2A,HCMV Early Events,0.0035991342504849175,1,0,1,0.00394240108231347
4702,TBB2A,Aggrephagy,0.0027320823126335434,0,0,1,0.0029926542097852508
4703,TBB2A,Aggrephagy,0.0035991342504849175,1,0,1,0.00394240108231347
4704,TBB2A,MHC class II antigen presentation,0.0027320823126335434,0,0,1,0.0029926542097852508
4705,TBB2A,MHC class II antigen presentation,0.0035991342504849175,1,0,1,0.00394240108231347
4706,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0027320823126335434,0,0,1,0.0029926542097852508
4707,TBB2A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0035991342504849175,1,0,1,0.00394240108231347
4708,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0027320823126335434,0,0,1,0.0029926542097852508
4709,TBB2A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0035991342504849175,1,0,1,0.00394240108231347
4710,TBB2A,Post-chaperonin tubulin folding pathway,0.0027320823126335434,0,0,1,0.0029926542097852508
4711,TBB2A,Post-chaperonin tubulin folding pathway,0.0035991342504849175,1,0,1,0.00394240108231347
4712,TBB2A,Intraflagellar transport,0.0027320823126335434,0,0,1,0.0029926542097852508
4713,TBB2A,Intraflagellar transport,0.0035991342504849175,1,0,1,0.00394240108231347
4714,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.0027320823126335434,0,0,1,0.0029926542097852508
4715,TBB2A,Carboxyterminal post-translational modifications of tubulin,0.0035991342504849175,1,0,1,0.00394240108231347
4716,TBB2A,Kinesins,0.0027320823126335434,0,0,1,0.0029926542097852508
4717,TBB2A,Kinesins,0.0035991342504849175,1,0,1,0.00394240108231347
4718,DAG1,Signaling by ROBO receptors,0.0053542069044805645,0,0,1,0.005864863499412521
4719,DAG1,Signaling by ROBO receptors,0.004922576408199777,1,0,1,0.005392066316182245
4720,DAG1,Diseases associated with O-glycosylation of proteins,0.0053542069044805645,0,0,1,0.005864863499412521
4721,DAG1,Diseases associated with O-glycosylation of proteins,0.004922576408199777,1,0,1,0.005392066316182245
4722,DAG1,ECM proteoglycans,0.0053542069044805645,0,0,1,0.005864863499412521
4723,DAG1,ECM proteoglycans,0.004922576408199777,1,0,1,0.005392066316182245
4724,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0053542069044805645,0,0,1,0.005864863499412521
4725,DAG1,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.004922576408199777,1,0,1,0.005392066316182245
4726,KRT81,Formation of the cornified envelope,5.278966850271687e-05,0,0,1,5.782447437520294e-05
4727,KRT81,Formation of the cornified envelope,5.127891969963743e-05,1,0,1,5.6169638155753295e-05
4728,ITIH4,Platelet degranulation ,0.0010920059818000495,0,0,1,0.0011961558710851818
4729,ITIH4,Platelet degranulation ,0.0008554282521176647,1,0,1,0.0009370145796967221
4730,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.003469390343156109,0,0,1,0.0038002828713554447
4731,PLSI,Sensory processing of sound by inner hair cells of the cochlea,0.0022196893608032106,1,0,1,0.0024313918652107097
4732,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.003469390343156109,0,0,1,0.0038002828713554447
4733,PLSI,Sensory processing of sound by outer hair cells of the cochlea,0.0022196893608032106,1,0,1,0.0024313918652107097
4734,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.005547111161965593,0,0,1,0.006076165968440841
4735,GANAB,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,0.005218774533528021,1,0,1,0.005716514288556702
4736,GANAB,SARS-CoV-1 Infection,0.005547111161965593,0,0,1,0.006076165968440841
4737,GANAB,SARS-CoV-1 Infection,0.005218774533528021,1,0,1,0.005716514288556702
4738,GANAB,SARS-CoV-2 Infection,0.005547111161965593,0,0,1,0.006076165968440841
4739,GANAB,SARS-CoV-2 Infection,0.005218774533528021,1,0,1,0.005716514288556702
4740,PCOC1,Crosslinking of collagen fibrils,0.004681179492597274,0,0,1,0.005127646209816328
4741,PCOC1,Crosslinking of collagen fibrils,0.0037595236793321173,1,0,1,0.004118087626318781
4742,PON3,Arachidonic acid metabolism,0.0013506814832534321,0,0,1,0.0014795025055599573
4743,PON3,Arachidonic acid metabolism,0.0015074871825334246,1,0,1,0.0016512635223853436
4744,PON3,Atorvastatin ADME,0.0013506814832534321,0,0,1,0.0014795025055599573
4745,PON3,Atorvastatin ADME,0.0015074871825334246,1,0,1,0.0016512635223853436
4746,FCN2,Initial triggering of complement,9.054096896073729e-05,0,0,1,9.91762988492104e-05
4747,FCN2,Initial triggering of complement,9.617849772333328e-05,1,0,1,0.00010535150598193607
4748,BGH3,Amyloid fiber formation,0.0009253064240187696,0,0,1,0.0010135573706459304
4749,BGH3,Amyloid fiber formation,0.000989222241971709,1,0,1,0.0010835691491286779
4750,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.0007686636988429721,0,0,1,0.0008419748715528799
4751,ADIPO,Transcriptional regulation of white adipocyte differentiation,0.0006322067571381737,1,0,1,0.0006925033716793473
4752,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.0007686636988429721,0,0,1,0.0008419748715528799
4753,ADIPO,AMPK inhibits chREBP transcriptional activation activity,0.0006322067571381737,1,0,1,0.0006925033716793473
4754,ECM1,Platelet degranulation ,0.00011200652838528795,0,0,1,0.00012268913244145853
4755,ECM1,Platelet degranulation ,8.744910488665917e-05,1,0,1,9.578954875219208e-05
4756,UGPA,Glucuronidation,0.004632849946528257,0,0,1,0.005074707241311738
4757,UGPA,Glucuronidation,0.004469484037029448,1,0,1,0.004895760335306647
4758,UGPA,Glycogen synthesis,0.004632849946528257,0,0,1,0.005074707241311738
4759,UGPA,Glycogen synthesis,0.004469484037029448,1,0,1,0.004895760335306647
4760,TKFC,Fructose catabolism,0.0016478013717344854,0,0,1,0.0018049601540949466
4761,TKFC,Fructose catabolism,0.0018351986972664762,1,0,1,0.0020102304684491367
4762,TKFC,SARS-CoV-2 Infection,0.0016478013717344854,0,0,1,0.0018049601540949466
4763,TKFC,SARS-CoV-2 Infection,0.0018351986972664762,1,0,1,0.0020102304684491367
4764,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0006534460558837308,0,0,1,0.000715768365017893
4765,CTRB2,"Cobalamin (Cbl, vitamin B12) transport and metabolism",0.0005444328545230479,1,0,1,0.0005963580476692393
4766,CTRB2,Activation of Matrix Metalloproteinases,0.0006534460558837308,0,0,1,0.000715768365017893
4767,CTRB2,Activation of Matrix Metalloproteinases,0.0005444328545230479,1,0,1,0.0005963580476692393
4768,OLFM4,Neutrophil degranulation,0.0010171503841765886,0,0,1,0.0011141609332614001
4769,OLFM4,Neutrophil degranulation,0.001071037306523584,1,0,1,0.0011731873118841797
4770,LDH6A,Pyruvate metabolism,0.0001140546606265286,0,0,1,0.00012493260495529998
4771,LDH6A,Pyruvate metabolism,0.00018283991711735506,1,0,1,0.00020027824386835457
4772,TBA1A,Activation of NMDA receptors and postsynaptic events,0.0006255927846238596,0,0,1,0.0006852585926341336
4773,TBA1A,Activation of NMDA receptors and postsynaptic events,0.0004579331924724286,1,0,1,0.0005016084947060052
4774,TBA1A,Gap junction trafficking,0.0006255927846238596,0,0,1,0.0006852585926341336
4775,TBA1A,Gap junction trafficking,0.0004579331924724286,1,0,1,0.0005016084947060052
4776,TBA1A,RHO GTPase Effectors,0.0006255927846238596,0,0,1,0.0006852585926341336
4777,TBA1A,RHO GTPase Effectors,0.0004579331924724286,1,0,1,0.0005016084947060052
4778,TBA1A,COPI-mediated anterograde transport,0.0006255927846238596,0,0,1,0.0006852585926341336
4779,TBA1A,COPI-mediated anterograde transport,0.0004579331924724286,1,0,1,0.0005016084947060052
4780,TBA1A,Mitotic Metaphase and Anaphase,0.0006255927846238596,0,0,1,0.0006852585926341336
4781,TBA1A,Mitotic Metaphase and Anaphase,0.0004579331924724286,1,0,1,0.0005016084947060052
4782,TBA1A,L1CAM interactions,0.0006255927846238596,0,0,1,0.0006852585926341336
4783,TBA1A,L1CAM interactions,0.0004579331924724286,1,0,1,0.0005016084947060052
4784,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0006255927846238596,0,0,1,0.0006852585926341336
4785,TBA1A,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.0004579331924724286,1,0,1,0.0005016084947060052
4786,TBA1A,G2/M Transition,0.0006255927846238596,0,0,1,0.0006852585926341336
4787,TBA1A,G2/M Transition,0.0004579331924724286,1,0,1,0.0005016084947060052
4788,TBA1A,Golgi-to-ER retrograde transport,0.0006255927846238596,0,0,1,0.0006852585926341336
4789,TBA1A,Golgi-to-ER retrograde transport,0.0004579331924724286,1,0,1,0.0005016084947060052
4790,TBA1A,Mitotic Prometaphase,0.0006255927846238596,0,0,1,0.0006852585926341336
4791,TBA1A,Mitotic Prometaphase,0.0004579331924724286,1,0,1,0.0005016084947060052
4792,TBA1A,HCMV Early Events,0.0006255927846238596,0,0,1,0.0006852585926341336
4793,TBA1A,HCMV Early Events,0.0004579331924724286,1,0,1,0.0005016084947060052
4794,TBA1A,Aggrephagy,0.0006255927846238596,0,0,1,0.0006852585926341336
4795,TBA1A,Aggrephagy,0.0004579331924724286,1,0,1,0.0005016084947060052
4796,TBA1A,MHC class II antigen presentation,0.0006255927846238596,0,0,1,0.0006852585926341336
4797,TBA1A,MHC class II antigen presentation,0.0004579331924724286,1,0,1,0.0005016084947060052
4798,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0006255927846238596,0,0,1,0.0006852585926341336
4799,TBA1A,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0004579331924724286,1,0,1,0.0005016084947060052
4800,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0006255927846238596,0,0,1,0.0006852585926341336
4801,TBA1A,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0004579331924724286,1,0,1,0.0005016084947060052
4802,TBA1A,Post-chaperonin tubulin folding pathway,0.0006255927846238596,0,0,1,0.0006852585926341336
4803,TBA1A,Post-chaperonin tubulin folding pathway,0.0004579331924724286,1,0,1,0.0005016084947060052
4804,TBA1A,Anchoring of the basal body to the plasma membrane,0.0006255927846238596,0,0,1,0.0006852585926341336
4805,TBA1A,Anchoring of the basal body to the plasma membrane,0.0004579331924724286,1,0,1,0.0005016084947060052
4806,TBA1A,Intraflagellar transport,0.0006255927846238596,0,0,1,0.0006852585926341336
4807,TBA1A,Intraflagellar transport,0.0004579331924724286,1,0,1,0.0005016084947060052
4808,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.0006255927846238596,0,0,1,0.0006852585926341336
4809,TBA1A,Carboxyterminal post-translational modifications of tubulin,0.0004579331924724286,1,0,1,0.0005016084947060052
4810,TBA1A,Kinesins,0.0006255927846238596,0,0,1,0.0006852585926341336
4811,TBA1A,Kinesins,0.0004579331924724286,1,0,1,0.0005016084947060052
4812,DCXR,Essential pentosuria,0.0006898867907735335,0,0,1,0.000755684628950115
4813,DCXR,Essential pentosuria,0.0008235720594485673,1,0,1,0.0009021201079386556
4814,DCXR,Formation of xylulose-5-phosphate,0.0006898867907735335,0,0,1,0.000755684628950115
4815,DCXR,Formation of xylulose-5-phosphate,0.0008235720594485673,1,0,1,0.0009021201079386556
4816,K2C1B,Formation of the cornified envelope,0.00012961007090835588,0,0,1,0.00014197160991118445
4817,K2C1B,Formation of the cornified envelope,0.00012795116130716455,1,0,1,0.00014015448208209172
4818,URP2,Platelet degranulation ,0.002013249540829152,0,0,1,0.0022052628816673276
4819,URP2,Platelet degranulation ,0.0015700392183956458,1,0,1,0.0017197814482868032
4820,C163A,Leishmania parasite growth and survival,0.0032918948659590307,0,0,1,0.003605858792477801
4821,C163A,Leishmania parasite growth and survival,0.003767420033159512,1,0,1,0.004126737093581987
4822,C163A,Scavenging of heme from plasma,0.0032918948659590307,0,0,1,0.003605858792477801
4823,C163A,Scavenging of heme from plasma,0.003767420033159512,1,0,1,0.004126737093581987
4824,K2C78,Formation of the cornified envelope,0.0003073049016618335,0,0,1,0.00033661405565758406
4825,K2C78,Formation of the cornified envelope,0.00030313984941966537,1,0,1,0.00033205176224905016
4826,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0015448392804671873,0,0,1,0.0016921780704605934
4827,LIRA3,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0016415337076100998,1,0,1,0.0017980947125448778
4828,LIRA3,Neutrophil degranulation,0.0015448392804671873,0,0,1,0.0016921780704605934
4829,LIRA3,Neutrophil degranulation,0.0016415337076100998,1,0,1,0.0017980947125448778
4830,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.008385493889271381,0,0,1,0.009185258977306111
4831,GOLM1,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009005134825672728,1,0,1,0.009863998065181278
4832,GOLM1,Post-translational protein phosphorylation,0.008385493889271381,0,0,1,0.009185258977306111
4833,GOLM1,Post-translational protein phosphorylation,0.009005134825672728,1,0,1,0.009863998065181278
4834,TXND5,Lysosome Vesicle Biogenesis,0.00013665819952236608,0,0,1,0.00014969195262205017
4835,TXND5,Lysosome Vesicle Biogenesis,0.00025124994879448877,1,0,1,0.0002752128709633827
4836,TXND5,Golgi Associated Vesicle Biogenesis,0.00013665819952236608,0,0,1,0.00014969195262205017
4837,TXND5,Golgi Associated Vesicle Biogenesis,0.00025124994879448877,1,0,1,0.0002752128709633827
4838,TXND5,Neutrophil degranulation,0.00013665819952236608,0,0,1,0.00014969195262205017
4839,TXND5,Neutrophil degranulation,0.00025124994879448877,1,0,1,0.0002752128709633827
4840,BHMT1,Choline catabolism,0.0004542718326340803,0,0,1,0.0004975979332807127
4841,BHMT1,Choline catabolism,0.0008402248948805393,1,0,1,0.0009203612047862514
4842,H2B1A,Packaging Of Telomere Ends,0.0010238890149247971,0,0,1,0.0011215422597988776
4843,H2B1A,Packaging Of Telomere Ends,0.0009275837657089584,1,0,1,0.001016051913421874
4844,H2B1A,Inhibition of DNA recombination at telomere,0.0010238890149247971,0,0,1,0.0011215422597988776
4845,H2B1A,Inhibition of DNA recombination at telomere,0.0009275837657089584,1,0,1,0.001016051913421874
4846,H2B1A,Pre-NOTCH Transcription and Translation,0.0010238890149247971,0,0,1,0.0011215422597988776
4847,H2B1A,Pre-NOTCH Transcription and Translation,0.0009275837657089584,1,0,1,0.001016051913421874
4848,H2B1A,RHO GTPase Effectors,0.0010238890149247971,0,0,1,0.0011215422597988776
4849,H2B1A,RHO GTPase Effectors,0.0009275837657089584,1,0,1,0.001016051913421874
4850,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.0010238890149247971,0,0,1,0.0011215422597988776
4851,H2B1A,Formation of the beta-catenin:TCF transactivating complex,0.0009275837657089584,1,0,1,0.001016051913421874
4852,H2B1A,Transcriptional regulation by RUNX1,0.0010238890149247971,0,0,1,0.0011215422597988776
4853,H2B1A,Transcriptional regulation by RUNX1,0.0009275837657089584,1,0,1,0.001016051913421874
4854,H2B1A,Oxidative Stress Induced Senescence,0.0010238890149247971,0,0,1,0.0011215422597988776
4855,H2B1A,Oxidative Stress Induced Senescence,0.0009275837657089584,1,0,1,0.001016051913421874
4856,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.0010238890149247971,0,0,1,0.0011215422597988776
4857,H2B1A,Senescence-Associated Secretory Phenotype (SASP),0.0009275837657089584,1,0,1,0.001016051913421874
4858,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.0010238890149247971,0,0,1,0.0011215422597988776
4859,H2B1A,DNA Damage/Telomere Stress Induced Senescence,0.0009275837657089584,1,0,1,0.001016051913421874
4860,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0010238890149247971,0,0,1,0.0011215422597988776
4861,H2B1A,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,0.0009275837657089584,1,0,1,0.001016051913421874
4862,H2B1A,B-WICH complex positively regulates rRNA expression,0.0010238890149247971,0,0,1,0.0011215422597988776
4863,H2B1A,B-WICH complex positively regulates rRNA expression,0.0009275837657089584,1,0,1,0.001016051913421874
4864,H2B1A,SIRT1 negatively regulates rRNA expression,0.0010238890149247971,0,0,1,0.0011215422597988776
4865,H2B1A,SIRT1 negatively regulates rRNA expression,0.0009275837657089584,1,0,1,0.001016051913421874
4866,H2B1A,NoRC negatively regulates rRNA expression,0.0010238890149247971,0,0,1,0.0011215422597988776
4867,H2B1A,NoRC negatively regulates rRNA expression,0.0009275837657089584,1,0,1,0.001016051913421874
4868,H2B1A,Ub-specific processing proteases,0.0010238890149247971,0,0,1,0.0011215422597988776
4869,H2B1A,Ub-specific processing proteases,0.0009275837657089584,1,0,1,0.001016051913421874
4870,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0010238890149247971,0,0,1,0.0011215422597988776
4871,H2B1A,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),0.0009275837657089584,1,0,1,0.001016051913421874
4872,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0010238890149247971,0,0,1,0.0011215422597988776
4873,H2B1A,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,0.0009275837657089584,1,0,1,0.001016051913421874
4874,H2B1A,Assembly of the ORC complex at the origin of replication,0.0010238890149247971,0,0,1,0.0011215422597988776
4875,H2B1A,Assembly of the ORC complex at the origin of replication,0.0009275837657089584,1,0,1,0.001016051913421874
4876,H2B1A,Mitotic Prophase,0.0010238890149247971,0,0,1,0.0011215422597988776
4877,H2B1A,Mitotic Prophase,0.0009275837657089584,1,0,1,0.001016051913421874
4878,H2B1A,G2/M DNA damage checkpoint,0.0010238890149247971,0,0,1,0.0011215422597988776
4879,H2B1A,G2/M DNA damage checkpoint,0.0009275837657089584,1,0,1,0.001016051913421874
4880,H2B1A,RNA Polymerase I Promoter Opening,0.0010238890149247971,0,0,1,0.0011215422597988776
4881,H2B1A,RNA Polymerase I Promoter Opening,0.0009275837657089584,1,0,1,0.001016051913421874
4882,H2B1A,RNA Polymerase I Promoter Escape,0.0010238890149247971,0,0,1,0.0011215422597988776
4883,H2B1A,RNA Polymerase I Promoter Escape,0.0009275837657089584,1,0,1,0.001016051913421874
4884,H2B1A,Depurination,0.0010238890149247971,0,0,1,0.0011215422597988776
4885,H2B1A,Depurination,0.0009275837657089584,1,0,1,0.001016051913421874
4886,H2B1A,Depyrimidination,0.0010238890149247971,0,0,1,0.0011215422597988776
4887,H2B1A,Depyrimidination,0.0009275837657089584,1,0,1,0.001016051913421874
4888,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.0010238890149247971,0,0,1,0.0011215422597988776
4889,H2B1A,Deposition of new CENPA-containing nucleosomes at the centromere,0.0009275837657089584,1,0,1,0.001016051913421874
4890,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.0010238890149247971,0,0,1,0.0011215422597988776
4891,H2B1A,E3 ubiquitin ligases ubiquitinate target proteins,0.0009275837657089584,1,0,1,0.001016051913421874
4892,H2B1A,Estrogen-dependent gene expression,0.0010238890149247971,0,0,1,0.0011215422597988776
4893,H2B1A,Estrogen-dependent gene expression,0.0009275837657089584,1,0,1,0.001016051913421874
4894,H2B1A,HCMV Early Events,0.0010238890149247971,0,0,1,0.0011215422597988776
4895,H2B1A,HCMV Early Events,0.0009275837657089584,1,0,1,0.001016051913421874
4896,H2B1A,HCMV Late Events,0.0010238890149247971,0,0,1,0.0011215422597988776
4897,H2B1A,HCMV Late Events,0.0009275837657089584,1,0,1,0.001016051913421874
4898,H2B1A,Transcriptional regulation of granulopoiesis,0.0010238890149247971,0,0,1,0.0011215422597988776
4899,H2B1A,Transcriptional regulation of granulopoiesis,0.0009275837657089584,1,0,1,0.001016051913421874
4900,H2B1A,Meiotic synapsis,0.0010238890149247971,0,0,1,0.0011215422597988776
4901,H2B1A,Meiotic synapsis,0.0009275837657089584,1,0,1,0.001016051913421874
4902,H2B1A,Meiotic recombination,0.0010238890149247971,0,0,1,0.0011215422597988776
4903,H2B1A,Meiotic recombination,0.0009275837657089584,1,0,1,0.001016051913421874
4904,H2B1A,Transcriptional regulation by small RNAs,0.0010238890149247971,0,0,1,0.0011215422597988776
4905,H2B1A,Transcriptional regulation by small RNAs,0.0009275837657089584,1,0,1,0.001016051913421874
4906,H2B1A,PRC2 methylates histones and DNA,0.0010238890149247971,0,0,1,0.0011215422597988776
4907,H2B1A,PRC2 methylates histones and DNA,0.0009275837657089584,1,0,1,0.001016051913421874
4908,H2B1A,DNA methylation,0.0010238890149247971,0,0,1,0.0011215422597988776
4909,H2B1A,DNA methylation,0.0009275837657089584,1,0,1,0.001016051913421874
4910,H2B1A,HDACs deacetylate histones,0.0010238890149247971,0,0,1,0.0011215422597988776
4911,H2B1A,HDACs deacetylate histones,0.0009275837657089584,1,0,1,0.001016051913421874
4912,H2B1A,HATs acetylate histones,0.0010238890149247971,0,0,1,0.0011215422597988776
4913,H2B1A,HATs acetylate histones,0.0009275837657089584,1,0,1,0.001016051913421874
4914,H2B1A,Amyloid fiber formation,0.0010238890149247971,0,0,1,0.0011215422597988776
4915,H2B1A,Amyloid fiber formation,0.0009275837657089584,1,0,1,0.001016051913421874
4916,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0010238890149247971,0,0,1,0.0011215422597988776
4917,H2B1A,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0009275837657089584,1,0,1,0.001016051913421874
4918,H2B1A,Nonhomologous End-Joining (NHEJ),0.0010238890149247971,0,0,1,0.0011215422597988776
4919,H2B1A,Nonhomologous End-Joining (NHEJ),0.0009275837657089584,1,0,1,0.001016051913421874
4920,H2B1A,Defective pyroptosis,0.0010238890149247971,0,0,1,0.0011215422597988776
4921,H2B1A,Defective pyroptosis,0.0009275837657089584,1,0,1,0.001016051913421874
4922,CBPB2,Regulation of Complement cascade,0.0009409814588783553,0,0,1,0.001030727409353824
4923,CBPB2,Regulation of Complement cascade,0.0008162701109803802,1,0,1,0.0008941217373471447
4924,CBPB2,Metabolism of Angiotensinogen to Angiotensins,0.0009409814588783553,0,0,1,0.001030727409353824
4925,CBPB2,Metabolism of Angiotensinogen to Angiotensins,0.0008162701109803802,1,0,1,0.0008941217373471447
4926,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.0012725939771828542,0,0,1,0.0013939674165572816
4927,PSB7,Downstream signaling events of B Cell Receptor (BCR),0.0009444984348584942,1,0,1,0.0010345798163343921
4928,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0012725939771828542,0,0,1,0.0013939674165572816
4929,PSB7,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,0.0009444984348584942,1,0,1,0.0010345798163343921
4930,PSB7,Antigen processing-Cross presentation,0.0012725939771828542,0,0,1,0.0013939674165572816
4931,PSB7,Antigen processing-Cross presentation,0.0009444984348584942,1,0,1,0.0010345798163343921
4932,PSB7,PTEN Regulation,0.0012725939771828542,0,0,1,0.0013939674165572816
4933,PSB7,PTEN Regulation,0.0009444984348584942,1,0,1,0.0010345798163343921
4934,PSB7,Host Interactions of HIV factors,0.0012725939771828542,0,0,1,0.0013939674165572816
4935,PSB7,Host Interactions of HIV factors,0.0009444984348584942,1,0,1,0.0010345798163343921
4936,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0012725939771828542,0,0,1,0.0013939674165572816
4937,PSB7,Regulation of activated PAK-2p34 by proteasome mediated degradation,0.0009444984348584942,1,0,1,0.0010345798163343921
4938,PSB7,APC/C-mediated degradation of cell cycle proteins,0.0012725939771828542,0,0,1,0.0013939674165572816
4939,PSB7,APC/C-mediated degradation of cell cycle proteins,0.0009444984348584942,1,0,1,0.0010345798163343921
4940,PSB7,Degradation of AXIN,0.0012725939771828542,0,0,1,0.0013939674165572816
4941,PSB7,Degradation of AXIN,0.0009444984348584942,1,0,1,0.0010345798163343921
4942,PSB7,Degradation of DVL,0.0012725939771828542,0,0,1,0.0013939674165572816
4943,PSB7,Degradation of DVL,0.0009444984348584942,1,0,1,0.0010345798163343921
4944,PSB7,Downstream TCR signaling,0.0012725939771828542,0,0,1,0.0013939674165572816
4945,PSB7,Downstream TCR signaling,0.0009444984348584942,1,0,1,0.0010345798163343921
4946,PSB7,Transcriptional regulation by RUNX3,0.0012725939771828542,0,0,1,0.0013939674165572816
4947,PSB7,Transcriptional regulation by RUNX3,0.0009444984348584942,1,0,1,0.0010345798163343921
4948,PSB7,Transcriptional regulation by RUNX2,0.0012725939771828542,0,0,1,0.0013939674165572816
4949,PSB7,Transcriptional regulation by RUNX2,0.0009444984348584942,1,0,1,0.0010345798163343921
4950,PSB7,Transcriptional regulation by RUNX1,0.0012725939771828542,0,0,1,0.0013939674165572816
4951,PSB7,Transcriptional regulation by RUNX1,0.0009444984348584942,1,0,1,0.0010345798163343921
4952,PSB7,FCERI mediated NF-kB activation,0.0012725939771828542,0,0,1,0.0013939674165572816
4953,PSB7,FCERI mediated NF-kB activation,0.0009444984348584942,1,0,1,0.0010345798163343921
4954,PSB7,Mitotic Metaphase and Anaphase,0.0012725939771828542,0,0,1,0.0013939674165572816
4955,PSB7,Mitotic Metaphase and Anaphase,0.0009444984348584942,1,0,1,0.0010345798163343921
4956,PSB7,Regulation of ornithine decarboxylase (ODC),0.0012725939771828542,0,0,1,0.0013939674165572816
4957,PSB7,Regulation of ornithine decarboxylase (ODC),0.0009444984348584942,1,0,1,0.0010345798163343921
4958,PSB7,Signaling by ROBO receptors,0.0012725939771828542,0,0,1,0.0013939674165572816
4959,PSB7,Signaling by ROBO receptors,0.0009444984348584942,1,0,1,0.0010345798163343921
4960,PSB7,PCP/CE pathway,0.0012725939771828542,0,0,1,0.0013939674165572816
4961,PSB7,PCP/CE pathway,0.0009444984348584942,1,0,1,0.0010345798163343921
4962,PSB7,Interleukin-1 family signaling,0.0012725939771828542,0,0,1,0.0013939674165572816
4963,PSB7,Interleukin-1 family signaling,0.0009444984348584942,1,0,1,0.0010345798163343921
4964,PSB7,G2/M Transition,0.0012725939771828542,0,0,1,0.0013939674165572816
4965,PSB7,G2/M Transition,0.0009444984348584942,1,0,1,0.0010345798163343921
4966,PSB7,G1/S Transition,0.0012725939771828542,0,0,1,0.0013939674165572816
4967,PSB7,G1/S Transition,0.0009444984348584942,1,0,1,0.0010345798163343921
4968,PSB7,Hh mutants are degraded by ERAD,0.0012725939771828542,0,0,1,0.0013939674165572816
4969,PSB7,Hh mutants are degraded by ERAD,0.0009444984348584942,1,0,1,0.0010345798163343921
4970,PSB7,CLEC7A (Dectin-1) signaling,0.0012725939771828542,0,0,1,0.0013939674165572816
4971,PSB7,CLEC7A (Dectin-1) signaling,0.0009444984348584942,1,0,1,0.0010345798163343921
4972,PSB7,Degradation of GLI1 by the proteasome,0.0012725939771828542,0,0,1,0.0013939674165572816
4973,PSB7,Degradation of GLI1 by the proteasome,0.0009444984348584942,1,0,1,0.0010345798163343921
4974,PSB7,Degradation of GLI2 by the proteasome,0.0012725939771828542,0,0,1,0.0013939674165572816
4975,PSB7,Degradation of GLI2 by the proteasome,0.0009444984348584942,1,0,1,0.0010345798163343921
4976,PSB7,GLI3 is processed to GLI3R by the proteasome,0.0012725939771828542,0,0,1,0.0013939674165572816
4977,PSB7,GLI3 is processed to GLI3R by the proteasome,0.0009444984348584942,1,0,1,0.0010345798163343921
4978,PSB7,Defective CFTR causes cystic fibrosis,0.0012725939771828542,0,0,1,0.0013939674165572816
4979,PSB7,Defective CFTR causes cystic fibrosis,0.0009444984348584942,1,0,1,0.0010345798163343921
4980,PSB7,NIK-->noncanonical NF-kB signaling,0.0012725939771828542,0,0,1,0.0013939674165572816
4981,PSB7,NIK-->noncanonical NF-kB signaling,0.0009444984348584942,1,0,1,0.0010345798163343921
4982,PSB7,RAF/MAP kinase cascade,0.0012725939771828542,0,0,1,0.0013939674165572816
4983,PSB7,RAF/MAP kinase cascade,0.0009444984348584942,1,0,1,0.0010345798163343921
4984,PSB7,UCH proteinases,0.0012725939771828542,0,0,1,0.0013939674165572816
4985,PSB7,UCH proteinases,0.0009444984348584942,1,0,1,0.0010345798163343921
4986,PSB7,Ub-specific processing proteases,0.0012725939771828542,0,0,1,0.0013939674165572816
4987,PSB7,Ub-specific processing proteases,0.0009444984348584942,1,0,1,0.0010345798163343921
4988,PSB7,Orc1 removal from chromatin,0.0012725939771828542,0,0,1,0.0013939674165572816
4989,PSB7,Orc1 removal from chromatin,0.0009444984348584942,1,0,1,0.0010345798163343921
4990,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.0012725939771828542,0,0,1,0.0013939674165572816
4991,PSB7,CDK-mediated phosphorylation and removal of Cdc6,0.0009444984348584942,1,0,1,0.0010345798163343921
4992,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.0012725939771828542,0,0,1,0.0013939674165572816
4993,PSB7,Cyclin A:Cdk2-associated events at S phase entry,0.0009444984348584942,1,0,1,0.0010345798163343921
4994,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.0012725939771828542,0,0,1,0.0013939674165572816
4995,PSB7,Ubiquitin-dependent degradation of Cyclin D,0.0009444984348584942,1,0,1,0.0010345798163343921
4996,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.0012725939771828542,0,0,1,0.0013939674165572816
4997,PSB7,p53-Dependent G1/S DNA damage checkpoint,0.0009444984348584942,1,0,1,0.0010345798163343921
4998,PSB7,p53-Independent G1/S DNA damage checkpoint,0.0012725939771828542,0,0,1,0.0013939674165572816
4999,PSB7,p53-Independent G1/S DNA damage checkpoint,0.0009444984348584942,1,0,1,0.0010345798163343921
5000,PSB7,Negative regulation of NOTCH4 signaling,0.0012725939771828542,0,0,1,0.0013939674165572816
5001,PSB7,Negative regulation of NOTCH4 signaling,0.0009444984348584942,1,0,1,0.0010345798163343921
5002,PSB7,KEAP1-NFE2L2 pathway,0.0012725939771828542,0,0,1,0.0013939674165572816
5003,PSB7,KEAP1-NFE2L2 pathway,0.0009444984348584942,1,0,1,0.0010345798163343921
5004,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.0012725939771828542,0,0,1,0.0013939674165572816
5005,PSB7,Antigen processing: Ubiquitination & Proteasome degradation,0.0009444984348584942,1,0,1,0.0010345798163343921
5006,PSB7,Neutrophil degranulation,0.0012725939771828542,0,0,1,0.0013939674165572816
5007,PSB7,Neutrophil degranulation,0.0009444984348584942,1,0,1,0.0010345798163343921
5008,PSB7,Degradation of beta-catenin by the destruction complex,0.0012725939771828542,0,0,1,0.0013939674165572816
5009,PSB7,Degradation of beta-catenin by the destruction complex,0.0009444984348584942,1,0,1,0.0010345798163343921
5010,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0012725939771828542,0,0,1,0.0013939674165572816
5011,PSB7,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0009444984348584942,1,0,1,0.0010345798163343921
5012,PSB7,Hedgehog ligand biogenesis,0.0012725939771828542,0,0,1,0.0013939674165572816
5013,PSB7,Hedgehog ligand biogenesis,0.0009444984348584942,1,0,1,0.0010345798163343921
5014,PSB7,Hedgehog 'on' state,0.0012725939771828542,0,0,1,0.0013939674165572816
5015,PSB7,Hedgehog 'on' state,0.0009444984348584942,1,0,1,0.0010345798163343921
5016,PSB7,MAPK6/MAPK4 signaling,0.0012725939771828542,0,0,1,0.0013939674165572816
5017,PSB7,MAPK6/MAPK4 signaling,0.0009444984348584942,1,0,1,0.0010345798163343921
5018,PSB7,Neddylation,0.0012725939771828542,0,0,1,0.0013939674165572816
5019,PSB7,Neddylation,0.0009444984348584942,1,0,1,0.0010345798163343921
5020,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0012213722223576708,0,0,1,0.0013378603953663963
5021,PARK7,SUMO E3 ligases SUMOylate target proteins,0.0006343492808773036,1,0,1,0.0006948502382645239
5022,PARK7,Aggrephagy,0.0012213722223576708,0,0,1,0.0013378603953663963
5023,PARK7,Aggrephagy,0.0006343492808773036,1,0,1,0.0006948502382645239
5024,PARK7,Chaperone Mediated Autophagy,0.0012213722223576708,0,0,1,0.0013378603953663963
5025,PARK7,Chaperone Mediated Autophagy,0.0006343492808773036,1,0,1,0.0006948502382645239
5026,PARK7,Late endosomal microautophagy,0.0012213722223576708,0,0,1,0.0013378603953663963
5027,PARK7,Late endosomal microautophagy,0.0006343492808773036,1,0,1,0.0006948502382645239
5028,RARR2,Platelet degranulation ,0.0006444006888662716,0,0,1,0.0007058602976223105
5029,RARR2,Platelet degranulation ,0.0005007414869682835,1,0,1,0.000548499623184948
5030,FUCO2,Neutrophil degranulation,0.0038063083479871153,0,0,1,0.004169334374982378
5031,FUCO2,Neutrophil degranulation,0.00392498272420309,1,0,1,0.004299327300134781
5032,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.0038063083479871153,0,0,1,0.004169334374982378
5033,FUCO2,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.00392498272420309,1,0,1,0.004299327300134781
5034,FUCO2,Post-translational protein phosphorylation,0.0038063083479871153,0,0,1,0.004169334374982378
5035,FUCO2,Post-translational protein phosphorylation,0.00392498272420309,1,0,1,0.004299327300134781
5036,COL11,Initial triggering of complement,0.00046838455230772063,0,0,1,0.0005130566512510829
5037,COL11,Initial triggering of complement,0.0004876964708296674,1,0,1,0.0005342104407970591
5038,COL11,Scavenging by Class A Receptors,0.00046838455230772063,0,0,1,0.0005130566512510829
5039,COL11,Scavenging by Class A Receptors,0.0004876964708296674,1,0,1,0.0005342104407970591
5040,FHR5,Regulation of Complement cascade,0.0007815402969237286,0,0,1,0.0008560795730385914
5041,FHR5,Regulation of Complement cascade,0.0008349874954794836,1,0,1,0.0009146242892865175
5042,CHM4A,HIV Life Cycle,0.0009087399316763713,0,0,1,0.000995410851845747
5043,CHM4A,HIV Life Cycle,0.0005453014343360623,1,0,1,0.0005973094681377707
5044,CHM4A,Mitotic Metaphase and Anaphase,0.0009087399316763713,0,0,1,0.000995410851845747
5045,CHM4A,Mitotic Metaphase and Anaphase,0.0005453014343360623,1,0,1,0.0005973094681377707
5046,CHM4A,HCMV Late Events,0.0009087399316763713,0,0,1,0.000995410851845747
5047,CHM4A,HCMV Late Events,0.0005453014343360623,1,0,1,0.0005973094681377707
5048,CHM4A,SARS-CoV-1 Infection,0.0009087399316763713,0,0,1,0.000995410851845747
5049,CHM4A,SARS-CoV-1 Infection,0.0005453014343360623,1,0,1,0.0005973094681377707
5050,CHM4A,SARS-CoV-2 Infection,0.0009087399316763713,0,0,1,0.000995410851845747
5051,CHM4A,SARS-CoV-2 Infection,0.0005453014343360623,1,0,1,0.0005973094681377707
5052,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.0009087399316763713,0,0,1,0.000995410851845747
5053,CHM4A,Endosomal Sorting Complex Required For Transport (ESCRT),0.0005453014343360623,1,0,1,0.0005973094681377707
5054,CHM4A,Pyroptosis,0.0009087399316763713,0,0,1,0.000995410851845747
5055,CHM4A,Pyroptosis,0.0005453014343360623,1,0,1,0.0005973094681377707
5056,CHM4A,Late endosomal microautophagy,0.0009087399316763713,0,0,1,0.000995410851845747
5057,CHM4A,Late endosomal microautophagy,0.0005453014343360623,1,0,1,0.0005973094681377707
5058,TBB1,Activation of NMDA receptors and postsynaptic events,0.012976544819356221,0,0,1,0.014214180627918096
5059,TBB1,Activation of NMDA receptors and postsynaptic events,0.014253884227710024,1,0,1,0.015613346070356705
5060,TBB1,Gap junction trafficking,0.012976544819356221,0,0,1,0.014214180627918096
5061,TBB1,Gap junction trafficking,0.014253884227710024,1,0,1,0.015613346070356705
5062,TBB1,RHO GTPase Effectors,0.012976544819356221,0,0,1,0.014214180627918096
5063,TBB1,RHO GTPase Effectors,0.014253884227710024,1,0,1,0.015613346070356705
5064,TBB1,COPI-mediated anterograde transport,0.012976544819356221,0,0,1,0.014214180627918096
5065,TBB1,COPI-mediated anterograde transport,0.014253884227710024,1,0,1,0.015613346070356705
5066,TBB1,Mitotic Metaphase and Anaphase,0.012976544819356221,0,0,1,0.014214180627918096
5067,TBB1,Mitotic Metaphase and Anaphase,0.014253884227710024,1,0,1,0.015613346070356705
5068,TBB1,L1CAM interactions,0.012976544819356221,0,0,1,0.014214180627918096
5069,TBB1,L1CAM interactions,0.014253884227710024,1,0,1,0.015613346070356705
5070,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.012976544819356221,0,0,1,0.014214180627918096
5071,TBB1,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,0.014253884227710024,1,0,1,0.015613346070356705
5072,TBB1,G2/M Transition,0.012976544819356221,0,0,1,0.014214180627918096
5073,TBB1,G2/M Transition,0.014253884227710024,1,0,1,0.015613346070356705
5074,TBB1,Golgi-to-ER retrograde transport,0.012976544819356221,0,0,1,0.014214180627918096
5075,TBB1,Golgi-to-ER retrograde transport,0.014253884227710024,1,0,1,0.015613346070356705
5076,TBB1,Mitotic Prometaphase,0.012976544819356221,0,0,1,0.014214180627918096
5077,TBB1,Mitotic Prometaphase,0.014253884227710024,1,0,1,0.015613346070356705
5078,TBB1,HCMV Early Events,0.012976544819356221,0,0,1,0.014214180627918096
5079,TBB1,HCMV Early Events,0.014253884227710024,1,0,1,0.015613346070356705
5080,TBB1,Aggrephagy,0.012976544819356221,0,0,1,0.014214180627918096
5081,TBB1,Aggrephagy,0.014253884227710024,1,0,1,0.015613346070356705
5082,TBB1,MHC class II antigen presentation,0.012976544819356221,0,0,1,0.014214180627918096
5083,TBB1,MHC class II antigen presentation,0.014253884227710024,1,0,1,0.015613346070356705
5084,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.012976544819356221,0,0,1,0.014214180627918096
5085,TBB1,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.014253884227710024,1,0,1,0.015613346070356705
5086,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.012976544819356221,0,0,1,0.014214180627918096
5087,TBB1,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.014253884227710024,1,0,1,0.015613346070356705
5088,TBB1,Post-chaperonin tubulin folding pathway,0.012976544819356221,0,0,1,0.014214180627918096
5089,TBB1,Post-chaperonin tubulin folding pathway,0.014253884227710024,1,0,1,0.015613346070356705
5090,TBB1,Intraflagellar transport,0.012976544819356221,0,0,1,0.014214180627918096
5091,TBB1,Intraflagellar transport,0.014253884227710024,1,0,1,0.015613346070356705
5092,TBB1,Carboxyterminal post-translational modifications of tubulin,0.012976544819356221,0,0,1,0.014214180627918096
5093,TBB1,Carboxyterminal post-translational modifications of tubulin,0.014253884227710024,1,0,1,0.015613346070356705
5094,TBB1,Kinesins,0.012976544819356221,0,0,1,0.014214180627918096
5095,TBB1,Kinesins,0.014253884227710024,1,0,1,0.015613346070356705
5096,RETN,FOXO-mediated transcription,0.0014095327280329417,0,0,1,0.0015439666780433744
5097,RETN,FOXO-mediated transcription,0.0014855478698775398,1,0,1,0.0016272317514259465
5098,RETN,Neutrophil degranulation,0.0014095327280329417,0,0,1,0.0015439666780433744
5099,RETN,Neutrophil degranulation,0.0014855478698775398,1,0,1,0.0016272317514259465
5100,SAE1,Processing and activation of SUMO,0.0005306272935459088,0,0,1,0.0005812357836050731
5101,SAE1,Processing and activation of SUMO,0.0006000343783313011,1,0,1,0.0006572625575830893
5102,GRHPR,Glyoxylate metabolism and glycine degradation,7.892739476059442e-05,0,0,1,8.645508193711486e-05
5103,GRHPR,Glyoxylate metabolism and glycine degradation,1.369607736035009e-05,1,0,1,1.500233846559581e-05
5104,CATZ,COPII-mediated vesicle transport,0.012871892918326754,0,0,1,0.014099547569195946
5105,CATZ,COPII-mediated vesicle transport,0.013395615950283515,1,0,1,0.014673220598408636
5106,CATZ,Cargo concentration in the ER,0.012871892918326754,0,0,1,0.014099547569195946
5107,CATZ,Cargo concentration in the ER,0.013395615950283515,1,0,1,0.014673220598408636
5108,CATZ,Lysosome Vesicle Biogenesis,0.012871892918326754,0,0,1,0.014099547569195946
5109,CATZ,Lysosome Vesicle Biogenesis,0.013395615950283515,1,0,1,0.014673220598408636
5110,CATZ,Neutrophil degranulation,0.012871892918326754,0,0,1,0.014099547569195946
5111,CATZ,Neutrophil degranulation,0.013395615950283515,1,0,1,0.014673220598408636
5112,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.012871892918326754,0,0,1,0.014099547569195946
5113,CATZ,Metabolism of Angiotensinogen to Angiotensins,0.013395615950283515,1,0,1,0.014673220598408636
5114,FBLN5,Molecules associated with elastic fibres,0.0008188941897613356,0,0,1,0.0008969960872063421
5115,FBLN5,Molecules associated with elastic fibres,0.0008543028907759085,1,0,1,0.0009357818872037605
5116,DMBT1,Surfactant metabolism,0.0003027898773450084,0,0,1,0.00033166841164585415
5117,DMBT1,Surfactant metabolism,0.0002831909293356868,1,0,1,0.00031020021722278013
5118,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006163733045911894,0,0,1,0.006751598062234103
5119,ZPI,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.006657063215797404,1,0,1,0.007291979515199487
5120,ZPI,Post-translational protein phosphorylation,0.006163733045911894,0,0,1,0.006751598062234103
5121,ZPI,Post-translational protein phosphorylation,0.006657063215797404,1,0,1,0.007291979515199487
5122,MINP1,Synthesis of IPs in the ER lumen,0.0007190663192591388,0,0,1,0.0007876471501224076
5123,MINP1,Synthesis of IPs in the ER lumen,0.0007578502348588713,1,0,1,0.0008301300752358952
5124,TLN1,Semaphorin interactions,0.01016681067891381,0,0,1,0.011136468560133785
5125,TLN1,Semaphorin interactions,0.008901634719222784,1,0,1,0.009750626653255523
5126,TLN1,IRE1alpha activates chaperones,0.01016681067891381,0,0,1,0.011136468560133785
5127,TLN1,IRE1alpha activates chaperones,0.008901634719222784,1,0,1,0.009750626653255523
5128,TLN1,RAF/MAP kinase cascade,0.01016681067891381,0,0,1,0.011136468560133785
5129,TLN1,RAF/MAP kinase cascade,0.008901634719222784,1,0,1,0.009750626653255523
5130,TLN1,Signaling by RAS mutants,0.01016681067891381,0,0,1,0.011136468560133785
5131,TLN1,Signaling by RAS mutants,0.008901634719222784,1,0,1,0.009750626653255523
5132,TLN1,Signaling by moderate kinase activity BRAF mutants,0.01016681067891381,0,0,1,0.011136468560133785
5133,TLN1,Signaling by moderate kinase activity BRAF mutants,0.008901634719222784,1,0,1,0.009750626653255523
5134,TLN1,Signaling by high-kinase activity BRAF mutants,0.01016681067891381,0,0,1,0.011136468560133785
5135,TLN1,Signaling by high-kinase activity BRAF mutants,0.008901634719222784,1,0,1,0.009750626653255523
5136,TLN1,Signaling by BRAF and RAF1 fusions,0.01016681067891381,0,0,1,0.011136468560133785
5137,TLN1,Signaling by BRAF and RAF1 fusions,0.008901634719222784,1,0,1,0.009750626653255523
5138,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.01016681067891381,0,0,1,0.011136468560133785
5139,TLN1,Paradoxical activation of RAF signaling by kinase inactive BRAF,0.008901634719222784,1,0,1,0.009750626653255523
5140,TLN1,Signaling by RAF1 mutants,0.01016681067891381,0,0,1,0.011136468560133785
5141,TLN1,Signaling by RAF1 mutants,0.008901634719222784,1,0,1,0.009750626653255523
5142,TLN1,Platelet degranulation ,0.01016681067891381,0,0,1,0.011136468560133785
5143,TLN1,Platelet degranulation ,0.008901634719222784,1,0,1,0.009750626653255523
5144,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.01016681067891381,0,0,1,0.011136468560133785
5145,TLN1,GRB2:SOS provides linkage to MAPK signaling for Integrins ,0.008901634719222784,1,0,1,0.009750626653255523
5146,TLN1,p130Cas linkage to MAPK signaling for integrins,0.01016681067891381,0,0,1,0.011136468560133785
5147,TLN1,p130Cas linkage to MAPK signaling for integrins,0.008901634719222784,1,0,1,0.009750626653255523
5148,TLN1,Smooth Muscle Contraction,0.01016681067891381,0,0,1,0.011136468560133785
5149,TLN1,Smooth Muscle Contraction,0.008901634719222784,1,0,1,0.009750626653255523
5150,HYOU1,IRE1alpha activates chaperones,0.00682987957816987,0,0,1,0.007481278209452666
5151,HYOU1,IRE1alpha activates chaperones,0.006110626856706621,1,0,1,0.006693426879046865
5152,HYOU1,Scavenging by Class F Receptors,0.00682987957816987,0,0,1,0.007481278209452666
5153,HYOU1,Scavenging by Class F Receptors,0.006110626856706621,1,0,1,0.006693426879046865
5154,COL10,Initial triggering of complement,0.0003999809469043178,0,0,1,0.0004381290633345763
5155,COL10,Initial triggering of complement,0.0004256636407424289,1,0,1,0.0004662612398352036
5156,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,0.0008577003413455284,0,1,2,0.02146451204515
5157,Activation of BH3-only proteins,Intrinsic Pathway for Apoptosis,0.0009945899143859066,1,1,2,0.024890263146952283
5158,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.0008696503079687862,0,1,2,0.021763567776108054
5159,Apoptotic cleavage of cellular proteins,Apoptotic execution phase,0.0013994730769287705,1,1,2,0.03502272911478227
5160,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,0.0005819726554230139,0,1,2,0.01456424635750827
5161,"GABA synthesis, release, reuptake and degradation",Neurotransmitter release cycle,0.0010787852371151696,1,1,2,0.02699730616856572
5162,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,6.636195224198645e-05,0,1,2,0.0016607512607529095
5163,Serotonin clearance from the synaptic cleft,Neurotransmitter clearance,8.53228037546065e-05,1,1,2,0.002135258971733262
5164,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,0.0024258292822768855,0,1,2,0.06070796447069789
5165,Activation of NMDA receptors and postsynaptic events,Neurotransmitter receptors and postsynaptic signal transmission,0.0036859857797478493,1,1,2,0.09224420506063007
5166,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),0.00012932476857652311,0,1,2,0.0032364369221216573
5167,Downstream signaling events of B Cell Receptor (BCR),Signaling by the B Cell Receptor (BCR),0.00016423822082315797,1,1,2,0.004110168900716923
5168,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,5.8276393145501853e-05,0,1,2,0.001458404855776548
5169,Antiviral mechanism by IFN-stimulated genes,Interferon Signaling,0.0001473067777947408,1,1,2,0.003686448464445318
5170,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.002403350739602737,0,1,2,0.06014542423755566
5171,Latent infection - Other responses of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.002262380448947684,1,1,2,0.05661755050833828
5172,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.002863610473722645,0,1,2,0.07166372512970186
5173,Events associated with phagocytolytic activity of PMN cells,ROS and RNS production in phagocytes,0.002763924290996924,1,1,2,0.06916901320444536
5174,Downregulation of ERBB2 signaling,Signaling by ERBB2,9.467796700320214e-05,0,1,2,0.0023693780510364274
5175,Downregulation of ERBB2 signaling,Signaling by ERBB2,2.3950546117891905e-05,1,1,2,0.0005993780821270645
5176,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,3.0082324532680285e-05,0,1,2,0.0007528298476188938
5177,Drug-mediated inhibition of ERBB2 signaling,Signaling by ERBB2,7.653627252428811e-06,1,1,2,0.00019153702806172144
5178,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,6.9997305399045744e-06,0,1,2,0.00017517283513130707
5179,Constitutive Signaling by Overexpressed ERBB2,Signaling by ERBB2 in Cancer,3.721253669198465e-05,1,1,2,0.0009312680706208455
5180,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,6.160612172279429e-06,0,1,2,0.00015417334913257104
5181,Signaling by ERBB2 KD Mutants,Signaling by ERBB2 in Cancer,3.2701562530502056e-05,1,1,2,0.0008183779917005006
5182,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,8.209880248905208e-06,0,1,2,0.0002054576231314259
5183,Drug resistance in ERBB2 KD mutants,Signaling by ERBB2 in Cancer,4.367501647896364e-05,1,1,2,0.001092995854256258
5184,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,1.2660171598885621e-05,0,1,2,0.00031682907500263304
5185,Signaling by ERBB2 ECD mutants,Signaling by ERBB2 in Cancer,6.72661491648219e-05,1,1,2,0.001683379380162239
5186,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,9.641168987728094e-06,0,1,2,0.00024127655999503492
5187,Signaling by ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,5.1261899561215274e-05,1,1,2,0.001282862565803398
5188,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,5.438712167742456e-06,0,1,2,0.00013610732934007643
5189,Drug resistance in ERBB2 TMD/JMD mutants,Signaling by ERBB2 in Cancer,2.891279365921669e-05,1,1,2,0.0007235615725459786
5190,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.00031341452216208883,0,1,2,0.007843403414669936
5191,Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha,Cellular response to hypoxia,0.00022892464945080312,1,1,2,0.0057289890870977
5192,Nuclear signaling by ERBB4,Signaling by ERBB4,1.195561261343746e-05,0,1,2,0.0002991970255552161
5193,Nuclear signaling by ERBB4,Signaling by ERBB4,5.890948186194188e-06,1,1,2,0.00014742483149949014
5194,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.00364548627049739,0,1,2,0.09123067835179675
5195,Antigen processing-Cross presentation,Class I MHC mediated antigen processing & presentation,0.004107978089358292,1,1,2,0.10280483862454398
5196,PTEN Regulation,PIP3 activates AKT signaling,0.00047030307096665544,0,1,2,0.01176964196586237
5197,PTEN Regulation,PIP3 activates AKT signaling,0.00044115998066145086,1,1,2,0.01104031706911856
5198,Defensins,Antimicrobial peptides,0.0003745486555918585,0,1,2,0.009373325090245518
5199,Defensins,Antimicrobial peptides,0.00037825780525289595,1,1,2,0.009466148986586407
5200,Glycerophospholipid biosynthesis,Phospholipid metabolism,0.0008274841520918751,0,1,2,0.020708332145330778
5201,Glycerophospholipid biosynthesis,Phospholipid metabolism,0.0005790790856011013,1,1,2,0.014491832880094365
5202,Antagonism of Activin by Follistatin,Signaling by Activin,8.098832328643101e-05,0,1,2,0.0020267857629285807
5203,Antagonism of Activin by Follistatin,Signaling by Activin,4.690055320471923e-05,1,1,2,0.0011737170205711064
5204,Methylation,Phase II - Conjugation of compounds,0.0006440874455948147,0,1,2,0.016118709609479243
5205,Methylation,Phase II - Conjugation of compounds,0.0005567658201822075,1,1,2,0.013933428818369113
5206,Glucuronidation,Phase II - Conjugation of compounds,0.0024003396558263316,0,1,2,0.060070069896567276
5207,Glucuronidation,Phase II - Conjugation of compounds,0.0020793991495481677,1,1,2,0.05203832380681144
5208,Glutathione conjugation,Phase II - Conjugation of compounds,0.0009575501998217521,0,1,2,0.023963320063119548
5209,Glutathione conjugation,Phase II - Conjugation of compounds,0.0008358704840686399,1,1,2,0.0209182055883651
5210,Packaging Of Telomere Ends,Telomere Maintenance,0.0007969054941863276,0,1,2,0.019943081230415112
5211,Packaging Of Telomere Ends,Telomere Maintenance,9.580302470068796e-05,1,1,2,0.0023975333557915697
5212,Inhibition of DNA recombination at telomere,Telomere Maintenance,0.0002959353449778941,0,1,2,0.007405975572889103
5213,Inhibition of DNA recombination at telomere,Telomere Maintenance,4.4383114928091646e-05,1,1,2,0.0011107164810973485
5214,Gap junction trafficking,Gap junction trafficking and regulation,0.0011352661952463824,0,1,2,0.028410779088755028
5215,Gap junction trafficking,Gap junction trafficking and regulation,0.0013098849310804995,1,1,2,0.03278072716728836
5216,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.004493390697923691,0,1,2,0.11245004124382568
5217,"Gamma-carboxylation, transport, and amino-terminal cleavage of proteins","Gamma carboxylation, hypusine formation and arylsulfatase activation",0.004862393291946065,1,1,2,0.12168457251573764
5218,Methionine salvage pathway,Sulfur amino acid metabolism,0.000144798676342246,0,1,2,0.0036236815851024957
5219,Methionine salvage pathway,Sulfur amino acid metabolism,0.0002984528790907946,1,1,2,0.007468978510728275
5220,Cysteine formation from homocysteine,Sulfur amino acid metabolism,3.815408926113013e-06,0,1,2,9.548310395125922e-05
5221,Cysteine formation from homocysteine,Sulfur amino acid metabolism,7.35251826963669e-06,1,1,2,0.0001840015788185683
5222,HIV Life Cycle,HIV Infection,0.0005594315097447447,0,1,2,0.014000139443240673
5223,HIV Life Cycle,HIV Infection,0.00043276475912650225,1,1,2,0.010830221159076229
5224,Host Interactions of HIV factors,HIV Infection,8.105341576770184e-05,0,1,2,0.0020284147448479473
5225,Host Interactions of HIV factors,HIV Infection,6.272864297214342e-05,1,1,2,0.0015698253198071974
5226,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.00035632256158397253,0,1,2,0.0089172051664099
5227,Keratan sulfate/keratin metabolism,Glycosaminoglycan metabolism,0.0004888448431375962,1,1,2,0.012233661942206596
5228,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.002135194772009402,0,1,2,0.05343464575359652
5229,Heparan sulfate/heparin (HS-GAG) metabolism,Glycosaminoglycan metabolism,0.0028991119717165052,1,1,2,0.07255217333774927
5230,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,0.00034042385575653477,0,1,2,0.008519329654083554
5231,Chondroitin sulfate/dermatan sulfate metabolism,Glycosaminoglycan metabolism,0.00046402894523790163,1,1,2,0.011612627865732302
5232,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.0024786860359859828,0,1,2,0.06203073930471114
5233,Hyaluronan metabolism,Glycosaminoglycan metabolism,0.003417532220317363,1,1,2,0.0855259791462979
5234,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",0.00015570343480779918,0,1,2,0.0038965802982662613
5235,Respiratory electron transport,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",0.00011777123575202818,1,1,2,0.002947302206276297
5236,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,6.175625918068053e-06,0,1,2,0.00015454907794109314
5237,Signaling by EGFRvIII in Cancer,Signaling by EGFR in Cancer,4.599487915399508e-06,1,1,2,0.00011510519350702055
5238,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,0.00012315413825056423,0,1,2,0.003082012862140603
5239,Signaling by Ligand-Responsive EGFR Variants in Cancer,Signaling by EGFR in Cancer,9.17101446303526e-05,1,1,2,0.002295106354968358
5240,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.003142487586485216,0,1,2,0.07864280728398702
5241,Collagen chain trimerization,Collagen biosynthesis and modifying enzymes,0.0023817096163451065,1,1,2,0.05960384097304948
5242,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.0009150002898159674,0,1,2,0.022898480734262056
5243,Toll Like Receptor 4 (TLR4) Cascade,Toll-like Receptor Cascades,0.0010415312158214053,1,1,2,0.02606499991865117
5244,Signaling by NTRK1 (TRKA),Signaling by NTRKs,0.0005769966076232191,0,1,2,0.0144397175065947
5245,Signaling by NTRK1 (TRKA),Signaling by NTRKs,0.0005749294204580678,1,1,2,0.01438798479568501
5246,Initial triggering of complement,Complement cascade,0.003877990404112905,0,1,2,0.09704924637137843
5247,Initial triggering of complement,Complement cascade,0.004379447715912873,1,1,2,0.10959854359139996
5248,Terminal pathway of complement,Complement cascade,7.407337119012172e-05,0,1,2,0.0018537345637999658
5249,Terminal pathway of complement,Complement cascade,8.28933293553522e-05,1,1,2,0.0020744597858260135
5250,Activation of C3 and C5,Complement cascade,0.000869049954869717,0,1,2,0.021748543547126055
5251,Activation of C3 and C5,Complement cascade,0.0009689316292157305,1,1,2,0.02424814777804716
5252,Regulation of Complement cascade,Complement cascade,0.0032202083880471673,0,1,2,0.08058782117854621
5253,Regulation of Complement cascade,Complement cascade,0.003607272863692156,1,1,2,0.09027436285194465
5254,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.00021974892612183447,0,1,2,0.005499360609150916
5255,Toll Like Receptor 9 (TLR9) Cascade,Toll-like Receptor Cascades,0.00024977316208481986,1,1,2,0.006250736752318736
5256,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.0002266799783683382,0,1,2,0.005672814725068902
5257,Toll Like Receptor 10 (TLR10) Cascade,Toll-like Receptor Cascades,0.0002578527437366445,1,1,2,0.006452933567832766
5258,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.0001388477203249461,0,1,2,0.0034747550183797785
5259,Toll Like Receptor 3 (TLR3) Cascade,Toll-like Receptor Cascades,0.0001576108242088848,1,1,2,0.003944313965609994
5260,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0006884543909109198,0,1,2,0.01722902143546044
5261,Toll Like Receptor 5 (TLR5) Cascade,Toll-like Receptor Cascades,0.0007808522628334653,1,1,2,0.019541338615743264
5262,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.0009607676004606713,0,1,2,0.024043837618539683
5263,Toll Like Receptor 7/8 (TLR7/8) Cascade,Toll-like Receptor Cascades,0.001089540867996668,1,1,2,0.027266472866397433
5264,Virus Assembly and Release,Influenza Infection,0.0024262214103727814,0,1,2,0.060717777732780066
5265,Virus Assembly and Release,Influenza Infection,0.0020998411576693813,1,1,2,0.05254989843071389
5266,Influenza Viral RNA Transcription and Replication,Influenza Infection,0.0002159192114733077,0,1,2,0.0054035194951391925
5267,Influenza Viral RNA Transcription and Replication,Influenza Infection,0.00018524832160848542,1,1,2,0.004635960415115774
5268,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.00014909328103551836,0,1,2,0.003731156876558357
5269,Inflammasomes,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",0.00024143026144551657,1,1,2,0.006041950206911879
5270,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,0.00022444108261080898,0,1,2,0.005616784894324132
5271,Trafficking and processing of endosomal TLR,Toll-like Receptor Cascades,0.00025590141001718855,1,1,2,0.0064041001651788014
5272,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.000574161814491966,0,1,2,0.014368774954309087
5273,Toll Like Receptor 2 (TLR2) Cascade,Toll-like Receptor Cascades,0.0006515000066724382,1,1,2,0.016304213798840363
5274,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.0011078267251357064,0,1,2,0.027724088401679895
5275,Regulation of TLR by endogenous ligand,Toll-like Receptor Cascades,0.001262728884400443,1,1,2,0.03160061625538425
5276,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.00033986023747423775,0,1,2,0.008505224737918718
5277,TRAF6 mediated NF-kB activation,DDX58/IFIH1-mediated induction of interferon-alpha/beta,0.00044378809579615944,1,1,2,0.0111060873693571
5278,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,0.0004070659548962822,0,1,2,0.010187091774190873
5279,Regulation of activated PAK-2p34 by proteasome mediated degradation,Regulation of Apoptosis,0.0005462927657589056,1,1,2,0.013671333781230829
5280,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,0.00014075245345167954,0,1,2,0.003522422210720438
5281,TGF-beta receptor signaling activates SMADs,Signaling by TGF-beta Receptor Complex,6.233853416007395e-05,1,1,2,0.0015600625916235423
5282,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.004654510587874592,0,1,2,0.11648217187483254
5283,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Generic Transcription Pathway,0.0034898188923069553,1,1,2,0.08733500039396387
5284,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.004654510587874592,0,1,2,0.11648217187483254
5285,Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer,Signaling by TGF-beta Receptor Complex,0.0034898188923069553,1,1,2,0.08733500039396387
5286,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,0.0007575200104626217,0,1,2,0.018957433739048457
5287,APC/C-mediated degradation of cell cycle proteins,Regulation of mitotic cell cycle,0.0002729539430663235,1,1,2,0.006830850958421194
5288,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,0.0019481962955083172,0,1,2,0.04875488656755552
5289,Pre-NOTCH Transcription and Translation,Pre-NOTCH Expression and Processing,0.0014019340337031027,1,1,2,0.03508431616771777
5290,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,0.002666710374330532,0,1,2,0.06673617135437857
5291,Pre-NOTCH Processing in Golgi,Pre-NOTCH Expression and Processing,0.0019219470415946904,1,1,2,0.04809798181930584
5292,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,0.0004647299367373072,0,1,2,0.011630170636508088
5293,"Cell death signalling via NRAGE, NRIF and NADE",p75 NTR receptor-mediated signalling,0.0006657757888386158,1,1,2,0.01666147458502491
5294,Bile acid and bile salt metabolism,Metabolism of steroids,0.00013084761757902366,0,1,2,0.0032745472144713596
5295,Bile acid and bile salt metabolism,Metabolism of steroids,0.00018191259483486195,1,1,2,0.004552481670780139
5296,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,1.8558773476283464e-05,0,1,2,0.0004644454451306061
5297,Neurophilin interactions with VEGF and VEGFR,Signaling by VEGF,1.7465178621146e-05,1,1,2,0.0004370775185843863
5298,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.0021293097390049196,0,1,2,0.05328736895338835
5299,VEGFA-VEGFR2 Pathway,Signaling by VEGF,0.002010840430382001,1,1,2,0.05032259701692387
5300,RHO GTPase Effectors,Signaling by Rho GTPases,0.005115241928394753,0,1,2,0.1280122750256125
5301,RHO GTPase Effectors,Signaling by Rho GTPases,0.0034664486920178783,1,1,2,0.08675014584579438
5302,RHO GTPase cycle,Signaling by Rho GTPases,0.0008306232486648894,0,1,2,0.02078689009028467
5303,RHO GTPase cycle,Signaling by Rho GTPases,0.0005614271657379255,1,1,2,0.014050082039784832
5304,Metabolism of steroid hormones,Metabolism of steroids,0.0006055190313967669,0,1,2,0.015153509817419435
5305,Metabolism of steroid hormones,Metabolism of steroids,0.0008501706730981906,1,1,2,0.021276077172269547
5306,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,9.588868121871311e-05,0,1,2,0.0023996769661811987
5307,"Cobalamin (Cbl, vitamin B12) transport and metabolism",Metabolism of water-soluble vitamins and cofactors,0.00010292307035624294,1,1,2,0.002575717155387506
5308,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,0.0001602770231689591,0,1,2,0.004011037338488106
5309,Metabolism of folate and pterines,Metabolism of water-soluble vitamins and cofactors,0.00016577572946724491,1,1,2,0.004148646060185874
5310,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,0.0005580977734705369,0,1,2,0.013966761820610985
5311,Biotin transport and metabolism,Metabolism of water-soluble vitamins and cofactors,0.0006019436646344965,1,1,2,0.015064033925624649
5312,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,6.642394266218339e-05,0,1,2,0.001662302611564912
5313,Nicotinate metabolism,Metabolism of water-soluble vitamins and cofactors,7.123989740039132e-05,1,1,2,0.0017828250288989135
5314,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.00014610222329829967,0,1,2,0.0036563037002992067
5315,Vitamin C (ascorbate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.00015689275198087788,1,1,2,0.003926343738428829
5316,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.0004227334389115594,0,1,2,0.010579180809430785
5317,Vitamin B5 (pantothenate) metabolism,Metabolism of water-soluble vitamins and cofactors,0.0004513016099708278,1,1,2,0.011294117976002976
5318,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.003031203671673608,0,1,2,0.07585785452745905
5319,COPII-mediated vesicle transport,ER to Golgi Anterograde Transport,0.003362066941493135,1,1,2,0.08413792426509946
5320,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.0028589389159587603,0,1,2,0.07154681634109719
5321,Cargo concentration in the ER,ER to Golgi Anterograde Transport,0.003162724146318281,1,1,2,0.07914924043009933
5322,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,0.001300781535254029,0,1,2,0.032552908732399424
5323,COPI-mediated anterograde transport,ER to Golgi Anterograde Transport,0.001448816491025299,1,1,2,0.036257580326992625
5324,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.002937132747800132,0,1,2,0.07350366812779761
5325,Lysosome Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0036284231400852407,1,1,2,0.09080366235261342
5326,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.0022585630498018283,0,1,2,0.0565220175978362
5327,Golgi Associated Vesicle Biogenesis,trans-Golgi Network Vesicle Budding,0.002820972970150556,1,1,2,0.07059669371455457
5328,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,4.0072082783393074e-05,0,1,2,0.0010028300819247108
5329,Formation of the beta-catenin:TCF transactivating complex,TCF dependent signaling in response to WNT,4.213563781912701e-05,1,1,2,0.0010544718964200337
5330,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,2.2660192089784078e-05,0,1,2,0.0005670861285814025
5331,Deactivation of the beta-catenin transactivating complex,TCF dependent signaling in response to WNT,2.3849059203795486e-05,1,1,2,0.0005968383057214373
5332,Degradation of AXIN,TCF dependent signaling in response to WNT,0.0003449400077175218,0,1,2,0.008632349310823182
5333,Degradation of AXIN,TCF dependent signaling in response to WNT,0.0003667093105509293,1,1,2,0.009177140353052641
5334,Degradation of DVL,TCF dependent signaling in response to WNT,0.0010447341903023597,0,1,2,0.026145156450032396
5335,Degradation of DVL,TCF dependent signaling in response to WNT,0.0011077007598794411,1,1,2,0.02772093603875074
5336,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,0.0011297300176717408,0,1,2,0.028272232623857318
5337,Anchoring fibril formation,Assembly of collagen fibrils and other multimeric structures,0.0008797963016800838,1,1,2,0.022017477905005193
5338,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0038530010032570366,0,1,2,0.09642387026994141
5339,Crosslinking of collagen fibrils,Assembly of collagen fibrils and other multimeric structures,0.0029849750626915568,1,1,2,0.07470095335056419
5340,Downstream TCR signaling,TCR signaling,0.00012300099592288562,0,1,2,0.003078180375223409
5341,Downstream TCR signaling,TCR signaling,2.872900872230408e-05,1,1,2,0.000718962234290045
5342,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0015143389376291987,0,1,2,0.03789732241005019
5343,FCGR activation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0015536115412577588,1,1,2,0.03888014500320343
5344,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0034497117849703147,0,1,2,0.08633129379968535
5345,Regulation of actin dynamics for phagocytic cup formation,Fcgamma receptor (FCGR) dependent phagocytosis,0.0035365744249898612,1,1,2,0.08850508818112186
5346,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.00028323018306620443,0,1,2,0.007088020585881372
5347,Role of phospholipids in phagocytosis,Fcgamma receptor (FCGR) dependent phagocytosis,0.0002896102098509865,1,1,2,0.007247684929206106
5348,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,9.193020630079773e-05,0,1,2,0.0023006135422087588
5349,alpha-linolenic (omega3) and linoleic (omega6) acid metabolism,Fatty acid metabolism,7.55776519386918e-05,1,1,2,0.0018913801734499708
5350,Catecholamine biosynthesis,Metabolism of amine-derived hormones,1.0165130411607565e-05,0,1,2,0.000254389037339292
5351,Catecholamine biosynthesis,Metabolism of amine-derived hormones,2.8664641870231263e-06,1,1,2,7.173514117159768e-05
5352,Ethanol oxidation,Phase I - Functionalization of compounds,0.0010337590788482797,0,1,2,0.025870497107314403
5353,Ethanol oxidation,Phase I - Functionalization of compounds,0.0007849136743573992,1,1,2,0.01964297809560989
5354,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,5.120675392773883e-06,0,1,2,0.00012814825102561007
5355,Aryl hydrocarbon receptor signalling,Phase I - Functionalization of compounds,3.890599328899163e-06,1,1,2,9.736479296137565e-05
5356,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.00010986826646100047,0,1,2,0.002749525230609481
5357,YAP1- and WWTR1 (TAZ)-stimulated gene expression,Generic Transcription Pathway,0.00011529497591217834,1,1,2,0.0028853321841168147
5358,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.0005237796461829552,0,1,2,0.013107928238505021
5359,Transcriptional Regulation by TP53,Generic Transcription Pathway,0.0005552308371379648,1,1,2,0.013895014863688205
5360,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.001013045479025843,0,1,2,0.02535212572344667
5361,Transcriptional Regulation by VENTX,Generic Transcription Pathway,0.0010719679605965102,1,1,2,0.026826699364655246
5362,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.0007143233890024091,0,1,2,0.017876410033044132
5363,Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors,Generic Transcription Pathway,0.0007525020852516705,1,1,2,0.018831856878529597
5364,Transcriptional regulation by RUNX3,Generic Transcription Pathway,0.0013929420792227192,0,1,2,0.034859286625406
5365,Transcriptional regulation by RUNX3,Generic Transcription Pathway,0.0014644278847479627,1,1,2,0.03664826566597246
5366,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.0019305775312375606,0,1,2,0.04831396546763262
5367,Transcriptional regulation by RUNX2,Generic Transcription Pathway,0.0020222527256208447,1,1,2,0.0506081971698079
5368,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.0016207290443028606,0,1,2,0.04055980441699351
5369,Transcriptional regulation by RUNX1,Generic Transcription Pathway,0.0017116796567962654,1,1,2,0.042835902983441435
5370,FOXO-mediated transcription,Generic Transcription Pathway,0.001627805546834259,0,1,2,0.040736898521426826
5371,FOXO-mediated transcription,Generic Transcription Pathway,0.0017241160854046676,1,1,2,0.04314713274376184
5372,Arachidonic acid metabolism,Fatty acid metabolism,0.000490057661598368,0,1,2,0.01226401351746536
5373,Arachidonic acid metabolism,Fatty acid metabolism,0.0003998864109479687,1,1,2,0.010007418990902127
5374,DAP12 signaling,DAP12 interactions,0.0013394263450841601,0,1,2,0.03352002037512083
5375,DAP12 signaling,DAP12 interactions,0.0017800379271343421,1,1,2,0.04454661341029688
5376,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.0014839870340909117,0,1,2,0.03713774617149027
5377,IGF1R signaling cascade,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),0.0011806437919426916,1,1,2,0.02954638312657073
5378,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,0.00010283911698361916,0,1,2,0.0025736161673255366
5379,"Metabolism of ingested SeMet, Sec, MeSec into H2Se",Selenoamino acid metabolism,6.439000670643e-05,1,1,2,0.0016114020339192926
5380,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0005554874975711806,0,1,2,0.013901437958905388
5381,Role of LAT2/NTAL/LAB on calcium mobilization,Fc epsilon receptor (FCERI) signaling,0.0009318406728152002,1,1,2,0.023319922333742957
5382,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.00041055591490877873,0,1,2,0.010274430306209885
5383,FCERI mediated MAPK activation,Fc epsilon receptor (FCERI) signaling,0.0006870235972101785,1,1,2,0.017193214887248613
5384,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0001894535490914752,0,1,2,0.004741198983424641
5385,FCERI mediated Ca+2 mobilization,Fc epsilon receptor (FCERI) signaling,0.0003177777179694965,1,1,2,0.007952595243620976
5386,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.00026377672979412456,0,1,2,0.006601185193670532
5387,FCERI mediated NF-kB activation,Fc epsilon receptor (FCERI) signaling,0.0004412967624804952,1,1,2,0.011043740123606132
5388,Retinoid cycle disease events,Diseases associated with visual transduction,0.0005343544969041501,0,1,2,0.013372570794580802
5389,Retinoid cycle disease events,Diseases associated with visual transduction,0.0010661937464559335,1,1,2,0.026682195879000514
5390,Retinoid metabolism disease events,Diseases associated with visual transduction,0.00011937668559974942,0,1,2,0.0029874796388050487
5391,Retinoid metabolism disease events,Diseases associated with visual transduction,0.0002397207006878244,1,1,2,0.0059991673307644424
5392,Mitotic Metaphase and Anaphase,M Phase,0.0007268189441222183,0,1,2,0.01818911947298585
5393,Mitotic Metaphase and Anaphase,M Phase,0.0002989687893117255,1,1,2,0.007481889501452629
5394,Oxidative Stress Induced Senescence,Cellular Senescence,0.0003066661973202757,0,1,2,0.007674522171572319
5395,Oxidative Stress Induced Senescence,Cellular Senescence,0.00022908622723468217,1,1,2,0.0057330326768237575
5396,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,0.0003842606796761313,0,1,2,0.009616374845376347
5397,Senescence-Associated Secretory Phenotype (SASP),Cellular Senescence,0.00028618222899849617,1,1,2,0.007161897466205458
5398,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,1.5968787873684107e-05,0,1,2,0.0003996293613727903
5399,DNA Damage/Telomere Stress Induced Senescence,Cellular Senescence,1.1929055870791557e-05,1,1,2,0.00029853242570031957
5400,EPH-Ephrin signaling,Axon guidance,0.001114826205852536,0,1,2,0.027899254984825345
5401,EPH-Ephrin signaling,Axon guidance,0.0011103032857828494,1,1,2,0.027786065951738638
5402,SUMO E3 ligases SUMOylate target proteins,SUMOylation,0.0008096495728353558,0,1,2,0.020262010134229326
5403,SUMO E3 ligases SUMOylate target proteins,SUMOylation,0.00039587966935398285,1,1,2,0.009907147661790848
5404,Processing and activation of SUMO,SUMOylation,0.00035804481079227524,0,1,2,0.008960305579333102
5405,Processing and activation of SUMO,SUMOylation,0.0001664829343205157,1,1,2,0.0041663443242061565
5406,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,0.0024375023057090113,0,1,2,0.061000089517155395
5407,Defects in biotin (Btn) metabolism,Defects in vitamin and cofactor metabolism,0.003151541743764351,1,1,2,0.07886939349202304
5408,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,0.0023643031459582996,0,1,2,0.059168232666429184
5409,Regulation of HSF1-mediated heat shock response,Cellular response to heat stress,0.001974733948363653,1,1,2,0.04941900868795688
5410,HSF1 activation,Cellular response to heat stress,2.293179863377629e-05,0,1,2,0.0005738832599966898
5411,HSF1 activation,Cellular response to heat stress,1.9418914216380865e-05,1,1,2,0.00048597102975073305
5412,HSF1-dependent transactivation,Cellular response to heat stress,0.0010600289664243466,0,1,2,0.026527918226462662
5413,HSF1-dependent transactivation,Cellular response to heat stress,0.0008872295967233897,1,1,2,0.022203500975419146
5414,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,8.86412837256652e-05,0,1,2,0.0022183061035539586
5415,Regulation of ornithine decarboxylase (ODC),Metabolism of polyamines,7.715795365751844e-05,1,1,2,0.0019309282576042948
5416,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.0014920318177075553,0,1,2,0.03733907214341327
5417,Diseases associated with glycosaminoglycan metabolism,Diseases of glycosylation,0.00225348814973849,1,1,2,0.05639501490437034
5418,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.0023974907315824465,0,1,2,0.05999877370394519
5419,Class A/1 (Rhodopsin-like receptors),GPCR ligand binding,0.001778829098945381,1,1,2,0.044516361694200125
5420,Semaphorin interactions,Axon guidance,0.0029641290530349664,0,1,2,0.07417926832399038
5421,Semaphorin interactions,Axon guidance,0.0029600229233073135,1,1,2,0.0740765097418265
5422,L1CAM interactions,Axon guidance,0.001674725706280572,0,1,2,0.04191110620101782
5423,L1CAM interactions,Axon guidance,0.0016692110682712607,1,1,2,0.04177309877783106
5424,NCAM signaling for neurite out-growth,Axon guidance,0.0027426302885157432,0,1,2,0.06863611686441391
5425,NCAM signaling for neurite out-growth,Axon guidance,0.002740558927277751,1,1,2,0.06858427969460121
5426,Signaling by ROBO receptors,Axon guidance,0.0020112014165044392,0,1,2,0.050331630930750985
5427,Signaling by ROBO receptors,Axon guidance,0.0020061408046651917,1,1,2,0.05020498580943863
5428,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.0003094485741020052,0,1,2,0.007744152970426717
5429,Diseases associated with N-glycosylation of proteins,Diseases of glycosylation,0.0004703639348781161,1,1,2,0.011771165125056424
5430,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.000835375352669197,0,1,2,0.02090581460123945
5431,Diseases associated with O-glycosylation of proteins,Diseases of glycosylation,0.0012600067697496739,1,1,2,0.03153249355577328
5432,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,0.00018834954022481885,0,1,2,0.004713570439428584
5433,Diseases associated with glycosylation precursor biosynthesis,Diseases of glycosylation,0.0002815937297440874,1,1,2,0.007047067271127173
5434,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),0.004645570714634176,0,1,2,0.11625844569961617
5435,ATF6 (ATF6-alpha) activates chaperones,Unfolded Protein Response (UPR),0.002757759789023721,1,1,2,0.06901474251050045
5436,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),0.0024515474564087677,0,1,2,0.06135157860004176
5437,IRE1alpha activates chaperones,Unfolded Protein Response (UPR),0.0014454658399275099,1,1,2,0.036173728091683066
5438,PERK regulates gene expression,Unfolded Protein Response (UPR),0.0002731424856595975,0,1,2,0.00683556936013945
5439,PERK regulates gene expression,Unfolded Protein Response (UPR),0.00016160738728265337,1,1,2,0.0040443305705952885
5440,PCP/CE pathway,Beta-catenin independent WNT signaling,0.0007949594329115341,0,1,2,0.019894379774137414
5441,PCP/CE pathway,Beta-catenin independent WNT signaling,0.00030135364576736593,1,1,2,0.007541572094137321
5442,G alpha (q) signalling events,GPCR downstream signalling,0.005635121916559813,0,1,2,0.1410226117715389
5443,G alpha (q) signalling events,GPCR downstream signalling,0.004292286495825548,1,1,2,0.10741727704847262
5444,G alpha (s) signalling events,GPCR downstream signalling,0.00031043792798097136,0,1,2,0.007768912198362514
5445,G alpha (s) signalling events,GPCR downstream signalling,0.00023700420405277077,1,1,2,0.005931185225671367
5446,G alpha (i) signalling events,GPCR downstream signalling,0.0008679999069490666,0,1,2,0.021722265411098465
5447,G alpha (i) signalling events,GPCR downstream signalling,0.0006617886663195632,1,1,2,0.01656169423609624
5448,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.000601919539242998,0,1,2,0.015063430171922512
5449,Cooperation of Prefoldin and TriC/CCT  in actin and tubulin folding,Chaperonin-mediated protein folding,0.00011033451089830576,1,1,2,0.0027611933026133045
5450,Peroxisomal lipid metabolism,Fatty acid metabolism,0.00012820786726705348,0,1,2,0.003208485736311534
5451,Peroxisomal lipid metabolism,Fatty acid metabolism,0.00010540278848852468,1,1,2,0.00263777372357709
5452,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.0016206796885553604,0,1,2,0.0405585692571298
5453,PPARA activates gene expression,Regulation of lipid metabolism by PPARalpha,0.0021331603927880914,1,1,2,0.05338373408294039
5454,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,5.737482207698888e-05,0,1,2,0.0014358424500891525
5455,Free fatty acids regulate insulin secretion,Regulation of insulin secretion,2.0832355976513875e-06,1,1,2,5.213433342993106e-05
5456,Adherens junctions interactions,Cell-cell junction organization,0.003531020674345569,0,1,2,0.088366101938662
5457,Adherens junctions interactions,Cell-cell junction organization,0.002281453802351081,1,1,2,0.057094873652720333
5458,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,0.000705123399023846,0,1,2,0.01764617426631896
5459,Glucagon-like Peptide-1 (GLP1) regulates insulin secretion,Regulation of insulin secretion,6.904168521064578e-05,1,1,2,0.0017278133310481595
5460,Netrin-1 signaling,Axon guidance,4.843371037717644e-05,0,1,2,0.001212085281616322
5461,Netrin-1 signaling,Axon guidance,4.8232556021267665e-05,1,1,2,0.0012070512622890533
5462,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0011343442464089195,0,1,2,0.02838770671607101
5463,Metal ion SLC transporters,"Transport of bile salts and organic acids, metal ions and amine compounds",0.0011198206787638566,1,1,2,0.02802424493620631
5464,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,0.00032749840957059425,0,1,2,0.008195861909029585
5465,Amino acid transport across the plasma membrane,Transport of inorganic cations/anions and amino acids/oligopeptides,0.00031736586154273094,1,1,2,0.007942288267154915
5466,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,0.00022474425453497665,0,1,2,0.0056243719700245325
5467,Bicarbonate transporters,Transport of inorganic cations/anions and amino acids/oligopeptides,0.0002133215653921624,1,1,2,0.005338511702895214
5468,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",0.000552247736474095,0,1,2,0.013820360818394157
5469,Transport of fatty acids,"Transport of vitamins, nucleosides, and related molecules",0.000430585345125779,1,1,2,0.01077567989820124
5470,Glycosphingolipid metabolism,Sphingolipid metabolism,7.980117209114312e-05,0,1,2,0.0019970765277769467
5471,Glycosphingolipid metabolism,Sphingolipid metabolism,0.0007803774139486953,1,1,2,0.01952945521181365
5472,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,0.0052416755263482,0,1,2,0.13117635851184037
5473,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,Asparagine N-linked glycosylation,0.004556461425294625,1,1,2,0.11402842744946254
5474,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,5.757116000287691e-05,0,1,2,0.0014407559351048308
5475,Localization of the PINCH-ILK-PARVIN complex to focal adhesions,Cell-extracellular matrix interactions,3.814469236836368e-05,1,1,2,0.0009545958761248103
5476,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,3.639860989756824e-05,0,1,2,0.0009108990202189135
5477,Regulation of cytoskeletal remodeling and cell spreading by IPP complex components,Cell-extracellular matrix interactions,2.346005641100668e-05,1,1,2,0.0005871032563937042
5478,Interleukin-1 family signaling,Signaling by Interleukins,0.000465528965463158,0,1,2,0.011650166852999664
5479,Interleukin-1 family signaling,Signaling by Interleukins,0.00061652553046809,1,1,2,0.01542895465578889
5480,Interleukin-12 family signaling,Signaling by Interleukins,0.0011199942480692845,0,1,2,0.02802858862160252
5481,Interleukin-12 family signaling,Signaling by Interleukins,0.0014873891179681801,1,1,2,0.03722288554574735
5482,Other interleukin signaling,Signaling by Interleukins,0.0005644482806430257,0,1,2,0.01412568741632995
5483,Other interleukin signaling,Signaling by Interleukins,0.0007545234305473312,1,1,2,0.018882442366671123
5484,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.0002978651944634612,0,1,2,0.007454271318537633
5485,"Interleukin-3, Interleukin-5 and GM-CSF signaling",Signaling by Interleukins,0.00039927678838739205,1,1,2,0.00999216278758295
5486,Interleukin-10 signaling,Signaling by Interleukins,0.0013315726165611121,0,1,2,0.03332347568188
5487,Interleukin-10 signaling,Signaling by Interleukins,0.0017707785416867059,1,1,2,0.044314891233108875
5488,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.0016112183280840447,0,1,2,0.040321792522866794
5489,Interleukin-4 and Interleukin-13 signaling,Signaling by Interleukins,0.0021454492176084857,1,1,2,0.0536912699619215
5490,G2/M Transition,Mitotic G2-G2/M phases,0.0018458792944100512,0,1,2,0.04619433669176549
5491,G2/M Transition,Mitotic G2-G2/M phases,0.0006595661811635704,1,1,2,0.016506075091388735
5492,G1/S Transition,Mitotic G1 phase and G1/S transition,0.000921049907137693,0,1,2,0.023049876364660226
5493,G1/S Transition,Mitotic G1 phase and G1/S transition,0.00025483547933664126,1,1,2,0.00637742455269623
5494,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.001270303544654129,0,1,2,0.03179017708265186
5495,O-glycosylation of TSR domain-containing proteins,O-linked glycosylation,0.0010900588981181721,1,1,2,0.027279436909020217
5496,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,9.706841448518722e-05,0,1,2,0.0024292005628123634
5497,Regulation of necroptotic cell death,RIPK1-mediated regulated necrosis,0.0005933638417007174,1,1,2,0.01484931824483286
5498,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,0.00043152567317356256,0,1,2,0.010799212222644973
5499,ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression,Positive epigenetic regulation of rRNA expression,0.0003173380828749092,1,1,2,0.00794159308782326
5500,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.0008969237246928231,0,1,2,0.022446102868570666
5501,B-WICH complex positively regulates rRNA expression,Positive epigenetic regulation of rRNA expression,0.0006625061712626573,1,1,2,0.016579650266601416
5502,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,4.7023162150118447e-05,0,1,2,0.0011767853896255433
5503,SIRT1 negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.00016110667678186487,1,1,2,0.004031799962809301
5504,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,7.383180315725075e-05,0,1,2,0.0018476891657730184
5505,NoRC negatively regulates rRNA expression,Negative epigenetic regulation of rRNA expression,0.00023635858065640167,1,1,2,0.00591502807788913
5506,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,6.295582694421803e-05,0,1,2,0.0015755107473044167
5507,Uptake and function of diphtheria toxin,Uptake and actions of bacterial toxins,8.75882801023271e-06,1,1,2,0.0002191953999133352
5508,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.006851743381985631,0,1,2,0.17146935970923188
5509,Caspase activation via Death Receptors in the presence of ligand,Caspase activation via extrinsic apoptotic signalling pathway,0.009215174869509818,1,1,2,0.23061577855321472
5510,RA biosynthesis pathway,Signaling by Retinoic Acid,0.004420053558057732,0,1,2,0.11061473135046564
5511,RA biosynthesis pathway,Signaling by Retinoic Acid,0.003269120727885552,1,1,2,0.0818118844754903
5512,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.0005860736479898783,0,1,2,0.01466687637886333
5513,Hh mutants are degraded by ERAD,Hh mutants abrogate ligand secretion,0.00048550462694530404,1,1,2,0.012150070847232346
5514,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,5.235150571154129e-05,0,1,2,0.001310130672402787
5515,Defective AHCY causes HMAHCHD,Metabolic disorders of biological oxidation enzymes,0.00013125192002326233,1,1,2,0.0032846651475837924
5516,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,4.572477832349471e-06,0,1,2,0.00011442924851199054
5517,Defective GSS causes GSS deficiency,Metabolic disorders of biological oxidation enzymes,1.141161279233783e-05,1,1,2,0.0002855830742138484
5518,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,0.0001647895833922504,0,1,2,0.004123967109642622
5519,Defective ACY1 causes encephalopathy,Metabolic disorders of biological oxidation enzymes,0.00038739979482222786,1,1,2,0.00969493325513377
5520,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.003963147150958311,0,1,2,0.09918034966034478
5521,MyD88 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.004635834913439475,1,1,2,0.11601480090674478
5522,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.0036033056563001035,0,1,2,0.09017508089209521
5523,IRAK4 deficiency (TLR2/4),Diseases associated with the TLR signaling cascade,0.004213101396579141,1,1,2,0.10543561814659493
5524,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),0.0002973285429896369,0,1,2,0.007440841264393224
5525,CLEC7A (Dectin-1) signaling,C-type lectin receptors (CLRs),0.00038014516540011193,1,1,2,0.009513381408751357
5526,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,0.00017547755527777951,0,1,2,0.00439144059684594
5527,Degradation of GLI1 by the proteasome,Hedgehog 'off' state,0.00024151906354330228,1,1,2,0.00604417253749247
5528,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,0.00020561043457841208,0,1,2,0.0051455356105996036
5529,Degradation of GLI2 by the proteasome,Hedgehog 'off' state,0.000284288940011242,1,1,2,0.007114516670940629
5530,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,5.092013405433614e-05,0,1,2,0.0012743096604524266
5531,GLI3 is processed to GLI3R by the proteasome,Hedgehog 'off' state,7.100218039026751e-05,1,1,2,0.0017768760052350838
5532,Defective CFTR causes cystic fibrosis,ABC transporter disorders,0.0001162043516917481,0,1,2,0.0029080899078032965
5533,Defective CFTR causes cystic fibrosis,ABC transporter disorders,8.906073292929263e-05,1,1,2,0.0022288030942272576
5534,Defective ABCA1 causes TGD,ABC transporter disorders,0.0006548004784914331,0,1,2,0.016386810264876928
5535,Defective ABCA1 causes TGD,ABC transporter disorders,0.0004929285830516404,1,1,2,0.012335860204640245
5536,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,4.858190405354341e-06,0,1,2,0.00012157939252976383
5537,Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages),SLC transporter disorders,2.1009139980783795e-05,1,1,2,0.0005257674696367045
5538,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,5.922682983620532e-05,0,1,2,0.0014821901556211921
5539,"Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)",SLC transporter disorders,0.00025629746860754795,1,1,2,0.0064140117904557805
5540,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,2.0888280611471523e-05,0,1,2,0.0005227428848682028
5541,Defective CP causes aceruloplasminemia (ACERULOP),SLC transporter disorders,9.032544606127558e-05,1,1,2,0.0022604533675762467
5542,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,7.091855584037476e-05,0,1,2,0.0017747832461770339
5543,Defective SLC7A7 causes lysinuric protein intolerance (LPI),SLC transporter disorders,0.00030925258373466985,1,1,2,0.007739248183291149
5544,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),0.0012368543379642257,0,1,2,0.030953088806844695
5545,CD209 (DC-SIGN) signaling,C-type lectin receptors (CLRs),0.0015805440979683536,1,1,2,0.0395541498508806
5546,Fructose biosynthesis,Fructose metabolism,9.746407759770323e-05,0,1,2,0.002439102290997639
5547,Fructose biosynthesis,Fructose metabolism,0.00018071288262584914,1,1,2,0.0045224580880441545
5548,Fructose catabolism,Fructose metabolism,0.0009302622446587054,0,1,2,0.02328042113671144
5549,Fructose catabolism,Fructose metabolism,0.001700450959059925,1,1,2,0.04255489747814465
5550,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.0014447931399447533,0,1,2,0.03615689333461629
5551,Hereditary fructose intolerance,Diseases of carbohydrate metabolism,0.001829422884266531,1,1,2,0.04578250426414702
5552,Essential pentosuria,Diseases of carbohydrate metabolism,0.000540754910395067,0,1,2,0.013532745328561059
5553,Essential pentosuria,Diseases of carbohydrate metabolism,0.0006756041401957025,1,1,2,0.016907435506245027
5554,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,5.4943679743945754e-05,0,1,2,0.0013750015230478796
5555,Pentose phosphate pathway disease,Diseases of carbohydrate metabolism,6.869001899666253e-05,1,1,2,0.0017190126540260727
5556,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,0.0010006816288471686,0,1,2,0.02504271228580216
5557,NIK-->noncanonical NF-kB signaling,TNFR2 non-canonical NF-kB pathway,0.0010261374690007361,1,1,2,0.025679761335751818
5558,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.00033765214131359833,0,1,2,0.008449965687231456
5559,RAF/MAP kinase cascade,MAPK1/MAPK3 signaling,0.0001256407730635068,1,1,2,0.0031442425247877734
5560,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,0.0004058370988953121,0,1,2,0.010156338848998843
5561,Defective pro-SFTPB causes SMDP1 and RDS,Diseases associated with surfactant metabolism,0.0006700388562444806,1,1,2,0.01676816063523555
5562,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,0.000917169556782822,0,1,2,0.02295276805897753
5563,Defective CSF2RB causes SMDP5,Diseases associated with surfactant metabolism,0.0015142597580153666,1,1,2,0.037895340888424396
5564,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,0.00016824365135513928,0,1,2,0.004210407419644
5565,Defective CSF2RA causes SMDP4,Diseases associated with surfactant metabolism,0.00027777052365230434,1,1,2,0.006951389038005067
5566,UCH proteinases,Deubiquitination,0.00030874271708698824,0,1,2,0.007726488436940329
5567,UCH proteinases,Deubiquitination,0.00028613680970680474,1,1,2,0.007160760818723119
5568,Ub-specific processing proteases,Deubiquitination,0.0005912148120897576,0,1,2,0.014795537373185466
5569,Ub-specific processing proteases,Deubiquitination,0.0005467692811637369,1,1,2,0.013683258890915009
5570,Metalloprotease DUBs,Deubiquitination,0.0001751631247925662,0,1,2,0.004383571768291393
5571,Metalloprotease DUBs,Deubiquitination,0.00016207913700449825,1,1,2,0.004056136415945601
5572,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,0.0006314783599664963,0,1,2,0.01580315899430427
5573,HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA),Homology Directed Repair,0.00032423889715943086,1,1,2,0.008114290478964654
5574,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,0.00011570900307080666,0,1,2,0.0028956934845675705
5575,Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks,DNA Double Strand Break Response,1.8913687778113914e-05,1,1,2,0.0004733274076755723
5576,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),0.0053535248932722575,0,1,2,0.13397546207733224
5577,DNA Damage Recognition in GG-NER,Global Genome Nucleotide Excision Repair (GG-NER),0.004268974919135973,1,1,2,0.10683388959422507
5578,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0016366423880828022,0,1,2,0.04095804625365563
5579,Signaling by RAS mutants,Oncogenic MAPK signaling,0.0013013336072035969,1,1,2,0.03256672469403551
5580,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,8.659654106903304e-05,0,1,2,0.002167135081150422
5581,Signaling by moderate kinase activity BRAF mutants,Oncogenic MAPK signaling,6.851262544144904e-05,1,1,2,0.0017145732642776218
5582,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,3.319000215257922e-05,0,1,2,0.0008306015127206236
5583,Signaling by high-kinase activity BRAF mutants,Oncogenic MAPK signaling,2.6314620295849017e-05,1,1,2,0.000658540584719501
5584,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.0007880218276423058,0,1,2,0.01972076166453956
5585,Signaling by BRAF and RAF1 fusions,Oncogenic MAPK signaling,0.0006254192237808874,1,1,2,0.015651525148111342
5586,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.0010971671579354365,0,1,2,0.027457325760304064
5587,Paradoxical activation of RAF signaling by kinase inactive BRAF,Oncogenic MAPK signaling,0.0008710889889172285,1,1,2,0.021799571707852468
5588,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.0011837874973824158,0,1,2,0.029625056411428596
5589,Signaling by RAF1 mutants,Oncogenic MAPK signaling,0.0009401359807986229,1,1,2,0.02352751784180709
5590,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,0.00018798976423124887,0,1,2,0.00470456680986791
5591,Signaling by MRAS-complex mutants,Oncogenic MAPK signaling,0.00015032710360700257,1,1,2,0.003762034093426027
5592,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.004165571066403175,0,1,2,0.10424614054539509
5593,Metal sequestration by antimicrobial proteins,Antimicrobial peptides,0.004164074624706589,1,1,2,0.10420869111314832
5594,MET Receptor Activation,Signaling by MET,0.00508164737966858,0,1,2,0.12717154947028267
5595,MET Receptor Activation,Signaling by MET,0.004630727719282953,1,1,2,0.11588699003247417
5596,MET promotes cell motility,Signaling by MET,0.0033252249186896707,0,1,2,0.08321592854688384
5597,MET promotes cell motility,Signaling by MET,0.003031598016736707,1,1,2,0.07586772327059556
5598,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0011312528262222138,0,1,2,0.02831034190386857
5599,Intra-Golgi traffic,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0011520406428067401,1,1,2,0.028830570610751154
5600,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0016334929477319017,0,1,2,0.040879229448894494
5601,Golgi-to-ER retrograde transport,Intra-Golgi and retrograde Golgi-to-ER traffic,0.0016639448597712881,1,1,2,0.04164130846560779
5602,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,0.0006404518266356205,0,1,2,0.016027725867046802
5603,Assembly of the ORC complex at the origin of replication,Assembly of the pre-replicative complex,0.0014119365515227566,1,1,2,0.0353346357185821
5604,Mitotic Prophase,M Phase,0.0005673014031141656,0,1,2,0.014197088672335047
5605,Mitotic Prophase,M Phase,0.00023953179677541788,1,1,2,0.005994439886798564
5606,Mitotic Prometaphase,M Phase,0.0004307667307764093,0,1,2,0.010780219192748639
5607,Mitotic Prometaphase,M Phase,0.0001814766729571175,1,1,2,0.004541572440662646
5608,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.0002471482368380905,0,1,2,0.006185046281113313
5609,Orc1 removal from chromatin,Switching of origins to a post-replicative state,0.0009744247779289147,1,1,2,0.024385617417542665
5610,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,0.0006822223826422146,0,1,2,0.01707306135231619
5611,CDK-mediated phosphorylation and removal of Cdc6,Switching of origins to a post-replicative state,0.0027313890225944626,1,1,2,0.06835479683206842
5612,Cyclin A:Cdk2-associated events at S phase entry,S Phase,7.385213175924032e-05,0,1,2,0.0018481979023343002
5613,Cyclin A:Cdk2-associated events at S phase entry,S Phase,8.57249131890511e-05,1,1,2,0.0021453220233411986
5614,Ubiquitin-dependent degradation of Cyclin D,S Phase,4.071998833482498e-05,0,1,2,0.0010190443421301024
5615,Ubiquitin-dependent degradation of Cyclin D,S Phase,4.532942120025661e-05,1,1,2,0.0011343984145164505
5616,G2/M DNA damage checkpoint,G2/M Checkpoints,0.000841279049861267,0,1,2,0.02105355848494983
5617,G2/M DNA damage checkpoint,G2/M Checkpoints,0.00037190125028379277,1,1,2,0.009307072040801435
5618,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.0014577128420230022,0,1,2,0.036480217329618175
5619,p53-Dependent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.0005857489449789946,1,1,2,0.014658750473634845
5620,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.0008791699428773169,0,1,2,0.022001802866278397
5621,p53-Independent G1/S DNA damage checkpoint,G1/S DNA Damage Checkpoints,0.00036967565493487107,1,1,2,0.009251375061481574
5622,Glycolysis,Glucose metabolism,0.0008336883056391496,0,1,2,0.020863595145852062
5623,Glycolysis,Glucose metabolism,0.001114994714451863,1,1,2,0.02790347202274128
5624,Gluconeogenesis,Glucose metabolism,0.0004770513592841914,0,1,2,0.011938522294916062
5625,Gluconeogenesis,Glucose metabolism,0.000637528520508459,1,1,2,0.015954568219144174
5626,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.00035403220663583805,0,1,2,0.008859887535761907
5627,Pyruvate metabolism,Pyruvate metabolism and Citric Acid (TCA) cycle,0.0005295801239667942,1,1,2,0.013253088989010866
5628,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,0.0002285469938750641,0,1,2,0.005719538009298604
5629,Citric acid cycle (TCA cycle),Pyruvate metabolism and Citric Acid (TCA) cycle,0.00031787979805166595,1,1,2,0.007955149864445609
5630,mRNA Splicing - Major Pathway,mRNA Splicing,0.00046964777938768667,0,1,2,0.01175324286548683
5631,mRNA Splicing - Major Pathway,mRNA Splicing,0.001072897643458363,1,1,2,0.026849965286358277
5632,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,0.0001654413538994151,0,1,2,0.0041402780928932095
5633,RNA Polymerase I Promoter Opening,RNA Polymerase I Promoter Clearance,8.338378063226305e-05,1,1,2,0.002086733649824129
5634,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,0.0003803263373194873,0,1,2,0.009517915354534303
5635,RNA Polymerase I Promoter Escape,RNA Polymerase I Promoter Clearance,0.0002228107456928602,1,1,2,0.00557598464658485
5636,Depurination,"Base-Excision Repair, AP Site Formation",7.723678312418619e-05,0,1,2,0.0019329010165682803
5637,Depurination,"Base-Excision Repair, AP Site Formation",0.00032671823690844543,1,1,2,0.008176337577865487
5638,Depyrimidination,"Base-Excision Repair, AP Site Formation",2.9066213137227308e-05,0,1,2,0.0007274009953315095
5639,Depyrimidination,"Base-Excision Repair, AP Site Formation",0.00012146192421837648,1,1,2,0.0030396640991450278
5640,Utilization of Ketone Bodies,Ketone body metabolism,0.00012749454458917817,0,1,2,0.0031906343697289882
5641,Utilization of Ketone Bodies,Ketone body metabolism,0.00012845887678000499,1,1,2,0.003214767413552962
5642,Synthesis of Ketone Bodies,Ketone body metabolism,0.00015627596447413295,0,1,2,0.003910908227645359
5643,Synthesis of Ketone Bodies,Ketone body metabolism,0.00015745775337637694,1,1,2,0.003940483267906212
5644,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.010928525997624184,0,1,2,0.27349351119966436
5645,Platelet degranulation ,Response to elevated platelet cytosolic Ca2+,0.008083075642181551,1,1,2,0.2022842549080548
5646,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,0.0009359793380976469,0,1,2,0.023423495139446356
5647,Deposition of new CENPA-containing nucleosomes at the centromere,Nucleosome assembly,0.00025881286091120975,1,1,2,0.006476961128117844
5648,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,5.723986113789671e-05,0,1,2,0.0014324649643133814
5649,E3 ubiquitin ligases ubiquitinate target proteins,Protein ubiquitination,0.00011451065898276061,1,1,2,0.0028657041399536383
5650,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.0053403053625285055,0,1,2,0.13364463467386475
5651,Cargo recognition for clathrin-mediated endocytosis,Clathrin-mediated endocytosis,0.006168098609656494,1,1,2,0.15436070212464656
5652,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0008257942300809786,0,1,2,0.020666040741667176
5653,Neurodegenerative Diseases,Defective Intrinsic Pathway for Apoptosis,0.0012729784343603657,1,1,2,0.031857117947137116
5654,Extra-nuclear estrogen signaling,ESR-mediated signaling,0.0001121642309612403,0,1,2,0.0028069832439679963
5655,Extra-nuclear estrogen signaling,ESR-mediated signaling,0.00016931309147565367,1,1,2,0.004237170858157195
5656,Estrogen-dependent gene expression,ESR-mediated signaling,0.0007987202771630275,0,1,2,0.019988497361416762
5657,Estrogen-dependent gene expression,ESR-mediated signaling,0.0011794050851261224,1,1,2,0.02951538367827513
5658,Pyrimidine catabolism,Nucleotide catabolism,1.4374782458423793e-05,0,1,2,0.00035973833325192607
5659,Pyrimidine catabolism,Nucleotide catabolism,4.4744078697504355e-05,1,1,2,0.0011197498355253847
5660,Pyrimidine salvage,Nucleotide salvage,0.0004614210191335255,0,1,2,0.011547362809183032
5661,Pyrimidine salvage,Nucleotide salvage,0.00014949620511976123,1,1,2,0.003741240315310339
5662,Vitamin D (calciferol) metabolism,Metabolism of steroids,0.0014642957815847748,0,1,2,0.036644959697907896
5663,Vitamin D (calciferol) metabolism,Metabolism of steroids,0.0020643160490868783,1,1,2,0.051660859352242544
5664,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,0.00034184052666080735,0,1,2,0.008554782770076336
5665,Tyrosine catabolism,Phenylalanine and tyrosine metabolism,0.00046403474908831487,1,1,2,0.011612773110885063
5666,VLDL assembly,Plasma lipoprotein assembly,0.001634746484397432,0,1,2,0.040910600023860225
5667,VLDL assembly,Plasma lipoprotein assembly,0.0015101944508812272,1,1,2,0.03779360391836434
5668,Chylomicron assembly,Plasma lipoprotein assembly,0.0022905892052443645,0,1,2,0.057323493085391385
5669,Chylomicron assembly,Plasma lipoprotein assembly,0.0021220882380046458,1,1,2,0.05310664616743111
5670,HDL assembly,Plasma lipoprotein assembly,0.0023686594911038446,0,1,2,0.05927725305308625
5671,HDL assembly,Plasma lipoprotein assembly,0.0021768219824475567,1,1,2,0.05447639392225652
5672,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.0014852173924755612,0,1,2,0.03716853669481656
5673,Assembly of active LPL and LIPC lipase complexes,Plasma lipoprotein remodeling,0.001098911934122537,1,1,2,0.027500989925606092
5674,Chylomicron remodeling,Plasma lipoprotein remodeling,0.006147360498751017,0,1,2,0.1538417173348936
5675,Chylomicron remodeling,Plasma lipoprotein remodeling,0.004521004773141151,1,1,2,0.11314110153790345
5676,LDL remodeling,Plasma lipoprotein remodeling,0.0005995148611432549,0,1,2,0.015003251529629244
5677,LDL remodeling,Plasma lipoprotein remodeling,0.00043793527685639667,1,1,2,0.01095961674718906
5678,HDL remodeling,Plasma lipoprotein remodeling,0.0007745714344266824,0,1,2,0.019384156776711438
5679,HDL remodeling,Plasma lipoprotein remodeling,0.0005649306244771337,1,1,2,0.014137758386269022
5680,HDL clearance,Plasma lipoprotein clearance,0.0009684009009000191,0,1,2,0.02423486595480873
5681,HDL clearance,Plasma lipoprotein clearance,0.0007479416112639533,1,1,2,0.01871772803408098
5682,Chylomicron clearance,Plasma lipoprotein clearance,0.0006428858367393433,0,1,2,0.01608863856192508
5683,Chylomicron clearance,Plasma lipoprotein clearance,0.0004976819244765821,1,1,2,0.012454815682855764
5684,LDL clearance,Plasma lipoprotein clearance,0.00133615174886957,0,1,2,0.03343807146300915
5685,LDL clearance,Plasma lipoprotein clearance,0.0010369439132681215,1,1,2,0.02595019967180127
5686,VLDL clearance,Plasma lipoprotein clearance,0.0016659779985413738,0,1,2,0.04169218909316066
5687,VLDL clearance,Plasma lipoprotein clearance,0.0012897855693080403,1,1,2,0.03227772749238094
5688,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,6.0175467629489716e-05,0,1,2,0.001505930436881305
5689,Mitochondrial Fatty Acid Beta-Oxidation,Fatty acid metabolism,4.7736763188340356e-05,1,1,2,0.0011946437223578315
5690,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,2.2433681492495757e-05,0,1,2,0.0005614175527286495
5691,"Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation",Metabolism of cofactors,3.9938203351227787e-05,1,1,2,0.0009994796615671747
5692,NADPH regeneration,Metabolism of cofactors,0.0002938705877794501,0,1,2,0.007354303673485652
5693,NADPH regeneration,Metabolism of cofactors,0.000518717010609503,1,1,2,0.012981232471920508
5694,Triglyceride catabolism,Triglyceride metabolism,0.00033063160500496265,0,1,2,0.008274272174129054
5695,Triglyceride catabolism,Triglyceride metabolism,0.00065591636061081,1,1,2,0.01641473594478835
5696,Glycogen synthesis,Glycogen metabolism,0.0009718416317232807,0,1,2,0.0243209724941674
5697,Glycogen synthesis,Glycogen metabolism,0.0011140216008201892,1,1,2,0.02787911921761636
5698,Glycogen breakdown (glycogenolysis),Glycogen metabolism,1.5005879594918306e-05,0,1,2,0.0003755319518794941
5699,Glycogen breakdown (glycogenolysis),Glycogen metabolism,1.697767596757275e-05,1,1,2,0.00042487744581392407
5700,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,0.00026862521496746775,0,1,2,0.006722521706421238
5701,RAB GEFs exchange GTP for GDP on RABs,Rab regulation of trafficking,0.00026333112132098516,1,1,2,0.006590033550167492
5702,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,0.0015200468730058835,0,1,2,0.038040167226287044
5703,NOTCH4 Intracellular Domain Regulates Transcription,Signaling by NOTCH4,0.0012111392676890345,1,1,2,0.030309552353544676
5704,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,9.009183512714536e-05,0,1,2,0.002254607101149851
5705,NOTCH4 Activation and Transmission of Signal to the Nucleus,Signaling by NOTCH4,7.210198723205256e-05,1,1,2,0.0018043993908102834
5706,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,0.00017644613760890693,0,1,2,0.004415680003210859
5707,Negative regulation of NOTCH4 signaling,Signaling by NOTCH4,0.00013981589516219505,1,1,2,0.003498984226943856
5708,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),8.200700744387615e-05,0,1,2,0.002052279000267606
5709,Biosynthesis of DHA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.00018884846767047798,1,1,2,0.004726056425093701
5710,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.00027768414222775973,0,1,2,0.006949227286355642
5711,Biosynthesis of EPA-derived SPMs,Biosynthesis of specialized proresolving mediators (SPMs),0.0006394716097735729,1,1,2,0.016003195298935714
5712,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.0037601761473593925,0,1,2,0.0941008675364009
5713,NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux,NR1H2 and NR1H3-mediated signaling,0.003134183693416582,1,1,2,0.07843499692855016
5714,Interferon gamma signaling,Interferon Signaling,0.0004012878953359306,0,1,2,0.010042492054391068
5715,Interferon gamma signaling,Interferon Signaling,0.0010204738190516991,1,1,2,0.025538024791307977
5716,Interferon alpha/beta signaling,Interferon Signaling,8.818772874830184e-05,0,1,2,0.0022069555935850796
5717,Interferon alpha/beta signaling,Interferon Signaling,0.0002236985820733016,1,1,2,0.005598203332719697
5718,HCMV Early Events,HCMV Infection,2.4513554184572574e-06,0,1,2,6.134677272469741e-05
5719,HCMV Early Events,HCMV Infection,2.863346732437617e-06,1,1,2,7.165712483153665e-05
5720,HCMV Late Events,HCMV Infection,0.001526554614387637,0,1,2,0.0382030277109363
5721,HCMV Late Events,HCMV Infection,0.001781145752007839,1,1,2,0.044574337452360085
5722,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.002820142993917488,0,1,2,0.07057592301645281
5723,Modulation by Mtb of host immune system,Infection with Mycobacterium tuberculosis,0.002666183639185934,1,1,2,0.0667229894628591
5724,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.0005548267442376121,0,1,2,0.013884902174548576
5725,Response of Mtb to phagocytosis,Infection with Mycobacterium tuberculosis,0.0005196309153171998,1,1,2,0.013004103534995645
5726,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0014048012396235235,0,1,2,0.0351560698712528
5727,Defective factor XII causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.001353205663270338,1,1,2,0.033864856825479676
5728,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0006283410062207835,0,1,2,0.015724644664743544
5729,Defective SERPING1 causes hereditary angioedema,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0006029722053057329,1,1,2,0.015089773828668234
5730,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.000925020301722351,0,1,2,0.02314923808608929
5731,Defective factor VIII causes hemophilia A,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0008933799459407567,1,1,2,0.022357417487392263
5732,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0018557637070439272,0,1,2,0.04644170058310571
5733,Defective factor IX causes hemophilia B,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0017950313180114194,1,1,2,0.04492183282384381
5734,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.001989274666150634,0,1,2,0.049782899661340606
5735,Defective factor IX causes thrombophilia,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),0.0019263296816401643,1,1,2,0.04820766025303254
5736,Parasite infection,Leishmania infection,0.005305704460846441,0,1,2,0.13277872447758035
5737,Parasite infection,Leishmania infection,0.005469944193132067,1,1,2,0.13688893120363413
5738,Cell recruitment (pro-inflammatory response),Leishmania infection,0.0016507820326176462,0,1,2,0.04131190010657141
5739,Cell recruitment (pro-inflammatory response),Leishmania infection,0.0017021085368815613,1,1,2,0.04259637944731639
5740,Leishmania parasite growth and survival,Leishmania infection,0.002589177760010127,0,1,2,0.06479586696862821
5741,Leishmania parasite growth and survival,Leishmania infection,0.002660702136306566,1,1,2,0.06658581126797211
5742,Lipophagy,Selective autophagy,0.0008279035583807411,0,1,2,0.020718828062034105
5743,Lipophagy,Selective autophagy,0.001099491439911012,1,1,2,0.027515492437004702
5744,Aggrephagy,Selective autophagy,0.0002982655454707648,0,1,2,0.007464290364356217
5745,Aggrephagy,Selective autophagy,0.00038325666917491644,1,1,2,0.009591248825882201
5746,SARS-CoV-1 Infection,SARS-CoV Infections,0.001176228540653536,0,1,2,0.029435888575140595
5747,SARS-CoV-1 Infection,SARS-CoV Infections,0.0011884432178796054,1,1,2,0.029741568862075407
5748,Potential therapeutics for SARS,SARS-CoV Infections,0.006860644530603666,0,1,2,0.17169211677544427
5749,Potential therapeutics for SARS,SARS-CoV Infections,0.006947018018948298,1,1,2,0.17385366981627265
5750,SARS-CoV-2 Infection,SARS-CoV Infections,0.0029498421139033796,0,1,2,0.07382172832744896
5751,SARS-CoV-2 Infection,SARS-CoV Infections,0.0029951839811857388,1,1,2,0.07495643821331073
5752,ALK mutants bind TKIs,Signaling by ALK in cancer,6.043106107863182e-07,0,1,2,1.5123268301241544e-05
5753,ALK mutants bind TKIs,Signaling by ALK in cancer,9.986451664889822e-07,1,1,2,2.4991748483283194e-05
5754,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,0.00037307895353003146,0,1,2,0.009336544834848417
5755,Signaling by ALK fusions and activated point mutants,Signaling by ALK in cancer,0.0006194801438321492,1,1,2,0.015502895787772258
5756,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.0015818291457098386,0,1,2,0.039586309011132796
5757,Detoxification of Reactive Oxygen Species,Cellular response to chemical stress,0.0011450864464774531,1,1,2,0.02865653729902348
5758,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0019296736535288986,0,1,2,0.048291345336766774
5759,Cytoprotection by HMOX1,Cellular response to chemical stress,0.0014040517876148747,1,1,2,0.03513731434453624
5760,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.0011306555653728136,0,1,2,0.02829539506045711
5761,KEAP1-NFE2L2 pathway,Cellular response to chemical stress,0.0008173339552316061,1,1,2,0.020454316829881445
5762,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,3.2787238190909186e-05,0,1,2,0.0008205220811407589
5763,Antigen processing: Ubiquitination & Proteasome degradation,Class I MHC mediated antigen processing & presentation,3.671357344665773e-05,1,1,2,0.0009187811890456262
5764,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.001681989384361273,0,1,2,0.04209288449599985
5765,"Antigen Presentation: Folding, assembly and peptide loading of class I MHC",Class I MHC mediated antigen processing & presentation,0.0019021307460594832,1,1,2,0.04760206606213308
5766,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0026131600601531067,0,1,2,0.06539603971600272
5767,CD22 mediated BCR regulation,Signaling by the B Cell Receptor (BCR),0.0033562026028864105,1,1,2,0.08399116535573094
5768,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.0018596643506032077,0,1,2,0.04653931673950209
5769,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,Signaling by the B Cell Receptor (BCR),0.0023774150144218686,1,1,2,0.05949636575091554
5770,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0026831670658960085,0,1,2,0.06714801082476556
5771,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.00267590680607266,1,1,2,0.06696631807390958
5772,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,9.021139723658338e-05,0,1,2,0.002257599221141491
5773,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0005494710662026079,1,1,2,0.013750872828691078
5774,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,0.0028923467581648188,0,1,2,0.07238286944364054
5775,Interaction With Cumulus Cells And The Zona Pellucida,Interaction With Cumulus Cells And The Zona Pellucida,0.002991641448582224,1,1,2,0.07486778401781491
5776,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,0.00016082105476928097,0,1,2,0.004024652085125296
5777,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,5.562545389384376e-06,1,1,2,0.00013920633670825926
5778,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0006442882113391035,0,1,2,0.016123733903546537
5779,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0008542385741302635,1,1,2,0.021377879056322
5780,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.0014321433285442882,0,1,2,0.0358403235303555
5781,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.0017935403143960246,1,1,2,0.044884519483135786
5782,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.00024081687499882565,0,1,2,0.006026599809880819
5783,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,0.0008049894805171697,1,1,2,0.020145388275902558
5784,MHC class II antigen presentation,MHC class II antigen presentation,0.00043979055634491454,0,1,2,0.011006046329886835
5785,MHC class II antigen presentation,MHC class II antigen presentation,0.0007537501673681535,1,1,2,0.018863090949837718
5786,Rap1 signalling,Rap1 signalling,0.0003852448965968681,0,1,2,0.009641005517572484
5787,Rap1 signalling,Rap1 signalling,0.0005556870004157105,1,1,2,0.013906430648080184
5788,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.00617829149289114,0,1,2,0.1546157856945349
5789,Extrinsic Pathway of Fibrin Clot Formation,Extrinsic Pathway of Fibrin Clot Formation,0.004197984874777544,1,1,2,0.10505731730112466
5790,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.004897479405071909,0,1,2,0.1225626254457688
5791,Intrinsic Pathway of Fibrin Clot Formation,Intrinsic Pathway of Fibrin Clot Formation,0.004079376258555685,1,1,2,0.10208905910087865
5792,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.006161175082271085,0,1,2,0.15418743632329934
5793,Common Pathway of Fibrin Clot Formation,Common Pathway of Fibrin Clot Formation,0.004582988681300628,1,1,2,0.11469228938190898
5794,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.00170913358512647,0,1,2,0.04277218587457517
5795,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0013836938594346496,1,1,2,0.03462784387615188
5796,Collagen degradation,Collagen degradation,0.00450511741666726,0,1,2,0.112743510050573
5797,Collagen degradation,Collagen degradation,0.0035662524228035663,1,1,2,0.08924779948813717
5798,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.0009410602356483604,0,1,2,0.023550647923956593
5799,Activation of Matrix Metalloproteinases,Activation of Matrix Metalloproteinases,0.0010531842648801065,1,1,2,0.02635662509334893
5800,Fibronectin matrix formation,Fibronectin matrix formation,0.001242435083039141,0,1,2,0.03109275060258738
5801,Fibronectin matrix formation,Fibronectin matrix formation,0.0009261847312244509,1,1,2,0.023178378696007133
5802,Integrin cell surface interactions,Integrin cell surface interactions,0.012373731323419762,0,1,2,0.3096607197547993
5803,Integrin cell surface interactions,Integrin cell surface interactions,0.011529736304229758,1,1,2,0.28853919236094183
5804,Laminin interactions,Laminin interactions,0.00027070517281401575,0,1,2,0.006774574011985902
5805,Laminin interactions,Laminin interactions,0.000476062835921046,1,1,2,0.0119137838511819
5806,ECM proteoglycans,ECM proteoglycans,0.005769904613226586,0,1,2,0.14439563691403012
5807,ECM proteoglycans,ECM proteoglycans,0.004157507611065749,1,1,2,0.10404434730144674
5808,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0010197034348424366,0,1,2,0.02551874542257977
5809,Erythrocytes take up carbon dioxide and release oxygen,Erythrocytes take up carbon dioxide and release oxygen,0.0015357698723192203,1,1,2,0.038433645568172234
5810,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.0034360190875489067,0,1,2,0.0859886250906216
5811,Erythrocytes take up oxygen and release carbon dioxide,Erythrocytes take up oxygen and release carbon dioxide,0.003086299053097834,1,1,2,0.07723665248428069
5812,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,0.0003252419334928491,0,1,2,0.008139392119272509
5813,Synthesis of IPs in the ER lumen,Synthesis of IPs in the ER lumen,0.0006075093734224662,1,1,2,0.015203319428451616
5814,Meiotic synapsis,Meiotic synapsis,0.000796371455337602,0,1,2,0.019929716558922658
5815,Meiotic synapsis,Meiotic synapsis,0.001313004931676536,1,1,2,0.03285880722292812
5816,Meiotic recombination,Meiotic recombination,0.000557248337758081,0,1,2,0.013945504136309511
5817,Meiotic recombination,Meiotic recombination,0.0013168621611802692,1,1,2,0.03295533691418825
5818,Nephrin family interactions,Nephrin family interactions,0.000707115423095362,0,1,2,0.017696025971647898
5819,Nephrin family interactions,Nephrin family interactions,0.0001373944270504271,1,1,2,0.0034383854036176905
5820,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.003474853401084733,0,1,2,0.08696047918752825
5821,Molecules associated with elastic fibres,Molecules associated with elastic fibres,0.0034882895027659303,1,1,2,0.08729672642035959
5822,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,3.9485380101017066e-05,0,1,2,0.0009881474635488967
5823,Transcriptional activation of mitochondrial biogenesis,Transcriptional activation of mitochondrial biogenesis,9.269837822190718e-05,1,1,2,0.0023198375469789248
5824,Cristae formation,Cristae formation,0.0001451506149106503,0,1,2,0.0036324890779721097
5825,Cristae formation,Cristae formation,0.00019294670363046053,1,1,2,0.004828617460558504
5826,Signaling by Hippo,Signaling by Hippo,5.036265191632387e-05,0,1,2,0.0012603583053118327
5827,Signaling by Hippo,Signaling by Hippo,0.00039530421604537096,1,1,2,0.00989274656635145
5828,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,9.248801633034625e-05,0,1,2,0.002314573103049514
5829,AMPK inhibits chREBP transcriptional activation activity,AMPK inhibits chREBP transcriptional activation activity,0.0002814716290658492,1,1,2,0.007044011621790887
5830,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.0010412796395316691,0,1,2,0.02605870405744999
5831,Insulin effects increased synthesis of Xylulose-5-Phosphate,Insulin effects increased synthesis of Xylulose-5-Phosphate,0.00054112175158355,1,1,2,0.013541925769245622
5832,mTORC1-mediated signalling,mTORC1-mediated signalling,3.763178580446933e-05,0,1,2,0.0009417600538824222
5833,mTORC1-mediated signalling,mTORC1-mediated signalling,2.1921383654097815e-05,1,1,2,0.000548596964239963
5834,Neutrophil degranulation,Neutrophil degranulation,0.008892240595612628,0,1,2,0.2225341371247131
5835,Neutrophil degranulation,Neutrophil degranulation,0.009698511238699203,1,1,2,0.24271158733189538
5836,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,8.786256483655065e-05,0,1,2,0.002198818154010924
5837,Advanced glycosylation endproduct receptor signaling,Advanced glycosylation endproduct receptor signaling,4.357493637319075e-05,1,1,2,0.0010904912841490897
5838,Heme biosynthesis,Heme biosynthesis,0.00016383414655132413,0,1,2,0.004100056677768163
5839,Heme biosynthesis,Heme biosynthesis,0.0003655700901026879,1,1,2,0.009148630616196297
5840,Heme degradation,Heme degradation,9.848149260391193e-05,0,1,2,0.0024645637669968483
5841,Heme degradation,Heme degradation,0.00013087306248430627,1,1,2,0.003275183989869011
5842,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,0.000560124537080667,0,1,2,0.014017482905616106
5843,Degradation of beta-catenin by the destruction complex,Degradation of beta-catenin by the destruction complex,0.0005296158351807507,1,1,2,0.013253982685498052
5844,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0033390590869166216,0,1,2,0.08356213765538924
5845,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Translocation of SLC2A4 (GLUT4) to the plasma membrane,0.0035199966141128596,1,1,2,0.08809021762074247
5846,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),0.0008944662188553266,0,1,2,0.022384602177586654
5847,Endosomal Sorting Complex Required For Transport (ESCRT),Endosomal Sorting Complex Required For Transport (ESCRT),0.00130740805339366,1,1,2,0.03271874168310384
5848,eNOS activation,eNOS activation,0.00042549079999996606,0,1,2,0.010648185574197564
5849,eNOS activation,eNOS activation,0.0005370986314465618,1,1,2,0.013441244556382861
5850,PECAM1 interactions,PECAM1 interactions,0.0001989547341638292,0,1,2,0.00497897235437703
5851,PECAM1 interactions,PECAM1 interactions,3.352953523792194e-05,1,1,2,0.000839098550262468
5852,Basigin interactions,Basigin interactions,0.00044842089643361527,0,1,2,0.0112220262355227
5853,Basigin interactions,Basigin interactions,0.0005892313077814197,1,1,2,0.01474589888050265
5854,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,0.0007742228176170019,0,1,2,0.019375432413026573
5855,Transcriptional regulation by small RNAs,Transcriptional regulation by small RNAs,0.00038820720210816463,1,1,2,0.009715139150571732
5856,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,0.00010070430501857607,0,1,2,0.0025201911015666576
5857,PIWI-interacting RNA (piRNA) biogenesis,PIWI-interacting RNA (piRNA) biogenesis,7.996492292343457e-05,1,1,2,0.0020011744994608673
5858,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0005124158639858447,0,1,2,0.012823542156221678
5859,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis","tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",0.0007334531047365948,1,1,2,0.018355143681619546
5860,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,0.0006128899420098624,0,1,2,0.015337971676663089
5861,Aflatoxin activation and detoxification,Aflatoxin activation and detoxification,0.0005942609970431851,1,1,2,0.014871770144087745
5862,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.00011826611869610086,0,1,2,0.002959686975643794
5863,PRC2 methylates histones and DNA,PRC2 methylates histones and DNA,0.00039623584484269747,1,1,2,0.009916061186362506
5864,DNA methylation,DNA methylation,0.00029892875303409115,0,1,2,0.0074808875674179775
5865,DNA methylation,DNA methylation,0.00045116317198270675,1,1,2,0.011290653474800995
5866,Abacavir metabolism,Abacavir metabolism,0.003698188219122532,0,1,2,0.09254957908732941
5867,Abacavir metabolism,Abacavir metabolism,0.004248010452014162,1,1,2,0.10630924009210371
5868,Scavenging of heme from plasma,Scavenging of heme from plasma,0.005769023953514176,0,1,2,0.14437359782870687
5869,Scavenging of heme from plasma,Scavenging of heme from plasma,0.006102570289448093,1,1,2,0.15272081305079455
5870,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0033563050092463415,0,1,2,0.08399372814186996
5871,Scavenging by Class B Receptors,Scavenging by Class B Receptors,0.0033552775894903912,1,1,2,0.08396801629046458
5872,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.005135111957430948,0,1,2,0.1285095354987934
5873,Scavenging by Class A Receptors,Scavenging by Class A Receptors,0.0056051061498512385,1,1,2,0.14027144757700227
5874,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.0065725876194505295,0,1,2,0.16448330416213044
5875,Scavenging by Class F Receptors,Scavenging by Class F Receptors,0.0073462092278638695,1,1,2,0.18384369092159764
5876,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.001192877218438972,0,1,2,0.029852532626256055
5877,Scavenging by Class H Receptors,Scavenging by Class H Receptors,0.0013060331749435818,1,1,2,0.0326843344506128
5878,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.0004472737658455008,0,1,2,0.011193318542242184
5879,The canonical retinoid cycle in rods (twilight vision),The canonical retinoid cycle in rods (twilight vision),0.0005406426942195117,1,1,2,0.013529937045369648
5880,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.016884459286304176,0,1,2,0.4225446373941917
5881,Retinoid metabolism and transport,Metabolism of fat-soluble vitamins,0.0166395454678441,1,1,2,0.4164155088944722
5882,Retinoid metabolism and transport,Retinoid metabolism and transport,0.016884459286304176,0,1,2,0.4225446373941917
5883,Retinoid metabolism and transport,Retinoid metabolism and transport,0.0166395454678441,1,1,2,0.4164155088944722
5884,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0012354048368981266,0,1,2,0.030916814094578717
5885,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,0.0011537969970287505,1,1,2,0.028874524523949733
5886,Heme signaling,Heme signaling,0.0031558830428389576,0,1,2,0.07897803734091355
5887,Heme signaling,Heme signaling,0.0021826285879903255,1,1,2,0.05462170802393761
5888,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.003433824565770107,0,1,2,0.0859337057477186
5889,Metabolism of Angiotensinogen to Angiotensins,Metabolism of Angiotensinogen to Angiotensins,0.0033061411278385126,1,1,2,0.08273834419854464
5890,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",8.795855596018476e-05,0,1,2,0.002201220394665556
5891,"Synthesis, secretion, and deacylation of Ghrelin","Synthesis, secretion, and deacylation of Ghrelin",5.422132651254721e-05,1,1,2,0.0013569241609567284
5892,Syndecan interactions,Syndecan interactions,0.005179580447424234,0,1,2,0.1296223885467392
5893,Syndecan interactions,Syndecan interactions,0.003795899170082119,1,1,2,0.09499485954568264
5894,HDACs deacetylate histones,HDACs deacetylate histones,0.00048293561034425613,0,1,2,0.012085779526453719
5895,HDACs deacetylate histones,HDACs deacetylate histones,0.00072445921118119,1,1,2,0.01813006561268706
5896,PKMTs methylate histone lysines,PKMTs methylate histone lysines,0.0009297100123287495,0,1,2,0.023266601161451246
5897,PKMTs methylate histone lysines,PKMTs methylate histone lysines,0.0002073839855187414,1,1,2,0.005189919882922109
5898,HDMs demethylate histones,HDMs demethylate histones,0.00027144167629581154,0,1,2,0.006793005493348612
5899,HDMs demethylate histones,HDMs demethylate histones,0.00021163517285550845,1,1,2,0.005296308626633084
5900,HATs acetylate histones,HATs acetylate histones,0.0018929868614609888,0,1,2,0.04737323436924143
5901,HATs acetylate histones,HATs acetylate histones,0.0008325241032943162,1,1,2,0.02083446022069339
5902,RMTs methylate histone arginines,RMTs methylate histone arginines,0.0010913411414766032,0,1,2,0.0273115258877522
5903,RMTs methylate histone arginines,RMTs methylate histone arginines,0.0011118322612036983,1,1,2,0.027824329561714663
5904,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,5.180382222058069e-05,0,1,2,0.0012964245348137408
5905,GRB2:SOS provides linkage to MAPK signaling for Integrins ,GRB2:SOS provides linkage to MAPK signaling for Integrins ,9.667872185725847e-05,1,1,2,0.002419448249909047
5906,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.00020176012259269806,0,1,2,0.005049179034752504
5907,p130Cas linkage to MAPK signaling for integrins,p130Cas linkage to MAPK signaling for integrins,0.00016162719289922035,1,1,2,0.004044826219104296
5908,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.00032206889934664084,0,1,2,0.008059984864351617
5909,Miscellaneous transport and binding events,Miscellaneous transport and binding events,1.556613960352008e-05,1,1,2,0.0003895528250485348
5910,Intracellular oxygen transport,Intracellular oxygen transport,0.00012731621280707877,0,1,2,0.003186171500239045
5911,Intracellular oxygen transport,Intracellular oxygen transport,0.0008992352506658771,1,1,2,0.022503950317964774
5912,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.0025966108774154407,0,1,2,0.06498188559353522
5913,ABC transporters in lipid homeostasis,ABC transporters in lipid homeostasis,0.0016102911916088378,1,1,2,0.040298590326155105
5914,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,0.0004188931981052012,0,1,2,0.010483076271434402
5915,Post-chaperonin tubulin folding pathway,Post-chaperonin tubulin folding pathway,0.0005969623911239858,1,1,2,0.014939374297882389
5916,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.012168404768985758,0,1,2,0.3045222884304932
5917,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.013979082801311306,1,1,2,0.3498356905142207
5918,Surfactant metabolism,Surfactant metabolism,0.0021692151180113936,0,1,2,0.05428602716425838
5919,Surfactant metabolism,Surfactant metabolism,0.0017547691125673274,1,1,2,0.04391424479798004
5920,Amyloid fiber formation,Amyloid fiber formation,0.010624807097666618,0,1,2,0.26589274707235644
5921,Amyloid fiber formation,Amyloid fiber formation,0.011393442555336012,1,1,2,0.2851283521481245
5922,Striated Muscle Contraction,Striated Muscle Contraction,0.0013205310159007245,0,1,2,0.03304715240328503
5923,Striated Muscle Contraction,Striated Muscle Contraction,0.0016466096556235596,1,1,2,0.04120748364323413
5924,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0023433324718652453,0,1,2,0.058643427830792606
5925,Smooth Muscle Contraction,Smooth Muscle Contraction,0.003658511775532406,1,1,2,0.09155665013499513
5926,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0016035746347494802,0,1,2,0.04013050409759718
5927,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0015159674153691583,1,1,2,0.03793807613064425
5928,Platelet sensitization by LDL,Platelet sensitization by LDL,0.004387160890399883,0,1,2,0.10979157082795564
5929,Platelet sensitization by LDL,Platelet sensitization by LDL,0.0027983816315025963,1,1,2,0.07003133068839036
5930,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.0030087575796273,0,1,2,0.07529612639250377
5931,Type I hemidesmosome assembly,Type I hemidesmosome assembly,0.002377135098231058,1,1,2,0.059489360665153465
5932,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.0002741643525249334,0,1,2,0.006861142246825182
5933,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,0.00011114417537811938,1,1,2,0.002781455685804415
5934,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.0015369996188378467,0,1,2,0.03846442077915108
5935,AUF1 (hnRNP D0) binds and destabilizes mRNA,AUF1 (hnRNP D0) binds and destabilizes mRNA,0.002465079102031328,1,1,2,0.061690216882498906
5936,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.0003967466579852413,0,1,2,0.009928844619366335
5937,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA","Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",0.00046142603559236323,1,1,2,0.011547488349346602
5938,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,0.0001252535409876515,0,1,2,0.003134551788809488
5939,KSRP (KHSRP) binds and destabilizes mRNA,KSRP (KHSRP) binds and destabilizes mRNA,7.330571724417082e-06,1,1,2,0.0001834523521696938
5940,Pyroptosis,Pyroptosis,0.0009199782321347765,0,1,2,0.023023056996753128
5941,Pyroptosis,Pyroptosis,0.0018495800631619555,1,1,2,0.04628695085037355
5942,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,6.170381700404657e-05,0,1,2,0.0015441783796393892
5943,Hedgehog ligand biogenesis,Hedgehog ligand biogenesis,0.00041009536921061447,1,1,2,0.010262904848880485
5944,Hedgehog 'on' state,Hedgehog 'on' state,0.00010089510329302828,0,1,2,0.00252496595318179
5945,Hedgehog 'on' state,Hedgehog 'on' state,0.00017406845506395932,1,1,2,0.00435617694233355
5946,Physiological factors,Physiological factors,0.0008194295213460865,0,1,2,0.02050675974256014
5947,Physiological factors,Physiological factors,0.002240234747207558,1,1,2,0.05606333983727392
5948,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,0.00044917954646356875,0,1,2,0.01124101194873863
5949,Anchoring of the basal body to the plasma membrane,Anchoring of the basal body to the plasma membrane,0.0006236088579037082,1,1,2,0.015606219557914327
5950,Intraflagellar transport,Intraflagellar transport,0.001023713088456097,0,1,2,0.025619089626888088
5951,Intraflagellar transport,Intraflagellar transport,0.002721286868099785,1,1,2,0.06810198380824148
5952,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0014924667701763361,0,1,2,0.03734995711343738
5953,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of anterior HOX genes in hindbrain development during early embryogenesis,0.0016939325732661195,1,1,2,0.04239177061012151
5954,Metallothioneins bind metals,Metallothioneins bind metals,0.003589611389995718,0,1,2,0.08983237292070878
5955,Metallothioneins bind metals,Metallothioneins bind metals,0.0036050096156576713,1,1,2,0.09021772358954078
5956,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0011010915719074324,0,1,2,0.027555536786826356
5957,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,0.0017650012526103309,1,1,2,0.04417031079517454
5958,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.0015282854421577194,0,1,2,0.03824634280797909
5959,MAPK6/MAPK4 signaling,MAPK6/MAPK4 signaling,0.0016980460514893594,1,1,2,0.042494713093193956
5960,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),0.001300905386179799,0,1,2,0.03255600818282499
5961,Nonhomologous End-Joining (NHEJ),Nonhomologous End-Joining (NHEJ),0.000351011359146418,1,1,2,0.008784288851469094
5962,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.0007769928169168244,0,1,2,0.019444753457300415
5963,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational modification: synthesis of GPI-anchored proteins,0.00046389152406831974,1,1,2,0.011609188811079342
5964,RAB geranylgeranylation,RAB geranylgeranylation,0.00017772958305156374,0,1,2,0.004447799064886854
5965,RAB geranylgeranylation,RAB geranylgeranylation,0.00019569787356567528,1,1,2,0.0048974672876671566
5966,Protein methylation,Protein methylation,0.0005804122396659692,0,1,2,0.01452519593255451
5967,Protein methylation,Protein methylation,0.0004898209457503168,1,1,2,0.012258089548537233
5968,Neddylation,Neddylation,5.3739768631905074e-05,0,1,2,0.001344872860017213
5969,Neddylation,Neddylation,5.7452879943785205e-06,1,1,2,0.0001437795899261669
5970,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,0.0016619946095465475,0,1,2,0.04159250217811777
5971,Carboxyterminal post-translational modifications of tubulin,Carboxyterminal post-translational modifications of tubulin,0.0013033638230813336,1,1,2,0.03261753217429554
5972,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.011221626153284314,0,1,2,0.2808285343054413
5973,Post-translational protein phosphorylation,Post-translational protein phosphorylation,0.011367828200006447,1,1,2,0.2844873361522143
5974,Formation of the cornified envelope,Formation of the cornified envelope,0.0021551369360574154,0,1,2,0.05393371145263009
5975,Formation of the cornified envelope,Formation of the cornified envelope,0.00215212611186788,1,1,2,0.0538583636079729
5976,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,0.00012223219313879785,0,1,2,0.003058940582694576
5977,Glyoxylate metabolism and glycine degradation,Glyoxylate metabolism and glycine degradation,5.4774134590160185e-05,1,1,2,0.0013707585446786298
5978,Choline catabolism,Choline catabolism,0.00028024730025134686,0,1,2,0.007013371992401346
5979,Choline catabolism,Choline catabolism,0.0005735358885024925,1,1,2,0.014353110747018056
5980,Urea cycle,Urea cycle,0.0009583889446629041,0,1,2,0.02398431020137398
5981,Urea cycle,Urea cycle,0.0008670353861188818,1,1,2,0.021698127646451175
5982,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,0.00018626792459564904,0,1,2,0.00466147664676949
5983,Branched-chain amino acid catabolism,Branched-chain amino acid catabolism,0.00014265922423680242,1,1,2,0.0035701403967950797
5984,Tryptophan catabolism,Tryptophan catabolism,0.00026750748320825417,0,1,2,0.0066945497380630934
5985,Tryptophan catabolism,Tryptophan catabolism,0.00017378240893772202,1,1,2,0.0043490184509279665
5986,Threonine catabolism,Threonine catabolism,1.65857027194978e-05,0,1,2,0.00041506805889974553
5987,Threonine catabolism,Threonine catabolism,3.550823726592231e-06,1,1,2,8.886168627387676e-05
5988,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,0.0002122894397617358,0,1,2,0.005312682083903055
5989,Aspartate and asparagine metabolism,Aspartate and asparagine metabolism,0.0007003348001319121,1,1,2,0.017526336446930826
5990,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,8.22029358709289e-05,0,1,2,0.002057182237307087
5991,Glutamate and glutamine metabolism,Glutamate and glutamine metabolism,0.00024149928817839887,1,1,2,0.00604367764605113
5992,Alanine metabolism,Alanine metabolism,0.0004913161440337606,0,1,2,0.012295507863556814
5993,Alanine metabolism,Alanine metabolism,0.0005139333253157878,1,1,2,0.012861517618541674
5994,Lactose synthesis,Lactose synthesis,0.000704226136504122,0,1,2,0.017623719684883136
5995,Lactose synthesis,Lactose synthesis,0.0008333250314092484,1,1,2,0.020854503970639076
5996,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,0.00038530220649013686,0,1,2,0.009642439735136678
5997,Formation of xylulose-5-phosphate,Formation of xylulose-5-phosphate,0.00035032487856572836,1,1,2,0.008767109225925447
5998,Galactose catabolism,Galactose catabolism,7.045413904190614e-05,0,1,2,0.0017631609120305164
5999,Galactose catabolism,Galactose catabolism,0.00018497744353281555,1,1,2,0.0046291815140967274
6000,Pentose phosphate pathway,Pentose phosphate pathway,0.00014781211019756018,0,1,2,0.0036990947383527127
6001,Pentose phosphate pathway,Pentose phosphate pathway,1.4929203880522408e-05,1,1,2,0.00037361309197483396
6002,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,1.782751092223361e-05,0,1,2,0.00044614512141271344
6003,Eukaryotic Translation Elongation,Eukaryotic Translation Elongation,5.354324997164542e-06,1,1,2,0.00013399548520056704
6004,GPVI-mediated activation cascade,GPVI-mediated activation cascade,0.0029368905373021656,0,1,2,0.07349760665166144
6005,GPVI-mediated activation cascade,GPVI-mediated activation cascade,0.002550957288042297,1,1,2,0.06383937465846098
6006,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,2.6144057823980317e-05,0,1,2,0.0006542721472998156
6007,GP1b-IX-V activation signalling,GP1b-IX-V activation signalling,1.3597731887251022e-05,1,1,2,0.0003402921344565948
6008,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0017380199289692626,0,1,2,0.043495085523164896
6009,Thrombin signalling through proteinase activated receptors (PARs),Thrombin signalling through proteinase activated receptors (PARs),0.0016442133362084713,1,1,2,0.04114751418249158
6010,Signaling by SCF-KIT,Signaling by SCF-KIT,0.0018811309674688554,0,1,2,0.04707653286740811
6011,Signaling by SCF-KIT,Signaling by SCF-KIT,0.0014931136688458625,1,1,2,0.0373661461757645
6012,Signaling by PDGF,Signaling by PDGF,0.006699641106901679,0,1,2,0.16766290078849447
6013,Signaling by PDGF,Signaling by PDGF,0.005168435281420852,1,1,2,0.12934347347769592
6014,Signaling by MST1,Signaling by MST1,0.0007311132919178627,0,1,2,0.01829658833541054
6015,Signaling by MST1,Signaling by MST1,0.0004425245204258899,1,1,2,0.011074465569239174
6016,Signaling by BMP,Signaling by BMP,0.002821965617609924,0,1,2,0.0706215353664942
6017,Signaling by BMP,Signaling by BMP,0.001798824017139407,1,1,2,0.04501674760024299
6018,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,0.00044032319120620734,0,1,2,0.011019375865675465
6019,TYSND1 cleaves peroxisomal proteins,TYSND1 cleaves peroxisomal proteins,6.722028399796963e-05,1,1,2,0.0016822315743623615
6020,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0010156323872732098,0,1,2,0.025416864794376964
6021,Transferrin endocytosis and recycling,Transferrin endocytosis and recycling,0.0010724532829501675,1,1,2,0.026838844873994225
6022,Mitochondrial protein import,Mitochondrial protein import,0.0004273141160773715,0,1,2,0.010693815251625683
6023,Mitochondrial protein import,Mitochondrial protein import,0.00016160096126082254,1,1,2,0.004044169755195851
6024,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.0070180016226161195,0,1,2,0.1756300809268779
6025,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.009193711810412009,1,1,2,0.23007865146077594
6026,Late endosomal microautophagy,Late endosomal microautophagy,0.0032501521086787714,0,1,2,0.0813371823728829
6027,Late endosomal microautophagy,Late endosomal microautophagy,0.003777822145133227,1,1,2,0.09454247017255116
6028,Defective pyroptosis,Defective pyroptosis,5.1566985909981476e-05,0,1,2,0.0012904975512315602
6029,Defective pyroptosis,Defective pyroptosis,9.980159382098002e-06,1,1,2,0.0002497600163403225
6030,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,0.00044810778329376844,0,1,2,0.011214190374397599
6031,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound by inner hair cells of the cochlea,0.00021259565626673905,1,1,2,0.0053203453522302595
6032,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.004476978070937927,0,1,2,0.11203930451836767
6033,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound by outer hair cells of the cochlea,0.003071386068546731,1,1,2,0.07686344529163328
6034,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0023887687324910295,0,1,2,0.05978049997181421
6035,EGR2 and SOX10-mediated initiation of Schwann cell myelination,EGR2 and SOX10-mediated initiation of Schwann cell myelination,0.0022009754917456715,1,1,2,0.05508085129072242
6036,Aspirin ADME,Aspirin ADME,0.00021675110163409884,0,1,2,0.005424338090534097
6037,Aspirin ADME,Aspirin ADME,0.0008725627045532054,1,1,2,0.02183645240556786
6038,Paracetamol ADME,Paracetamol ADME,2.7075869315045143e-06,0,1,2,6.775913393411682e-05
6039,Paracetamol ADME,Paracetamol ADME,5.320679993296442e-06,1,1,2,0.00013315349697230888
6040,Atorvastatin ADME,Atorvastatin ADME,0.0043462668089042445,0,1,2,0.10876816969060563
6041,Atorvastatin ADME,Atorvastatin ADME,0.005528049280623661,1,1,2,0.13834304902337435
6042,Kinesins,Kinesins,0.0007162176998601611,0,1,2,0.017923816401286555
6043,Kinesins,Kinesins,0.0004643358402917407,1,1,2,0.011620308115187947
6044,Stimuli-sensing channels,Stimuli-sensing channels,1.06895647777815e-05,0,1,2,0.0002675133503738093
6045,Stimuli-sensing channels,Stimuli-sensing channels,6.916466481740785e-06,1,1,2,0.00017308909761456435
6046,Integrin cell surface interactions,Integrin cell surface interactions,0.009921534279367868,0,2,3,0.3741242521819979
6047,Integrin cell surface interactions,Integrin cell surface interactions,0.008982297546155798,1,2,3,0.3387072258894458
6048,Cellular response to hypoxia,Cellular responses to stress,7.157284012828082e-06,0,2,3,0.00026988905682882755
6049,Cellular response to hypoxia,Cellular responses to stress,4.307995806302965e-06,1,2,3,0.00016244722479948615
6050,Abacavir metabolism,Abacavir ADME,0.0026836318621615203,0,2,3,0.10119521187875488
6051,Abacavir metabolism,Abacavir ADME,0.0036550381529348226,1,2,3,0.1378252976968533
6052,Sphingolipid metabolism,Metabolism of lipids,0.00023535904627462357,0,2,3,0.00887499097441731
6053,Sphingolipid metabolism,Metabolism of lipids,0.00047034217595172395,1,2,3,0.01773580677068464
6054,Paracetamol ADME,Paracetamol ADME,1.245092666261551e-06,0,2,3,4.695033545679302e-05
6055,Paracetamol ADME,Paracetamol ADME,2.3489980608353458e-07,1,2,3,8.857673804690811e-06
6056,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",0.0007358710379794779,0,2,3,0.027748450394307705
6057,Mitotic G1 phase and G1/S transition,"Cell Cycle, Mitotic",0.00013698020819010985,1,2,3,0.005165291628274692
6058,Miscellaneous transport and binding events,Miscellaneous transport and binding events,0.0007505930957605705,0,2,3,0.028303594256420365
6059,Miscellaneous transport and binding events,Miscellaneous transport and binding events,2.2141996437322726e-05,1,2,3,0.0008349371806492026
6060,GPCR ligand binding,Signaling by GPCR,0.002086176365530615,0,2,3,0.07866617709490259
6061,GPCR ligand binding,Signaling by GPCR,0.0015610977432141983,1,2,3,0.0588663516465951
6062,HDMs demethylate histones,Chromatin modifying enzymes,9.97938467510255e-05,0,2,3,0.0037630569261583057
6063,HDMs demethylate histones,Chromatin modifying enzymes,6.509177844148829e-05,1,2,3,0.0024545007099617323
6064,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0001906666079037511,0,2,3,0.007189714825297559
6065,Scavenging by Class H Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0002175173308085927,1,2,3,0.008202210105207022
6066,S Phase,"Cell Cycle, Mitotic",0.00015297285727420475,0,2,3,0.005768347336245025
6067,S Phase,"Cell Cycle, Mitotic",2.8157701085327866e-05,1,2,3,0.0010617792132835027
6068,Metallothioneins bind metals,Response to metal ions,0.002955453569922823,0,2,3,0.11144514805591543
6069,Metallothioneins bind metals,Response to metal ions,0.002717277547167283,1,2,3,0.10246393366991056
6070,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,5.034459772287398e-05,0,2,3,0.001898409504429368
6071,KSRP (KHSRP) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,6.887009080832849e-05,1,2,3,0.002596974469458146
6072,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,0.00024879605188275284,0,2,3,0.00938167769576047
6073,Formation of xylulose-5-phosphate,Metabolism of carbohydrates,0.00034645835827352945,1,2,3,0.013064357845422403
6074,Late endosomal microautophagy,Late endosomal microautophagy,0.002494824516273687,0,2,3,0.09407560667478498
6075,Late endosomal microautophagy,Late endosomal microautophagy,0.0029579145457272935,1,2,3,0.11153794728500241
6076,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,0.005096346772269808,0,2,3,0.19217460438558906
6077,Global Genome Nucleotide Excision Repair (GG-NER),Nucleotide Excision Repair,0.0037960986297816287,1,2,3,0.1431444493448492
6078,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,0.0009919342038915717,0,2,3,0.03740415865078521
6079,Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R),Signaling by Receptor Tyrosine Kinases,0.0007985528800833756,1,2,3,0.03011207648702579
6080,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,0.0002703354473438596,0,2,3,0.010193891814306289
6081,Transport of inorganic cations/anions and amino acids/oligopeptides,SLC-mediated transmembrane transport,0.0001854638538937478,1,2,3,0.006993527784213889
6082,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.001314662773586348,0,2,3,0.04957370636337113
6083,Thrombin signalling through proteinase activated receptors (PARs),"Platelet activation, signaling and aggregation",0.0009489257135225722,1,2,3,0.03578238132847738
6084,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",0.0007489801940436092,0,2,3,0.028242774464671418
6085,Regulation of mitotic cell cycle,"Cell Cycle, Mitotic",0.0001395449166159266,1,2,3,0.0052620024388061746
6086,Influenza Infection,Infectious disease,0.0012496140248350195,0,2,3,0.047120828230139904
6087,Influenza Infection,Infectious disease,0.0013134734993580396,1,2,3,0.04952886084666204
6088,Neddylation,Post-translational protein modification,3.950901753360362e-05,0,2,3,0.0014898181292325949
6089,Neddylation,Post-translational protein modification,3.7475709350797234e-05,1,2,3,0.001413145521757973
6090,Cellular response to heat stress,Cellular responses to stress,0.0021733395192106014,0,2,3,0.08195295197972689
6091,Cellular response to heat stress,Cellular responses to stress,0.0013213176403526626,1,2,3,0.049824650116848425
6092,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.0011650839703871447,0,2,3,0.04393334305730939
6093,Transcriptional regulation of testis differentiation,Transcriptional regulation of testis differentiation,0.001442969729818712,1,2,3,0.05441194435142149
6094,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.000522983566233407,0,2,3,0.019720824432107282
6095,Defective Intrinsic Pathway for Apoptosis,Diseases of programmed cell death,0.0010123634798083233,1,2,3,0.03817451204167844
6096,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,7.669393912369442e-05,0,2,3,0.0028919985370823077
6097,"Synthesis, secretion, and deacylation of Ghrelin",Peptide hormone metabolism,7.413146192960496e-05,1,2,3,0.002795371862519911
6098,Triglyceride metabolism,Metabolism of lipids,0.00014087712329201906,0,2,3,0.005312237696016486
6099,Triglyceride metabolism,Metabolism of lipids,0.0002765972310187281,1,2,3,0.01043001307022507
6100,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.005522149457393254,0,2,3,0.20823090239991648
6101,Caspase activation via extrinsic apoptotic signalling pathway,Apoptosis,0.007940746114100013,1,2,3,0.2994320856082406
6102,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,0.0032001865553778364,0,2,3,0.12067361439887082
6103,Signaling by Retinoic Acid,Signaling by Nuclear Receptors,0.0022483002097490076,1,2,3,0.08477959264850399
6104,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,7.255475054304218e-05,0,2,3,0.002735916746829657
6105,GRB2:SOS provides linkage to MAPK signaling for Integrins ,Integrin signaling,0.0001357873318549426,1,2,3,0.005120310282217348
6106,ROS and RNS production in phagocytes,Innate Immune System,0.0014777515663559723,0,2,3,0.05572350849237088
6107,ROS and RNS production in phagocytes,Innate Immune System,0.001658963100532032,1,2,3,0.06255668850278055
6108,HATs acetylate histones,Chromatin modifying enzymes,0.0013141948829013068,0,2,3,0.049556062998170246
6109,HATs acetylate histones,Chromatin modifying enzymes,0.0008590421765407873,1,2,3,0.032393025397236694
6110,HCMV Infection,Infectious disease,0.001662300833771868,0,2,3,0.06268254876966824
6111,HCMV Infection,Infectious disease,0.0017470486394084192,1,2,3,0.06587824497098804
6112,Retinoid metabolism and transport,Visual phototransduction,0.01204522010819457,0,2,3,0.4542048476027616
6113,Retinoid metabolism and transport,Visual phototransduction,0.009125416343836313,1,2,3,0.34410399332961444
6114,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,0.00010508869838054932,0,2,3,0.00396271681247545
6115,Biosynthesis of specialized proresolving mediators (SPMs),Metabolism of lipids,0.00020862155772912846,1,2,3,0.0078667655703979
6116,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.004275227213630909,0,2,3,0.16121157667458036
6117,Plasma lipoprotein assembly,"Plasma lipoprotein assembly, remodeling, and clearance",0.0032867970903680543,1,2,3,0.12393955096895165
6118,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,0.0016145854183770528,0,2,3,0.06088328127741542
6119,Activation of anterior HOX genes in hindbrain development during early embryogenesis,Activation of HOX genes during differentiation,0.001825805965912656,1,2,3,0.06884805035114225
6120,HDACs deacetylate histones,Chromatin modifying enzymes,0.0006793688006223304,0,2,3,0.025617846729327036
6121,HDACs deacetylate histones,Chromatin modifying enzymes,0.0004430547858295734,1,2,3,0.016706845509654917
6122,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.0002463724275460243,0,2,3,0.009290286927254612
6123,Post-translational modification: synthesis of GPI-anchored proteins,Post-translational protein modification,0.00023507274799675114,1,2,3,0.008864195151302254
6124,Platelet sensitization by LDL,Platelet homeostasis,0.002816379702219215,0,2,3,0.10620090807371123
6125,Platelet sensitization by LDL,Platelet homeostasis,0.0017170521930680931,1,2,3,0.06474712978867907
6126,Galactose catabolism,Metabolism of carbohydrates,0.00012110720907806579,0,2,3,0.004566747718082471
6127,Galactose catabolism,Metabolism of carbohydrates,0.00016587359627712043,1,2,3,0.006254812352255479
6128,Intraflagellar transport,Cilium Assembly,0.0008581458158947073,0,2,3,0.03235922515556466
6129,Intraflagellar transport,Cilium Assembly,0.0024280279601787023,1,2,3,0.09155682168713071
6130,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.00115091577998119,0,2,3,0.04339908459575039
6131,Activation of Matrix Metalloproteinases,Degradation of the extracellular matrix,0.0009157541065820245,1,2,3,0.03453153621814851
6132,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00014204107490716842,0,2,3,0.005356128339875806
6133,Signaling by ERBB2 in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00011312279111088483,1,2,3,0.004265668840867686
6134,Aflatoxin activation and detoxification,Biological oxidations,0.0003674975932465847,0,2,3,0.013857711759155707
6135,Aflatoxin activation and detoxification,Biological oxidations,0.0004027964031163646,1,2,3,0.015188770088804227
6136,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.00462707725348756,0,2,3,0.1744792456998556
6137,Scavenging of heme from plasma,Binding and Uptake of Ligands by Scavenger Receptors,0.005281516119434001,1,2,3,0.19915702681987874
6138,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,4.038349193333869e-05,0,2,3,0.0015227930776267689
6139,DDX58/IFIH1-mediated induction of interferon-alpha/beta,Innate Immune System,4.5454080339119216e-05,1,2,3,0.001713996377642602
6140,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",1.9419872420987332e-05,0,2,3,0.0007322904948361066
6141,GP1b-IX-V activation signalling,"Platelet activation, signaling and aggregation",1.4070183275958125e-05,1,2,3,0.0005305627786952395
6142,Smooth Muscle Contraction,Smooth Muscle Contraction,0.001548809594408058,0,2,3,0.05840298636927519
6143,Smooth Muscle Contraction,Smooth Muscle Contraction,0.0030234976818300204,1,2,3,0.11401097626008813
6144,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.0003058471993813443,0,2,3,0.011532979832408967
6145,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,Adaptive Immune System,0.00048225767994172476,1,2,3,0.018185120243188684
6146,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.001701521795167089,0,2,3,0.06416150478984348
6147,Class I MHC mediated antigen processing & presentation,Adaptive Immune System,0.002675408859717864,1,2,3,0.10088513638505618
6148,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,0.00019074941844665231,0,2,3,0.007192837470602542
6149,Signaling by NTRKs,Signaling by Receptor Tyrosine Kinases,0.00015358565369890387,1,2,3,0.00579145485144125
6150,Cellular Senescence,Cellular responses to stress,0.00019694986048801317,0,2,3,0.007426645637424675
6151,Cellular Senescence,Cellular responses to stress,0.00011958987102511417,1,2,3,0.004509531470233759
6152,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,0.00010065847203490941,0,2,3,0.0037956604810765603
6153,Aspartate and asparagine metabolism,Metabolism of amino acids and derivatives,0.0002185487033683171,1,2,3,0.008241101417453992
6154,Pentose phosphate pathway,Metabolism of carbohydrates,7.724781245101647e-05,0,2,3,0.002912884162082751
6155,Pentose phosphate pathway,Metabolism of carbohydrates,0.00011076383442589292,1,2,3,0.004176716579972151
6156,Regulation of Apoptosis,Apoptosis,0.0002814681849052106,0,2,3,0.010613688490667138
6157,Regulation of Apoptosis,Apoptosis,0.0004002137949068553,1,2,3,0.015091384307749069
6158,Meiotic recombination,Meiosis,0.000196361141511284,0,2,3,0.007404446042008048
6159,Meiotic recombination,Meiosis,0.0006723271295496825,1,2,3,0.02535231724064256
6160,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.004059650033152397,0,2,3,0.15308252635201616
6161,Defects of contact activation system (CAS) and kallikrein/kinin system (KKS),Diseases of hemostasis,0.0041654140138239265,1,2,3,0.15707070691586425
6162,Anchoring of the basal body to the plasma membrane,Cilium Assembly,0.00014823158314500106,0,2,3,0.005589561919793166
6163,Anchoring of the basal body to the plasma membrane,Cilium Assembly,0.0003933684925878757,1,2,3,0.014833259552148155
6164,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.00010890364738692102,0,2,3,0.004106572077591986
6165,Phenylalanine and tyrosine metabolism,Metabolism of amino acids and derivatives,0.0002361981652181851,1,2,3,0.008906632728445671
6166,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,0.00014771402626313732,0,2,3,0.0055700457264367025
6167,RNA Polymerase I Promoter Clearance,RNA Polymerase I Transcription,0.00040478641907436307,1,2,3,0.015263810219811448
6168,SARS-CoV Infections,Infectious disease,0.006227651086215138,0,2,3,0.23483417381581548
6169,SARS-CoV Infections,Infectious disease,0.006535023547839586,1,2,3,0.24642466870386145
6170,Telomere Maintenance,Chromosome Maintenance,0.0004968651307263378,0,2,3,0.018735942469590032
6171,Telomere Maintenance,Chromosome Maintenance,0.00022835206356535426,1,2,3,0.008610769525159302
6172,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,0.0015187341683522944,0,2,3,0.05726889299567608
6173,Signaling by TGF-beta Receptor Complex,Signaling by TGFB family members,0.0007643642732495356,1,2,3,0.0288228820333561
6174,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.006324902829033947,0,2,3,0.23850137230860755
6175,Chaperone Mediated Autophagy,Chaperone Mediated Autophagy,0.008009925820514753,1,2,3,0.30204073515777713
6176,Metabolism of cofactors,Metabolism of vitamins and cofactors,0.0001779363109410485,0,2,3,0.006709676889921971
6177,Metabolism of cofactors,Metabolism of vitamins and cofactors,0.00038494697244847336,1,2,3,0.014515698292400103
6178,Cristae formation,Mitochondrial biogenesis,4.9956845452405954e-05,0,2,3,0.0018837880231003768
6179,Cristae formation,Mitochondrial biogenesis,0.00019871928334442383,1,2,3,0.0074933675762204706
6180,Generic Transcription Pathway,RNA Polymerase II Transcription,0.0055391973095501625,0,2,3,0.20887374802841735
6181,Generic Transcription Pathway,RNA Polymerase II Transcription,0.0061390373269616045,1,2,3,0.23149269905190667
6182,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,0.0012689776411918252,0,2,3,0.0478509974040845
6183,Signaling by SCF-KIT,Signaling by Receptor Tyrosine Kinases,0.0010192316759148432,1,2,3,0.03843350008322908
6184,Choline catabolism,Metabolism of amino acids and derivatives,0.00012137685918815312,0,2,3,0.004576915766989685
6185,Choline catabolism,Metabolism of amino acids and derivatives,0.0002637628347998211,1,2,3,0.009946049728225515
6186,Signaling by Hippo,Signaling by Hippo,0.00024611390799137426,0,2,3,0.009280538592739555
6187,Signaling by Hippo,Signaling by Hippo,0.0005153691399662854,1,2,3,0.019433697315194946
6188,Physiological factors,Cardiac conduction,0.00045942454445199466,0,2,3,0.017324121379552266
6189,Physiological factors,Cardiac conduction,0.0021303078102959594,1,2,3,0.08033029912539137
6190,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,0.0005509059317469087,0,2,3,0.020773729539598055
6191,Assembly of the pre-replicative complex,DNA Replication Pre-Initiation,0.0010704919070934375,1,2,3,0.04036643657433696
6192,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.002373475346120806,0,2,3,0.08949973501441459
6193,Dissolution of Fibrin Clot,Dissolution of Fibrin Clot,0.0025113469942732594,1,2,3,0.09469864133371247
6194,Leishmania infection,Infectious disease,0.005872453811073494,0,2,3,0.22144028621762457
6195,Leishmania infection,Infectious disease,0.006126453483624675,1,2,3,0.23101818363468993
6196,O-linked glycosylation,Post-translational protein modification,0.0006095628369566008,0,2,3,0.022985582079635296
6197,O-linked glycosylation,Post-translational protein modification,0.0005819790742834396,1,2,3,0.021945445111714684
6198,Diseases of glycosylation,Diseases of metabolism,0.001755532076583273,0,2,3,0.0661981410172654
6199,Diseases of glycosylation,Diseases of metabolism,0.002369287895489464,1,2,3,0.08934183334397865
6200,Complement cascade,Innate Immune System,0.0036336805990773834,0,2,3,0.13701994051717117
6201,Complement cascade,Innate Immune System,0.004099789248929884,1,2,3,0.15459610818957054
6202,Diseases of carbohydrate metabolism,Diseases of metabolism,0.0008269021704256772,0,2,3,0.031181080206668196
6203,Diseases of carbohydrate metabolism,Diseases of metabolism,0.0011194402883757456,1,2,3,0.04221219712176004
6204,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,1.777623178503316e-05,0,2,3,0.0006703115905187517
6205,Transcriptional activation of mitochondrial biogenesis,Mitochondrial biogenesis,7.262109899004038e-05,1,2,3,0.002738418634382296
6206,Striated Muscle Contraction,Striated Muscle Contraction,0.0007628351942905634,0,2,3,0.02876522305582857
6207,Striated Muscle Contraction,Striated Muscle Contraction,0.0013708523422536845,1,2,3,0.0516925198216698
6208,Fibronectin matrix formation,Fibronectin matrix formation,0.00107896446393239,0,2,3,0.040685922341577044
6209,Fibronectin matrix formation,Fibronectin matrix formation,0.0010278428153400326,1,2,3,0.03875821156505941
6210,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,0.00011787447860672678,0,2,3,0.004444846927736896
6211,"Transport of vitamins, nucleosides, and related molecules",SLC-mediated transmembrane transport,8.109572349450374e-05,1,2,3,0.003057982369786494
6212,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.004532167666179633,0,2,3,0.17090036592414187
6213,Signaling by Rho GTPases,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",0.0032435529651570157,1,2,3,0.12230888825587828
6214,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.0002172200475026588,0,2,3,0.00819100005529065
6215,p130Cas linkage to MAPK signaling for integrins,Integrin signaling,0.00042537693537218876,1,2,3,0.01604024371235955
6216,Homology Directed Repair,DNA Double-Strand Break Repair,0.000700850729052885,0,2,3,0.026427893863490693
6217,Homology Directed Repair,DNA Double-Strand Break Repair,0.00020567125285210957,1,2,3,0.00775551457083033
6218,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,0.00022793717355940724,0,2,3,0.008595124725792385
6219,"Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA",Regulation of mRNA stability by proteins that bind AU-rich elements,0.0002959509481951301,1,2,3,0.011159808962844273
6220,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,3.4898518744709694e-05,0,2,3,0.0013159640293512963
6221,Platelet Adhesion to exposed collagen,Platelet Adhesion to exposed collagen,0.0004292061965449837,1,2,3,0.01618463866502938
6222,Type I hemidesmosome assembly,Cell junction organization,0.0025769250758753397,0,2,3,0.09717147971214032
6223,Type I hemidesmosome assembly,Cell junction organization,0.0016715580542562387,1,2,3,0.06303162287388227
6224,Deubiquitination,Post-translational protein modification,0.0003309272796295911,0,2,3,0.012478707176923835
6225,Deubiquitination,Post-translational protein modification,0.0003155208854587002,1,2,3,0.011897758148708323
6226,Chaperonin-mediated protein folding,Protein folding,0.0005787917303507295,0,2,3,0.021825255770863264
6227,Chaperonin-mediated protein folding,Protein folding,0.0002875531868800683,1,2,3,0.010843143608118456
6228,Post-chaperonin tubulin folding pathway,Protein folding,0.00034369855894986217,0,2,3,0.012960290487585768
6229,Post-chaperonin tubulin folding pathway,Protein folding,0.0001590500564810695,1,2,3,0.00599750822453197
6230,mTORC1-mediated signalling,MTOR signalling,1.1498368531661279e-05,0,2,3,0.0004335840009308394
6231,mTORC1-mediated signalling,MTOR signalling,1.8202389670883986e-05,1,2,3,0.0006863812825508553
6232,Protein methylation,Post-translational protein modification,0.0006804197189294104,0,2,3,0.02565747507859941
6233,Protein methylation,Post-translational protein modification,0.0006508896761718041,1,2,3,0.02454394718538169
6234,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,0.0012073153892498308,0,2,3,0.045525818329349044
6235,G1/S DNA Damage Checkpoints,Cell Cycle Checkpoints,0.0002957273046071948,1,2,3,0.011151375741959721
6236,PECAM1 interactions,Cell surface interactions at the vascular wall,6.271895954295577e-05,0,2,3,0.002365025728473955
6237,PECAM1 interactions,Cell surface interactions at the vascular wall,8.269868648391179e-05,1,2,3,0.0031184273889540252
6238,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,0.0012381267074234358,0,2,3,0.046687660948228356
6239,Endosomal Sorting Complex Required For Transport (ESCRT),Membrane Trafficking,0.0014215519129969936,1,2,3,0.05360431475743223
6240,Nucleotide catabolism,Metabolism of nucleotides,0.00020157325583531374,0,2,3,0.0076009860446787795
6241,Nucleotide catabolism,Metabolism of nucleotides,7.046907505475228e-05,1,2,3,0.0026572694569670955
6242,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.009535305538548033,0,2,3,0.35956022057542447
6243,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),0.01157806291938393,1,2,3,0.43658914130230814
6244,Neurotransmitter clearance,Transmission across Chemical Synapses,3.1265347270671895e-05,0,2,3,0.0011789632870769914
6245,Neurotransmitter clearance,Transmission across Chemical Synapses,4.194700283322366e-05,1,2,3,0.001581750425323917
6246,Toll-like Receptor Cascades,Innate Immune System,0.0020366076901593474,0,2,3,0.0767970263080639
6247,Toll-like Receptor Cascades,Innate Immune System,0.002299489926372189,1,2,3,0.08670987015516765
6248,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,0.00041751992681954595,0,2,3,0.015743969228355817
6249,Metabolism of water-soluble vitamins and cofactors,Metabolism of vitamins and cofactors,0.0009149152849433938,1,2,3,0.0344999056749855
6250,Rap1 signalling,Adaptive Immune System,0.00041133088439675175,0,2,3,0.0155105909218407
6251,Rap1 signalling,Adaptive Immune System,0.0006511085069626659,1,2,3,0.024552198923840717
6252,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.00013947232381779863,0,2,3,0.005259265087349364
6253,Pyruvate metabolism and Citric Acid (TCA) cycle,The citric acid (TCA) cycle and respiratory electron transport,0.00043016115966501215,1,2,3,0.016220648706730793
6254,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,0.0009820826413432847,0,2,3,0.03703267291406135
6255,Carboxyterminal post-translational modifications of tubulin,Post-translational protein modification,0.0009381580339738187,1,2,3,0.035376350371421665
6256,Clathrin-mediated endocytosis,Membrane Trafficking,0.004543992557337148,0,2,3,0.17134626254021654
6257,Clathrin-mediated endocytosis,Membrane Trafficking,0.005234851885568805,1,2,3,0.19739739760257444
6258,MHC class II antigen presentation,Adaptive Immune System,0.00019699917351523154,0,2,3,0.007428505148152695
6259,MHC class II antigen presentation,Adaptive Immune System,0.0003110613370108002,1,2,3,0.01172959613050016
6260,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,3.698811254017634e-05,0,2,3,0.0013947590719405067
6261,Branched-chain amino acid catabolism,Metabolism of amino acids and derivatives,8.031135243774382e-05,1,2,3,0.003028405065835254
6262,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.0028975444362918166,0,2,3,0.10926149271550491
6263,Assembly of collagen fibrils and other multimeric structures,Collagen formation,0.0021850215916625706,1,2,3,0.08239346314432747
6264,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.002754154483045106,0,2,3,0.10385450045822923
6265,Oncogenic MAPK signaling,Diseases of signal transduction by growth factor receptors and second messengers,0.0021998925048446927,1,2,3,0.08295422009147568
6266,SLC transporter disorders,Disorders of transmembrane transporters,2.873930576113876e-06,0,2,3,0.00010837105404629887
6267,SLC transporter disorders,Disorders of transmembrane transporters,1.531378420303403e-05,1,2,3,0.0005774568631941095
6268,Basigin interactions,Cell surface interactions at the vascular wall,0.00036885237751462435,0,2,3,0.013908798379115513
6269,Basigin interactions,Cell surface interactions at the vascular wall,0.000509026744074973,1,2,3,0.019194536309138262
6270,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,0.0018925908640676195,0,2,3,0.071366395737625
6271,Signaling by VEGF,Signaling by Receptor Tyrosine Kinases,0.001520722880104124,1,2,3,0.057343883947277796
6272,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.001263528939180013,0,2,3,0.04764553608044921
6273,Intra-Golgi and retrograde Golgi-to-ER traffic,Membrane Trafficking,0.00145616960797242,1,2,3,0.05490968939811442
6274,Beta-catenin independent WNT signaling,Signaling by WNT,0.00020902409847405054,0,2,3,0.007881944700049243
6275,Beta-catenin independent WNT signaling,Signaling by WNT,0.00016301438733802372,1,2,3,0.006146996426204998
6276,PIP3 activates AKT signaling,Intracellular signaling by second messengers,0.0003489262510021926,0,2,3,0.013157417900004537
6277,PIP3 activates AKT signaling,Intracellular signaling by second messengers,0.000318898706258745,1,2,3,0.012025130049589572
6278,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,3.660563006956481e-05,0,2,3,0.0013803363058379056
6279,PIWI-interacting RNA (piRNA) biogenesis,Gene Silencing by RNA,3.932229639001446e-05,1,2,3,0.0014827771911836145
6280,Laminin interactions,Laminin interactions,0.0003555926643900702,0,2,3,0.013408797057022847
6281,Laminin interactions,Laminin interactions,0.0001167927789636331,1,2,3,0.004404057866422103
6282,Cellular response to chemical stress,Cellular responses to stress,0.0021362035288221165,0,2,3,0.08055261668460809
6283,Cellular response to chemical stress,Cellular responses to stress,0.0013018281521636262,1,2,3,0.04908973452931717
6284,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,0.0003676617147325926,0,2,3,0.013863900502397502
6285,eNOS activation,Metabolism of nitric oxide: NOS3 activation and regulation,0.0004770897001915654,1,2,3,0.017990244480541692
6286,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.000110900265795738,0,2,3,0.0041818611758360795
6287,Advanced glycosylation endproduct receptor signaling,Innate Immune System,0.00012380742708151485,1,2,3,0.004668568365254908
6288,Nephrin family interactions,Nephrin family interactions,0.00031687490945149494,0,2,3,0.01194881609997643
6289,Nephrin family interactions,Nephrin family interactions,0.00023691740246129504,1,2,3,0.008933753946610437
6290,Apoptotic execution phase,Apoptosis,0.0009570396422218275,0,2,3,0.036088343836028214
6291,Apoptotic execution phase,Apoptosis,0.0013757944875832607,1,2,3,0.05187887975084401
6292,Meiotic synapsis,Meiosis,0.00032352013931294035,0,2,3,0.01219939646209449
6293,Meiotic synapsis,Meiosis,0.0010963600581960565,1,2,3,0.04134188073590417
6294,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0007160976994302547,0,2,3,0.02700283129049094
6295,Regulation of lipid metabolism by PPARalpha,Metabolism of lipids,0.0014275804269391994,1,2,3,0.05383163980685394
6296,Threonine catabolism,Metabolism of amino acids and derivatives,8.504047376254905e-06,0,2,3,0.00032067322206181555
6297,Threonine catabolism,Metabolism of amino acids and derivatives,1.7999188186674155e-05,1,2,3,0.000678718898772132
6298,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.002296539693709973,0,2,3,0.08659862187869796
6299,Metabolism of Angiotensinogen to Angiotensins,Peptide hormone metabolism,0.0022072108904022955,1,2,3,0.08323018401467772
6300,Defects in vitamin and cofactor metabolism,Diseases of metabolism,0.0019523719768904132,0,2,3,0.07362064024252434
6301,Defects in vitamin and cofactor metabolism,Diseases of metabolism,0.002628844891466362,1,2,3,0.09912928801421032
6302,Signaling by NOTCH4,Signaling by NOTCH,0.0009274879383428463,0,2,3,0.034973999138613925
6303,Signaling by NOTCH4,Signaling by NOTCH,0.0006904741716988874,1,2,3,0.026036611461900748
6304,Cell-extracellular matrix interactions,Cell junction organization,4.243016202611273e-05,0,2,3,0.0015999695400933315
6305,Cell-extracellular matrix interactions,Cell junction organization,2.8173447762869005e-05,1,2,3,0.0010623729938212245
6306,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,0.00013815369198839228,0,2,3,0.005209541714613967
6307,Sulfur amino acid metabolism,Metabolism of amino acids and derivatives,0.000299818472532546,1,2,3,0.011305646754640282
6308,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,0.0005956834064735294,0,2,3,0.02246221226565508
6309,Signaling by MST1,Signaling by Receptor Tyrosine Kinases,0.0004783215227842004,1,2,3,0.01803669442399941
6310,Signaling by BMP,Signaling by TGFB family members,0.001967977387901528,0,2,3,0.07420909385868196
6311,Signaling by BMP,Signaling by TGFB family members,0.0010027004690098618,1,2,3,0.03781013627206397
6312,Cell-cell junction organization,Cell junction organization,0.002800978879797536,0,2,3,0.10562016914672084
6313,Cell-cell junction organization,Cell junction organization,0.0018084755935384874,1,2,3,0.06819455136379263
6314,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,0.0005172871516477124,0,2,3,0.019506022286896386
6315,The canonical retinoid cycle in rods (twilight vision),Visual phototransduction,0.00039384697184377635,1,2,3,0.0148513021944208
6316,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,1.830164694926915e-05,0,2,3,0.0006901241063927981
6317,Signaling by ERBB4,Signaling by Receptor Tyrosine Kinases,1.4865155981977591e-05,1,2,3,0.0005605398528825577
6318,Hedgehog ligand biogenesis,Signaling by Hedgehog,0.00016529783036548445,0,2,3,0.006233101194983096
6319,Hedgehog ligand biogenesis,Signaling by Hedgehog,0.0002200083633840504,1,2,3,0.008296142724216577
6320,Nucleosome assembly,Chromosome Maintenance,0.0005943454074738303,0,2,3,0.022411758589732832
6321,Nucleosome assembly,Chromosome Maintenance,0.00027408233399956556,1,2,3,0.010335180563465959
6322,Axon guidance,Nervous system development,0.003972865767079804,0,2,3,0.14981003867709167
6323,Axon guidance,Nervous system development,0.004149233707259906,1,2,3,0.15646057496218768
6324,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.00020515806559368163,0,2,3,0.0077361631485721866
6325,MAPK1/MAPK3 signaling,MAPK family signaling cascades,0.0002071010821257656,1,2,3,0.007809431010837688
6326,ER to Golgi Anterograde Transport,Membrane Trafficking,0.004909832249413647,0,2,3,0.18514145765446785
6327,ER to Golgi Anterograde Transport,Membrane Trafficking,0.005634315144395495,1,2,3,0.21246048046602858
6328,Pre-NOTCH Expression and Processing,Signaling by NOTCH,0.0023909506859948627,0,2,3,0.09015870048063322
6329,Pre-NOTCH Expression and Processing,Signaling by NOTCH,0.0017882557580110718,1,2,3,0.06743209561522273
6330,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.004622621405120336,0,2,3,0.1743112232054224
6331,Extrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.003167110295632903,1,2,3,0.11942636466978566
6332,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,0.0003445503624013516,0,2,3,0.012992410552922561
6333,Hh mutants abrogate ligand secretion,Diseases of signal transduction by growth factor receptors and second messengers,0.0002736541673267325,1,2,3,0.01031903512347932
6334,Signaling by Activin,Signaling by TGFB family members,7.045479434438057e-05,0,2,3,0.0026567309555682187
6335,Signaling by Activin,Signaling by TGFB family members,3.2625463337713825e-05,1,2,3,0.0012302509601459597
6336,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.002361156237485989,0,2,3,0.08903520229439628
6337,Erythrocytes take up oxygen and release carbon dioxide,O2/CO2 exchange in erythrocytes,0.002285673403814033,1,2,3,0.08618887249248001
6338,Fatty acid metabolism,Metabolism of lipids,0.00024381255490295978,0,2,3,0.009193758465899671
6339,Fatty acid metabolism,Metabolism of lipids,0.00048595037576213947,1,2,3,0.018324365547740133
6340,Hedgehog 'on' state,Signaling by Hedgehog,8.092839063262226e-05,0,2,3,0.003051672531000061
6341,Hedgehog 'on' state,Signaling by Hedgehog,0.00010481296120247529,1,2,3,0.0039523192305449765
6342,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.0007152614597922588,0,2,3,0.026971298110198376
6343,Fc epsilon receptor (FCERI) signaling,Innate Immune System,0.000813987409320514,1,2,3,0.030694086440933185
6344,Heme biosynthesis,Metabolism of porphyrins,9.024949491933586e-05,0,2,3,0.003403155585191486
6345,Heme biosynthesis,Metabolism of porphyrins,0.000108421391886476,1,2,3,0.004088387039533926
6346,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.002082360654877831,0,2,3,0.07852229310938996
6347,Metabolism of fat-soluble vitamins,Metabolism of vitamins and cofactors,0.004577856541606527,1,2,3,0.1726232160268391
6348,Alanine metabolism,Metabolism of amino acids and derivatives,0.00011948940023495627,0,2,3,0.004505742886918361
6349,Alanine metabolism,Metabolism of amino acids and derivatives,0.0002588497489637005,1,2,3,0.009760785583327384
6350,Molecules associated with elastic fibres,Elastic fibre formation,0.003407586498825981,0,2,3,0.1284943149639521
6351,Molecules associated with elastic fibres,Elastic fibre formation,0.0030283199639921194,1,2,3,0.1141928163522458
6352,Unfolded Protein Response (UPR),Cellular responses to stress,0.004629373550636642,0,2,3,0.17456583517578722
6353,Unfolded Protein Response (UPR),Cellular responses to stress,0.0028225758551297295,1,2,3,0.10643455450467423
6354,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,0.0022324409523770817,0,2,3,0.08418156691605531
6355,Neurotransmitter receptors and postsynaptic signal transmission,Transmission across Chemical Synapses,0.0030855158765547373,1,2,3,0.11634957733424986
6356,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,2.3354718199409383e-06,0,2,3,8.80666864140697e-05
6357,Transcriptional regulation of white adipocyte differentiation,Transcriptional regulation of white adipocyte differentiation,2.559501872455724e-06,1,2,3,9.651448022330785e-05
6358,G2/M Checkpoints,Cell Cycle Checkpoints,0.0007684633727701208,0,2,3,0.028977452133058086
6359,G2/M Checkpoints,Cell Cycle Checkpoints,0.0001890377130208149,1,2,3,0.007128291958349562
6360,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.004095473975743295,0,2,3,0.1544333865470872
6361,Sensory processing of sound by outer hair cells of the cochlea,Sensory processing of sound,0.0025444010884319622,1,2,3,0.09594505523608585
6362,DAP12 interactions,Innate Immune System,0.0007878633720612953,0,2,3,0.029708993245830848
6363,DAP12 interactions,Innate Immune System,0.0008939842408527663,1,2,3,0.033710631456170495
6364,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.0016378186839671434,0,2,3,0.061759368369380015
6365,AUF1 (hnRNP D0) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.002239491564539791,1,2,3,0.08444743355810123
6366,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0011777540710357032,0,2,3,0.04441111109164154
6367,Reversible hydration of carbon dioxide,Reversible hydration of carbon dioxide,0.0009391499578655177,1,2,3,0.03541375414121714
6368,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.0036247016626471053,0,2,3,0.13668136003326828
6369,"Gamma carboxylation, hypusine formation and arylsulfatase activation",Post-translational protein modification,0.003470217389937905,1,2,3,0.1308560197810657
6370,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0020815223833132532,0,2,3,0.07849068330858776
6371,Signaling by the B Cell Receptor (BCR),Adaptive Immune System,0.0032737848305409876,1,2,3,0.12344888069156092
6372,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.0008377963592839631,0,2,3,0.031591881615499834
6373,Insulin effects increased synthesis of Xylulose-5-Phosphate,Integration of energy metabolism,0.0006273277865475762,1,2,3,0.023655468237726362
6374,DNA methylation,Epigenetic regulation of gene expression,6.802819854159181e-05,0,2,3,0.002565228138110417
6375,DNA methylation,Epigenetic regulation of gene expression,0.00011495845124299365,1,2,3,0.004334888475134703
6376,ESR-mediated signaling,Signaling by Nuclear Receptors,0.0006672794605471752,0,2,3,0.025161978192502356
6377,ESR-mediated signaling,Signaling by Nuclear Receptors,0.0004731973494003588,1,2,3,0.01784347052522528
6378,Metabolism of steroids,Metabolism of lipids,0.0009992087386289945,0,2,3,0.037678469033834525
6379,Metabolism of steroids,Metabolism of lipids,0.0019967641723278714,1,2,3,0.07529459473918855
6380,RMTs methylate histone arginines,Chromatin modifying enzymes,0.001165213232072836,0,2,3,0.04393821729652818
6381,RMTs methylate histone arginines,Chromatin modifying enzymes,0.0007599377851025556,1,2,3,0.028655966663096766
6382,Diseases associated with visual transduction,Diseases of the neuronal system,0.0003712193935872958,0,2,3,0.013998054545869129
6383,Diseases associated with visual transduction,Diseases of the neuronal system,0.0004089800711065824,1,2,3,0.015421945734570314
6384,TCF dependent signaling in response to WNT,Signaling by WNT,0.0007471688342941653,0,2,3,0.02817447115667373
6385,TCF dependent signaling in response to WNT,Signaling by WNT,0.0005840825735854912,1,2,3,0.022024764507403503
6386,Signaling by Interleukins,Cytokine Signaling in Immune system,0.0020626788536901586,0,2,3,0.07778012572442762
6387,Signaling by Interleukins,Cytokine Signaling in Immune system,0.0034317085370774497,1,2,3,0.12940391616753846
6388,Protein ubiquitination,Post-translational protein modification,6.546172129314128e-05,0,2,3,0.002468450628273517
6389,Protein ubiquitination,Post-translational protein modification,6.243935004114539e-05,1,2,3,0.0023544821277744817
6390,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,0,2,3,0.0
6391,Platelet Aggregation (Plug Formation),"Platelet activation, signaling and aggregation",0.0,1,2,3,0.0
6392,C-type lectin receptors (CLRs),Innate Immune System,0.0006570325064051662,0,2,3,0.024775582908509383
6393,C-type lectin receptors (CLRs),Innate Immune System,0.0007377468038409142,1,2,3,0.02781918234769497
6394,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.002214063207889543,0,2,3,0.08348857330039143
6395,Plasma lipoprotein clearance,"Plasma lipoprotein assembly, remodeling, and clearance",0.0017053317665689752,1,2,3,0.06430517235792614
6396,M Phase,"Cell Cycle, Mitotic",0.0010705404546094686,0,2,3,0.040368267218934765
6397,M Phase,"Cell Cycle, Mitotic",0.0001882825627520101,1,2,3,0.007099816520816767
6398,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0031181981804656784,0,2,3,0.11758197165613339
6399,Scavenging by Class A Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.003576126018225725,1,2,3,0.13484965476151414
6400,Glucose metabolism,Metabolism of carbohydrates,0.0008971851561655796,0,2,3,0.03383133255077785
6401,Glucose metabolism,Metabolism of carbohydrates,0.0013011246314841064,1,2,3,0.049063205956144045
6402,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0008584832362274647,0,2,3,0.03237194870477684
6403,Transcriptional regulation of granulopoiesis,Transcriptional regulation of granulopoiesis,0.0007352432720160015,1,2,3,0.027724778403160198
6404,Lactose synthesis,Metabolism of carbohydrates,0.00024899857552448566,0,2,3,0.009389314519247542
6405,Lactose synthesis,Metabolism of carbohydrates,0.00036027299935030067,1,2,3,0.013585284560633936
6406,Phase II - Conjugation of compounds,Biological oxidations,0.0011838187342734184,0,2,3,0.04463979926976578
6407,Phase II - Conjugation of compounds,Biological oxidations,0.0013192651871955826,1,2,3,0.04974725558482248
6408,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,0.0010453105356359883,0,2,3,0.03941688970989419
6409,Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate,Diseases of metabolism,0.0013886958344125656,1,2,3,0.052365367686958035
6410,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,0.0004780532011873358,0,2,3,0.018026576471075535
6411,TYSND1 cleaves peroxisomal proteins,Peroxisomal protein import,0.00011989986769595599,1,2,3,0.004521220919606401
6412,Phospholipid metabolism,Metabolism of lipids,0.000277044925159718,0,2,3,0.010446894857959497
6413,Phospholipid metabolism,Metabolism of lipids,0.0005540932121073241,1,2,3,0.02089391648324592
6414,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.005995339358595246,0,2,3,0.2260740920661974
6415,Plasma lipoprotein remodeling,"Plasma lipoprotein assembly, remodeling, and clearance",0.004630428003724889,1,2,3,0.17460559681567003
6416,Hedgehog 'off' state,Signaling by Hedgehog,0.00012076427651086744,0,2,3,0.004553816311846367
6417,Hedgehog 'off' state,Signaling by Hedgehog,0.00015756517666489755,1,2,3,0.005941515921813154
6418,Signaling by MET,Signaling by Receptor Tyrosine Kinases,0.00485490787553682,0,2,3,0.18307035254868156
6419,Signaling by MET,Signaling by Receptor Tyrosine Kinases,0.0039015360193682077,1,2,3,0.14712031471207687
6420,Syndecan interactions,Non-integrin membrane-ECM interactions,0.004518669055772444,0,2,3,0.17039135619017487
6421,Syndecan interactions,Non-integrin membrane-ECM interactions,0.0035855466191472072,1,2,3,0.1352048896652713
6422,ABC transporter disorders,Disorders of transmembrane transporters,3.4289090037215507e-05,0,2,3,0.0012929835050664946
6423,ABC transporter disorders,Disorders of transmembrane transporters,0.00026704895789486085,1,2,3,0.010069963863972277
6424,Intrinsic Pathway for Apoptosis,Apoptosis,0.0006535948860584013,0,2,3,0.024645956068012193
6425,Intrinsic Pathway for Apoptosis,Apoptosis,0.0009363113788494587,1,2,3,0.03530671613462062
6426,Interferon Signaling,Cytokine Signaling in Immune system,0.00014555571943370744,0,2,3,0.0054886596317256335
6427,Interferon Signaling,Cytokine Signaling in Immune system,0.0002423995319484647,1,2,3,0.009140475763720655
6428,Nucleotide salvage,Metabolism of nucleotides,0.00037298102862098805,0,2,3,0.01406448281906154
6429,Nucleotide salvage,Metabolism of nucleotides,0.00013039557716137314,1,2,3,0.004916996345493342
6430,Defective pyroptosis,Diseases of programmed cell death,1.3547224102593608e-05,0,2,3,0.0005108428740769004
6431,Defective pyroptosis,Diseases of programmed cell death,2.569628483734523e-05,1,2,3,0.0009689633758177076
6432,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,0.0023469396725542165,0,2,3,0.08849911971140742
6433,Interaction With Cumulus Cells And The Zona Pellucida,Fertilization,0.0025834655097821033,1,2,3,0.09741810839631493
6434,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,3.6190672458361938e-06,0,2,3,0.00013646889571913016
6435,Synthesis of IPs in the ER lumen,Inositol phosphate metabolism,0.0002253673741562046,1,2,3,0.008498221943126983
6436,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.0001332368342976912,0,2,3,0.0050241353394685235
6437,Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA,Regulation of mRNA stability by proteins that bind AU-rich elements,0.0001729829067985266,1,2,3,0.006522892409982213
6438,Ketone body metabolism,Metabolism of lipids,0.00013436653357599556,0,2,3,0.005066734385723404
6439,Ketone body metabolism,Metabolism of lipids,0.0002665148473576392,1,2,3,0.010049823460311514
6440,SUMOylation,Post-translational protein modification,0.0004795860931970744,0,2,3,0.01808437923228877
6441,SUMOylation,Post-translational protein modification,0.0004572731936628207,1,2,3,0.017242997585336827
6442,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.001004159520409746,0,2,3,0.03786515462895378
6443,"BMAL1:CLOCK,NPAS2 activates circadian gene expression","BMAL1:CLOCK,NPAS2 activates circadian gene expression",0.0009661015469715624,1,2,3,0.036430052914722746
6444,"Base-Excision Repair, AP Site Formation",Base Excision Repair,7.361048191281962e-05,0,2,3,0.002775726588543798
6445,"Base-Excision Repair, AP Site Formation",Base Excision Repair,0.00045134272023012833,1,2,3,0.017019369477463915
6446,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,0.001049193559596539,0,2,3,0.03956331196622472
6447,HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand,Cellular responses to stress,0.0006363205587652646,1,2,3,0.023994570445736888
6448,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.004370466987921151,0,2,3,0.16480290724211322
6449,Intrinsic Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.0029814578611336486,1,2,3,0.11242572583036352
6450,GPCR downstream signalling,Signaling by GPCR,0.00482591685584819,0,2,3,0.181977150302376
6451,GPCR downstream signalling,Signaling by GPCR,0.0035990714597463167,1,2,3,0.1357148884953459
6452,Amyloid fiber formation,Amyloid fiber formation,0.008741656929556613,0,2,3,0.3296330758442251
6453,Amyloid fiber formation,Amyloid fiber formation,0.009216804965686366,1,2,3,0.3475501034618644
6454,Phase I - Functionalization of compounds,Biological oxidations,0.0006539306714468952,0,2,3,0.024658617966245532
6455,Phase I - Functionalization of compounds,Biological oxidations,0.0007212896210698146,1,2,3,0.02719860986123349
6456,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",0.0026357028356204897,0,2,3,0.09938788947200142
6457,GPVI-mediated activation cascade,"Platelet activation, signaling and aggregation",0.001896946061624753,1,2,3,0.0715306228604961
6458,Atorvastatin ADME,Atorvastatin ADME,0.0035361566248871055,0,2,3,0.1333424766404774
6459,Atorvastatin ADME,Atorvastatin ADME,0.004885238614189276,1,2,3,0.1842140733278432
6460,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,7.992415996184183e-05,0,2,3,0.0030138046934111455
6461,Signaling by EGFR in Cancer,Diseases of signal transduction by growth factor receptors and second messengers,6.365772309538147e-05,1,2,3,0.0024004249119205455
6462,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0006914766296340716,0,2,3,0.026074412452633065
6463,Erythrocytes take up carbon dioxide and release oxygen,O2/CO2 exchange in erythrocytes,0.0006702167626877634,1,2,3,0.02527273888090368
6464,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.0003193077858400633,0,2,3,0.012040555747685672
6465,Negative epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.0005385390665148134,1,2,3,0.020307395999188415
6466,HIV Infection,Infectious disease,0.0005069191590872681,0,2,3,0.019115062849163953
6467,HIV Infection,Infectious disease,0.0005291544347041479,1,2,3,0.019953517429674238
6468,TCR signaling,Adaptive Immune System,1.6184976140584348e-05,0,2,3,0.0006103080354992628
6469,TCR signaling,Adaptive Immune System,2.506293498356897e-05,1,2,3,0.0009450808256252066
6470,Neutrophil degranulation,Innate Immune System,0.005572448973750771,0,2,3,0.2101276119624189
6471,Neutrophil degranulation,Innate Immune System,0.006272465382705012,1,2,3,0.2365240450281946
6472,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.006795826733752324,0,2,3,0.25625911508572713
6473,Diseases associated with the TLR signaling cascade,Diseases of Immune System,0.007384738795855792,1,2,3,0.2784659914247621
6474,Uptake and actions of bacterial toxins,Infectious disease,6.636139744560164e-05,0,2,3,0.0025023758920752212
6475,Uptake and actions of bacterial toxins,Infectious disease,6.961249391794722e-05,1,2,3,0.002624969233209685
6476,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,0.0011648199084299963,0,2,3,0.043923385728184064
6477,Nonhomologous End-Joining (NHEJ),DNA Double-Strand Break Repair,0.0003489653670304658,1,2,3,0.01315889289917442
6478,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,9.458168841980194e-05,0,2,3,0.0035665152640508378
6479,PRC2 methylates histones and DNA,Epigenetic regulation of gene expression,0.00015928476643393925,1,2,3,0.00600635873929355
6480,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0026948301813713373,0,2,3,0.10161748152799457
6481,Collagen biosynthesis and modifying enzymes,Collagen formation,0.0020343910365702724,1,2,3,0.07671344005587669
6482,Intracellular oxygen transport,Intracellular oxygen transport,0.0001520811047388458,0,2,3,0.005734720858622875
6483,Intracellular oxygen transport,Intracellular oxygen transport,0.00047279498200074105,1,2,3,0.017828297932131747
6484,Asparagine N-linked glycosylation,Post-translational protein modification,0.003686078469612314,0,2,3,0.1389957754614273
6485,Asparagine N-linked glycosylation,Post-translational protein modification,0.0035124208075034274,1,2,3,0.13244743917161905
6486,Degradation of beta-catenin by the destruction complex,Signaling by WNT,0.00023217998820336785,0,2,3,0.008755114079366409
6487,Degradation of beta-catenin by the destruction complex,Signaling by WNT,0.00018159980472000594,1,2,3,0.0068478210349536585
6488,Eukaryotic Translation Elongation,Translation,1.5350312388054497e-06,0,2,3,5.7883427917832544e-05
6489,Eukaryotic Translation Elongation,Translation,6.646981923926996e-07,1,2,3,2.5064642942652683e-05
6490,Infection with Mycobacterium tuberculosis,Infectious disease,0.003062818076812868,0,2,3,0.11549368175242816
6491,Infection with Mycobacterium tuberculosis,Infectious disease,0.003214783744812354,1,2,3,0.12122404968714115
6492,ECM proteoglycans,ECM proteoglycans,0.005092461164869359,0,2,3,0.1920280847121159
6493,ECM proteoglycans,ECM proteoglycans,0.0038436230820226057,1,2,3,0.14493651594003185
6494,Heme signaling,Cellular responses to stress,0.002639428845121508,0,2,3,0.09952839097902039
6495,Heme signaling,Cellular responses to stress,0.0016074397047992847,1,2,3,0.060613828522094244
6496,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,3.200353374702133e-05,0,2,3,0.0012067990487302479
6497,"Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways",Innate Immune System,3.599066141372172e-05,1,2,3,0.0013571468794846536
6498,Stimuli-sensing channels,Ion channel transport,1.049063925867425e-05,0,2,3,0.0003955842369787865
6499,Stimuli-sensing channels,Ion channel transport,2.0954697973757177e-05,1,2,3,0.0007901661666819357
6500,Surfactant metabolism,Surfactant metabolism,0.0015668546146273537,0,2,3,0.059083433516365344
6501,Surfactant metabolism,Surfactant metabolism,0.001494217224638947,1,2,3,0.056344400576029
6502,Mitochondrial protein import,Mitochondrial protein import,0.0003790045132788794,0,2,3,0.014291618222690556
6503,Mitochondrial protein import,Mitochondrial protein import,0.00014890300381713076,1,2,3,0.005614880056059895
6504,p75 NTR receptor-mediated signalling,Death Receptor Signalling,0.0001055808749493605,0,2,3,0.003981275957216893
6505,p75 NTR receptor-mediated signalling,Death Receptor Signalling,0.000766977646682402,1,2,3,0.028921427918872686
6506,Transcriptional regulation by small RNAs,Gene Silencing by RNA,0.000672686448268245,0,2,3,0.02536586654089109
6507,Transcriptional regulation by small RNAs,Gene Silencing by RNA,0.000718888162920609,1,2,3,0.027108054942113144
6508,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,4.3635995236658586e-05,0,2,3,0.0016454394679743273
6509,"Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.",The citric acid (TCA) cycle and respiratory electron transport,0.0001326889654278441,1,2,3,0.0050034761323888705
6510,DNA Double Strand Break Response,DNA Double-Strand Break Repair,0.0001209589830525636,0,2,3,0.004561158365731975
6511,DNA Double Strand Break Response,DNA Double-Strand Break Repair,3.590607887736272e-05,1,2,3,0.0013539574153078506
6512,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.0053319553996059275,0,2,3,0.20105900663908496
6513,Signaling by PDGF,Signaling by Receptor Tyrosine Kinases,0.004287858189033111,1,2,3,0.16168786936214427
6514,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.0001328863105153823,0,2,3,0.005010917681368907
6515,Signaling by ALK in cancer,Diseases of signal transduction by growth factor receptors and second messengers,0.00010455707660200003,1,2,3,0.003942670255688661
6516,Selective autophagy,Macroautophagy,0.00026913762626994646,0,2,3,0.010148724010526432
6517,Selective autophagy,Macroautophagy,0.0008409883043930741,1,2,3,0.031712244458919674
6518,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,0.00023022346758253537,0,2,3,0.00868133700078797
6519,Signaling by ERBB2,Signaling by Receptor Tyrosine Kinases,0.00018440100131260923,1,2,3,0.006953449413681513
6520,Heme degradation,Metabolism of porphyrins,3.9089933200935355e-05,0,2,3,0.0014740151689095371
6521,Heme degradation,Metabolism of porphyrins,4.85950845263243e-05,1,2,3,0.0018324383251831489
6522,Aspirin ADME,Aspirin ADME,0.0003321451394249772,0,2,3,0.012524630606948046
6523,Aspirin ADME,Aspirin ADME,0.000610774082160049,1,2,3,0.023031256084601586
6524,PKMTs methylate histone lysines,Chromatin modifying enzymes,0.0008851025492274368,0,2,3,0.03337571790914506
6525,PKMTs methylate histone lysines,Chromatin modifying enzymes,0.0005772989742613875,1,2,3,0.02176896646722435
6526,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0007254765233843445,0,2,3,0.02735649085557123
6527,"Transport of bile salts and organic acids, metal ions and amine compounds",SLC-mediated transmembrane transport,0.0005007593086390915,1,2,3,0.01888278532256513
6528,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,3.247413888970266e-06,0,2,3,0.00012245447715308823
6529,Metabolism of amine-derived hormones,Metabolism of amino acids and derivatives,7.033846666482609e-06,1,2,3,0.0002652344435812712
6530,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.004410617037576442,0,2,3,0.16631689760684873
6531,Common Pathway of Fibrin Clot Formation,Formation of Fibrin Clot (Clotting Cascade),0.002999191110787708,1,2,3,0.11309441663752812
6532,Switching of origins to a post-replicative state,Synthesis of DNA,0.00034931982625651097,0,2,3,0.01317225895619132
6533,Switching of origins to a post-replicative state,Synthesis of DNA,0.002006219202406742,1,2,3,0.07565112790815334
6534,MAPK6/MAPK4 signaling,MAPK family signaling cascades,0.0011859912313591822,0,2,3,0.04472172045500718
6535,MAPK6/MAPK4 signaling,MAPK family signaling cascades,0.0011903734990427516,1,2,3,0.044886968346493694
6536,RAB geranylgeranylation,Post-translational protein modification,0.00013816560896820132,0,2,3,0.005209991083737108
6537,RAB geranylgeranylation,Post-translational protein modification,0.00012988128591026225,1,2,3,0.004897603293541113
6538,Tryptophan catabolism,Metabolism of amino acids and derivatives,5.053239885621898e-05,0,2,3,0.001905491167062711
6539,Tryptophan catabolism,Metabolism of amino acids and derivatives,0.00010997537796596552,1,2,3,0.004146985222387486
6540,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0017785001115888858,0,2,3,0.06706422671314755
6541,Scavenging by Class B Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.002023239636940988,1,2,3,0.07629293966454462
6542,RIPK1-mediated regulated necrosis,Regulated Necrosis,0.00019957147917824296,0,2,3,0.0075255024376302835
6543,RIPK1-mediated regulated necrosis,Regulated Necrosis,0.0005129195904438408,1,2,3,0.019341328951848848
6544,Post-translational protein phosphorylation,Post-translational protein modification,0.009017669503397333,0,2,3,0.34004104248258327
6545,Post-translational protein phosphorylation,Post-translational protein modification,0.008623896632491267,1,2,3,0.32519253450900837
6546,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.0026459098204065926,0,2,3,0.09977277757928488
6547,Translocation of SLC2A4 (GLUT4) to the plasma membrane,Membrane Trafficking,0.0030477337112167478,1,2,3,0.11492487587630232
6548,Collagen degradation,Degradation of the extracellular matrix,0.003651526513941153,0,2,3,0.1376928797385571
6549,Collagen degradation,Degradation of the extracellular matrix,0.002930192295237705,1,2,3,0.11049258817610054
6550,Antimicrobial peptides,Innate Immune System,0.002608887614514554,0,2,3,0.09837673290479433
6551,Antimicrobial peptides,Innate Immune System,0.0029515399772318987,1,2,3,0.11129757310454104
6552,Kinesins,Factors involved in megakaryocyte development and platelet production,0.0008122327191333244,0,2,3,0.030627920046138932
6553,Kinesins,Factors involved in megakaryocyte development and platelet production,0.000515237765608008,1,2,3,0.01942874341067146
6554,Rab regulation of trafficking,Membrane Trafficking,9.505257140762328e-05,0,2,3,0.0035842714639210765
6555,Rab regulation of trafficking,Membrane Trafficking,0.00010877123110781975,1,2,3,0.0041015788839990856
6556,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,4.4924336937117284e-05,0,2,3,0.0016940206512537448
6557,Selenoamino acid metabolism,Metabolism of amino acids and derivatives,9.683467576878268e-05,1,2,3,0.0036514716007805055
6558,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",0.0014016645306403033,0,2,3,0.05285439525480786
6559,Mitotic G2-G2/M phases,"Cell Cycle, Mitotic",0.0002450647130099749,1,2,3,0.009240975227159555
6560,Pyroptosis,Regulated Necrosis,0.0006456588745663217,0,2,3,0.02434670251698065
6561,Pyroptosis,Regulated Necrosis,0.0016211889402617033,1,2,3,0.061132288902375195
6562,Transferrin endocytosis and recycling,Iron uptake and transport,0.0006500974763367146,0,2,3,0.024514074671460342
6563,Transferrin endocytosis and recycling,Iron uptake and transport,0.0011142551661151134,1,2,3,0.042016674944079783
6564,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,0.0003987824858838768,0,2,3,0.015037412068901218
6565,mRNA Splicing,Processing of Capped Intron-Containing Pre-mRNA,0.0006198057714852074,1,2,3,0.023371825790815447
6566,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.0029876648639965355,0,2,3,0.11265978139465241
6567,Glycosaminoglycan metabolism,Metabolism of carbohydrates,0.004301806755725449,1,2,3,0.1622138461854703
6568,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.00035519957553074833,0,2,3,0.013393974341967506
6569,"tRNA-derived small RNA (tsRNA or tRNA-related fragment, tRF) biogenesis",Gene Silencing by RNA,0.00038298456473076205,1,2,3,0.014441699221370162
6570,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,0.0003740173386380184,0,2,3,0.014103560314460254
6571,TNFR2 non-canonical NF-kB pathway,Cytokine Signaling in Immune system,0.0006201871206931034,1,2,3,0.02338620582350061
6572,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,0.001680510159378616,0,2,3,0.06336919159461217
6573,EGR2 and SOX10-mediated initiation of Schwann cell myelination,Nervous system development,0.0017472553858178938,1,2,3,0.06588604102789396
6574,Regulation of insulin secretion,Integration of energy metabolism,0.0003249935971556449,0,2,3,0.012254958061540849
6575,Regulation of insulin secretion,Integration of energy metabolism,0.0002433509939807576,1,2,3,0.009176353785333841
6576,Diseases associated with surfactant metabolism,Diseases of metabolism,0.0009349820302766252,0,2,3,0.03525658865164303
6577,Diseases associated with surfactant metabolism,Diseases of metabolism,0.0012593309269144867,1,2,3,0.047487236148677885
6578,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,3.1903740464627926e-06,0,2,3,0.00012030360130850595
6579,Glutamate and glutamine metabolism,Metabolism of amino acids and derivatives,6.883406338943709e-06,1,2,3,0.000259561593651644
6580,Glycogen metabolism,Metabolism of carbohydrates,0.00027818033558345593,0,2,3,0.01048970926183491
6581,Glycogen metabolism,Metabolism of carbohydrates,0.0004006515655142204,1,2,3,0.015107891895839382
6582,Formation of the cornified envelope,Keratinization,0.0016319262203534364,0,2,3,0.06153717354739849
6583,Formation of the cornified envelope,Keratinization,0.0017135819313489034,1,2,3,0.064616272097317
6584,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.0003190344857303728,0,2,3,0.012030250063475939
6585,Positive epigenetic regulation of rRNA expression,Epigenetic regulation of gene expression,0.0005396125508258624,1,2,3,0.020347875274247265
6586,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,1.4382466890753957e-05,0,2,3,0.0005423384648506701
6587,Glyoxylate metabolism and glycine degradation,Metabolism of amino acids and derivatives,3.068040720287809e-05,1,2,3,0.0011569061879154504
6588,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.003461074051043157,0,2,3,0.13051123995869915
6589,NR1H2 and NR1H3-mediated signaling,Signaling by Nuclear Receptors,0.002447953588648142,1,2,3,0.09230818338588405
6590,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.003432760391337679,0,2,3,0.12944357981001875
6591,trans-Golgi Network Vesicle Budding,Membrane Trafficking,0.003927992125996004,1,2,3,0.14811792968059584
6592,Neurotransmitter release cycle,Transmission across Chemical Synapses,0.0005565408703978623,0,2,3,0.020986213531440267
6593,Neurotransmitter release cycle,Transmission across Chemical Synapses,0.0007961688167001901,1,2,3,0.030022177495068105
6594,Fructose metabolism,Metabolism of carbohydrates,0.0006069106463198715,0,2,3,0.022885572463111185
6595,Fructose metabolism,Metabolism of carbohydrates,0.0008737644957964129,1,2,3,0.032948179119111104
6596,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.0026871147662310196,0,2,3,0.10132654629173303
6597,Fcgamma receptor (FCGR) dependent phagocytosis,Innate Immune System,0.00303626390692434,1,2,3,0.11449236898445046
6598,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.0001377986852093143,0,2,3,0.0051961550102996665
6599,AMPK inhibits chREBP transcriptional activation activity,Integration of energy metabolism,0.00010354172354421044,1,2,3,0.0039043830117251764
6600,Gap junction trafficking and regulation,Membrane Trafficking,0.0009479808069797774,0,2,3,0.03574675050326921
6601,Gap junction trafficking and regulation,Membrane Trafficking,0.001091833102672986,1,2,3,0.041171176911068134
6602,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.002337261527980002,0,2,3,0.0881341732727435
6603,ABC transporters in lipid homeostasis,ABC-family proteins mediated transport,0.000936199697782267,1,2,3,0.03530250483074669
6604,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,0.00020586413108323568,0,2,3,0.007762787682221206
6605,Metabolic disorders of biological oxidation enzymes,Diseases of metabolism,0.00027416852670857626,1,2,3,0.010338430744526084
6606,Urea cycle,Metabolism of amino acids and derivatives,0.00027109617379205634,0,2,3,0.010222577520118795
6607,Urea cycle,Metabolism of amino acids and derivatives,0.0005892778233108513,1,2,3,0.022220668574624337
6608,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,0.0007805911786148462,0,2,3,0.02943477114889839
6609,Sensory processing of sound by inner hair cells of the cochlea,Sensory processing of sound,0.00048539397929222466,1,2,3,0.018303384779306316
6610,Metabolism of polyamines,Metabolism of amino acids and derivatives,7.502122241995554e-05,0,2,3,0.0028289232234990024
6611,Metabolism of polyamines,Metabolism of amino acids and derivatives,0.0001633821441546711,1,2,3,0.006160863912839515
6612,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0050102349513725655,0,2,3,0.1889274734792124
6613,Scavenging by Class F Receptors,Binding and Uptake of Ligands by Scavenger Receptors,0.0057510517098524885,1,2,3,0.216862418616332
6614,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.009390936819390338,0,2,3,0.35411632071351856
6615,Response to elevated platelet cytosolic Ca2+,"Platelet activation, signaling and aggregation",0.006732600429293293,1,2,3,0.25387495823982914
6616,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.003136970272091534,0,3,4,0.21497069395890936
6617,Non-integrin membrane-ECM interactions,Extracellular matrix organization,0.0026018176531508535,1,3,4,0.17829768787686479
6618,Ion channel transport,Transport of small molecules,3.2541227169946845e-06,0,3,4,0.0002229989314605105
6619,Ion channel transport,Transport of small molecules,2.1363868962178432e-06,1,3,4,0.00014640259033709752
6620,Inositol phosphate metabolism,Metabolism,2.8699697086175073e-05,0,3,4,0.0019667364571204714
6621,Inositol phosphate metabolism,Metabolism,4.884441460226899e-05,1,3,4,0.0033472161966219827
6622,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.007512904316052318,0,3,4,0.5148452533443473
6623,"Plasma lipoprotein assembly, remodeling, and clearance",Transport of small molecules,0.004981562181114319,1,3,4,0.34137712065712417
6624,RNA Polymerase II Transcription,Gene expression (Transcription),0.005021006907637794,0,3,4,0.3440801938450372
6625,RNA Polymerase II Transcription,Gene expression (Transcription),0.00455254409417893,1,3,4,0.31197731515372884
6626,"Cell Cycle, Mitotic",Cell Cycle,0.0016780549000022663,0,3,4,0.11499395756598027
6627,"Cell Cycle, Mitotic",Cell Cycle,0.00020995608038529192,1,3,4,0.014387896724066176
6628,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0013865221241993715,0,3,4,0.09501576278240957
6629,Diseases of signal transduction by growth factor receptors and second messengers,Disease,0.0017925210278691582,1,3,4,0.12283810679533484
6630,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.008556912819424119,0,3,4,0.586389199573459
6631,Binding and Uptake of Ligands by Scavenger Receptors,Vesicle-mediated transport,0.010453932443417982,1,3,4,0.7163883993273452
6632,Metabolism of amino acids and derivatives,Metabolism,0.00019291517293284986,0,3,4,0.013220115271582546
6633,Metabolism of amino acids and derivatives,Metabolism,0.0003263068090949082,1,3,4,0.02236119411736745
6634,Cell surface interactions at the vascular wall,Hemostasis,0.0003964143686574472,0,3,4,0.02716553379026978
6635,Cell surface interactions at the vascular wall,Hemostasis,0.00021091845321030532,1,3,4,0.014453846330245386
6636,Platelet Adhesion to exposed collagen,Hemostasis,2.3600342810212354e-05,0,3,4,0.0016172872649497234
6637,Platelet Adhesion to exposed collagen,Hemostasis,1.2629011291098668e-05,1,3,4,0.0008654424765881764
6638,Elastic fibre formation,Extracellular matrix organization,0.002367743680741594,0,3,4,0.16225703721013482
6639,Elastic fibre formation,Extracellular matrix organization,0.0019645416121392865,1,3,4,0.13462635506302117
6640,Metabolism of nucleotides,Metabolism,6.184112871917282e-05,0,3,4,0.004237856658775156
6641,Metabolism of nucleotides,Metabolism,0.00010563192409989164,1,3,4,0.007238757800796257
6642,Visual phototransduction,Sensory Perception,0.008730610687052831,0,3,4,0.5982923889264239
6643,Visual phototransduction,Sensory Perception,0.005531597557787306,1,3,4,0.37907001423577646
6644,Response to metal ions,Cellular responses to stimuli,0.0024166051475662115,0,3,4,0.1656054219635979
6645,Response to metal ions,Cellular responses to stimuli,0.001251540736822402,1,3,4,0.08576574126511391
6646,SLC-mediated transmembrane transport,Transport of small molecules,0.00044661981216685383,0,3,4,0.030606018747284077
6647,SLC-mediated transmembrane transport,Transport of small molecules,0.00029552735954755657,1,3,4,0.020251936121608426
6648,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.008108357633927928,0,3,4,0.55565055331887
6649,Formation of Fibrin Clot (Clotting Cascade),Hemostasis,0.004339359341387822,1,3,4,0.29736816356033247
6650,Signaling by WNT,Signal Transduction,0.0009221489617907145,0,3,4,0.06319314021342863
6651,Signaling by WNT,Signal Transduction,0.0007261441397683951,1,3,4,0.04976129707985078
6652,Collagen formation,Extracellular matrix organization,0.0024496365050960455,0,3,4,0.16786899899324537
6653,Collagen formation,Extracellular matrix organization,0.0020494324178817174,1,3,4,0.14044376289233224
6654,Death Receptor Signalling,Signal Transduction,0.0006607382268429767,0,3,4,0.045279152439946804
6655,Death Receptor Signalling,Signal Transduction,0.0005205022013063075,1,3,4,0.03566904041693511
6656,Innate Immune System,Immune System,0.007692424976089639,0,3,4,0.5271474677489658
6657,Innate Immune System,Immune System,0.010323346345103346,1,3,4,0.707439578732572
6658,DNA Double-Strand Break Repair,DNA Repair,0.0009168370625832671,0,3,4,0.06282912571541958
6659,DNA Double-Strand Break Repair,DNA Repair,0.0005784801655563616,1,3,4,0.039642161654341375
6660,Activation of HOX genes during differentiation,Developmental Biology,0.0012647839121846718,0,3,4,0.08667327125453538
6661,Activation of HOX genes during differentiation,Developmental Biology,0.001440584932886499,1,3,4,0.09872058574622133
6662,Atorvastatin ADME,Drug ADME,0.002255436779867218,0,3,4,0.15456085576011358
6663,Atorvastatin ADME,Drug ADME,0.0036112212916483205,1,3,4,0.24747022756681594
6664,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0017940550523636942,0,3,4,0.12294323061913204
6665,O2/CO2 exchange in erythrocytes,Transport of small molecules,0.0011852984546744595,1,3,4,0.08122628180977436
6666,Translation,Metabolism of proteins,1.8832170889517639e-06,0,3,4,0.00012905333789386484
6667,Translation,Metabolism of proteins,1.8470724814372072e-06,1,3,4,0.00012657641567709926
6668,Diseases of Immune System,Disease,0.004033424303397716,0,3,4,0.27640300873939466
6669,Diseases of Immune System,Disease,0.005235394366010332,1,3,4,0.35877176459801835
6670,Regulated Necrosis,Programmed Cell Death,0.0006705680246036513,0,3,4,0.04595277005911508
6671,Regulated Necrosis,Programmed Cell Death,0.00104122928691565,1,3,4,0.07135349173371648
6672,Cardiac conduction,Muscle contraction,0.0005487130440300009,0,3,4,0.03760227660072419
6673,Cardiac conduction,Muscle contraction,0.0017622373936116355,1,3,4,0.12076282609221331
6674,Fertilization,Reproduction,0.0015695807393095137,0,3,4,0.10756042661792198
6675,Fertilization,Reproduction,0.0017333296589474466,1,3,4,0.11878183320974095
6676,Integrin signaling,Signal Transduction,0.00033255097331272255,0,3,4,0.022789094989441056
6677,Integrin signaling,Signal Transduction,0.00026305315598765353,1,3,4,0.018026539809395132
6678,Meiosis,Reproduction,0.00015643693442249742,0,3,4,0.01072032994791077
6679,Meiosis,Reproduction,0.0004363825921023843,1,3,4,0.029904481241159797
6680,Meiosis,Cell Cycle,0.00015643693442249742,0,3,4,0.01072032994791077
6681,Meiosis,Cell Cycle,0.0004363825921023843,1,3,4,0.029904481241159797
6682,Apoptosis,Programmed Cell Death,0.004200904800463231,0,3,4,0.2878801333392246
6683,Apoptosis,Programmed Cell Death,0.006587835271496486,1,3,4,0.4514520053313583
6684,Metabolism of lipids,Metabolism,0.0008764393498678852,0,3,4,0.06006074616970328
6685,Metabolism of lipids,Metabolism,0.0014912409675198986,1,3,4,0.10219194886854
6686,Striated Muscle Contraction,Muscle contraction,0.0004010678617116533,0,3,4,0.02748442894847243
6687,Striated Muscle Contraction,Muscle contraction,0.001290637222192422,1,3,4,0.08844495013939627
6688,Abacavir ADME,Drug ADME,0.0022092101570138434,0,3,4,0.15139303192621376
6689,Abacavir ADME,Drug ADME,0.0034416289592331967,1,3,4,0.23584838284812765
6690,Miscellaneous transport and binding events,Transport of small molecules,0.00031569085154002223,0,3,4,0.021633702440791696
6691,Miscellaneous transport and binding events,Transport of small molecules,0.0002084153641839395,1,3,4,0.014282314330141342
6692,Signaling by NOTCH,Signal Transduction,0.0013145241698532054,0,3,4,0.09008187789764852
6693,Signaling by NOTCH,Signal Transduction,0.0010404956950230192,1,3,4,0.07130322005609031
6694,Infectious disease,Disease,0.008065336145997845,0,3,4,0.552702371374733
6695,Infectious disease,Disease,0.010481370231932973,1,3,4,0.7182686595549413
6696,Cilium Assembly,Organelle biogenesis and maintenance,0.00019567952780294567,0,3,4,0.013409551330336451
6697,Cilium Assembly,Organelle biogenesis and maintenance,0.001331262691431031,1,3,4,0.09122893741282595
6698,Metabolism of porphyrins,Metabolism,8.078563492127097e-05,0,3,4,0.005536088166164803
6699,Metabolism of porphyrins,Metabolism,0.0001379182873395489,1,3,4,0.009451281767882173
6700,Integration of energy metabolism,Metabolism,0.00037542035763439585,0,3,4,0.025726853558341
6701,Integration of energy metabolism,Metabolism,0.0006345328390776319,1,3,4,0.04348334632616349
6702,Iron uptake and transport,Transport of small molecules,0.000914867586842322,0,3,4,0.06269416123375621
6703,Iron uptake and transport,Transport of small molecules,0.0006054015058479479,1,3,4,0.041487030653028965
6704,Peptide hormone metabolism,Metabolism of proteins,0.0005072548589809516,0,3,4,0.03476122487334239
6705,Peptide hormone metabolism,Metabolism of proteins,0.0004965627249014129,1,3,4,0.034028512962289544
6706,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.0003665518493177062,0,3,4,0.025119111303280345
6707,Factors involved in megakaryocyte development and platelet production,Hemostasis,0.00019674693263590284,1,3,4,0.01348269858318654
6708,Metabolism of vitamins and cofactors,Metabolism,0.001941311543679301,0,3,4,0.13303444200538594
6709,Metabolism of vitamins and cofactors,Metabolism,0.003314332705338132,1,3,4,0.22712500912614897
6710,Signaling by TGFB family members,Signal Transduction,0.0017315693826824637,0,3,4,0.11866120477611845
6711,Signaling by TGFB family members,Signal Transduction,0.001365833133385316,1,3,4,0.09359798501378518
6712,Diseases of metabolism,Disease,0.002506344326043683,0,3,4,0.17175507969042816
6713,Diseases of metabolism,Disease,0.003256471713934774,1,3,4,0.22315990381871578
6714,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,7.663908254102269e-05,0,3,4,0.00525193270232465
6715,Processing of Capped Intron-Containing Pre-mRNA,Metabolism of RNA,0.00018538222318015247,1,3,4,0.012703896342030733
6716,Metabolism of carbohydrates,Metabolism,0.0021060839501884114,0,3,4,0.14432598623443796
6717,Metabolism of carbohydrates,Metabolism,0.003608321043485297,1,3,4,0.24727147899536628
6718,Membrane Trafficking,Vesicle-mediated transport,0.008584633936055434,0,3,4,0.5882888757459006
6719,Membrane Trafficking,Vesicle-mediated transport,0.010435765289150765,1,3,4,0.7151434382912694
6720,Smooth Muscle Contraction,Muscle contraction,0.0007510326710212558,0,3,4,0.05146686148466684
6721,Smooth Muscle Contraction,Muscle contraction,0.002422151449411962,1,3,4,0.16598549963513148
6722,Nephrin family interactions,Cell-Cell communication,0.00031295683015626397,0,3,4,0.02144634507901053
6723,Nephrin family interactions,Cell-Cell communication,0.00015196767613760207,1,3,4,0.010414060053186845
6724,Post-translational protein modification,Metabolism of proteins,0.007581224145128706,0,3,4,0.5195270831973007
6725,Post-translational protein modification,Metabolism of proteins,0.007472838797877031,1,3,4,0.5120996384679201
6726,MAPK family signaling cascades,Signal Transduction,0.0010170094329591363,0,3,4,0.0696937505308954
6727,MAPK family signaling cascades,Signal Transduction,0.0007990898076211591,1,3,4,0.05476012699517209
6728,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,0.00012581606103056973,0,3,4,0.008621938878905916
6729,The citric acid (TCA) cycle and respiratory electron transport,Metabolism,0.00021367603698294963,1,3,4,0.014642818378380202
6730,Transcriptional regulation of granulopoiesis,Developmental Biology,0.0003131731308153714,0,3,4,0.021461167757824473
6731,Transcriptional regulation of granulopoiesis,Developmental Biology,0.00035637699781031917,1,3,4,0.024421847797492166
6732,ABC-family proteins mediated transport,Transport of small molecules,0.0010885839546764667,0,3,4,0.0745986183711293
6733,ABC-family proteins mediated transport,Transport of small molecules,0.000716325489059291,1,3,4,0.049088443347236686
6734,Signaling by GPCR,Signal Transduction,0.003854422245298993,0,3,4,0.2641363331537509
6735,Signaling by GPCR,Signal Transduction,0.0030365621678356547,1,3,4,0.20808991474240965
6736,Platelet homeostasis,Hemostasis,0.0012733401634930864,0,3,4,0.08725961512199905
6737,Platelet homeostasis,Hemostasis,0.0006811172907472042,1,3,4,0.04667569149825412
6738,Biological oxidations,Metabolism,0.00027234887217643524,0,3,4,0.01866355781932837
6739,Biological oxidations,Metabolism,0.00046226809040328897,1,3,4,0.03167836592942862
6740,Epigenetic regulation of gene expression,Gene expression (Transcription),0.00031599679476379707,0,3,4,0.02165466815656912
6741,Epigenetic regulation of gene expression,Gene expression (Transcription),0.00028843312884245867,1,3,4,0.019765781786214395
6742,Cell Cycle Checkpoints,Cell Cycle,0.0009836107870732638,0,3,4,0.06740500391851934
6743,Cell Cycle Checkpoints,Cell Cycle,0.00012706393632645716,1,3,4,0.008707453434372917
6744,Base Excision Repair,DNA Repair,0.0001756480003881143,0,3,4,0.012036828296352416
6745,Base Excision Repair,DNA Repair,0.00011076370086174841,1,3,4,0.007590428845164498
6746,Reversible hydration of carbon dioxide,Metabolism,0.0003957333492821113,0,3,4,0.02711886480873117
6747,Reversible hydration of carbon dioxide,Metabolism,0.0006745411179453264,1,3,4,0.04622503870010987
6748,Chaperone Mediated Autophagy,Autophagy,0.003546767411378288,0,3,4,0.2430533239406444
6749,Chaperone Mediated Autophagy,Autophagy,0.0053740659380582196,1,3,4,0.3682746675552821
6750,Synthesis of DNA,DNA Replication,0.00022180996341048372,0,3,4,0.015200221113208127
6751,Synthesis of DNA,DNA Replication,0.0019181043705619341,1,3,4,0.13144409792267372
6752,Gene Silencing by RNA,Gene expression (Transcription),0.0004981815964486851,0,3,4,0.03413945119560453
6753,Gene Silencing by RNA,Gene expression (Transcription),0.0004556334742469078,1,3,4,0.03122370811772506
6754,Diseases of the neuronal system,Disease,3.171002557724824e-06,0,3,4,0.00021730286271571378
6755,Diseases of the neuronal system,Disease,4.119953743263275e-06,1,3,4,0.0002823327090943084
6756,DNA Replication Pre-Initiation,DNA Replication,0.00015837902887382333,0,3,4,0.010853418041109984
6757,DNA Replication Pre-Initiation,DNA Replication,0.0013507491287593329,1,3,4,0.09256430644469724
6758,Amyloid fiber formation,Metabolism of proteins,0.005756199898185394,0,3,4,0.394461591710937
6759,Amyloid fiber formation,Metabolism of proteins,0.005686697620753852,1,3,4,0.3896987308881528
6760,Keratinization,Developmental Biology,0.0015377184449431843,0,3,4,0.10537696329600592
6761,Keratinization,Developmental Biology,0.0017518169994901898,1,3,4,0.12004873601123879
6762,Chromatin modifying enzymes,Chromatin organization,0.00114639346469778,0,3,4,0.07856019575592882
6763,Chromatin modifying enzymes,Chromatin organization,0.0006228579164543668,1,3,4,0.042683285757987785
6764,Macroautophagy,Autophagy,0.00046482305301628565,0,3,4,0.03185345272921164
6765,Macroautophagy,Autophagy,0.0007234077621331676,1,3,4,0.04957377824857212
6766,Cellular responses to stress,Cellular responses to stimuli,0.005043414643508643,0,3,4,0.34561575399141775
6767,Cellular responses to stress,Cellular responses to stimuli,0.0026144478165152406,1,3,4,0.17916320930287638
6768,RNA Polymerase I Transcription,Gene expression (Transcription),0.0001400770587711607,0,3,4,0.009599218328480447
6769,RNA Polymerase I Transcription,Gene expression (Transcription),0.00012819199812649348,1,3,4,0.008784757395503748
6770,Intracellular oxygen transport,Transport of small molecules,2.0587709987289207e-05,0,3,4,0.0014108371833697728
6771,Intracellular oxygen transport,Transport of small molecules,1.3528736560474869e-05,1,3,4,0.0009270989631831902
6772,Degradation of the extracellular matrix,Extracellular matrix organization,0.0021681115348463273,0,3,4,0.1485766203692705
6773,Degradation of the extracellular matrix,Extracellular matrix organization,0.001808793521737188,1,3,4,0.12395323030491152
6774,ECM proteoglycans,Extracellular matrix organization,0.003737714458240709,0,3,4,0.25613856722095474
6775,ECM proteoglycans,Extracellular matrix organization,0.00309658039277842,1,3,4,0.2122028512215704
6776,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.006578369627032739,0,3,4,0.45080334245519293
6777,Signaling by Receptor Tyrosine Kinases,Signal Transduction,0.00518416047505405,1,3,4,0.3552608020648147
6778,Paracetamol ADME,Drug ADME,1.6284028665818812e-08,0,3,4,1.1159139676525755e-06
6779,Paracetamol ADME,Drug ADME,2.5374990744829552e-08,1,3,4,1.7389005621592777e-06
6780,Transmission across Chemical Synapses,Neuronal System,0.0014752631088533216,0,3,4,0.10109701615716261
6781,Transmission across Chemical Synapses,Neuronal System,0.0021207863180191956,1,3,4,0.1453335119491511
6782,Chromosome Maintenance,Cell Cycle,0.00025245798344701424,0,3,4,0.01730047249089389
6783,Chromosome Maintenance,Cell Cycle,3.1871079719273216e-05,1,3,4,0.0021840653656892447
6784,Disorders of transmembrane transporters,Disease,0.0003836839807014156,0,3,4,0.02629314416081702
6785,Disorders of transmembrane transporters,Disease,0.0004940655620294141,1,3,4,0.03385738707043846
6786,Peroxisomal protein import,Protein localization,0.00030875127080905954,0,3,4,0.021158145978305908
6787,Peroxisomal protein import,Protein localization,6.568676488932581e-05,1,3,4,0.004501390898664551
6788,Fibronectin matrix formation,Extracellular matrix organization,0.001380281182608244,0,3,4,0.09458808275090351
6789,Fibronectin matrix formation,Extracellular matrix organization,0.0011486858809314007,1,3,4,0.07871729074435392
6790,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0029499799342199463,0,3,4,0.20215659653073545
6791,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",Signal Transduction,0.0023292621596004114,1,3,4,0.1596199706819911
6792,Dissolution of Fibrin Clot,Hemostasis,0.002181487628976019,0,3,4,0.14949325903272917
6793,Dissolution of Fibrin Clot,Hemostasis,0.001167282425324763,1,3,4,0.079991677081083
6794,Integrin cell surface interactions,Extracellular matrix organization,0.008506708823721785,0,3,4,0.5829488138319502
6795,Integrin cell surface interactions,Extracellular matrix organization,0.007065909037143873,1,3,4,0.4842135045648993
6796,Signaling by Hippo,Signal Transduction,0.0005707243893403078,0,3,4,0.039110672844840016
6797,Signaling by Hippo,Signal Transduction,0.0004496816486630797,1,3,4,0.030815840664386127
6798,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,3.0180803025487404e-07,0,3,4,2.0682338714993295e-05
6799,Transcriptional regulation of white adipocyte differentiation,Developmental Biology,3.444018489296044e-07,1,3,4,2.3601213286527505e-05
6800,Aspirin ADME,Drug ADME,0.0002473803364274793,0,3,4,0.01695251085632601
6801,Aspirin ADME,Drug ADME,0.0003941975315605037,1,3,4,0.02701361809844333
6802,Nervous system development,Developmental Biology,0.0030170424483382014,0,3,4,0.2067522649458583
6803,Nervous system development,Developmental Biology,0.0034386068402851877,1,3,4,0.2356412827001729
6804,Mitochondrial biogenesis,Organelle biogenesis and maintenance,4.9517846745501176e-05,0,3,4,0.003393365239363257
6805,Mitochondrial biogenesis,Organelle biogenesis and maintenance,0.00030335430117992045,1,3,4,0.020788301763723142
6806,Diseases of programmed cell death,Disease,0.0005503495359441105,0,3,4,0.03771442232475737
6807,Diseases of programmed cell death,Disease,0.0007042918044387337,1,3,4,0.048263797491718566
6808,Laminin interactions,Extracellular matrix organization,0.0002404013342263359,0,3,4,0.016474252914365897
6809,Laminin interactions,Extracellular matrix organization,0.00019948769070924293,1,3,4,0.013670517597679966
6810,Surfactant metabolism,Metabolism of proteins,0.0007499048516194473,0,3,4,0.0513895741346323
6811,Surfactant metabolism,Metabolism of proteins,0.0007358284935716842,1,3,4,0.050424947697186286
6812,Cytokine Signaling in Immune system,Immune System,0.0019368753211187705,0,3,4,0.13273043598694267
6813,Cytokine Signaling in Immune system,Immune System,0.0025971350245605476,1,3,4,0.17797679611497416
6814,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.007207531725753558,0,3,4,0.49391864200965163
6815,Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs),Metabolism of proteins,0.007100121049671511,1,3,4,0.4865579896689592
6816,MTOR signalling,Signal Transduction,2.3820474177740335e-05,0,3,4,0.0016323724550328486
6817,MTOR signalling,Signal Transduction,1.8810525108363684e-05,1,3,4,0.0012890500341210878
6818,Nucleotide Excision Repair,DNA Repair,0.004207952143260258,0,3,4,0.288363074534148
6819,Nucleotide Excision Repair,DNA Repair,0.002639939133708366,1,3,4,0.1809100814985377
6820,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,0.001039103952921854,0,3,4,0.07120784657806885
6821,Regulation of mRNA stability by proteins that bind AU-rich elements,Metabolism of RNA,0.002511495551691854,1,3,4,0.17210808353052764
6822,Cell junction organization,Cell-Cell communication,0.0032116393936513733,0,3,4,0.22008762892696646
6823,Cell junction organization,Cell-Cell communication,0.0015470208727400383,1,3,4,0.10601444123986258
6824,Late endosomal microautophagy,Autophagy,0.0019410280183180433,0,3,4,0.13301501254371498
6825,Late endosomal microautophagy,Autophagy,0.002958685409134079,1,3,4,0.20275316641224894
6826,Adaptive Immune System,Immune System,0.0023938982149832506,0,3,4,0.164049358427241
6827,Adaptive Immune System,Immune System,0.0032152856702264516,1,3,4,0.22033750142741199
6828,Signaling by Hedgehog,Signal Transduction,0.00022781967449417507,0,3,4,0.01561205535137332
6829,Signaling by Hedgehog,Signal Transduction,0.00017802275144408367,1,3,4,0.012199565535854853
6830,Diseases of hemostasis,Disease,0.0021828091621593124,0,3,4,0.14958382122518277
6831,Diseases of hemostasis,Disease,0.002842522455392811,1,3,4,0.19479273688563198
6832,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,0.00022250448608727237,0,3,4,0.015247815450689659
6833,Metabolism of nitric oxide: NOS3 activation and regulation,Metabolism,0.00037623421678456673,1,3,4,0.025782625800702858
6834,Transcriptional regulation of testis differentiation,Developmental Biology,0.0010174572365834365,0,3,4,0.06972443767406968
6835,Transcriptional regulation of testis differentiation,Developmental Biology,0.001168489964392125,1,3,4,0.08007442747040061
6836,"Platelet activation, signaling and aggregation",Hemostasis,0.006966572146015336,0,3,4,0.477406133576527
6837,"Platelet activation, signaling and aggregation",Hemostasis,0.003733633987232984,1,3,4,0.25585894018973493
6838,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,0.00024838085199303236,0,3,4,0.017021074313033627
6839,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",Circadian Clock,0.0006723840123215019,1,3,4,0.046077216294197476
6840,Sensory processing of sound,Sensory Perception,0.003380436647580263,0,3,4,0.23165498840699691
6841,Sensory processing of sound,Sensory Perception,0.0021614293699837666,1,3,4,0.14811870413384035
6842,Intracellular signaling by second messengers,Signal Transduction,0.0003412396316367809,0,3,4,0.0233845124615516
6843,Intracellular signaling by second messengers,Signal Transduction,0.0002677252709942097,1,3,4,0.018346711095094167
6844,Protein folding,Metabolism of proteins,0.001012582859656098,0,3,4,0.06939040575798505
6845,Protein folding,Metabolism of proteins,0.0009938839085167311,1,3,4,0.06810900167886595
6846,Mitochondrial protein import,Protein localization,0.00021286292539691906,0,3,4,0.014587097365187918
6847,Mitochondrial protein import,Protein localization,4.5057583981486757e-05,1,3,4,0.0030877117908273935
6848,Signaling by Nuclear Receptors,Signal Transduction,0.00312712225409802,0,3,4,0.21429582774132994
6849,Signaling by Nuclear Receptors,Signal Transduction,0.002459059878194313,1,3,4,0.1685147650919523
6850,Cell Cycle,root,0.0010280290487059162,0,4,5,0.17134961412825994
6851,Cell Cycle,root,0.00021153057052581366,1,4,5,0.03525744888391523
6852,Sensory Perception,root,0.005130717454485975,0,4,5,0.8551766675600948
6853,Sensory Perception,root,0.001155104966048458,1,4,5,0.19253034771652655
6854,Extracellular matrix organization,root,0.008591524716366206,0,4,5,1.432016387840311
6855,Extracellular matrix organization,root,0.0070317014765235485,1,4,5,1.1720284910082344
6856,Transport of small molecules,root,0.004763671035744216,0,4,5,0.7939981801450455
6857,Transport of small molecules,root,0.0030964036035362684,1,4,5,0.5161017223386557
6858,Protein localization,root,0.0002879902982238094,0,4,5,0.04800158763553453
6859,Protein localization,root,8.003845326171073e-05,1,4,5,0.013340632834335564
6860,DNA Repair,root,0.0019523198166744495,0,4,5,0.32540836045754523
6861,DNA Repair,root,0.0008882936587313655,1,4,5,0.14805882756698385
6862,Circadian Clock,root,4.2982171120466006e-05,0,4,5,0.007164173468792277
6863,Circadian Clock,root,0.00020257368264838031,1,4,5,0.03376453457033601
6864,Cell-Cell communication,root,0.0023063319049423845,0,4,5,0.38441431442140334
6865,Cell-Cell communication,root,0.0007242293396535702,1,4,5,0.12071294876950843
6866,Metabolism,root,0.0033855017484106633,0,4,5,0.5642879634101317
6867,Metabolism,root,0.0052822288375425856,1,4,5,0.8804302506718458
6868,Programmed Cell Death,root,0.0020040561434383525,0,4,5,0.33403165727835743
6869,Programmed Cell Death,root,0.0031049181822621497,1,4,5,0.5175209135385357
6870,Signal Transduction,root,0.006459179840203894,0,4,5,1.076601847581239
6871,Signal Transduction,root,0.0026161605194501675,1,4,5,0.43605586444241734
6872,Vesicle-mediated transport,root,0.007083233268969919,0,4,5,1.1806176965001787
6873,Vesicle-mediated transport,root,0.01107871965149141,1,4,5,1.8465765531702125
6874,Gene expression (Transcription),root,0.0023026904034730267,0,4,5,0.3838073569892107
6875,Gene expression (Transcription),root,0.0013372025020825862,1,4,5,0.2228819633371477
6876,Disease,root,0.007071461857102698,0,4,5,1.1786556635364875
6877,Disease,root,0.011269183063567592,1,4,5,1.8783225745553942
6878,Autophagy,root,0.0048930452874924295,0,4,5,0.8155619950421965
6879,Autophagy,root,0.004446270699680163,1,4,5,0.7410945922773513
6880,Muscle contraction,root,0.0015630106244671753,0,4,5,0.2605191630702991
6881,Muscle contraction,root,0.002112120903031868,1,4,5,0.3520436530293735
6882,Developmental Biology,root,0.001677164499440015,0,4,5,0.27954607914087526
6883,Developmental Biology,root,0.002261143215143771,1,4,5,0.37688236328665564
6884,Metabolism of proteins,root,0.01065074525765252,0,4,5,1.7752427252658538
6885,Metabolism of proteins,root,0.010158569532724896,1,4,5,1.6932079611161395
6886,Chromatin organization,root,0.000658174452699632,0,4,5,0.10970306592126514
6887,Chromatin organization,root,0.0004950710676547978,1,4,5,0.08251735348869726
6888,Metabolism of RNA,root,0.0014940473707694192,0,4,5,0.249024520068708
6889,Metabolism of RNA,root,0.0010572948355041859,1,4,5,0.17622757091494404
6890,Immune System,root,0.006573067563775038,0,4,5,1.0955844021232788
6891,Immune System,root,0.011499100914467267,1,4,5,1.9166447747718667
6892,DNA Replication,root,0.0009817093935344666,0,4,5,0.1636291561799433
6893,DNA Replication,root,0.0015093968238107862,1,4,5,0.25158293304257184
6894,Reproduction,root,0.00011416267021908102,0,4,5,0.019028382042818384
6895,Reproduction,root,0.0018776408826108983,1,4,5,0.3129610404606957
6896,Drug ADME,root,0.00038169754276944144,0,4,5,0.06362050444934318
6897,Drug ADME,root,0.0025174331409187583,1,4,5,0.41960020276967896
6898,Hemostasis,root,0.006278726967840679,0,4,5,1.0465243608733528
6899,Hemostasis,root,0.0023886746951709216,1,4,5,0.3981390290582757
6900,Neuronal System,root,0.0016014522140172574,0,4,5,0.26692652241892373
6901,Neuronal System,root,0.0003012260847818712,1,4,5,0.050207699342458376
6902,Cellular responses to stimuli,root,0.004608448218679427,0,4,5,0.7681259833997941
6903,Cellular responses to stimuli,root,0.0019039846057022642,1,4,5,0.31735195411443884
6904,Organelle biogenesis and maintenance,root,0.00030574114398728244,0,4,5,0.0509602594511317
6905,Organelle biogenesis and maintenance,root,0.00105214720180608,1,4,5,0.1753695746852126
